



PatBase Export

Created by: SIC9@patbase.com
Created on: 02 October 2024
Search: 1 AND 2

Records: 116 (1-116 of 116)
Export type: Family Export

1. Family 104517043 (WO24189127 A1)

[View in PatBase](#)

Title


[EN] COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS

Abstract

[EN] The present disclosure relates to the field of sustained release compositions of active ingredients able to enhance the dissolution rate of active ingredients with poor aqueous solubility.

International Class: A61K31/00; A61K31/192; A61K31/4422; A61K31/496; A61K9/14; A61K9/20

Cooperative Patent Class: A61K31/4422; A61K9/146; A61K9/2031; A61P9/00



Family Information

Patent Number	Publication Date	Application Number	Application Date
WO24189127 A1	20240919	WO2024EP56768	20240314

Priority Numbers: EP20230161909 [20230314]; EP20230205497 [20231024]

Probable Patent Assignee: PROLEVI BIO AB

Assignees: PROLEVI BIO AB

Inventors: GUPTA SAHIL; BAR SHALOM DANIEL

Agent(s): HOIBERG P S

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CV; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IQ; IR; IS; IT; JM; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MU; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

2. Family 96917990 (US2024285528 AA)

[View in PatBase](#)

Title

[EN] NANO-MOLECULE AGGREGATE CONSISTING OF ORGANIC MATERIAL, INORGANIC MATERIAL OR SALT THEREOF AND PREPARATION METHOD THEREFOR

Abstract

[EN] The present invention relates to a pharmacologically active ingredient-derived molecular association prepared by applying a shear stress to a solution containing a pharmacologically active ingredient.

International Class: A61K9/14; A61K31/167; A61K31/365; A61K31/436; A61K31/454; A61K31/7076; A61K38/13; A61P31/10; A61P33/00; A61P37/06; A61P9/10; C07C235/64; C07D259/00; C07D401/06; C07D493/10; C07D498/18; C07H19/167; C07K7/64; C12N9/99; A61K31/352; A61K9/10

Cooperative Patent Class: A61K9/14; A61K9/143; A61K31/167; A61K31/352; A61K31/436; A61K31/454; A61K31/7076; A61K38/13; A61K9/10; A61K9/5123

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN117915896 A	20240419	CN202280061023	20221014
EP4417194 A1	20240821	EP20220881423	20221014
JP2024534175 T2	20240918	JP20240513243T	20221014
KR20230053542 A	20230421	KR20220132521	20221014
US2024285528 AA	20240829	US20240421490	20240124
WO23063796 A1	20230420	WO2022KR15656	20221014

Priority Numbers: KR20210136324 [20211014]; WO2022KR15656 [20221014]; KR20220132521 [20221014]; US20240421490 [20240124]

Probable Patent Assignee: SCAI THERAPEUTICS CO LTD


Assignees: SKY PHARMACEUTICALS INC; SCAI THERAPEUTICS CO LTD

Non Std Assignees: SCAI THERAPEUTICS CO

Inventors: KIM CHEOLHWAN; KIM KYUNG HEE; KIM CHUL HWAN; KIM KYOUNG HEE

Agent(s): DOMPATENT VON KREISLER SELTING WERNER PARTNERSCHAFT VON PATENT U RECHTSANWAELTEN MBB; KIM SUNG HO

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AP; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; CV; DJ; DM; DO; DZ; EA; EC; EG; EP; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IQ; IR; JM; JO; JP; KE; KG; KM; KN; KP; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OA; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



3. Family 68275626 (US2020215079 AA)


[View in PatBase](#)

Title

[EN] OPHTHALMIC PHARMACEUTICAL COMPOSITION, OPHTHALMIC KIT, AND PHARMACEUTICAL APPLICATION THEREOF

Abstract

[EN] The present invention relates to an ophthalmic pharmaceutical composition, comprising 0.06 to 40 parts by weight of a solid matrix, 0.4 to 55 parts by weight of a liquid matrix and 1 part by weight of an active pharmaceutical ingredient; the solid matrix is selected from the group consisting of polylactic acid, polyglycolic acid, polylactic acid-co-glycolic acid copolymer, and polyethylene glycol with a number average molecular weight of 800 to 10,000; the liquid matrix is a first liquid matrix and/or a second liquid matrix; the first liquid matrix is selected from the group consisting of diethyl succinate, diethyl tartrate, dimethyl glutarate and glycerol triacetate; when the liquid matrix is the first and second liquid matrices, the second liquid matrix is selected from the group consisting of glycerol, propylene glycol, and polyethylene glycol with a number average molecular weight 70-750; when the liquid matrix is the second liquid matrix, the second liquid matrix is glycerol and/or propylene glycol, or a combination thereof with polyethylene glycol having a number average molecular weight of 70 to 750.



International Class: A61K45/00; A61K47/10; A61K47/34; A61K9/00; A61P27/02; A61K31/196; A61K31/404; A61K31/436; A61K31/4745; A61K31/506; A61K31/5377; A61K31/5575; A61K31/573; A61K31/58; A61K47/14; A61P25/00; A61P27/06; A61P29/00; A61P3/10; A61P35/00; A61P7/10; A61P9/14; A61K31/165; A61K31/395; A61K47/60; A61K9/10; A61P31/00; A61P37/06; A61P43/00; A61K9/08; A61P25/02; A61P27/12; A61P9/10; A61K31/216; A61K9/52; A61P37/00

Cooperative Patent Class: A61K31/165; A61K31/196; A61K31/216; A61K31/395; A61K31/404; A61K31/436; A61K31/4745; A61K31/506; A61K31/5377; A61K31/5575; A61K31/573; A61K31/58; A61K45/00; A61K45/06; A61K47/10; A61K47/14; A61K47/34; A61K47/60; A61K9/0002; A61K9/0019; A61K9/0024; A61K9/0048; A61K9/0051; A61K9/10; A61P25/00; A61P27/02; A61P31/00; A61P37/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN107595765 A	20180119	CN201710863869	20170922
CN109549918 A	20190402	CN201811099868	20180920
CN109549918 B	20230523	CN201811099868	20180920
CN114432231 A	20220506	CN202210307578	20180920
CN114432231 B	20240621	CN202210307578	20180920
DE602018048721 D1	20230427	DE201860048721T	20180920
EP3685828 A1	20200729	EP20180859935	20180920
EP3685828 A4	20210811	EP20180859935	20180920
EP3685828 B1	20230419	EP20180859935	20180920
EP4074306 A1	20221019	EP20220177066	20180920
ES2945159 T3	20230628	ES20180859935T	20180920
HK40064642 A1	20220708	HK20224054324	20220530
HK40064642 B	20240906	HK20224054324	20220530
HK40074896 A1	20230113	HK20224063428	20221105
JP2020535220 T2	20201203	JP20200537823T	20180920
JP2022180505 A2	20221206	JP20220149278	20180920
JP7173666 B2	20221116	JP20200537823T	20180920
JP7519413 B2	20240719	JP20220149278	20180920
US2020215079 AA	20200709	US20180649268	20180920
WO19056751 A1	20190328	WO2018CN084545	20180426
WO19057110 A1	20190328	WO2018CN106677	20180920

Priority Numbers: CN201710863869 [20170922]; CN201811099868 [20180920]; CN202210307578 [20180920]; EP20180859935 [20180920]; WO2018CN106677 [20180920]; JP20200537823T [20180920]; JP20220149278 [20220920]; JP20200537823 [20180920]

Probable Patent Assignee: SHENYANG XINGQI PHARMACEUTICAL CO LTD

Assignees: SHENYANG SINQI PHARMACEUTICAL CO LTD; SHENYANG XING EYE ALIGNING MEDICINE STOCK LTD CO; SHENYANG XINGQI PHARMACEUTICAL CO LTD

Non Std Assignees: SHENYANG SINQI PHARMACEUTICAL CO; SHENYANG XING EYE ALIGNING MEDICINE STOCK CO LTD; SHENYANG XINGQI PHARMACEUTICAL CO

Inventors: YANG QIANG; LIU JIDONG; TANG HAI

Non Std Inventors: QIANG YANG; JIDONG LIU

Agent(s): LAVOIX; ELZABURU SLP; LIU SHEN AND ASSOCIATES; BEIJING DIJIN INTELLECTUAL PROPERTY AGENCY LAW OFFICE; CCPIT PATENT AND TRADEMARK LAW OFFICE

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

4. Family 95789432 (US2024285652 AA)

[View in PatBase](#)

Title

[EN] AMORPHOUS NANO-MOLECULAR AGGREGATE COMPOSED OF ORGANIC MATERIAL, INORGANIC MATERIAL, OR SALT THEREOF, AND METHOD FOR PREPARING SAME

Abstract

[EN] The present invention relates to an amorphous nano-molecular association composed of an organic/inorganic material or a salt thereof, and more specifically, to an amorphous nano-molecular association, which is prepared by applying a shear stress to an organic/inorganic material or a salt thereof, and thus has excellent solubility and permeability to a lipid membrane.

International Class: A61K47/12; A61K47/22; A61K9/14; A61K31/403; A61K31/575; A61K31/609; A61K38/13; A61K45/00; A61K9/10; A61K9/51; A61K31/167; A61K31/352; A61K31/404

Cooperative Patent Class: A61K9/14; A61K9/145; A61K31/167; A61K31/192; A61K31/337; A61K31/352; A61K31/404; A61K31/575; A61K38/13; A61K47/12; A61K47/22; A61K9/5123

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN117915895 A	20240419	CN202280060736	20220728
EP4413975 A1	20240814	EP20220849903	20220728
JP2024526959 T2	20240719	JP20240503955T	20220728
KR20230017751 A	20230206	KR20220093820	20220728
US2024285652 AA	20240829	US20240423812	20240126
WO23008927 A1	20230202	WO2022KR11132	20220728

Priority Numbers: KR20210099485 [20210728]; WO2022KR11132 [20220728]; KR20220093820 [20220728]; US20240423812 [20240126]

Probable Patent Assignee: SCAI THERAPEUTICS CO LTD


Assignees: SKY PHARMACEUTICALS INC; SCAI THERAPEUTICS CO LTD

Non Std Assignees: SCAI THERAPEUTICS CO

Inventors: KIM CHEOLHWAN; KIM KYUNG HEE; KIM CHUL HWAN; KIM KYOUNG HEE

Agent(s): DOMPATENT VON KREISLER SELTING WERNER PARTNERSCHAFT VON PATENT U RECHTSANWAELTEN MBB; KIM SUNG HO

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; CV; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IQ; IR; JM; JO; JP; KE; KG; KM; KN; KP; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



5. Family 97004520 (US2023405080 AA)

[View in PatBase](#)

Title
[EN] METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS

Abstract
[EN] The disclosure generally relates to compounds (i.e. peptidomimetics), compositions (e.g. formulations or medicaments), methods and related uses for treating, preventing, inhibiting, amelioration or delaying the onset of ophthalmic diseases, disorders or conditions in a mammalian subject, such as a human. In some embodiments, the ophthalmic disease, disorder or condition may be associated with deterioration of the integrity of the ellipsoid zone of one or more eyes of the mammalian subject. The methods and uses comprise administering an effective amount of peptidomimetic (alone, as formulated and/or in combination with at least one additional therapeutic agent) to mammalian subjects in need thereof.

International Class: A61K38/07; A61P27/02; A61K31/4245; A61K38/05; A61K38/12; A61K38/13; A61K45/06; A61K9/00

Cooperative Patent Class: A61K2300/00; A61K31/4245; A61K38/05; A61K38/07; A61K38/12; A61K38/13; A61K45/06; A61K9/0019; A61K9/0048; A61P27/02

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2022370358 AA	20240502	AU20220370358	20221019
CA3234071 AA	20240405	CA20223234071	20221019
CN118434434 A	20240802	CN202280084402	20221019
EP4419123 A1	20240828	EP20220800952	20221019
IL312199 AA	20240601	IL20220312199	20221019
IN202447039280 A	20240531	IN202447039280	20240520
KR20240108412 A	20240709	KR20247016730	20221019
US2023405080 AA	20231221	US20230460346	20230901
WO23069255 A1	20230427	WO2022US45908	20221006
WO23069549 A1	20230427	WO2022US47172	20221019

Priority Numbers: US20210257738P [20211020]; US20220331412P [20220415]; WO2022US45908 [20221006]; WO2022US47172 [20221019]; US20230460346 [20230901]

Probable Patent Assignee: STEALTH BIOTHERAPEUTICS INC


Assignees: STEALTH BIOTHERAPEUTICS INC

Non Std Assignees: KEEFE DENNIS; REDMON MARTIN; HOTCHKISS BRIAN; ABBRUSCATO ANTHONY

Inventors: HOTCHKISS BRIAN; REDMON MARTIN; ABBRUSCATO ANTHONY; KEEFE DENNIS; RAMON MARIO; HOTCHKISS BRYAN; ABRUSCATO ALBERTO

Agent(s): PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; OSLER HOSKIN AND HARCOURT LLP; J A KEMP LLP; REINHOLD COHN AND PARTNERS; HAYS REBECCA L ET AL; FOLEY AND LARDNER LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; CV; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IQ; IR; JM; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



6. Family 64288733 (US2018147214 AA)

[View in PatBase](#)

Title

[EN] D20 STABILIZED PHARMACEUTICAL FORMULATIONS

Abstract

[EN] Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

International Class: A61K31/00; A61K47/02; A61K47/30; A61K9/00; A61P27/02; A61K45/00; A61K; A61P; A61K31/137; A61K31/167; A61K31/192; A61K31/216; A61K31/221; A61K31/277; A61K31/335; A61K31/352; A61K31/365; A61K31/381; A61K31/382; A61K31/403; A61K31/407; A61K31/4174; A61K31/4409; A61K31/4433; A61K31/445; A61K31/4535; A61K31/46; A61K31/4709; A61K31/4741; A61K31/496; A61K31/505; A61K31/522; A61K31/5377; A61K31/5383; A61K31/542; A61K31/55; A61K31/551; A61K31/573; A61K31/63; A61K31/7036; A61K31/7048; A61K31/7072; A61K33/22; A61K38/16; A61K39/395; A61K47/04; A61K47/10; A61K47/12; A61K47/16; A61K47/18; A61K47/26; A61K47/32; A61K47/36; A61K47/38; A61K47/42; A61K9/06; A61K9/08; A61K31/18; A61K31/5575; A61K31/565; A61K31/57; A61K47/34

Cooperative Patent Class: A61K31/18; A61K31/216; A61K31/5575; A61K31/565; A61K31/57; A61K47/02; A61K47/34; A61K47/38; A61K9/0048; A61K9/06; A61K9/08; A61P27/02

US Class: 1/1; 424/78.04

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN107847432 A	20180327	CN201680043657	20160527
CN118453493 A	20240809	CN202410210163	20160527
EP3302426 A1	20180411	EP20160804169	20160527
EP3302426 A4	20181205	EP20160804169	20160527
HK1248570 A1	20181019	HK20180108376	20180628
JP2018521000 T2	20180802	JP20170559857T	20160527
US11052094 BB	20210706	US20170578202	20160527
US11052095 BB	20210706	US20200805612	20200228
US12070466 BB	20240827	US20210335496	20210601
US2018147214 AA	20180531	US20170578202	20160527
US2020197410 AA	20200625	US20200805612	20200228
US2021283142 AA	20210916	US20210335490	20210601
US2021393649 AA	20211223	US20210335496	20210601
WO16196367 A1	20161208	WO2016US34823	20160527

Priority Numbers: US20150168538P [20150529]; WO2016US34823 [20160527]; CN201680043657 [20160527]; US20160578202 [20160527]; US20200805612 [20200228]; US20170578202 [20171129]; US20210335496 [20210601]; US20210335490 [20210601]


Probable Patent Assignee: SYDNEXIS INC

Assignees: SYDNEXIS INC

Inventors: OSTROW GREGORY I; WIDDER KENNETH J; BAKER DAVID S

Agent(s): CAMPABADAL I MONFA GEMMA; WILSON SONSINI GOODRICH AND ROSATI LLP; HNC INNOVATION LTD; WILSON SONSINI GOODRICH AND ROSATI; WILSON SONSINI GOODRICH AND ROSATI; YANG FRANK

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



7. Family 103914205 (WO24159768 A1)

[View in PatBase](#)

Title


[EN] PHARMACEUTICAL COMPOSITION FOR EYE DROP OIL DOSAGE FORM

Abstract

[EN] A pharmaceutical composition for an eye drop oil dosage form, comprising a lipid, white petrolatum, and liquid paraffin. Each gram of the ophthalmic pharmaceutical composition comprises 3-500 mg of a lipid, 100-250 mg of white petrolatum and 1-797 mg of liquid paraffin.

International Class: A61K47/14; A61K47/44; A61K9/00; A61P27/04; A61K47/06; A61K9/06; A61K9/08; A61P27/02

Cooperative Patent Class: A61K47/06; A61K47/14; A61K9/06; A61K9/08; A61P27/02



Family Information

Patent Number	Publication Date	Application Number	Application Date
TW202432089 A	20240816	TW20230128068	20230727
WO24159768 A1	20240808	WO2023CN119935	20230920

Priority Numbers: US20230442153P [20230131]

Probable Patent Assignee: WINSTON MEDICAL SUPPLY CO LTD

Assignees: WINSTON MEDICAL SUPPLY CO LTD

Non Std Assignees: WINSTON MEDICAL SUPPLY CO

Inventors: CHENG WAN JUNG; CHEN YI CHING; WANG YOU CHENG; WU PIN JUN; LIN SHIOU HUA; YEN WAN PING; HUNG I SHAN

Agent(s): DRAGON INTELLECTUAL PROPERTY LAW FIRM

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CV; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IQ; IR; IS; IT; JM; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MU; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

8. Family 83330897 (US2021038600 AA)


[View in PatBase](#)

Title
[EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS

Abstract
[EN] Compositions and methods for the treatment of hair growth and the prevention of hair loss.

International Class: A61K8/49; A61K8/64; A61P17/14; A61Q7/00; A61K8/37; A61K31/506; A61K31/5575; A61K38/13; A61K31/222; A61K31/25; A61K47/10; A61K47/12; A61K47/26; A61K31/4166; A61K8/67; A61Q5/00; A61K9/00; A61K31/58; A61K8/00; A61P17/00

Cooperative Patent Class: A61K2300/00; A61K2800/591; A61K31/222; A61K31/25; A61K31/506; A61K31/5575; A61K31/58; A61K38/13; A61K47/10; A61K47/12; A61K47/26; A61K8/37; A61K8/4953; A61K8/64; A61K9/0014; A61P17/14; A61Q7/00; A61K45/06



Family Information

Patent Number	Publication Date	Application Number	Application Date
AR124256 AA	20230301	AR2021P103395	20211207
AU2020324403 AA	20211223	AU20200324403	20200803
BR112022000229 A2	20220222	BR20221100229	20200803
CA3140841 AA	20211207	CA20203140841	20200803
CL2022000067 A1	20220819	CL20220000067	20220111
CN114007634 A	20220201	CN202080043888	20200803
CO20220000214 A2	20220117	CO20220000214	20220113
DE602020021163 D1	20231130	DE202060021163T	20200803
DK3886799 T3	20231218	DK20200760994T	20200803
ECSP22001774 A	20220225	EC20220001774	20220110
EP3886799 A1	20211006	EP20200760994	20200803
EP3886799 B1	20231115	EP20200760994	20200803
EP4331683 A2	20240306	EP20230209764	20200803
EP4331683 A3	20240807	EP20230209764	20200803
ES2966317 T3	20240419	ES20200760994T	20200803
FI3886799 T3	20231213	FI20200760994T	20200803
HK40068367 A1	20220916	HK20226057514	20220728
HR20231629 T1	20240315	HR20230001629	20200803
HU064366 T2	20240328	HU20200760994T	20200803
ID2021PID09489 A	20211213	ID2024P0002694	20200803
IL289687 AA	20220301	IL20200289687	20200803
IN202117062173 A	20220624	IN202117062173	20211231
JP2022543532 T2	20221013	JP20210578213T	20200803
KR20220044248 A	20220407	KR20217043127	20200803
MA54326 A	20211201	MA20200054326	20200803
MA54326 B1	20231130	MA20200054326	20200803
MD3886799 T2	20240131	MD2021E000977T	20200803
MX2021014220 A1	20220406	MX20210014220	20200803
MX2024005310 A1	20240517	MX20240005310	20211119
MX415610 B	20240805	MX20210014220	20200803
PL3886799 T3	20240318	PL20200760994T	20200803
PT3886799 T	20231222	PT20200760994T	20200803
RS64965 B1	20240131	RS20230001207	20200803
RU2021134597 A	20230526	RU20210134597	20200803

Patent Number	Publication Date	Application Number	Application Date
RU2021134597 A3	20240523	RU20210134597	20200803
SA522431538 B1	20240517	SA20220431538	20220202
SI3886799 T1	20240229	SI20200030326T	20200803
TR2023016664 T4	20231221	TR20230016664T	20200803
TW202220665 A	20220601	TW20210128416	20210802
US10987355 BB	20210427	US20200983740	20200803
US10993944 BB	20210504	US20200983894	20200803
US11166955 BB	20211109	US20210233507	20210418
US11253518 BB	20220222	US20200983870	20200803
US11369610 BB	20220628	US20210492946	20211004
US11541053 BB	20230103	US20220826922	20220527
US11541054 BB	20230103	US20220834268	20220607
US11696915 BB	20230711	US20210233506	20210418
US11918579 BB	20240305	US20210501130	20211014
US2021038600 AA	20210211	US20200983740	20200803
US2021038601 AA	20210211	US20200983894	20200803
US2021038683 AA	20210211	US20200983870	20200803
US2021236490 AA	20210805	US20210233506	20210418
US2021236491 AA	20210805	US20210233507	20210418
US2022023298 AA	20220127	US20210492946	20211004
US2022062283 AA	20220303	US20210501130	20211014
US2022288073 AA	20220915	US20220826922	20220527
US2022288090 AA	20220915	US20220632973	20200803
US2022296596 AA	20220922	US20220834268	20220607
US2024075034 AA	20240307	US20230494950	20231026
US2024197734 AA	20240620	US20240594494	20240304
VN85724 A	20220425	VN20220000452	20200803
WO21026084 A1	20210211	WO2020US44771	20200803

Priority Numbers: US20200100611P [20200323]; US20190883809P [20190807]; US20190895869P [20190904]; WO2020US44771 [20200803]; CL20220000067 [20220111]; EP20200760994 [20200803]; MX20210014220 [20211119]; RU20210134597 [20200803]; US20200983740 [20200803]; US20200983894 [20200803]; US20210233507 [20210418]; US20200983870 [20200803]; US20210492946 [20211004]; US20210501130 [20211014]; US20220826922 [20220527]; US20220834268 [20220607]; US20210233506 [20210418]; US20200632973 [20200803]; US20230494950 [20231026]; US20240594494 [20240304]

Probable Patent Assignee: ANEIRA PHARMA INC

Assignees: ANEIRA PHARMA INC; WURST JOHN EDWARD; ANEIRA PHRMA INC

Inventors: WURST JOHN EDWARD; JOHN EDWARD WURST

Agent(s): PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; GOWLING WLG CANADA LLP; JARRY IP JARRY IP SPA; HOFFMANN EITLE PATENT U RECHTSANWAELTE PARTMBB; HOFFMANN EITLE; SILVIA BERTRAN VALLS; CHINA PATENT AGENT HONG KONG LTD; REINHOLD COHN AND PARTNERS; KARLA LETICIA ISLAS ORTEGA; UGUR GUERSAD YALCINER; CONG TY CO PHAN TU VAN TRUNG THUC; TRUNG THUC JSC


Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; KH; MA; MD; TN; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

9. Family 57711523 (US2014330369 AA)

[View in PatBase](#)

Title
[EN] PROSTHETIC TISSUE VALVES AND METHODS FOR ANCHORING SAME TO CARDIOVASCULAR STRUCTURES

Abstract
[EN] A prosthetic atrioventricular tissue valve comprising a continuous tubular member formed from a first biocompatible material, the tubular member having proximal and distal ends, and at least one valve leaflet formed therein, the distal end of the tubular member including cardiovascular structure engagement means for connecting the tubular member to a cardiovascular structure, the cardiovascular structure engagement means comprising a plurality of elongated members that extend distally from the distal end of the tubular member.



International Class: A61F2/24; A61L27/36; A61F2/00; A61F2/02; A61L27/18; A61L27/54; A61L27/04; A61L27/38; A61L27/50; A61B17/04; A61K31/165; A61K31/4164; A61K31/43; A61K31/47; A61K31/505; A61K31/65; A61K31/702; A61K31/7028; A61K31/7048; A61K31/7056; A61K38/14; A61L27/58; A61K31/366; A61K31/40; A61K31/405; A61K31/436; A61K31/44; A61K31/57; A61K31/573; A61K38/13; A61L27/24; A61F2/95; A61L31/08; A61L31/14; A61L27/26; A61L27/06; A61L27/16; A61L27/22; A61L27/34; A61L27/40

Cooperative Patent Class: A61F2/2412; A61F2/2457; A61F2/2469; A61F2230/0067; A61F2220/0016; A61F2230/005; A61F2250/0067; A61K31/165; A61K31/4164; A61K31/43; A61K31/47; A61K31/505; A61K31/65; A61K31/702; A61K31/7028; A61K31/7048; A61K31/7056; A61K38/14; A61L2430/20; A61L27/18; A61L27/3633; A61L27/58; A61F2/2409; A61F2210/0004; A61F2210/0057; A61F2220/0075; A61F2230/0006; A61F2230/0023; A61F2230/0069; A61F2250/0036; A61F2/246; A61F2210/0014; A61L2300/104; A61L2300/404; A61L2300/406; A61L2300/41; A61L2300/414; A61L2300/416; A61L2300/42; A61L2300/606; A61L27/3604; A61L27/3629; A61L27/367; A61L27/3826; A61L27/3834; A61L27/3873; A61L27/50; A61F2/2418; A61F2/2445; A61F2/2475; A61F2/2415; A61F2250/0003; A61F2250/0039; A61L27/54; C08L75/04; A61L2300/64; A61L2400/16; A61L27/04; A61F2230/0013; A61L2300/252; A61F2/2454; C08L67/04; A61B17/04; A61B2017/0649; A61F2/2433; A61L27/3679; A61L27/3683; A61F2/2436; A61F2220/0008; A61F2230/0091; A61L27/3625; A61L27/507; A61K31/366; A61K31/40; A61K31/405; A61K31/436; A61K31/44; A61K31/57; A61K31/573; A61K38/13; A61L2300/204; A61L2300/216; A61L2300/434; A61L27/24; A61F2/9522; A61L2300/43; A61L2300/45; A61L27/16; A61L31/08; A61L31/14; A61L31/14; A61L2300/426; A61F2230/006; A61L2300/402; A61L2300/408; A61L27/3641; A61L27/042; A61L27/047; A61L27/06; A61L27/225; A61L27/227; A61L27/34; A61F2002/068; A61L2300/418; A61L27/40; A61L2300/222; A61L27/3637; A61L27/3687

US Class: 1/1; 623/2.13; 623/2.14; 623/2.17; D24/155

Locarno Class: 24/02

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA3010714 AA	20180705	CA20173010714	20170630
CA3010717 AA	20180705	CA20173010717	20170630
DE602014085212 D1	20221103	DE201460085212T	20140329
DE602017011297 D1	20200220	DE201760011297T	20170630
DE602017079395 D1	20240314	DE201760079395T	20170630
EP2991588 A1	20160309	EP20140791609	20140329
EP2991588 A4	20161026	EP20140791609	20140329
EP2991588 B1	20221012	EP20140791609	20140329
EP3380044 A1	20181003	EP20170828179	20170630
EP3380044 A4	20190731	EP20170828179	20170630
EP3380044 B1	20200129	EP20170828179	20170630
EP3380045 A1	20181003	EP20170828180	20170630
EP3380045 A4	20191030	EP20170828180	20170630
EP3380045 B1	20240221	EP20170828180	20170630
EP4176841 A1	20230510	EP20220200948	20140329
EP4294326 A1	20231227	EP20210926977	20210217
EP4294327 A1	20231227	EP20210926982	20210218
EP4294328 A1	20231227	EP20210926991	20210222
EP4335413 A2	20240313	EP20240153745	20170630
EP4335413 A3	20240515	EP20240153745	20170630
US10052409 BB	20180821	US20160206847	20160711

Patent Number	Publication Date	Application Number	Application Date
US10188509 BB	20190129	US20160206814	20160711
US10188510 BB	20190129	US20160206833	20160711
US10188513 BB	20190129	US20160206871	20160711
US10857263 BB	20201208	US20190238730	20190103
US10945838 BB	20210316	US20190553570	20190828
US10952843 BB	20210323	US20180129968	20180913
US10952845 BB	20210323	US20180193669	20181116
US11154395 BB	20211026	US20190553499	20190828
US11160903 BB	20211102	US20190440504	20190613
US11903833 BB	20240220	US20210177471	20210217
US11969339 BB	20240430	US20210177001	20210216
US12029645 BB	20240709	US20210234266	20210419
US12053372 BB	20240806	US20210177359	20210217
US2014330369 AA	20141106	US20140229854	20140329
US2016317292 AA	20161103	US20160206814	20160711
US2016317293 AA	20161103	US20160206833	20160711
US2016317294 AA	20161103	US20160206902	20160711
US2016317296 AA	20161103	US20160206847	20160711
US2016317300 AA	20161103	US20160206871	20160711
US2017156855 AA	20170608	US20150960354	20151205
US2018153686 AA	20180607	US20180877629	20180123
US2019008634 AA	20190110	US20180129968	20180913
US2019083257 AA	20190321	US20180193669	20181116
US2019134266 AA	20190509	US20190238730	20190103
US2019380831 AA	20191219	US20190553499	20190828
US2020022808 AA	20200123	US20190553570	20190828
US2020069840 AA	20200305	US20190440504	20190613
US2021161656 AA	20210603	US20210177001	20210216
US2021169643 AA	20210610	US20210177359	20210217
US2021169644 AA	20210610	US20210181161	20210222
US2021169647 AA	20210610	US20210178562	20210218
US2021177598 AA	20210617	US20210177471	20210217
US2021228358 AA	20210729	US20210231784	20210415
US2021236277 AA	20210805	US20210233890	20210419
US2021236278 AA	20210805	US20210234266	20210419
US2024180695 AA	20240606	US20230400252	20231229
US2024238082 AA	20240718	US20240623098	20240401
US2024252319 AA	20240801	US20240436364	20240208
US9308084 BB	20160412	US20140229854	20140329
US9907649 BB	20180306	US20150960354	20151205
USD790705 S1	20170627	US20160570671F	20160711
USD790706 S1	20170627	US20160570674F	20160711
WO14178971 A1	20141106	WO2014US32283	20140329
WO18013359 A1	20180118	WO2017US40216	20170630
WO18013361 A1	20180118	WO2017US40228	20170630
WO22177551 A1	20220825	WO2021US18296	20210217
WO22177552 A1	20220825	WO2021US18316	20210217
WO22177562 A1	20220825	WO2021US18506	20210218

Patent Number	Publication Date	Application Number	Application Date
WO22177576 A1	20220825	WO2021US18988	20210222

Priority Numbers: US20160206814 [20160711]; WO2017US40216 [20170630]; US20160206847 [20160711]; US20160206833 [20160711]; WO2017US40228 [20170630]; US20130819232P [20130503]; EP20140791609 [20140329]; WO2014US32283 [20140329]; EP20170828179 [20170630]; EP20170828180 [20170630]; WO2021US18296 [20210217]; US20210177359 [20210217]; WO2021US18506 [20210218]; US20210178562 [20210218]; WO2021US18988 [20210222]; US20210181161 [20210222]; US20140229854 [20140329]; US20150960354 [20151205]; US20160206871 [20160711]; US20180193669 [20181116]; US20190238730 [20190103]; US20180129968 [20180913]; US20190553570 [20190828]; US20190440504 [20190613]; US20190553499 [20190828]; US20210177471 [20210217]; US20210177001 [20210216]; US20210233890 [20210419]; US20210234266 [20210419]; US20160206902 [20160711]; US20180877629 [20180123]; US20210231784 [20210415]; US20230400252 [20231229]; US20240623098 [20240401]; US20240436364 [20240208]; US20160570671F [20160711]; US20160570674F [20160711]

Probable Patent Assignee: CORMATRIX CARDIOVASCULAR INC

Assignees: CORMATRIX CARDIOVASCULAR INC; MATHENY ROBERT G; CO MATRIX CARDIOVASCULAR INC; CORMATRIX CARDIOVASCULAR

Non Std Assignees: CORMATRIX CARDIOVASCULAR INC ROSWELL; MIDCAP FINANCIAL TRUST

Inventors: MATHENY ROBERT G; MATHENY ROBERT; VO MINH X; CHANG CARLOS C; NATARAJAN SELVAMUTHU K

Non Std Inventors: MATHENY ROBERT G NORCROSS

Agent(s): RIDOUT AND MAYBEE LLP; SMART AND BIGGAR LP; WITTHOFF JAEKEL STEINECKE PATENTANWAELTE PARTG MBB; CHARLTON PETER JOHN; ELKINGTON AND FIFE LLP; STEINECKE PETER; MUELLER FOTTNER STEINECKE; MORE SOLVEIG HELGA; FRANCIS LAW GROUP; FRANCIS LAW GROUP; THOMAS HORSTEMEYER LLP; THOMAS HORSTEMEYER LLP; FRANCIS RALPH C; FRANCIS LAW GROUP; GILES BRIAN; THOMAS HORSTEMEYER LLP; GILES BRIAN P ET AL; THOMAS HORSTEMEYER LLP; GILES BRIAN P; THOMAS HORSTEMEYER LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; KH; MA; MD; TN; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; DJ; JO; KW; WS

10. Family 74454236 (US2019151334 AA)


[View in PatBase](#)

Title

[EN] COMPOSITIONS AND METHODS OF USE FOR TREATING ABERRANT INFLAMMATION IN PERI-OCULAR SECRETORY GLANDS OR AT THE OCULAR SUFACE

Abstract

[EN] Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of a lipophilic compound and a pharmaceutically acceptable carrier adapted for pen-ocular transdermal delivery of the lipophilic compound to one or more periorbital glands and/or the ocular surface tissues of a subject. Further provided herein are methods of using such pharmaceutical compositions for providing relief of one or more signs or symptoms of an ocular disease, methods of using one or more Meibomian glands (and meibum therein) as a drug delivery system for a lipophilic compound (e.g., a steroid) to the ocular surface, and kits related thereto.



International Class: A61K47/06; A61K9/00; A61K31/196; A61K31/202; A61K31/232; A61K31/436; A61K31/454; A61K31/4725; A61K31/5575; A61K31/56; A61K31/568; A61K31/573; A61K31/7048; A61K31/7052; A61K9/06; A61K31/192; A61K31/496; A61K31/567; A61K31/58; A61K31/65; A61K31/7036; A61K38/13; A61K45/00; A61K47/04; A61K47/10; A61K47/12; A61K47/18; A61K47/30; A61K47/34; A61K9/08; A61K9/10; A61K9/107; A61K9/12; A61K9/70; A61P27/02; A61P27/04; A61P27/06; A61P27/12; A61P29/00; A61P31/04; A61P37/06; A61P43/00; A61K31/407; A61K47/24; A61P27/14; A61K31/569; A61K45/06; A61K47/02

Cooperative Patent Class: A61K2300/00; A61K31/196; A61K31/202; A61K31/232; A61K31/436; A61K31/454; A61K31/4725; A61K31/5575; A61K31/56; A61K31/568; A61K31/573; A61K31/7048; A61K31/7052; A61K45/06; A61K47/02; A61K47/06; A61K47/10; A61K47/12; A61K47/186; A61K47/34; A61K9/0014; A61K9/0048; A61K9/06; A61P27/02; A61P27/04

US Class: 1/1

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2018372185 AA	20200514	AU20180372185	20181121
AU2018372185 BB	20240516	AU20180372185	20181121
BR112020008046 A2	20201027	BR20201108046	20181121
CA3080166 AA	20200423	CA20183080166	20181121
CL2020001339 A1	20201023	CL20200001339	20200520
CN111372564 A	20200703	CN201880074872	20181121
EP3713544 A2	20200930	EP20180816410	20181121
HK40031764 A1	20210312	HK20206022176	20201216
ID2020PID03430 A	20201102	ID2020P0003937	20181121
IL274810 AA	20200730	IL20180274810	20181121
IN202017022751 A	20200828	IN202017022751	20200530
JP2021504451 T2	20210215	JP20200545082T	20181121
JP2024056898 A2	20240423	JP20240021166	20181121
JP7440419 B2	20240228	JP20200545082T	20181121
KR20200089703 A	20200727	KR20207017401	20181121
MA49912 A	20200624	MA20180049912	20181121
MX2020005155 A1	20200820	MX20200005155	20181121
MX2023014877 A1	20240429	MX20230014877	20200713
MX412867 B	20240508	MX20200005155	20181121
RU2020116802 A	20211122	RU20200116802	20181121
SG11202004307U A1	20200629	SG20201104307	20181121
TH2001002742 A	20240729	TH20201002742	20181121
US11759472 BB	20230919	US20180221135	20181214
US2019151334 AA	20190523	US20180221135	20181214
US2023372360 AA	20231123	US20230229105	20230801
WO19104207 A2	20190531	WO2018US62298	20181121
WO19104207 A3	20190704	WO2018US62298	20181121

Priority Numbers: US20170589493P [20171121]; WO2018US62298 [20181121]; JP20200545082T [20181121]; JP20200545082 [20181121]; JP20240021166 [20240215]; US20180221135 [20181214]; US20230229105 [20230801]

Probable Patent Assignee: CS PHARMACEUTICALS LTD

Assignees: AXEROVISION INC; CS PHARMACEUTICALS LTD

Non Std Assignees: BOSWORTH CHARLES F; KRAUSS ACHIM H; 5857 OWENS AVE SUITE 300

Inventors: KRAUSS ACHIM H; BOSWORTH CHARLES F; CHARLES F BOSWORTH; ACHIM HANS PETER KRAUSS

Non Std Inventors: C; A; ACHIM H KRAUSS

Agent(s): PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; ESTUDIO CLARKE MODET U0026 CO CHILE SPA; CABINET LAURENT AND CHARRAS; SHANGHAI INTELLECTUAL PROPERTY OFFICE; MAROLITA SETIATI; WOLFF BREGMAN AND GOLLER; ENRIQUE ALBERTO DIAZ MUCHARRAZ; JUAN CARLOS SUAREZ RAMIREZ; MORRISON AND FOERSTER LLP; MORRISON AND FOERSTER LLP; SCHMIDT JEFFREY W ET AL; MORRISON AND FOERSTER LLP


Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

11. Family 78074147 (US2020121724 AA)

[View in PatBase](#)

Title
[EN] COMPOSITIONS AND METHODS FOR GLAUCOMA

Abstract
[EN] This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.



International Class: A61B3/16; A61K9/00; A61K9/127; A61P27/02; C07D213/20; A61P27/06; G01N33/48; A61K31/4425; A61K31/7036; A61K31/727; A61K38/12; B01L3/00; G01F1/00; G01N33/68; A61K38/00; A61K9/08; A61K31/7056; A61K47/69; C12Q1/02; C12Q1/6895; A61F9/007; A61K38/20; A61K47/54; C12N9/02; A61K35/30; A61K45/00; A61K31/7042; A61K31/7048; A61K47/04; A61K47/12; A61K47/24; A61K47/26; A61K47/32; A61K47/36; A61K47/38; A61K47/40; A61K9/10; C12N5/079; A61K31/407; A61K31/436; A61K31/7052

Cooperative Patent Class: A61K35/30; A61K38/00; A61K9/0019; A61K9/0048; A61K9/08; A61K9/1271; B01L2300/0816; B01L2400/086; B01L3/502746; C12N2509/00; C12N2521/00; C12N2525/00; C12N2527/00; C12N5/0621; G01N2800/168; G01N33/6893; A61K31/407; A61K31/436; A61K31/4425; A61K31/7036; A61K31/7048; A61K31/7052; A61K31/727; A61K38/12; A61K47/02; A61K9/0051; A61P27/06

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2019343188 AA	20210520	AU20190343188	20190921
AU2020348176 AA	20220421	AU20200348176	20200325
CA3113528 AA	20210318	CA20193113528	20190921
CA3151625 AA	20220317	CA20203151625	20200325
CN113164043 A	20210723	CN201980076660	20190921
CN114929340 A	20220819	CN202080080832	20200325
EP3852608 A1	20210728	EP20190862254	20190921
EP3852608 A4	20220928	EP20190862254	20190921
EP4031244 A1	20220727	EP20200864492	20200325
EP4031244 A4	20231018	EP20200864492	20200325
IN202117018110 A	20220429	IN202117018110	20210419
IN202217022386 A	20221014	IN202217022386	20220414
JP2022501438 T2	20220106	JP20210540372T	20190921
JP2022551404 T2	20221209	JP20220517878T	20200325
JP7520851 B2	20240723	JP20210540372T	20190921
US11752175 BB	20230912	US20190578320	20190921
US2020121724 AA	20200423	US20190578320	20190921
US2022211800 AA	20220707	US20220696625	20220316
US2024000849 AA	20240104	US20230220683	20230711
WO20061550 A1	20200326	WO2019US52310	20190921
WO21055013 A1	20210325	WO2020US24592	20200325

Priority Numbers: US20180734699P [20180921]; WO2019US52310 [20190921]; US20190578320 [20190921]; WO2020US24592 [20200325]; US20220696625 [20220316]; US20230220683 [20230711]

Probable Patent Assignee: AUFBAU MEDICAL INNOVATIONS LTD

Assignees: PENA JOHN T G; CORNELL UNIV; AUFBAU MEDICAL INNOVATIONS LTD; UNIV CORNELL; PENA JOHN; OFBER MEDICAL INNOVATION CO LTD

Non Std Assignees: MITCHELL JAMES MURRAY; REMMEL HARMON LAWRENCE; MORGAN MELISSA A; OFBER MEDICAL INNOVATION CO; JOHN T G PENA

Inventors: MITCHELL JAMES MURRAY; PENA JOHN T G; REMMEL HARMON LAWRENCE; MORGAN MELISSA A; PENA JOHN; MITCHELL JAMES MICHAEL; REMMEL HENDRIK LOUIS; M A MORGAN

Non Std Inventors: MAMORGAN

Agent(s): FB RICE PTY LTD; CPST INTELLECTUAL PROPERTY INC; J A KEMP LLP; ECKMAN RICHARD R; FISHERBROYLES LLP; FISHERBROYLES LLP; GONSALVES ANDREW K


Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; WS

12. Family 93009544 (US2024130997 AA)

[View in PatBase](#)

Title
[EN] COMPOSITIONS FOR OPHTHALMIC CARE

Abstract
[EN] A controlled release pharmaceutical composition for eye injection for ophthalmic care. The composition comprises at least one active pharmaceutical ingredient and at least one biocompatible polymer and at least one biocompatible solvent. The composition, which is capable of forming an in-situ implant composition, comprises an injectable solution, suspension, emulsion or dispersion. The formulation can be injected through a needle that is suitable in size for an eye injection. The present compositions can be used for treatment of ophthalmic conditions, including glaucoma, dry and wet age-related macular degeneration, diabetic retinopathy, dry eye syndrome, and uveitis.



International Class: A61K9/00; A61K47/14; A61K47/34; A61P27/02; A61P27/06; A61F9/00; A61M5/24; A61P27/14; A61K31/235; A61K31/4045; A61K31/4412; A61K31/573

Cooperative Patent Class: A61F9/00; A61K31/235; A61K31/4045; A61K31/4412; A61K31/573; A61K47/14; A61K47/34; A61K9/0048; A61K9/0051; A61M5/24; A61P27/02; A61P27/06; A61P27/14

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN116963718 A	20231027	CN202280015489	20220221
EP4294366 A1	20231227	EP20220707476	20220221
FI20215186 A	20220820	FI20210005186	20210219
HK40095498 A1	20240202	HK20236082875	20231120
US2024130997 AA	20240425	US20230278017	20220221
US2024226053 A9	20240711	US20230278017	20220221
WO22175601 A1	20220825	WO2022FI50112	20220221

Priority Numbers: FI20210005186 [20210219]; WO2022FI50112 [20220221]

Probable Patent Assignee: REBIO TECH OY

Assignees: REBIO TECH AB; REBIO TECH OY

Non Std Assignees: REBIO TECHNOLOGIES AB; REBIO TECHNOLOGIES OY; RAISIONKAARI 55

Inventors: JUKARAINEN HARRI; TUOMINEN JUKKA; GLEN JONATHAN; WATSON ROBERT

Agent(s): LAINE IP OY; BARRON AND YOUNG INTELLECTUAL PROPERTY LTD

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JM; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

13. Family 72371940 (US2018353504 AA)

[View in PatBase](#)

Title
[EN] LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF

Abstract
[EN] The present invention is directed to compositions containing low-dose brimonidine and either a second glaucoma drug, an anti-histamine or non-steroidal anti-inflammatory drug. The present invention is further directed to methods of treating glaucoma or allergies or reducing inflammation by administering compositions of the present invention.


International Class: A61K31/498; A61K47/02; A61K9/08; A61K31/382; A61K31/407; A61K31/4535; A61K31/5575; A61K45/06; A61K47/12; A61K47/26; A61K47/38; A61P27/02; A61P27/06; A61P37/08; A61K31/5355; A61K9/00; A61K31/4402; A61K31/5377; A61K45/00; A61K47/04; A61P27/14; A61P29/00; A61P43/00; A61K31/4355; A61P37/04; A61K47/18; A61K31/472; A61K31/517; A61K31/395

Cooperative Patent Class: A61K2300/00; A61K31/382; A61K31/407; A61K31/4535; A61K31/498; A61K31/5355; A61K31/5377; A61K31/5575; A61K45/06; A61K47/02; A61K47/12; A61K47/26; A61K47/38; A61K9/0048; A61K9/08; A61P27/02; A61P27/06; A61P27/14; A61P37/08; A61K31/4355; A61K47/06; A61P37/04; A61K47/183; A61K31/472; A61K31/517

US Class: 1/1; 514/236.2

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2018279074 AA	20200116	AU20180279074	20180607
AU2018279074 BB	20231214	AU20180279074	20180607
AU2023282222 AA	20240104	AU20230282222	20231213
BR112019025987 A2	20200630	BR20191125987	20180607
BR122022026129 A0	20230214	BR20221226129	20180607
CA3066398 AA	20191205	CA20183066398	20180607
CL2019003572 A1	20200424	CL20190003572	20191206
CL2022002564 A1	20230526	CL20220002564	20220921
CL2022002566 A1	20230526	CL20220002566	20220921
CN110996954 A	20200410	CN201880052027	20180607
CN117122600 A	20231128	CN202311102693	20180607
EP3634415 A1	20200415	EP20180813969	20180607
EP3634415 A4	20210317	EP20180813969	20180607
HK40020724 A1	20201023	HK20206010793	20200708
ID2020PID02219 A	20200909	ID2020P0000148	20180607
IN202037000068 A	20200313	IN202037000068	20200101
IN401861 B	20220729	IN202037000068	20200101
JP2020523312 T2	20200806	JP20190567535T	20180607
JP2023055823 A2	20230418	JP20230012550	20180607
KR20200018580 A	20200219	KR20207000500	20180607
KR20240090655 A	20240621	KR20247016783	20180607
MX2019014748 A1	20200803	MX20190014748	20180607
MX2022008478 A1	20220802	MX20220008478	20191206
MX2022008479 A1	20220802	MX20220008479	20191206
MX400722 B	20230309	MX20190014748	20180607
RU2019144001 A	20210709	RU20190144001	20180607
RU2019144001 A3	20220305	RU20190144001	20180607
RU2801221 C2	20230803	RU20190144001	20180607
SG10202401329W A1	20240628	SG20241001329	20180607
SG11201911750R A1	20200130	SG20191111750	20180607
US2018353504 AA	20181213	US20180002106	20180607



Patent Number	Publication Date	Application Number	Application Date
US2019374537 AA	20191212	US20190257710	20190125
US2020108064 AA	20200409	US20190701803	20191203
US2020197398 AA	20200625	US20200810095	20200305
US2021369706 AA	20211202	US20210405773	20210818
US2022233524 AA	20220728	US20220699405	20220321
VN70652 A	20200625	VN20200000155	20180607
WO18226942 A1	20181213	WO2018US36440	20180607
WO19236148 A1	20191212	WO2019US15141	20190125

Priority Numbers: US20170516931P [20170608]; US20180621082P [20180124]; WO2018US36440 [20180607]; AU20230282222 [20231213]; AU20180279074 [20180607]; BR20191125987 [20180607]; CN201880052027 [20180607]; JP20190567535T [20180607]; JP20230012550 [20230131]; JP20190567535 [20180607]; KR20207000500 [20180607]; MX20190014748 [20191206]; RU20190144001 [20180607]; US20180002106 [20180607]; US20190257710 [20190125]; US20190701803 [20191203]; US20200810095 [20200305]; US20210405773 [20210818]; US20220699405 [20220321]

Probable Patent Assignee: EYE THERAPIES LLC

Assignees: EYE THERAPIES LLC; EYE THERAPEUTICS LLC

Non Std Assignees: HORN GERALD; 29633 CAMINO DE ESTRELLA 2ND FLOOR

Inventors: HORN GERALD; GERALD HORN

Non Std Inventors: KHORN DZHERALD

Agent(s): SPRUSON AND FERGUSON; DI BLASI PARENTE AND ADVOGADOS ASSOCIADOS; PERLEY ROBERTSON HILL AND MCDUGALL LLP; MARINO PORZIO; ELKINGTON AND FIFE LLP; MAROLITA SETIATI; HECTOR ELIAS CHAGOYA CORTES; VICENTE OCTAVIO ESPEJO HINOJOSA; JUAN CARLOS AMARO ALVARADO; ARS PATENT; SPRUSON AND FERGUSON ASIA PTE LTD; CONG TY TNHH TAM NHIN VA LIEN DANH; VISION AND ASSOCIATES CO LTD; RAINCROW JEREMY D ET AL; RAINCROWN JEREMY D ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

14. Family 63122011 (US2018015166 AA)

[View in PatBase](#)

Title
[EN] POLYAPHRONS AND PALPEBRAL ADMINISTRATION THEREOF

Abstract
[EN] Disclosed is a composition for use for topical administration onto the upper and/or lower eyelid of a subject. The composition includes a polyaphron, and the polyaphron includes: at least one hydrophilic phase; at least one hydrophobic phase; and at least one surfactant selected from ionic surfactants and/or non-ionic surfactants.

International Class: A61K9/00; A61K9/107; A61P27/00; A61K45/00; A61K47/14; A61K9/06; A61P27/02; A61K; A61P; A61K31/335; A61K31/382; A61K31/436; A61K31/5377; A61K31/55; A61K31/5575; A61K31/573; A61K31/7048; A61K31/7052; A61K38/13; A61K47/06; A61K47/10; A61K47/22; A61K47/26; A61K47/34; A61K47/44; A61K9/10; A61K9/14; A61K9/70; A61P37/08; A61K9/08; A61K45/06; A61K9/12

Cooperative Patent Class: A61K31/335; A61K31/55; A61K31/573; A61K31/7048; A61K38/13; A61K45/00; A61K45/06; A61K47/10; A61K47/14; A61K47/26; A61K47/34; A61K9/00; A61K9/0014; A61K9/0048; A61K9/06; A61K9/107; A61K9/1075; A61P27/00; A61P27/02; A61P37/08


US Class: 1/1; 424/489

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2975535 AA	20170801	CA20162975535	20160202
CA2975535 C	20240528	CA20162975535	20160202
CN107205929 A	20170926	CN201680008192	20160202
CN107205929 B	20220624	CN201680008192	20160202
CN115192517 A	20221018	CN202210879763	20160202
EP3253365 A1	20171213	EP20160702437	20160202
HK1242197 A1	20180622	HK20180101652	20180201
HK1242197 B	20221125	HK20180101652	20180201
HK1244431 A1	20180810	HK20180103838	20180320
JP2018503670 T2	20180208	JP20170540581T	20160202
JP2021001217 A2	20210107	JP20200161133	20160202
JP2022163213 A2	20221025	JP20220130351	20160202
JP2024071469 A2	20240524	JP20240045018	20160202
JP6839653 B2	20210310	JP20170540581T	20160202
JP7460707 B2	20240402	JP20220130351	20160202
KR102638112 B1	20240220	KR20177023578	20160202
KR20170129112 A	20171124	KR20177023578	20160202
KR20240023714 A	20240222	KR20247005121	20160202
RU2017127485 A	20190304	RU20170127485	20160202
RU2017127485 A3	20190904	RU20170127485	20160202
RU2758335 C2	20211028	RU20170127485	20160202
TW201636006 A	20161016	TW20160103254	20160202
TWI756168 B	20220301	TW20160103254	20160202
US2018015166 AA	20180118	US20160547909	20160202
WO16124601 A1	20160811	WO2016EP52188	20160202

Priority Numbers: US20150110740P [20150202]; WO2016EP52188 [20160202]; CN201680008192 [20160202]; JP20170540581T [20160202]; JP20200161133 [20200925]; JP20200161133 [20160202]; JP20220130351 [20220818]; JP20220130351 [20160202]; JP20240045018 [20240321]; KR20177023578 [20160202]; RU20170127485 [20160202]; US20160547909 [20160202]

Probable Patent Assignee: SANTEN PHARMACEUTICAL CO LTD



Assignees: SANTEN PHARMACEUTICAL CO LTD; SANTEN SAS; SANTEN PHARMA CO LTD; SANTEN AG; SANTEN PHARMACEUT CO LTD

Non Std Assignees: SCHMITT MATHIEU; BOUTTAZ ADELINE; KIDO KAZUTAKA; INAGAKI KOJI; SANTEN PHARMACEUTICAL CO; 9 19 SHIMOSHINJO 3 CHOME; 1 RUE PIERRE FONTAINE; SANTEN FARMASYUTIKAL KO LTD

Inventors: INAGAKI KOJI; BOUTTAZ ADELINE; SCHMITT MATHIEU; KIDO KAZUTAKA; SCHMIDT MATTHEW; BOUTAZ EDLINE; MATHIEU SCHMITT; ADELINE BOUTTAZ

Non Std Inventors: SHMIT METYU; INAGAKI KODZI; BUTTAS ADELIN

Agent(s): BORDEN LADNER GERVAIS LLP; ICOSA; SPRUSON AND FERGUSON HONG KONG LTD; BALANDINA LA


Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

15. Family 50499191 (US2012062840 AA)

[View in PatBase](#)

Title
[EN] METHOD AND SYSTEM FOR PERFORMING REMOTE TREATMENT AND MONITORING

Abstract
[EN] The disclosure relates to medical databases, remote monitoring, diagnosis and treatment systems and methods. In one particular embodiment, a system for remote monitoring, diagnosis, or treatment of eye conditions, disorders and diseases is provided. This method generally includes administering a stream of droplets to the eye of a subject from an ejector device, and storing data related to the administration in a memory of the ejector device. The data may then be monitored and analyzed.



FDA Data

Application Number	Active Ingredient	Proprietary Name	Applicant	Date Of Approval
215352	PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE	MYDCOMBI	EYENOVIA	20230505

International Class: A61F9/00; G16H20/10; G16H20/13; G16H40/67; G16H30/20; G16H40/63; A61K31/505; A61K31/717; A61K39/395; A61K47/06; A61K9/08; A61K9/113; A61P27/02; A61P27/06; A61F; A61K9/51; A61K31/05; A61K31/137; A61K31/192; A61K31/335; A61K31/4164; A61K31/4174; A61K31/4402; A61K31/4436; A61K31/4535; A61K31/4709; A61K31/496; A61K31/5383; A61K31/5575; A61K31/573; A61K47/10; A61K47/34; A61K47/44; A61K9/107; A61P31/04; A61F9/007; A61K31/047; A61K31/4409; A61K31/498; A61K31/542; A61K31/569; A61K31/7036; A61K31/7052; A61K33/30; A61K38/00; A61M11/00; A61J1/05; A61M35/00; A61M31/00; A61K9/00; A61K8/06; G16H10/60; G16H15/00; A61B5/00; A61M15/00; A61M15/02; G06F19/00; A61B5/11; A61M11/04; B05B17/00; B05B17/06; G16H20/17; A61B3/113; A61B3/117; A61B3/14; G16Z99/00; A61B3/10; A61K31/196; A61K31/245; A61K31/4545; A61K31/5377; A61K38/02; A61K38/13; A61K38/18; A61K38/43; A61K31/165; A61K31/216; A61K31/382; A61K31/55; A61K31/56; A61K31/695; A61F7/00

Cooperative Patent Class: A61F9/00; A61F9/0008; A61K2300/00; A61K39/395; A61K8/06; A61K9/0048; A61K9/08; A61M11/00; A61M2210/0612; A61P27/02; A61P27/06; A61P31/04; G16H10/60; G16H15/00; G16H20/10; G16H30/20; G16H40/63; G16H40/67; A61B5/0059; A61B5/4839; A61M15/008; A61M15/0083; A61M15/025; B05B17/0646; B05B17/0676; G16H20/13; A61B3/113; A61B3/117; A61B3/14; A61F9/0017; A61F9/0026; A61B5/0079; A61B5/1103; A61M11/005; A61M11/042; A61M2205/0205; A61M2205/0238; A61M2205/3306; A61M2205/3368; A61M2205/3553; A61M2205/3584; A61M2205/3592; A61M2205/36; A61M2205/3673; A61M2205/50; A61M2205/581; A61M2205/582; A61M2205/583; A61M2205/587; A61M2205/8206; A61M2209/086; B05B17/0661; G16H20/17; G16Z99/00; A61M31/00; G06F19/3406; G06F19/3418; G06F19/3456; A61K31/047; A61K31/165; A61K31/196; A61K31/216; A61K31/245; A61K31/335; A61K31/382; A61K31/4164; A61K31/4402; A61K31/4409; A61K31/4535; A61K31/4545; A61K31/4709; A61K31/496; A61K31/498; A61K31/5377; A61K31/5383; A61K31/542; A61K31/55; A61K31/56; A61K31/695; A61K31/7036; A61K31/7052; A61K31/717; A61K33/30; A61K38/13; G06F19/321

US Class: 1/1; 351/205; 351/205S; 351/206; 351/206P; 351/210; 351/246; 351/246S; 424/133.1; 424/133.100S; 424/400; 424/400P; 424/641; 424/94.1; 424/94.100S; 514/179; 514/180; 514/180S; 514/20.5; 514/20.8; 514/20.800S; 514/217.07; 514/226.5; 514/226.500S; 514/230.2; 514/236.2; 514/236.200S; 514/249; 514/253.08; 514/253.080S; 514/29; 514/300; 514/300S; 514/318; 514/318S; 514/324; 514/324S; 514/357; 514/357S; 514/401; 514/401S; 514/41; 514/432; 514/450; 514/530; 514/535; 514/535S; 514/567; 514/567S; 514/57; 514/57S; 514/619; 514/622; 514/63; 514/738; 514/8.1; 514/8.100S; 600/476; 604/290; 604/290S; 604/294; 604/295; 604/296; 604/298; 604/298P; 604/521

Family Information

Patent Number	Publication Date	Application Number	Application Date	
AU2011278924 AA	20130221	AU20110278924	20110715	
AU2011278924 BB	20150618	AU20110278924	20110715	
AU2011278934 AA	20130221	AU20110278934	20110715	
AU2011278934 BB	20150226	AU20110278934	20110715	
BR112013001030 A2	20160524	BR20131101030	20110715	
BR112013001030 B1	20200908	BR20131101030	20110715	
BR112013001030 B8	20210511	BR20131101030	20110715	
BR112013001045 A2	20190924	BR20131101045	20110715	
CA2805425 AA	20130114	CA20112805425	20110715	

Patent Number	Publication Date	Application Number	Application Date	
CA2805425 C	20190723	CA20112805425	20110715	
CA2805426 AA	20130114	CA20112805426	20110715	
CA2805426 C	20200324	CA20112805426	20110715	
CA2805635 AA	20130115	CA20112805635	20110715	
CL2013000152 A1	20130719	CL20130000152	20130115	
CL2013000153 A1	20130712	CL20130000153	20130115	
CL53243 B	20161025	CL20130000152	20130115	
CN103118642 A	20130522	CN201180040449	20110715	
CN103118642 B	20150909	CN201180040449	20110715	
CN103118643 A	20130522	CN201180040911	20110715	
CN103118643 B	20150610	CN201180040911	20110715	
CN103124541 A	20130529	CN201180040625	20110715	
CN103124541 B	20150930	CN201180040625	20110715	
DE602011065678 D1	20200409	DE201160065678T	20110715	
DE602011069007 D1	20201112	DE201160069007T	20110715	
EA201390120 A2	20130530	EA20130090120	20110715	
EA201390120 A3	20130930	EA20130090120	20110715	
EA201390121 A1	20130628	EA20130090121	20110715	
EA201390121 A8	20140228	EA20130090121	20110715	
EA201390122 A1	20140530	EA20130090122	20110715	
EP2485691 A1	20120815	EP20110738112	20110715	
EP2485691 B1	20200318	EP20110738112	20110715	
EP2593055 A1	20130522	EP20110738113	20110715	
EP2593056 A1	20130522	EP20110738114	20110715	
EP2593056 B1	20201021	EP20110738114	20110715	
ES2787254 T3	20201015	ES20110738112T	20110715	
ES2835886 T3	20210623	ES20110738114T	20110715	
HK1185253 A1	20140214	HK20130112866	20131118	
HK1185254 A1	20140214	HK20130112867	20131118	
HK1185254 B	20210312	HK20130112867	20131118	
HK1185784 A1	20140228	HK20130112906	20131119	
HK1185784 B	20171229	HK20130112906	20131119	
IL224211 A0	20130324	IL20110224211	20110715	
IL224211 A1	20180228	IL20110224211	20110715	
IL224248 A0	20130324	IL20110224248	20110715	
IL224248 A1	20180920	IL20110224248	20110715	
IN00154MN2013 A	20140725	IN2013MN00154	20130118	
IN00199MN2013 A	20140725	IN2013MN00199	20130125	
IN00203MN2013 A	20140725	IN2013MN00203	20130126	
IN367468 B	20210528	IN2013MN00154	20130118	
JP2013531044 T2	20130801	JP20130519863T	20110715	
JP2013531548 T2	20130808	JP20130519867T	20110715	
JP2013535250 T2	20130912	JP20130519869T	20110715	
JP2015120035 A2	20150702	JP20150048244	20150311	
JP2016154868 A2	20160901	JP20160060347	20160324	
JP2017213381 A2	20171207	JP20170137164	20170713	
JP2018153667 A2	20181004	JP20180094624	20180516	
JP5964826 B2	20160803	JP20130519869T	20110715	

Patent Number	Publication Date	Application Number	Application Date	
JP6039719 B2	20161207	JP20150048244	20150311	
JP6408504 B2	20181017	JP20160060347	20160324	
KR101545413 B1	20150818	KR20137003811	20110715	
KR20130051476 A	20130520	KR20137003800	20110715	
KR20130054352 A	20130524	KR20137003811	20110715	
KR20150031340 A	20150323	KR20157004382	20110715	
KR20170129298 A	20171124	KR20177033258	20110715	
MX2013000604 A1	20130705	MX20130000604	20110715	
MX2013000605 A1	20130628	MX20130000605	20110715	
MX339173 B	20160512	MX20130000605	20110715	
TH127319 A	20130920	TH20131000249	20110715	
TH129942 A	20131128	TH20131000248	20110715	
TH69506 B	20190426	TH20131000249	20110715	
US10073949 BB	20180911	US20170459529	20170315	
US10154923 BB	20181218	US20140200268	20140307	
US10839960 BB	20201117	US20180113231	20180827	
US11011270 BB	20210518	US20180107716	20180821	
US11398306 BB	20220726	US20200091607	20201106	
US11839487 BB	20231212	US20220849425	20220624	
US2012062840 AA	20120315	US20110184468	20110715	
US2012070467 AA	20120322	US20110184446	20110715	
US2012143152 AA	20120607	US20110184484	20110715	
US2014187969 AA	20140703	US20140200268	20140307	
US2014249491 AA	20140904	US20140275187	20140512	
US2015328151 AA	20151119	US20150793895	20150708	
US2017151088 AA	20170601	US20160370196	20161206	
US2017344714 AA	20171130	US20170459529	20170315	
US2019053945 AA	20190221	US20180107716	20180821	
US2019074086 AA	20190307	US20180113231	20180827	
US2021295989 AA	20210923	US20200091607	20201106	
US2021398651 AA	20211223	US20210239832	20210426	
US2021407663 AA	20211230	US20210319401	20210513	
US2022395221 AA	20221215	US20220849425	20220624	
US2024164708 AA	20240523	US20230524346	20231130	
US8684980 BB	20140401	US20110184484	20110715	
US8733935 BB	20140527	US20110184468	20110715	
US9087145 BB	20150721	US20110184446	20110715	
VN10025465 B	20200925	VN20130000461	20110715	
WO12009696 A2	20120119	WO2011US44278	20110715	
WO12009702 A1	20120119	WO2011US44286	20110715	
WO12009706 A1	20120119	WO2011US44291	20110715	
ZA201301154 A	20140430	ZA20130001154	20110715	
ZA201301155 A	20140430	ZA20130001155	20110715	

Priority Numbers: US20100400864P [20100715]; US20100401848P [20100820]; US20100401849P [20100820]; US20100401918P [20100820]; US20100401850P [20100820]; US20100401920P [20100820]; US20110516496P [20110404]; US20110516462P [20110404]; US20110463280P [20110215]; US20110462576P [20110204]; US20110516495P [20110404]; US20110516694P [20110406]; US20110462791P [20110205]; WO2011US44278 [20110715]; WO2011US44291 [20110715]; US20110462791P [20110204]; US20110462761P [20110205]; WO2011US44286 [20110715]; US20100404864P [20100715]; US20110184468 [20110715]; EP20110738112 [20110715]; EP20110738114 [20110715]; US20100401864P [20100820]; JP20130519863 [20110715]; JP20150048244 [20150311]; JP20130519863T [20110715]; JP20130519869T [20110715];

JP20160060347 [20160324]; US20110184446 [20110715]; JP20130519867T [20110715]; JP20170137164 [20170713]; JP20160060347 [20110715]; JP20180094624 [20180516]; US20170459529 [20170315]; US20150793895 [20150708]; US20110184484 [20110715]; US20140200268 [20140307]; US20180113231 [20180827]; US20180107716 [20180821]; US20200091607 [20201106]; US20220849425 [20220624]; US20140275187 [20140512]; US20160370196 [20161206]; US20210239832 [20210426]; US20210319401 [20210513]; US20230524346 [20231130]

Probable Patent Assignee: EYENOVIA INC

Assignees: CORINTHIAN OPHTHALMIC INC; EYENOVIA INC; PACKER MARK N; IANCHULEV TSONTCHO; MUMPER RUSSELL JOHN; BALLOU BERNARD L JR; INACHULEV TSONTCHO; PACKER MARK; FAULKS NATHAN R; CLEMENTS J SID; JOHNSON BRADLEY G; HUNTER CHARLES ERIC; ELLIOTT TROY; VOLLRATH JURGEN KLAUS; RUSSELL PHILLIP E; LEATH JAMES THORNHILL; TEW ARTHUR H; FIERSON WALTER M; HEBRANK JOHN H; LINDNER THOMAS J; BROWN JOSHUA RICHARD; SPARKS KELLY L; SPARKS KELLY C; CHARLES ERIC HUNTER; BERNARD L BALLUO JR; JURGEN KLAUS VOLLRATH; ARTHUR H TEW; JOSHUA RICHARD BROWN; JAMES THORNHILL LEATH; NATHAN R FAULKS; BRADLEY G JOHNSON; J SID CLEMENTS; PHILLIP E RUSSELL; JOHN H HEBRANK; TSONTCHO IANCHULEV; MARK N PACKER; TROY ELLIOTT; WALTER M FIERSON; THOMAS J LINDNER; BALLOU JR BERNARD L

Non Std Assignees: CORINTHIAN OPHTHALMIC INC8601 SIX FORKS RD.SUITE 400RALEIGHNC27615US; EYENOVIA INC400 - 2711 CENTERVILLE ROADWILMINGTONDE19808US; BALLUO BERNARD LJR; ELLIOT TROY; BALLOU BERNARD L; BERNARD L BALLOU JR; RUSSELL JOHN MUMPER; AVENUE CAPITAL MANAGEMENT II LP; ACADIA WOODS PARTNERS LLC; AMP FAMILY PARTNERSHIP III LP; ESHELMAN FRED N; MACK JOHN; MARIO 2002 GRANDCHILDREN S TRUST; MARK PACKER; MIDDLEMARCH LLC; PRINCETON OPHTHALMIC LLC; RK VENTURES GROUP II LLC; SAMBERG ARTHUR J; STERN THOMAS; WILLE AG; CLEMENTS J

Inventors: IANCHULEV TSONTCHO; BALLOU JR BERNARD L; PACKER MARK N; MUMPER RUSSELL JOHN; PACKER MARK; ELLIOTT TROY; FIERSON WALTER M; VOLLRATH JURGEN KLAUS; TEW ARTHUR H; LINDNER THOMAS J; HUNTER CHARLES ERIC; LEATH JAMES THORNHILL; HEBRANK JOHN H; JOHNSON BRADLEY G; CLEMENTS J SID; FAULKS NATHAN R; BROWN JOSHUA RICHARD; RUSSELL PHILLIP E; RUSSEL PHILLIP E; BALLOU BERNARD L JR; JOHN H HEBRANK; PHILLIP E RUSSEL; JURGEN KLAUS VOLLRATH; MARK N PACKER; CHARLES ERIC HUNTER; JOSHUA RICHARD BROWN; J SID CLEMENTS; TSONTCHO IANCHULEV; ARTHUR H TEW; BERNARD L BALLOU JR; BRADLEY G JOHNSON; WALTER M FIERSON; JAMES THORNHILL LEATH; THOMAS J LINDNER; NATHAN R FAULKS; TROY ELLIOTT; PHILLIP E RUSSELL; RUSSELL JOHN MUMPER; BALLOU BERNARD L; INACHULEV TSONTCHO; SPARKS KELLY L; SPARKS KELLY C; MUMPER RUSSEL JOHN; BALLOU BERNARD; MUMPER RUSSELL; HUNTER CHARLES; VOLLRATH JURGEN; TEW ARTHUR; BROWN JOSHUA; LEATH JAMES; FAULKS NATHAN; JOHNSON BRADLEY; CLEMENTS J; RUSSELL PHILLIP; HEBRANK JOHN; FIERSON WALTER; LINDNER THOMAS; MARK PACKER; BERNARD L BALLUO JR; RUSSEL JOHN MUMPER; KELLY C SPARKES; RUSSELL PHILIP E

Non Std Inventors: CHARLES ERICHUNTERREF RPI 2592 DE 08 09 2020 QUANTO AO INVENTOR; MUMPER RUSSELL JOHNUS; BALLOU BERNARD L JRUS; PACKER MARKUS; INACHULEV TSONTCHOUS; FIERSON WALTER MUS; JOHNSON BRADLEY GUS; TEW ARTHUR HUS; IANCHULEV TSONTCHOUS; RUSSELL PHILLIP EUS; FAULKS NATHAN RUS; BROWN JOSHUA RICHARDUS; CLEMENTS J SIDUS; HEBRANK JOHN HUS; LEATH JAMES THORNHILLUS; VOLLRATH JURGEN KLAUSUS; LINDNER THOMAS JUS; HUNTER CHARLES ERICUS; ELLIOTT TROYUS; SPARKS KELLY CUS; BALLOU BERNARD LJR; JR BERNARD L BALLOU; KELLY L SPARKS; BERNARD L JR BALLOU; BALLUO BERNARD LJR; ELLIOT TROY; HEBRANJ JOHN H; KELLY C SPARKS; BALLOU JR

Agent(s): DAVIES COLLISON CAVE; DAVIES COLLISON CAVE PTY LTD; SMART AND BIGGAR; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; ESTUDIO FEDERICO VILLASECA Y CIA; UEXKUELL AND STOLBERG PARTNERSCHAFT VON PATENT U RECHTSANWALTEN MBB; UEXKUELL AND STOLBERG; ISABEL CARVAJAL Y URQUIJO; ANGEL PONS ARINO; DEACONS; CLT PATENT AND TRADEMARK HK LTD; PROFESSIONAL PATENT SOLUTIONS; AOKI ATSUSHI; FUKUMOTO TSUMORU; ISHIDA TAKASHI; KOGA TETSUJI; SHIMADA TETSURO; FERNANDO ROSALES VAZQUEZ; POLSINELLI PC; POLSINELLI PC; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; CONG TY LUAT TNHH T AND G; TGVN; MARSH DAVID R ET AL; ARNOLD AND PORTER LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

16. Family 73648209 (US2020281854 AA)


[View in PatBase](#)

Title

[EN] BRANCHED PEPTIDES FOR ENZYMATIC ASSEMBLY AND MITOCHONDRIA DRUG DELIVERY

Abstract

[EN] The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.



International Class: A61K31/704; A61K47/42; A61K47/69; A61K9/107; A61P35/00; C07K7/06; A61P9/00; C07K19/00; C07K7/08; A61K47/48

Cooperative Patent Class: A61K31/704; A61K38/00; A61K45/06; A61K47/42; A61K47/6907; A61K9/107; A61K9/1075; A61P35/00; A61P9/00; C07K19/00; C07K2319/50; C07K2319/735; C07K5/0215; C07K5/0812; C07K5/1016; C07K7/06; C07K7/08; Y02A50/30

Family Information

Patent Number	Publication Date	Application Number	Application Date
US11191724 BB	20211207	US20200648295	20180918
US11834517 BB	20231205	US20210537418	20211129
US2020281854 AA	20200910	US20200648295	20180918
US2022112240 AA	20220414	US20210537418	20211129
US2024158441 AA	20240516	US20230498452	20231031
WO19055988 A1	20190321	WO2018US51521	20180918

Priority Numbers: US20170560094P [20170918]; WO2018US51521 [20180918]; US20180648295 [20180918]; US20210537418 [20211129]; US20200123230P [20201209]; US20200648295 [20200318]; US20230498452 [20231031]

Probable Patent Assignee: BRANDEIS UNIV

Assignees: UNIV BRANDEIS; BRANDEIS UNIV

Inventors: HE HONGJIAN; XU BING

Agent(s): TROUTMAN PEPPER HAMILTON SANDERS LLP ROCHESTER; TROUTMAN PEPPER HAMILTON SANDERS LLP ROCHESTER; MERKEL EDWIN V ET AL; LECLAIRRYAN PLLC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

17. Family 102554234 (IN202411026846 A)

[View in PatBase](#)

Title

[EN] HYDROGEL-BASED CONTACT LENS FOR OCULAR DRUG DELIVERY FOR SLOW, CONTROLLED RELEASE OF MEDICATIONS FOR EYE DISEASES

Abstract

[EN] A composition of Hydrogel-Based Contact Lens for Ocular Drug Delivery for Slow, Controlled release of medications for eye diseases comprises Hydrogel Matrix which is contact lens material is primarily composed of hydrophilic polymers, typically based on hydrogels; Drug: Various ophthalmic medications can be incorporated into the hydrogel matrix; and Stabilizers and Coating Agents. Additional components are included to enhance stability and biocompatibility.

International Class: A61F2/16; A61K47/34; A61K9/00; A61K9/70; A61L27/52; A61L27/54; A61P29/00; G02C7/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
IN202411026846 A	20240503	IN202411026846	20240331

Priority Numbers: IN202411026846 [20240331]

Probable Patent Assignee: GALGOTIAS UNIV

Non Std Assignees: GALGOTIAS UNIV

Non Std Inventors: DEEPIKA PALIWAL

18. Family 92792678 (US2024139166 AA)

[View in PatBase](#)

Title
[EN] OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA

Abstract
[EN] Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition comprises a low concentration of an ophthalmic agent for treatment of presbyopia. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water.

International Class: A61K31/4178; A61K31/439; A61K31/4409; A61K47/02; A61K47/18; A61K9/00; A61P27/00; A61P27/10; A61K45/06

Cooperative Patent Class: A61K31/4178; A61K31/439; A61K31/4409; A61K45/06; A61K9/0048; A61K9/08; A61P27/00; A61P27/10

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA3205883 AA	20230720	CA20223205883	20220203
EP4288049 A1	20231213	EP20220750380	20220203
TW202245759 A	20221201	TW20220104434	20220207
US2024139166 AA	20240502	US20230263952	20220203
WO22169959 A1	20220811	WO2022US15092	20220203

Priority Numbers: US20210145676P [20210204]; WO2022US15092 [20220203]; US20220263952 [20220203]

Probable Patent Assignee: SYDNEXIS INC


Assignees: SYDNEXIS INC

Non Std Assignees: OSTROW GREGORY I; WIDDER KENNETH J; BAKER DAVID S

Inventors: OSTROW GREGORY I; WIDDER KENNETH J; BAKER DAVID S

Agent(s): GOWLING WLG CANADA LLP; MEWBURN ELLIS LLP; ALVAREZ MALO CIARA

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



19. Family 90753927 (US2024000948 AA)

[View in PatBase](#)

Title

[EN] METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES

Abstract

[EN] Methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.

International Class: A61K31/573; A61K31/585; A61K31/6615; A61K31/7052; A61K9/00; A61K9/08; A61K9/127; A61P27/02; A61K38/13; A61K45/06; A61K31/192; A61K31/433; A61K31/444; A61K31/47; A61K31/517; A61K31/519; A61K31/706; A61K38/17; A61K45/00; A61K47/64; A61P27/04; A61P27/06; A61P29/00; C07D285/135; C07D471/04; C07K14/47; A61K47/54

Cooperative Patent Class: A61K2300/00; A61K31/573; A61K31/585; A61K31/7052; A61K38/13; A61K45/06; A61K47/544; A61K47/64; A61K9/0019; A61K9/0048; A61K9/0051; A61K9/08; A61K9/1271; A61K9/1275; A61P27/02; A61K31/6615

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2021354095 AA	20230608	AU20210354095	20211001
CA3197168 AA	20230328	CA20213197168	20211001
CN116322646 A	20230623	CN202180067629	20211001
EP4221686 A2	20230809	EP20210811456	20211001
HK40099552 A1	20240419	HK20246086070	20240129
IL301769 AA	20230501	IL20210301769	20211001
JP2023543498 T2	20231016	JP20230519881T	20211001
KR20230079132 A	20230605	KR20237014173	20211001
MX2023003877 A1	20230418	MX20230003877	20211001
US2024000948 AA	20240104	US20230247465	20211001
WO22069942 A2	20220407	WO2021IB00674	20211001
WO22069942 A3	20220707	WO2021IB00674	20211001

Priority Numbers: US20200086386P [20201001]; US20200092073P [20201015]; WO2021IB00674 [20211001]; US20210139015P [20210119]; US20210175337P [20210415]; US20210247465 [20211001]

Probable Patent Assignee: ABIONYX PHARMA SA

Assignees: ABIONYX PHARMA SA; ABIONIX PHARMACEUTICALS INC


Non Std Assignees: LALLEMAND FREDERIC; MARTINEZ JEROME; TUPIN CYRILLE

Inventors: MARTINEZ JEROME; TUPIN CYRILLE; LALLEMAND FREDERIC; TUPIN CLAIRE; J MARTINEZ; LALLEMAND FABRICE

Non Std Inventors: CYRILLE TUPIN; JEROME MARTINEZ; FREDERIC LALLEMAND

Agent(s): PHILLIPS ORMONDE FITZPATRICK; TORYS LLP; HOFFMANN EITLE; CHINA PATENT AGENT HONG KONG LTD; PEARL COHEN ZEDEK LATZER BARATZ; VICENTE OCTAVIO ESPEJO HINOJOSA; ICOSA

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



20. Family 77049244 (US2021228530 AA)



[View in PatBase](#)

Title

[EN] TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF

Abstract

[EN] The present invention pertains to a group of taxane-lipid-polysaccharide dual conjugates of the Formula I, a process for the preparation thereof, uses thereof, and pharmaceutical compositions comprising the same. The invention also relates to a series of intermediates for the preparation of taxane-lipid-polysaccharide dual conjugates, a process for their preparation, and their use as drug delivery vehicles.



International Class: A61K31/337; A61K31/715; A61K31/728; A61P35/00; C07D305/14; C07D405/12; C07D407/06; C07D493/00; C08B37/00; C08B37/08; C08B11/12; C08L1/28; C08L5/02; A61K31/07; A61K31/192; A61K31/282; A61K31/4745; A61K31/475; A61K31/506; A61K31/519; A61K31/7048; A61K38/13; A61K47/54; A61K47/61

Cooperative Patent Class: A61K31/07; A61K31/192; A61K31/282; A61K31/337; A61K31/4745; A61K31/475; A61K31/506; A61K31/519; A61K31/7048; A61K38/13; A61K47/543; A61K47/545; A61K47/61; A61P35/00; C07D305/14; C07D405/12; C07D487/04; C08B11/12; C08B11/15; C08B31/125; C08B37/00; C08B37/0021; C08B37/0072; C08L1/286; C08L5/02

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN112351976 A	20210209	CN201980041025	20190620
CN112351976 B	20240419	CN201980041025	20190620
EP3812376 A1	20210428	EP20190823597	20190620
EP3812376 A4	20220817	EP20190823597	20190620
US2021228530 AA	20210729	US20200054706	20190620
WO19242691 A1	20191226	WO2019CN092101	20190620

Priority Numbers: CN201810636499 [20180620]; WO2019CN092101 [20190620]

Probable Patent Assignee: SANTOLECAN PHARMACEUTICALS LLC

Assignees: SANTOLECAN PHARMACEUTICALS LLC; CHENG HAIJUN

Inventors: HU JINGHUA; LI XIAOHAI; SHI YIKANG; WANG SI; WANG HUI; ZHA ANG; CUI FENGYI; WANG ANNY; LI DAISY JIAQI; ZHANG TAINING; CHENG HAIJUN; LI DAISY J

Agent(s): BIANCHETTI BRACCO MINOJA SRL; ZHONGZI LAW OFFICE

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

21. Family 42999001 (US2009099626 AA)

[View in PatBase](#)

Title
[EN] LACRIMAL IMPLANT DETECTION

Abstract
[EN] This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.


International Class: A61F9/007; A61F2/02; A61F9/00; A61K9/00; A61M5/14; B23B5/16; B23K11/30; A61F2/14; A61L31/02; A61L31/14; A61L31/16; A61M31/00; G01N21/84; G01V3/08; G01V3/12; G01V8/12; A61L27/54; A61F; A61K; A61M; A61L; A61K31/5575; A61K47/34; A61P25/04; A61P27/02; A61P27/06; A61P29/00; A61P31/00; A61P31/04; A61P31/10; A61P37/08; A61P43/00; A61M37/00; A61B3/10; A61B5/06; A61K31/335; A61K31/728; A61K38/00; A61K45/00; A61K9/52; A61K31/5377; A61K31/573; A61K47/02; A61K47/30; A61K47/32; A61K47/38; A61K47/42; A61K9/06; A61L31/04; A61L31/06; A61K38/08; A61K38/12; A61K38/13; A61L31/12; A61K9/20; A61K9/22; A61K9/24; A61L27/00; A61M29/02; A61M29/00; A61B8/00; G06K19/07; A61B17/28; A61B17/50; A61K9/02; A61L27/52; A61B5/00; A61B8/08; G01R33/02; G01R33/07; A61N1/00; A61K9/14; A61P27/00; B23C3/12; B23C5/02; B28B11/12; A61M13/00; A61M5/00; A61F2/00; A61M35/00

Cooperative Patent Class: A61F2210/0061; A61F2220/0008; A61F2250/0067; A61F9/0017; A61F9/00772; Y10T407/19; Y10T409/304256; A61F2/02; A61F2230/0069; A61K31/5575; A61K47/34; A61K9/0051; A61K9/20; A61K9/2036; A61L2300/41; A61L2300/602; A61L2300/802; A61L27/54; A61M5/14; A61P25/04; A61P27/02; A61P27/06; A61P29/00; A61P31/00; A61P31/04; A61P31/10; A61P37/08; A61P43/00; Y02A50/30; A61B17/3468; A61B2090/036; A61B2562/08; A61B5/0031; A61B5/06; A61B5/411; A61B8/0833; A61F2250/0068; A61F2250/0096; A61L2300/404; A61L2300/43; A61L31/043; A61L31/044; A61L31/06; A61L31/145; A61L31/16; G01R33/0213; G01R33/072; B23B5/166; B23K11/3063; Y10T407/1952; Y10T407/1964

US Class: 1/1; 128/887; 264/157; 264/157P; 407/30; 407/30P; 409/140; 409/140S; 424/423; 424/423P; 424/427; 424/427P; 514/530; 600/431; 604/104; 604/171; 604/246; 604/294; 604/500; 604/500S; 604/514; 604/521; 604/59; 604/59S; 604/8; 604/891.1; 604/9; 604/93.01; 606/205; 606/205S; 606/206; 606/206P; 607/60; 607/60P; 623/11.11; 623/11.110S; 623/23.67

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2008296872 AA	20090312	AU20080296872	20080905
AU2008300013 AA	20090319	AU20080300013	20080905
AU2008300018 AA	20090319	AU20080300018	20080905
AU2008300022 AA	20090319	AU20080300022	20080905
BRPI0816735 A2	20170516	BR2008PI16735	20080906
BRPI0817074 A2	20150324	BR2008PI17074	20080905
BRPI0817075 A2	20160726	BR2008PI17075	20080905
BRPI0817082 A2	20150331	BR2008PI17082	20080905
BRPI0821193 A2	20150616	BR2008PI21193	20081210
BRPI0821193 B1	20200924	BR2008PI21193	20081210
CA2698508 AA	20100304	CA20082698508	20080905
CA2698508 C	20170606	CA20082698508	20080905
CA2698573 AA	20100304	CA20082698573	20080905
CA2698573 C	20171205	CA20082698573	20080905
CA2698574 AA	20090319	CA20082698574	20080905
CA2698580 AA	20100304	CA20082698580	20080905
CA2698580 C	20161011	CA20082698580	20080905
CN101861135 A	20101013	CN200880113681	20080905
CN101969897 A	20110209	CN200880113318	20080905
CN101984745 A	20110309	CN200880114948	20080905
CN101984745 B	20130814	CN200880114948	20080905
CN102112076 A	20110629	CN200880112670	20080905
CN102112076 B	20150422	CN200880112670	20080905



Patent Number	Publication Date	Application Number	Application Date
CN102670352 A	20120919	CN201210139720	20080905
CN103349799 A	20131016	CN201310300219	20080905
CN103349799 B	20160120	CN201310300219	20080905
CN104856782 A	20150826	CN201510224134	20080905
CN104856782 B	20170912	CN201510224134	20080905
DE502008006708 D1	20120510	DE200850006708T	20081210
DE602008035355 D1	20141224	DE200860035355T	20080905
DE602008036155 D1	20150219	DE200860036155T	20080905
DE602008037760 D1	20150528	DE200860037760T	20080905
DE602008060219 D1	20190613	DE200860060219T	20080905
DK2205191 T3	20141208	DK20080829084T	20080905
DK2207529 T3	20150309	DK20080830451T	20080905
DK2614844 T3	20150608	DK20120192860T	20080905
DK2865361 T3	20190708	DK20140192229T	20080905
EP2205191 A1	20100714	EP20080829084	20080905
EP2205191 B1	20141112	EP20080829084	20080905
EP2205192 A2	20100714	EP20080830516	20080905
EP2205193 A2	20100714	EP20080830574	20080905
EP2207529 A2	20100721	EP20080830451	20080905
EP2207529 B1	20141231	EP20080830451	20080905
EP2614844 A1	20130717	EP20120192860	20080905
EP2614844 B1	20150415	EP20120192860	20080905
EP2865361 A1	20150429	EP20140192229	20080905
EP2865361 B1	20190522	EP20140192229	20080905
EP3372205 A1	20180912	EP20180151269	20080905
ES2525125 T3	20141217	ES20080829084T	20080905
ES2533359 T3	20150409	ES20080830451T	20080905
ES2538838 T3	20150624	ES20120192860T	20080905
ES2732555 T3	20191125	ES20140192229T	20080905
HK1149471 A1	20111007	HK20110103743	20110413
HK1154196 A1	20120413	HK20110107975	20110802
HK1155104 A1	20120511	HK20110109558	20110909
HK1155104 B	20140417	HK20110109558	20110909
HK1156836 A1	20120622	HK20110111156	20111019
HK1156836 A3	20120622	HK20110111156	20111019
HK1156836 B	20160318	HK20110111156	20111019
HK1189521 A1	20140613	HK20140102722	20140318
HK1189521 B	20170331	HK20140102722	20140318
IL204244 A0	20101031	IL20080204244	20080905
IL204291 A0	20101031	IL20080204291	20080905
IL204304 A0	20101031	IL20080204304	20080905
IL204306 A0	20101031	IL20080204306	20080905
IL219952 A0	20120628	IL20080219952	20080905
IL253005 A0	20170831	IL20080253005	20080905
IL273683 AA	20200531	IL20080273683	20080905
IN01818DN2010 A	20100813	IN2010DN01818	20100316
IN02257DN2010 A	20111014	IN2010DN02257	20100331
IN02258DN2010 A	20111014	IN2010DN02258	20100331

Patent Number	Publication Date	Application Number	Application Date
IN02312DN2010 A	20100910	IN2010DN02312	20100405
IN331045 B	20200207	IN2010DN02258	20100331
JP2010537775 T2	20101209	JP20100524049T	20080905
JP2010537776 T2	20101209	JP20100524052T	20080905
JP2010537777 T2	20101209	JP20100524053T	20080905
JP2010538696 T2	20101216	JP20100524050T	20080905
JP2014113469 A2	20140626	JP20130230810	20131107
JP2014193367 A2	20141009	JP20140080703	20140410
JP2014236980 A2	20141218	JP20140111843	20140530
JP2016165503 A2	20160915	JP20160092471	20160502
JP2017029794 A2	20170209	JP20160204977	20161019
JP2017205545 A2	20171124	JP20170133916	20170707
JP2018140181 A2	20180913	JP20180056808	20180323
JP2020062381 A2	20200423	JP20190161681	20080905
JP5411140 B2	20140212	JP20100524053T	20080905
JP5524841 B2	20140618	JP20100524049T	20080905
JP5555162 B2	20140723	JP20100524050T	20080905
JP5880985 B2	20160309	JP20140080703	20140410
JP5933630 B2	20160615	JP20140111843	20140530
JP6503328 B2	20190417	JP20160204977	20161019
JP6672362 B2	20200325	JP20180056808	20180323
KR101571434 B1	20151124	KR20107007527	20080905
KR101696301 B1	20170113	KR20157032899	20080905
KR101996336 B1	20190704	KR20177000553	20080905
KR20100050566 A	20100513	KR20107007092	20080905
KR20100058620 A	20100603	KR20107007091	20080905
KR20100063111 A	20100610	KR20107007527	20080905
KR20100067099 A	20100618	KR20107007093	20080905
KR20150136140 A	20151204	KR20157032899	20080905
KR20170005905 A	20170116	KR20177000553	20080905
MX2010002616 A1	20100804	MX20100002616	20080905
MX2010002617 A1	20100601	MX20100002617	20080905
MX2010002618 A1	20101110	MX20100002618	20080905
MX2010002619 A1	20100601	MX20100002619	20080905
NZ583678 A	20120330	NZ20080583678	20080905
NZ583832 A	20120831	NZ20080583832	20080905
NZ583858 A	20120831	NZ20080583858	20080905
NZ583861 A	20120831	NZ20080583861	20080905
NZ598483 A	20130830	NZ20080598483	20080905
PL2219808 T3	20121031	PL20080860628T	20081210
RU2010112417 A	20111010	RU20100112417	20080905
RU2010112426 A	20111010	RU20100112426	20080905
RU2010112434 A	20111010	RU20100112434	20080905
RU2010113387 A	20111020	RU20100113387	20080905
RU2478366 C2	20130410	RU20100113387	20080905
RU2482822 C2	20130527	RU20100112426	20080905
SG184727 A1	20121030	SG20120066205	20080905
SG184728 A1	20121030	SG20120066213	20080905

Patent Number	Publication Date	Application Number	Application Date
SG184738 A1	20121030	SG20120067161	20080905
TW200924725 A	20090616	TW20080134435	20080908
TW200936115 A	20090901	TW20080134415	20080908
TW201002367 A	20100116	TW20080134438	20080908
TW201006451 A	20100216	TW20080134436	20080908
TWI543776 B	20160801	TW20080134438	20080908
US10434009 BB	20191008	US20170707386	20170918
US11141312 BB	20211012	US20150690874	20150420
US11951038 BB	20240409	US20190594576	20191007
US2009099626 AA	20090416	US20080231987	20080905
US2009104243 AA	20090423	US20080231986	20080905
US2009104248 AA	20090423	US20080231989	20080908
US2009105749 AA	20090423	US20080231984	20080905
US2011150581 AA	20110623	US20080747695	20081210
US2012187594 AA	20120726	US20120367823	20120207
US2012318281 AA	20121220	US20120598201	20120829
US2014180253 AA	20140626	US20140192915	20140228
US2014186420 AA	20140703	US20130098317	20131205
US2015374541 AA	20151231	US20150690874	20150420
US2016361199 AA	20161215	US20160247703	20160825
US2017304194 AA	20171026	US20170598035	20170517
US2018000642 AA	20180104	US20170707386	20170918
US2019105265 AA	20190411	US20180157712	20181011
US2020030144 AA	20200130	US20190594576	20191007
US2022031507 AA	20220203	US20210499656	20211012
US8333726 BB	20121218	US20080231989	20080908
US8628792 BB	20140114	US20120367823	20120207
US8702643 BB	20140422	US20120598201	20120829
US9011361 BB	20150421	US20080231987	20080905
US9445944 BB	20160920	US20140192915	20140228
US9763824 BB	20170919	US20160247703	20160825
WO09032328 A1	20090312	WO2008US10479	20080905
WO09035562 A2	20090319	WO2008US10487	20080905
WO09035562 A3	20090702	WO2008US10487	20080905
WO09035567 A2	20090319	WO2008US10497	20080905
WO09035567 A3	20090416	WO2008US10497	20080905
WO09035567 A8	20090611	WO2008US10497	20080905
WO09035571 A2	20090319	WO2008US10502	20080905
WO09035571 A3	20090430	WO2008US10502	20080905
ZA201001586 A	20110525	ZA20100001586	20100304
ZA201001684 A	20111130	ZA20100001684	20100309
ZA201001738 A	20111228	ZA20100001738	20100311
ZA201001739 A	20111228	ZA20100001739	20100311

Priority Numbers: US20070970720P [20070907]; US20070970696P [20070907]; US20080049360P [20080430]; US20070974367P [20070921]; US20080036816P [20080314]; US20080033211P [20080303]; US20080052595P [20080512]; US20080075309P [20080624]; WO2008US10479 [20080905]; US20070970699P [20070907]; US20070970820P [20070907]; US20080049317P [20080430]; US20070970709P [20070907]; WO2008US10487 [20080905]; US20070970840P [20070907]; WO2008US10497 [20080905]; US20070970807P [20070907]; US20080050901P [20080506]; WO2008US10502 [20080905]; DE200720017307U [20071212]; DE200820007251U [20080529]; WO2008EP10479 [20081210]; CN200880114948 [20080905]; CN200880112670 [20080905]; EP20080860628 [20081210]; US20080049360 [20080430]; US20080033211 [20080303];

US20080036816 [20080314]; EP20080829084 [20080905]; US20080052595 [20080512]; US20080075309 [20080624]; EP20080830451 [20080905]; US20080049317 [20080430]; EP20120192860 [20080905]; EP20140192229 [20080905]; US20080050901 [20080506]; EP20080830574 [20080905]; JP20100524053 [20080905]; JP20100524053T [20080905]; JP20100524049 [20080905]; JP20100524049T [20080905]; JP20100524050 [20080905]; JP20100524050T [20080905]; JP20140111843 [20080905]; JP20160092471 [20160502]; JP20130230810 [20080905]; JP20160204977 [20161019]; JP20160092471 [20080905]; JP20170133916 [20170707]; JP20160204977 [20080905]; JP20180056808 [20180323]; JP20170133916 [20080905]; JP20190161681 [20190905]; NZ20080583678 [20080905]; US20160247703 [20160825]; US20170707386 [20170918]; US20140192915 [20140228]; US20120598201 [20120829]; US20080231989 [20080908]; US20080231987 [20080905]; US20150690874 [20150420]; US20190594576 [20191007]; US20080231986 [20080905]; US20080231984 [20080905]; US20120367823 [20120207]; US20130098317 [20131205]; US20170598035 [20170517]; US20180157712 [20181011]; US20210499656 [20211012]

Probable Patent Assignee: 3088922 INC

Assignees: QLT PLUG DELIVERY INC; QUADRA LOGIC TECH INC; LUTZ PREC K S; MATI THERAPEUTICS INC; RAPACKI ALAN R; 3088922 INC; HOLDS JOHN B; RUBINCHIK VALERY; SHEN DANNY; SIM SYLVIE; SHIMIZU ROBERT W; REICH CARY J; GIFFORD HANSON S; JAIN RACHNA; BOYD STEPHEN; DE JUAN EUGENE JR; UTKHEDE DEEPANK; MA LORRIE; JEWELL TOMMY; CARDENAS CHRISTOPHER V; NGUYEN TUAN; KLT INK; QLT PLUG DELIVERY INC QPDI; DE JUAN EUGENE; DE JUAN JR EUGENE; NGUYEN NGOC TUAN; KJELLBOTN CHARLES RICHARD

Non Std Assignees: QLT INC; LUTZ PRECISION KS; LUTZ PRECISION K S; MATI THERAPEUTICS INC AUSTIN

Inventors: HOLDS JOHN B; SIM SYLVIE; RUBINCHIK VALERY; RAPACKI ALAN R; SHEN DANNY; DANNY SHEN; VALERY RUBINCHIK; ALAN R RAPACKI; JOHN B HOLDS; SYLVIE SIM; REICH CARY J; SHIMIZU ROBERT W; GIFFORD HANSON S; UTKHEDE DEEPANK; JUAN EUGENE DE JR; BOYD STEPHEN; JAIN RACHNA; EUGENE DE JUAN JR; ROBERT W SHIMIZU; RACHNA JAIN; CARY J REICH; DEEPANK UTKHEDE; STEPHEN BOYD; DE JUAN JR EUGENE; KJELLBOTN CHARLES RICHARD; CHARLES RICHARD KJELLBOTN; JEWELL TOMMY; NGUYEN TUAN; MA LORRIE; CARDENAS CHRISTOPHER V; TUAN NGUYEN; CHRISTOPHER V CARDENAS; TOMMY JEWELL; LORRIE MA; JUAN EUGENE DE; JR; HOLDS JONH B; JONH B HOLDS; LUTZ PETER STEFAN; PETER STEFAN LUTZ; DE JUAN EUGENE JR; KJELLBOTN CHARLES R; RICHARD KJELLBOTN CHARLES; RAPACKI ALAN; HOLDS JOHN; SIM SYLVIE S; RUBINCHIK VALERY V; HOLDS JOHN B JB; RAPACKI ALAN R AR; SHEN DANNY D; JAIN RACHNA R; REICH CARY J CJ; UTKHEDE DEEPANK D; GIFFORD HANSON S HS; BOYD STEPHEN S; DE JUAN JR EUGENE E; SHIMIZU ROBERT W RW; REICH CARY; SHIMIZU ROBERT; EUGENE JR DE JUAN; DE JUAN JR; DZHEJN RACHNA; BOJD STIVEN; UTKHEDE DIPANK; SHIMITSU ROBERT V; REJCH KEHRI DZH; DE DZHUAN ML JUDZHIN; DZHIFORD KHEHNSON S; RUBINCHIK VEHLER; DE DZHUAN JUDZHIN ML; RAPAKI ALAN R; K ELBOTN CHARLZ RICHARD; NGUYEN NGOC TUAN; DE JUAN EUGENE; UTKHEDE JR DEEPANK

Non Std Inventors: HANSON S GIFFORD; EUGENE DE JUAN; JONH BHOLDS; ALAN RRAPACKI; HOLDS JOHN B ST LOUIS; RAPACKI ALAN R REDWOOD CITY; SHEN DANNY STANFORD; SIM SYLVIE MOUNTAIN VIEW; RUBINCHIK VALERY RICHMOND; SHIMIZU ROBERT W LAGUNA NIGUEL; BOYD STEPHEN MURRIETA; UTKHEDE DEEPANK SURREY; GIFFORD HANSON S WOODSIDE; DE JUAN JR EUGENE SAN FRANCISCO; JAIN RACHNA MILPITAS; REICH CARY J LOS GATOS; DE JUAN EUGENEN JR; CARDENAS CHRISTOPHER; SHIMITSU ROBERT V.; DE DZHUAN ML. JUDZHIN; REJCH KEHRI DZH.; DZHIFORD KHEHNSON S.; RAPAKI ALAN R.; DE DZHUAN JUDZHIN ML.; K'ELBOTN CHARLZ RICHARD

Agent(s): PIZZEYS; PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; NORTON ROSE OR SENCRL SRL LLP; GRUENECKER PATENT U RECHTSANWAELTE PARTG MBB; PATENTANWALTSKANZLEI MEYER; WITTMANN HERNANDEZ PATENTANWAELTE PARTNERSCHAFT MBB; HERNANDEZ YORCK DIPL ING; VOSSIUS AND PARTNER; COUCHMAN JONATHAN HUGH; HGF; CAMENISCH ANDREW RICHARD; HGF; HGF LTD; LAZCANO JESUS; CLT PATENT AND TRADEMARK HK LTD; REINHOLD COHN AND PARTNERS; OSUGA AND ASSOCIATES; OSUGA YOSHIYUKI; CESAR RAMOS DE MIGUEL; RODYK AND DAVIDSON LLP; ANDERSON KOREN; SCHWEGMAN LUNDBERG AND WOESSNER PA; PILLSBURY WINTHROP SHAW PITTMAN LLP; KOREN ANDERSON MATI THERAPEUTICS INC; KOREN J; MATI THERAPEUTICS INC; KOREN; NELSON ALBIN JAMES ET AL


Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AL; BA; MK; RS; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

22. Family 71451440 (US2018325977 AA)

[View in PatBase](#)

Title
[EN] COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF

Abstract
[EN] The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases/disorders and rheumatic diseases/disorders.



International Class: A61K38/39; A61L17/08; A61L27/24; A61L27/54; C07K14/47; A61L27/22; A61K47/64; A61K47/66; A61K49/00; A61K51/08; C07K14/78; A61P27/02; A61L27/227; A61K31/07; A61K31/11; A61K31/136; A61K31/138; A61K31/165; A61K31/167; A61K31/192; A61K31/196; A61K31/203; A61K31/245; A61K31/282; A61K31/337; A61K31/382; A61K31/407; A61K31/4168; A61K31/424; A61K31/427; A61K31/429; A61K31/43; A61K31/431; A61K31/433; A61K31/436; A61K31/4375; A61K31/4704; A61K31/4709; A61K31/4725; A61K31/496; A61K31/498; A61K31/505; A61K31/5377; A61K31/5383; A61K31/542; A61K31/545; A61K31/546; A61K31/5575; A61K31/58; A61K31/616; A61K31/63; A61K31/635; A61K31/702; A61K31/7036; A61K31/704; A61K31/7068; A61K33/24; A61K38/08; A61K38/13; A61K38/18; A61K38/44; A61K38/48; A61K39/395; A61K47/60; A61K49/04; A61K49/06; A61L17/00; A61L27/50; A61L29/14; A61L31/14; A61P1/00; A61P1/04; A61P13/00; A61P15/00; A61P17/00; A61P17/02; A61P17/06; A61P19/02; A61P19/08; A61P19/10; A61P27/04; A61P27/06; A61P27/12; A61P35/00; A61P37/08; A61P9/00; A61P9/04; A61P9/06; A61P9/10; A61K38/02; A61K38/43; A61K45/00; A61K9/06; A61K9/08; A61K9/10; A61K9/14; A61K9/70; A61P23/02; A61P29/00; A61K31/00; A61K38/00; A61L31/16; A61K38/04; A61K39/00; A61L27/10; A61K45/06; A61K47/55; A61K9/00; A61K31/351; A61K31/497; A61K38/01; A61L29/04; A61L29/08; A61L29/16; A61L31/04; A61L31/10; A61K; A61L; C07K

Cooperative Patent Class: A61K2300/00; A61K31/351; A61K31/497; A61K38/014; A61K38/39; A61K45/06; A61K47/55; A61K9/0014; A61K9/0048; A61L17/005; A61L17/08; A61L2400/12; A61L27/10; A61L27/24; A61L27/54; A61L29/045; A61L29/085; A61L29/16; A61L31/044; A61L31/10; A61L31/16; A61P17/00; A61P19/02; A61P27/02; A61P27/06; A61P29/00; A61P35/00; C07K14/78; C07K14/47; A61L27/22

US Class: 1/1; 514/17.2

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2018248297 AA	20191024	AU20180248297	20180405
AU2018248297 BB	20200917	AU20180248297	20180405
AU2020286248 AA	20210114	AU20200286248	20201209
AU2020286248 BB	20230119	AU20200286248	20201209
AU2023200330 AA	20230223	AU20230200330	20230120
BR112019021056 A2	20200512	BR20191121056	20180405
BR112019021056 B1	20221122	BR20191121056	20180405
CA3058971 AA	20191002	CA20183058971	20180405
CN110869064 A	20200306	CN201880037471	20180405
EP3606570 A1	20200212	EP20180781472	20180405
EP3606570 A4	20201230	EP20180781472	20180405
HK40024464 A1	20201211	HK20206013454	20200811
IN201917040080 A	20191108	IN201917040080	20191003
JP2020516677 T2	20200611	JP20200504270T	20180405
JP2021063140 A2	20210422	JP20210012662	20180405
JP2022125137 A2	20220826	JP20220104150	20180405
JP6837598 B2	20210303	JP20200504270T	20180405
KR102462268 B1	20221102	KR20197032322	20180405
KR102642427 B1	20240228	KR20227037851	20180405
KR20200004302 A	20200113	KR20197032322	20180405

Patent Number	Publication Date	Application Number	Application Date
KR20220151029 A	20221111	KR20227037851	20180405
KR20240033102 A	20240312	KR20247006434	20180405
MX2019011965 A1	20200722	MX20190011965	20180405
MX2023010328 A1	20230914	MX20230010328	20191004
MX409627 B	20240115	MX20190011965	20180405
NZ757742 A	20210129	NZ20180757742	20180405
US10632168 BB	20200428	US20180945820	20180405
US11426440 BB	20220830	US20200839987	20200403
US11433112 BA	20220906	US20220749729	20220520
US11684651 BB	20230627	US20220820400	20220817
US2018325977 AA	20181115	US20180945820	20180405
US2020246415 AA	20200806	US20200839987	20200403
US2022280592 AA	20220908	US20220749729	20220520
US2023141917 AA	20230511	US20220820400	20220817
US2023338458 AA	20231026	US20230315250	20230510
US2024100118 AA	20240328	US20230452724	20230821
WO18187530 A1	20181011	WO2018US26180	20180405
ZA201906548 A	20201125	ZA20190006548	20191004

Priority Numbers: US20170482592P [20170406]; US20170581927P [20171106]; WO2018US26180 [20180405]; AU20200286248 [20201209]; AU20180248297 [20180405]; AU20230200330 [20230120]; JP20200504270T [20180405]; JP20210012662 [20210129]; JP20210012662 [20180405]; JP20220104150 [20220629]; KR20197032322 [20180405]; KR20227037851 [20180405]; MX20190011965 [20191004]; US20180945820 [20180405]; US20200839987 [20200403]; US20220749729 [20220520]; US20220820400 [20220817]; US20230315250 [20230510]; US20230452724 [20230821]

Probable Patent Assignee: SUSTAIN HOLDINGS LLC

Assignees: SUSTAIN HOLDINGS LLC

Non Std Assignees: SCHLUMPF RICHARD ERIC; BARATTA ROBERT; DELOREY SHAWN A

Inventors: SCHLUMPF ERIC; DELOREY SHAWN A; BARATTA ROBERT; SCHLUMPF RICHARD ERIC; ERIC SCHLUMPF; ROBERT BARATTA; SHAWN A DELOREY; SCHLUMPF R ERIC; RICHARD ERIC SCHLUMPF

Agent(s): WRAYS PTY LTD; ROBIC; ROBIC AGENCE PI SEC ROBIC IP AGENCY LP; LATSCHA SCHOELLHORN PARTNER AG; KING AND WOOD MALLESONS IP LTD; EUGENIO PEREZ PEREZ; FRANCISCO JAVIER UHTHOFF ORIVE; MEDLER FERRO WOODHOUSE AND MILLS PLLC; MEDLER FERRO WOODHOUSE AND MILLS PLLC; MEDLER FERRO WOODHOUSE AND MILLS; MEDLER FERRO WOODHOUSE AND MILLS; MILLS JEFFREY K; MEDLER FERRO WOODHOUSE AND MILLS PLLC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

23. Family 41158205 (US2008025941 AA)


[View in PatBase](#)

Title

[EN] COMPOSITIONS CONTAINING QUATERNARY AMMONIUM COMPOUNDS

Abstract

[EN] This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that said composition includes at least 20 percent in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5 percent, preferably more than 7 percent in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. This invention also relates to ophthalmic oil-in-water emulsions containing such compositions, said ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.



FDA Data

Application Number	Active Ingredient	Proprietary Name	Applicant	Date Of Approval
214965	CYCLOSPORINE	VERKAZIA	HARROW EYE	20210623
214965	CYCLOSPORINE	VERKAZIA	SANTEN	20210623

International Class: A61K31/14; A61K9/00; A61K9/107; A61K; A01N; A01N33/12; A61K31/5575; A61K38/13; A61P; A61P27/02; A61K1/14; A61K38/00; A61K47/10; A61K47/34; A61K47/44; A61P43/00; A61K47/18; A61K31/00; A01N25/04; A01N25/30; A61K31/765; A61L12/14; C07C211/63; A61K8/06; C11D1/62; A61K31/216; A61K31/4164; A61K31/428; A61K31/436; A61K31/4545; A61K31/517; A61K31/575; A61K47/46; A61P31/02; A61K38/12; A61K47/30; A61F2/00; A61K8/41; A61Q17/00; A61Q19/00

Cooperative Patent Class: A61K31/14; A61K31/765; A61K38/13; A61K47/186; A61K47/44; A61K9/0014; A61K9/0048; A61K9/107; A61K9/1075; A61L12/143; A61P27/02; A61P31/02; A61P43/00; C07C211/63; A61K8/416; A61Q1/14; A61Q19/10; A61K8/06; A61K8/062; A61Q17/005; A61Q19/00; A61Q19/005

US Class: 1/1; 424/400; 424/400P; 424/427; 424/70.28; 424/70.280P; 424/78.04; 514/11; 514/14; 514/15; 514/18.8; 514/18.800S; 514/182; 514/2; 514/20.5; 514/20.500S; 514/20.7; 514/20.700S; 514/20.8; 514/20.800S; 514/266.22; 514/266.220S; 514/290; 514/290S; 514/291; 514/291S; 514/367; 514/367S; 514/400; 514/400S; 514/530; 514/530S; 514/642; 514/642S; 514/643; 514/643S; 514/772.3; 514/783; 514/783S; 514/785; 514/786; 514/788; 514/788S; 514/9

Family Information

Patent Number	Publication Date	Application Number	Application Date	
AU2007278141 AA	20080131	AU20070278141	20070727	
AU2007278141 BB	20140116	AU20070278141	20070727	
AU2014201978 AA	20140424	AU20140201978	20140408	
AU2014201978 BB	20160310	AU20140201978	20140408	
CA2659322 AA	20090127	CA20072659322	20070727	
CA2659322 C	20140715	CA20072659322	20070727	
CN101534791 A	20090916	CN200780033784	20070727	
CN101534791 B	20120111	CN200780033784	20070727	
CY1114457 T1	20161005	CY20131100865T	20131007	
CY1118148 T1	20170628	CY20161100773T	20160805	
CY1118436 T1	20170628	CY20161101244T	20161202	
DE602006038336 D1	20131107	DE200660038336T	20060728	
DE602007046316 D1	20160623	DE200760046316T	20070727	
DE602007047841 D1	20161020	DE200760047841T	20070727	
DK1891939 T3	20131007	DK20060291236T	20060728	
DK2049079 T3	20170102	DK20070787998T	20070727	
DK2404593 T3	20160829	DK20110165011T	20070727	
EP1891939 A1	20080227	EP20060291236	20060728	
EP1891939 B1	20130911	EP20060291236	20060728	
EP2049079 A2	20090422	EP20070787998	20070727	
EP2049079 B1	20160907	EP20070787998	20070727	

Patent Number	Publication Date	Application Number	Application Date	
EP2404593 A1	20120111	EP20110165011	20070727	
EP2404593 B1	20160511	EP20110165011	20070727	
ES2428868 T3	20131112	ES20060291236T	20060728	
ES2586381 T3	20161014	ES20110165011T	20070727	
ES2606467 T3	20170324	ES20070787998T	20070727	
HK1112409 A1	20080905	HK20080106360	20080610	
HK1112409 A3	20080905	HK20080106360	20080610	
HK1112409 B	20140502	HK20080106360	20080610	
HK1165993 A1	20121019	HK20120106653	20120706	
HK1165993 B	20170728	HK20120106653	20120706	
HU029987 T2	20170428	HU20110165011T	20070727	
HU030841 T2	20170628	HU20070787998T	20070727	
HU1700007 I1	20170428	HU20170000007	20170228	
IL196740 A0	20091118	IL20070196740	20070727	
IL196740 A1	20151029	IL20070196740	20070727	
IL241753 A0	20151130	IL20070241753	20070727	
IL241753 A1	20180329	IL20070241753	20070727	
IN00197MN2009 A	20090703	IN2009MN00197	20090128	
IN00727MN2014 A	20150206	IN2014MN00727	20140417	
IN266491 B	20150515	IN2009MN00197	20090128	
IN528049 B	20240322	IN2014MN00727	20140417	
JP2009544667 T2	20091217	JP20090521280T	20070727	
JP5441058 B2	20140312	JP20090521280T	20070727	
KR101507097 B1	20150331	KR20147003945	20070727	
KR101507465 B1	20150331	KR20097004115	20070727	
KR20090047496 A	20090512	KR20097004115	20070727	
KR20140041845 A	20140404	KR20147003945	20070727	
LT2017003 I1	20170310	LT2017PA00003	20170215	
LT2049079 I2	20191227	LT2017PA00003	20170215	
LT2049079 T	20161212	LT20070787998T	20070727	
LUC00006 I1	20170228	LU2017C000006	20170223	
LUC00006 I2	20170502	LU2017C000006	20170223	
PL1891939 T3	20140131	PL20060291236T	20060728	
PL2049079 T3	20170331	PL20070787998T	20070727	
PL2404593 T3	20161130	PL20110165011T	20070727	
PT1891939 T	20131007	PT20060291236T	20060728	
PT2049079 T	20161209	PT20070787998T	20070727	
PT2404593 T	20160816	PT20110165011T	20070727	
SI1891939 T1	20131129	SI20060031655T	20060728	
SI2049079 T1	20170331	SI20070031866	20070727	
SI2404593 T1	20161130	SI20070031814	20070727	
TR201610989 T4	20160822	TR20160010989T	20070727	
TR201617758 T4	20161221	TR20160017758T	20070727	
US10842873 BB	20201124	US20180946325	20180405	
US11612658 BB	20230328	US20200949237	20201021	
US2008025941 AA	20080131	US20070822603	20070709	
US2008026013 AA	20080131	US20060494493	20060728	
US2008026991 AA	20080131	US20070829428	20070727	

Patent Number	Publication Date	Application Number	Application Date	
US2008194532 AA	20080814	US20080010778	20080130	
US2011201689 AA	20110818	US20110096512	20110428	
US2013337019 AA	20131219	US20130957621	20130802	
US2016082107 AA	20160324	US20150943649	20151117	
US2019022231 AA	20190124	US20180946325	20180405	
US2020000924 A9	20200102	US20180946325	20180405	
US2021038721 AA	20210211	US20200949237	20201021	
US2023181738 AA	20230615	US20230167125	20230210	
US7973081 BB	20110705	US20070829428	20070727	
US8071114 BB	20111206	US20070822603	20070709	
US8524779 BB	20130903	US20110096512	20110428	
US9132071 BB	20150915	US20080010778	20080130	
US9220694 BB	20151229	US20130957621	20130802	
US9956289 BB	20180501	US20150943649	20151117	
WO08012367 A2	20080131	WO2007EP57784	20070727	
WO08012367 A3	20080529	WO2007EP57784	20070727	
WO08035246 A2	20080327	WO2007IB53441	20070710	
WO08035246 A3	20080626	WO2007IB53441	20070710	

Priority Numbers: EP20060291236 [20060728]; US20060494493 [20060728]; EP20070112097 [20070709]; WO2007IB53441 [20070710]; WO2007EP57784 [20070727]; AU20070278141 [20070727]; AU20140201978 [20140408]; EP20070787998 [20070727]; EP20110165011 [20070727]; US20130957621 [20130802]; US20070829428 [20070727]; US20110096512 [20110428]; US20150943649 [20151117]; US20180946325 [20180405]; US20200949237 [20201021]; US20070822603 [20070709]; FR20070051637 [20070710]; US20080010778 [20080130]; US20230167125 [20230210]

Probable Patent Assignee: NOVAGALI PHARMA SA

Assignees: SANTEN SAS; NOVAGALI PHARMA SA; PHILIPS BETTY; LAMBERT GREGORY; RABINOVICH GUILATT LAURA; LALLEMAND FREDERIC; NOVAGALI PHARMA S A; NOVAGALIPHARMA SA; NOVAGLI PHARMA S A; RABINOVICH GUILATTI LAURA

Non Std Assignees: SANTEN SAS1 RUE PIERRE FONTAINEBATIMENT GENAVENIR IVF-91000EVRYFR; NOVAGALI PHARMA SA1, RUE PIERRE FONTAINEF-91000EVRYFR; NOVAGLI PHARMA SA

Inventors: PHILIPS BETTY; LAMBERT GREGORY; RABINOVICH GUILATT LAURA; LALLEMAND FREDERIC; LAURA RABINOVICH GUILATT; BETTY PHILIPS; GREGORY LAMBERT; FREDERIC LALLEMAND; LAMBERT GREGORY; LALLEMAND FREDERIC; RABINOVICH GUILATTI LAURA

Non Std Inventors: LALLEMAND FREDERICFR; RABINOVICH GUILATT LAURAIL; PHILIPS BETTYFR; LAMBERT GREGORYFR; LALLEMAND FREDERIC 94260; LAMBERT GREGORY 92290; RABINOVICH GUILATT LAURA 60920; PHILIPS BETTY 92160

Agent(s): PHILLIPS ORMONDE FITZPATRICK; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; OGILVY RENAULT LLP SENCRL SRL; PATENTANWALTSKANZLEI MEYER; HERNANDEZ YORCK DIPL ING; TOUATI CATHERINE ET AL; CABINET PLASSERAUD; ICOSA; CABINET PLASSERAUD; DE ELZABURU ALBERTO; LAZCANO JESUS; SAEZ ANA; WENPING AND CO; ELLA CHEONG HONG KONG LTD; SPRUSON AND FERGUSON HONG KONG LTD; REINHOLD COHN AND PARTNERS; BEN AMI AND ASSOCIATES; FUJITA KAZUKO; MUESERREF AKYOL; NIXON AND VANDERHYE; NIXON AND VANDERHYE; YOUNG AND THOMPSON; CABINET PLASSERAUD ET AL

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; MT; AL; BA; HR; MK; YU; RS; AE; AG; AM; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

24. Family 69192108 (US2018098937 AA)

[View in PatBase](#)

Title

[EN] ARTIFICIAL TEAR, CONTACT LENS AND DRUG VEHICLE COMPOSITIONS AND METHODS OF USE THEREOF

Abstract

[EN] The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte and methods of their use.


International Class: A61K47/00; A61K47/38; A61K9/00; A61K9/08; A61P27/00; A61P27/02; C09K3/00; A61K31/047; A61K47/02; A61K47/40; A61P17/02; A61P27/04; A61P29/00; G02C7/04; A61K31/167; A61K31/7072; A61K33/14; A61K47/10; A61K47/26; A61K47/34; A61K47/44; A61P23/02; A61K31/7028; A61K31/724; A61K31/765; C11D1/825; C11D3/04; C11D3/20; C11D3/22; C11D3/37; C11D3/60; A61K38/13; A61K45/00; A61K47/32; A61K47/36; A61L12/12; A61K31/415; A61K31415000; A61K47020000; A61K47260000; A61K90000000; G02C7040000; A61K47/12; A61K31/4174; A61K31/4725; A61K47/08; A61K47/14; A61K9/06; A61K9/107; G02C13/00; A61K31/045; A61K31/194; A61K31/717; A61K31/77; A61K33/00; A61K45/06; A61K47/04; A61K47/18; A61P43/00; A61K31/05; A61K31/4164; A61K31/60; A61K36/534; A61K36/61; A61K31/7016; A61K31/7084; A61K31/715; A61K31/4178; A61K36/47; A61K31/25; A61K31/341; C11D3/00; A45C11/00; A61K31/327; A61K8/22; A61P17/10

Cooperative Patent Class: A61K31/7028; A61K31/715; A61K31/724; A61K31/765; A61K38/13; A61K45/00; A61K47/02; A61K47/10; A61K47/24; A61K47/26; A61K47/32; A61K47/36; A61K47/38; A61K47/40; A61K9/0048; A61K9/08; A61L12/08; A61P17/02; A61P27/00; A61P27/02; A61P27/04; A61P29/00; C11D1/008; C11D1/74; C11D1/825; C11D3/0078; C11D3/046; C11D3/2044; C11D3/2065; C11D3/221; C11D3/222; C11D3/225; C11D3/3707; C11D3/3753; C11D3/3765; C11D3/3776; A61K31/167; A61K33/14; A61K47/44; A61K31/05; A61K31/4164; A61K31/60; A61K36/534; A61K36/61; A61K9/0014; A61K31/4725; A61K31/7016; A61K31/7084; A61K47/12; A61K47/183; A61K9/0051; A61K9/06; A61K9/1075; A61K31/047; A61K31/355; A61K31/4174; A61K31/4178; A61K31/717; A61K36/47; A61K31/045; A61K31/25; A61K31/341; A61K47/34; A61L12/00; A61L12/124; A61L12/14; A61L12/142; A61L12/145; A61L12/147; C11D1/667; C11D1/72; C11D1/76; A61K33/06; A61P23/02; C11D3/2037; C11D3/2082; A45C11/005; A61K31/196; A61K45/06; C11D1/8255; C11D3/0047; C11D3/2079; C11D3/2086; G02C7/04; A61K38/12; A61K31/136; A61K31/20; A61K31/7048; A61K31/7056; A61K8/345; A61K8/347; A61K8/362; A61K8/368; A61K8/38; A61K8/46; A61K8/4993; A61K8/731; A61K8/738; A61K8/86; A61P17/10; A61Q19/00

US Class: 1/1; 514/529; 514/57

Family Information

Patent Number	Publication Date	Application Number	Application Date
BR112019007405 A2	20190702	BR20191107405	20171012
BR112021005097 A2	20210608	BR20211105097	20190919
CA3039464 AA	20190403	CA20173039464	20171012
CA3112278 AA	20210308	CA20193112278	20190919
CN110114119 A	20190809	CN201780076389	20171012
CN110114119 B	20220531	CN201780076389	20171012
CN113227304 A	20210806	CN201980077116	20190919
CN115089547 A	20220923	CN202210633890	20171012
DE602017052898 D1	20220217	DE201760052898T	20171012
DE602017074344 D1	20230928	DE201760074344T	20171012
EP3525885 A1	20190821	EP20170860453	20171012
EP3525885 A4	20200923	EP20170860453	20171012
EP3525885 B1	20220126	EP20170860453	20171012
EP3853317 A2	20210728	EP20190863887	20190919
EP3853317 A4	20220622	EP20190863887	20190919
EP4008311 A1	20220608	EP20220151645	20171012
EP4008311 B1	20230913	EP20220151645	20171012
EP4241759 A1	20230913	EP20230187692	20171012
IN201917014316 A	20190705	IN201917014316	20190409
IN202117018101 A	20220311	IN202117018101	20210419
IN202118056054 A	20220218	IN202118056054	20211203



Patent Number	Publication Date	Application Number	Application Date
IN202218002684 A	20240126	IN202218002684	20220117
IN391267 B	20220311	IN201917014316	20190409
IN417426 B	20230113	IN202118056054	20211203
JP2019535657 T2	20191212	JP20190520562T	20171012
JP2022116007 A2	20220809	JP20220077362	20171012
JP2022511335 T2	20220131	JP20210515543T	20190919
JP7073358 B2	20220523	JP20190520562T	20171012
JP7432654 B2	20240216	JP20220077362	20171012
US11260035 BB	20220301	US20190668398	20191030
US11583496 BB	20230221	US20190372625	20190402
US2018098937 AA	20180412	US20170730837	20171012
US2019021990 AA	20190124	US20180137738	20180921
US2019224120 AA	20190725	US20190372625	20190402
US2019224136 AA	20190725	US20190372582	20190402
US2019225917 AA	20190725	US20190372596	20190402
US2019262290 AA	20190829	US20190412943	20190515
US2020009044 AA	20200109	US20190575759	20190919
US2020061002 AA	20200227	US20190668398	20191030
US2020397727 AA	20201224	US20200014324	20200908
US2022080048 AA	20220317	US20210533942	20211123
US2022133626 AA	20220505	US20220578669	20220119
US2023235247 AA	20230727	US20230295520	20230404
US2023285286 AA	20230914	US20230100142	20230123
WO18071619 A1	20180419	WO2017US56252	20171012
WO20061249 A2	20200326	WO2019US51825	20190919
WO20061249 A3	20200723	WO2019US51825	20190919
WO21087051 A1	20210506	WO2020US57870	20201029

Priority Numbers: US20160407271P [20161012]; US20160428031P [20161130]; US20170452045P [20170130]; US20170519011P [20170613]; US20170535380P [20170721]; US20170563154P [20170926]; WO2017US56252 [20171012]; US20180137738 [20180921]; US20190372625 [20190402]; US20190372582 [20190402]; US20190372596 [20190402]; US20190412943 [20190515]; WO2019US51825 [20190919]; CN201780076389 [20171012]; EP20170860453 [20171012]; EP20220151645 [20171012]; IN201917014316 [20190409]; JP20190520562T [20171012]; JP20220077362 [20220510]; JP20190520562 [20171012]; US20170730837 [20171012]; US20190668398 [20191030]; US20190575759 [20190919]; US20200014324 [20200908]; US20210533942 [20211123]; US20220578669 [20220119]; US20230295520 [20230404]; US20230100142 [20230123]

Probable Patent Assignee: PS THERAPY INC

Assignees: PS THERAPIES LTD; PS THERAPY LTD; HORN GERALD; PS THERAPY INC; PREMIUM OCULAR SOLUTIONS LLC; PS THERAPEUTICS GMBH; PS THERAPIES LLC

Inventors: GERALD HORN; HORN GERALD; GOSKONDA VENKAT R; NARENDRAN SIDDHARTH; GOSKONDA VENKAT

Agent(s): BERESKIN AND PARR LLP SENCRL SRL; ROBIC; HERNANDEZ YORCK DIPL ING; ELKINGTON AND FIFE LLP; WOOD PHILLIPS KATZ CLARK AND MORTIMER; WOOD PHILLIPS KATZ CLARK AND MORTIMER; RAINCROW JEREMY D ET AL

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; WS

25. Family 92365920 (US2024033124 AA)


[View in PatBase](#)

Title
[EN] DRUG DELIVERY CONTACT LENS AND OPHTHALMIC PHARMACEUTICAL COMPOSITION

Abstract
[EN] The present disclosure relates to a contact lens for drug delivery with improved drug delivery efficiency and bioavailability. Since the contact lens for drug delivery according to the present disclosure is capable of stably releasing a drug, compared to ophthalmic solutions in the art, bioavailability may be expected to be enhanced by reducing the dosage and frequency of administration. In addition, the contact lens for drug delivery according to the present disclosure may be easily applied to various drugs, has little irritation to the ocular mucosa, and is useful for mass production because of its easy preparation method.

International Class: A61K31/382; A61K31/4725; A61K31/5377; A61K31/5575; A61K47/02; A61K47/10; A61K47/26; A61K47/38; A61K9/00; A61P27/02; A61K31/385; A61F9/007; A61K45/00; A61K38/00; A61F9/00; A61K31/222; A61K31/4709; A61K38/26

Cooperative Patent Class: A61F9/0017; A61K31/222; A61K31/4709; A61K31/4725; A61K31/5575; A61K38/00; A61K38/26; A61K9/0048; A61K9/0051; A61P27/02; G02C7/04; A61K31/382; A61K31/5377; A61K47/02; A61K47/10; A61K47/26; A61K47/38



Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2022205341 AA	20230629	AU20220205341	20220107
BR112023013566 A2	20230815	BR20231113566	20220107
CA3204104 AA	20230704	CA20223204104	20220107
CN116761630 A	20230915	CN202280008993	20220107
EP4275675 A1	20231115	EP20220736891	20220107
JP2024502964 T2	20240124	JP20230540096T	20220107
KR20220100541 A	20220715	KR20220002785	20220107
MX2023008097 A1	20230714	MX20230008097	20220107
US2024033124 AA	20240201	US20230268614	20220107
VN100176 A	20240125	VN20230004346	20220107
WO22149914 A1	20220714	WO2022KR00314	20220107

Priority Numbers: KR20210002689 [20210108]; WO2022KR00314 [20220107]; KR20220002785 [20220107]

Probable Patent Assignee: DAEWON PHARMACEUTICAL CO LTD

Assignees: DAE WON PHARMACEUTICAL CO LTD; DAEWON PHARMACEUTICAL CO LTD; DAEWON PHARM CO LTD

Non Std Assignees: DAE WON PHARMACEUTICAL CO; JEONG OK CHAN; CHOI DU HYUNG; LEE AH RAM; PARK SANG WOOK; DAEWON PHARM

Inventors: JEONG OK CHAN; CHOI DU HYUNG; LEE AH RAM; PARK SANG WOOK; ZHENG YUZAN; CHOI DOO HYUNG; LI ANRAN

Non Std Inventors: OK CHAN JEONG; DU HYUNG CHOI; AH RAM LEE; SANG WOOK PARK

Agent(s): FPA PATENT ATTORNEYS PTY LTD; PERRY AND CURRIER; LAVOIX; MARIA ANGELICA PARDAVELL JUAREZ; CONG TY TNHH TAM NHIN VA LIEN DANH; VISION AND ASSOCIATES CO LTD; YPLEE MOCK AND PARTNERS

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AP; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EA; EC; EG; EP; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OA; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

26. Family 55003003 (US2014045741 AA)

[View in PatBase](#)

Title

[EN] METHOD OF TREATING AN OCULAR DISEASE AND COMPOSITIONS EFFECTIVE FOR TREATING AN OCULAR DISEASE

Abstract

[EN] Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subject's eye. In one aspect, the ocular disease is at least one of diabetic retinopathy, macular degeneration, endophthalmitis, glaucoma, cataracts, ocular herpes. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9).

International Class: A61K38/13; A61P27/02; A61K31/496; A61K31/53; A61K31/546; A61K31/573; A61K9/00; A61P27/00; A61P27/06; A61P31/00; A61P31/22; A61K38/14

Cooperative Patent Class: A61K31/496; A61K31/53; A61K31/546; A61K31/573; A61K38/13; A61K38/14; A61K9/0048; A61P27/00; A61P27/06; A61P31/00; A61P31/22

US Class: 514/1.2; 514/20.5

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2871070 AA	20141017	CA20132871070	20130315
CA2871070 C	20240102	CA20132871070	20130315
EP2844268 A1	20150311	EP20130777952	20130315
EP2844268 A4	20151125	EP20130777952	20130315
US2014045741 AA	20140213	US20130059035	20131021
US2015111833 AA	20150423	US20130395384	20130315
US2015352177 AA	20151210	US20150831030	20150820
WO13158296 A1	20131024	WO2013US32187	20130315

Priority Numbers: US20120636143P [20120420]; WO2013US32187 [20130315]; US20130059035 [20131021]; US20130395384 [20130315]; US20150831030 [20150820]

Probable Patent Assignee: HOWARD UNIV

Assignees: HOWARD UNIV; KARLA PRADEEP K; MANGAT HARPAL S; UNIV HOWARD

Non Std Assignees: HOWARD UNIV2400 SIXTH STREET NWWASHINGTONDC20059US; KARLA PRADEEP KC/O HOWARD UNIVERSITY2400 SIXTH STREET, N.W.WASHINGTONDC20059US; MANGAT HARPAL SC/O/ HOWARD UNIVERSITY2400 SIXTH STREETWASHINGTONDC20059US

Inventors: KARLA PRADEEP K; MANGAT HARPAL S

Non Std Inventors: MANGAT HARPAL SC/O/ HOWARD UNIVERSITY2400 SIXTH STREETWASHINGTONDC20059US; KARLA PRADEEP KC/O HOWARD UNIVERSITY2400 SIXTH STREET, N.W.WASHINGTONDC20059US

Agent(s): BERESKIN AND PARR LLP SENCRL SRL; SPINNER DAVID RICHARD; GREAVES BREWSTER LLP; KRATZ RUDY ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

27. Family 76270722 (US2021077401 AA)

[View in PatBase](#)

Title


[EN] NON-SURFACTANT TYPE OIL-WATER DISPERSION COMPOSITION, NON-SURFACTANT TYPE WATER-OIL DISPERSION COMPOSITION, AND MANUFACTURING METHODS FOR BOTH COMPOSITIONS

Abstract

[EN] The present invention relates to: a non-surfactant type oil-water (O/W) dispersion composition comprising non-polar solvent droplets in a polar solvent, the transparency of the dispersion composition being 90-100 percent; a non-surfactant type water-oil (W/O) dispersion composition comprising polar solvent droplets in a non-polar solvent, the transparency of the dispersion composition being 90-100 percent; and manufacturing methods for both of the compositions.

International Class: A61K31/337; A61K31/37; A61K38/13; A61K8/06; A61K8/49; A61K8/64; A61K9/107; A61Q19/00; A61K31/496; A61K31/5415; A61K8/37; A61K8/92; A61K31/197; A61K31/375; A61K31/4188; A61K31/4406; A61K45/00; A61K8/04; A61K8/34; A61K8/60; A61K8/67; A61K9/10; B01J13/00; A61K31/196; A61K31/352; A61K31/415; A61K31/704; A61K31/7068; A61K9/16

Cooperative Patent Class: A61K2800/10; A61K2800/262; A61K2800/33; A61K31/196; A61K31/337; A61K31/352; A61K31/37; A61K31/415; A61K31/496; A61K31/5415; A61K31/704; A61K31/7068; A61K38/13; A61K8/04; A61K8/062; A61K8/064; A61K8/375; A61K8/4973; A61K8/64; A61K8/922; A61K9/10; A61K9/107; A61K9/1611; A61Q19/00



Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3782601 A1	20210224	EP20190789497	20190416
EP3782601 A4	20220126	EP20190789497	20190416
JP2021517913 T2	20210729	JP20210505172T	20190416
JP7078796 B2	20220531	JP20210505172T	20190416
KR102067094 B1	20200115	KR20180044547	20180417
KR20190121055 A	20191025	KR20180044547	20180417
US11779539 BB	20231010	US20200046242	20190416
US2021077401 AA	20210318	US20200046242	20190416
US2023414513 AA	20231228	US20230243299	20230907
WO19203546 A1	20191024	WO2019KR04593	20190416

Priority Numbers: KR20180044547 [20180417]; WO2019KR04593 [20190416]; US20200046242 [20201008]; US20230243299 [20230907]

Probable Patent Assignee: ASTIN CO LTD

Assignees: ASTIN CO LTD; KIM CHUL HWAN

Non Std Assignees: ASTIN CO

Inventors: KIM CHUL HWAN; NA HYEON SEOB; KIM HYE MIN; LEE JA EUN; JO A REUM

Agent(s): DOMPATENT VON KREISLER SELTING WERNER PARTNERSCHAFT VON PATENT U RECHTSANWAELTEN MBB; SUGHRUE MION PLLC; SUGHRUE MION PLLC; KIM SUNG HO

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

28. Family 72328383 (US2020237925 AA)

[View in PatBase](#)

Title
[EN] POLYPEPTIDE EYE ABSORPTION ENHANCER AND USE THEREOF

Abstract
[EN] The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.

International Class: A61K45/00; A61P25/00; A61P27/02; A61P3/00; A61P31/02; A61P31/04; A61P31/10; A61P9/10; C07K7/08; A61K31/7088; A61K38/13; A61K38/21; A61K39/395; A61K47/42; A61K47/64; A61K48/00; A61K9/127; A61K9/14; A61P27/12; C07K14/435; A61K47/54; A61K9/00; A61K38/10

Cooperative Patent Class: A61K38/10; A61K45/00; A61K47/42; A61K47/545; A61K47/549; A61K47/595; A61K47/61; A61K47/64; A61K47/645; A61K47/6455; A61K9/0048; A61P25/00; A61P27/02; A61P3/00; A61P31/02; A61P31/04; A61P31/10; A61P9/10; C07K14/43581; C07K7/08

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN108976288 A	20181211	CN201710414334	20170605
CN108976288 B	20210921	CN201710414334	20170605
JP2020526574 T2	20200831	JP20200517261T	20180713
US11213591 BB	20220104	US20200618915	20180713
US11826431 BB	20231128	US20210410174	20210824
US2020237925 AA	20200730	US20200618915	20180713
US2022008546 AA	20220113	US20210410174	20210824
WO18224053 A1	20181213	WO2018CN095539	20180713

Priority Numbers: CN201710414334 [20170605]; WO2018CN095539 [20180713]; US20210410174 [20210824]; US20200618915 [20200122]

Probable Patent Assignee: UNIV FUDAN

Assignees: UNIV FUDAN; FUDAN UNIV

Inventors: LU WEIYUE; TAI LINGYU; WEI GANG; JIANG KUAN; LIU CHANG; GAO XIN

Agent(s): FAY SHARPE LLP; FAY SHARPE LLP; LIPPES MATHIAS LLP; LIPPES MATHIAS LLP; TEE AND HOWE INTELLECTUAL PROPERTY ATTORNEYS

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CU; CR; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW




FIG. 1

29. Family 100124463 (IN202311074288 A)

[View in PatBase](#)

Title
[EN] CHITOSAN-COATED PRONIOSOMES FOR OCULAR DELIVERY

Abstract
[EN] The present disclosure relates to an ocular drug delivery system comprising thiolated chitosan-coated proniosomes loaded with one or more therapeutic agents for treating ocular disorders/condition specially glaucoma or intraocular pressure; and a method of preparing the same.

International Class: A61F9/00; A61K9/00; A61K9/70; A61P27/02; A61P27/06

Family Information

Patent Number	Publication Date	Application Number	Application Date
IN202311074288 A	20231124	IN202311074288	20231031

Priority Numbers: IN202311074288 [20231031]

Probable Patent Assignee: CHITKARA INNOVATION INCUBATOR FOUNDATION

Non Std Assignees: CHITKARA INNOVATION INCUBATOR FOUNDATION

Non Std Inventors: NAGPAL MANJU; KAUSHAL UDESH; KAUR MALKIET; THAKUR GURJEET SINGH; ARORA SANDEEP

30. Family 99812143 (WO23194797 A1)

[View in PatBase](#)

Title


[EN] METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES

Abstract

[EN] Disclosed herein are methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.

International Class: A61K31/00; A61K38/17; A61K47/50; A61K9/00; A61P27/02

Cooperative Patent Class: A61K31/436; A61K31/573; A61K38/1709; A61K45/06; A61K47/02; A61K47/542; A61K47/6917; A61K9/0051; A61K9/08; A61P27/02; B23D47/04



Family Information

Patent Number	Publication Date	Application Number	Application Date
WO23194797 A1	20231012	WO2023IB00181	20230406

Priority Numbers: US20220328088P [20220406]

Probable Patent Assignee: ABIONYX PHARMA SA

Assignees: ABIONYX PHARMA SA

Inventors: TUPIN CYRILLE; MARTINEZ JEROME; LALLEMAND FREDERIC; ELENA PIERRE PAUL

Agent(s): HOFFMANN EITLE PATENT U RECHTSANWAELTE PARTMBB ASSOCIATION NO 151

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CV; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IQ; IR; IS; IT; JM; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MU; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

31. Family 49016293 (US2011136912 AA)

[View in PatBase](#)

Title
[EN] OPHTHALMIC EMULSION

Abstract
[EN] The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

International Class: C09K23/00; A61K47/02; A61K47/24; A61K47/36; A61K9/00; A61K9/107; A61P27/02; A61K47/06; A61K47/44; A61K9/06; A61P27/04; A61K; A61K47/04; A61K47/14; A61K47/34; A61K31/736; A61K9/08; A61K47/00; B01F17/00; C09K23/14; A61K31/14; A61P31/00; A61P27/06

Cooperative Patent Class: A61K31/736; A61K47/02; A61K47/06; A61K47/24; A61K47/36; A61K47/44; A61K9/0048; A61K9/06; A61K9/107; A61P27/02; A61P27/04; A61P27/06; A61P31/00; C09K23/017; C09K23/14; C09K23/34; B01F17/0028; B01F17/0064; B01F17/0085

US Class: 1/1; 424/400; 514/642; 514/769; 514/769S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR079258 AA	20120104	AR2010P104473	20101203
AU2010325994 AA	20120607	AU20100325994	20101202
AU2010325994 BB	20150122	AU20100325994	20101202
BR112012013039 A2	20161122	BR20121113039	20101202



Patent Number	Publication Date	Application Number	Application Date
BR112012013039 B1	20210720	BR20121113039	20101202
CA2780304 AA	20110609	CA20102780304	20101202
CA2780304 C	20180529	CA20102780304	20101202
CN102639112 A	20120815	CN201080055032	20101202
CN104161726 A	20141126	CN201410295580	20101202
CN107485602 A	20171219	CN201710711435	20101202
CY1118270 T1	20170628	CY20161101207T	20161123
DE602010035848 D1	20161006	DE201060035848T	20101202
DK2506830 T3	20161205	DK20100785299T	20101202
EP2506830 A1	20121010	EP20100785299	20101202
EP2506830 B1	20160824	EP20100785299	20101202
ES2605033 T3	20170310	ES20100785299T	20101202
HK1169320 A1	20130125	HK20120110073	20121011
HK1169320 B	20170721	HK20120110073	20121011
HR20161546 T1	20161230	HR20160001546	20161121
HU029786 T2	20170428	HU20100785299T	20101202
JP2013512917 T2	20130418	JP20120542182T	20101202
JP2016000761 A2	20160107	JP20150196474	20151002
JP5859976 B2	20160216	JP20120542182T	20101202
KR101734347 B1	20170511	KR20127014315	20101202
KR20120092650 A	20120821	KR20127014315	20101202
LT2506830 T	20161212	LT20100785299T	20101202
MK7434 T1	20171231	MK20160000778T	20161107
MX2012005346 A1	20120529	MX20120005346	20101202
MX343997 B	20161202	MX20120005346	20101202
NZ599952 A	20130830	NZ20100599952	20101202
PL2506830 T3	20170228	PL20100785299T	20101202
PT2506830 T	20161130	PT20100785299T	20101202
RS55300 B1	20170331	RS20160000978	20101202
SG181478 A1	20120730	SG20120040564	20101202
SI2506830 T1	20161230	SI20100031323	20101202
SMT201600424 B	20170110	SM20160000424T	20161122
TR201616846 T4	20161221	TR20160016846T	20101202
TW201125593 A	20110801	TW20100139702	20101118
TWI478730 B	20150401	TW20100139702	20101118
US10004685 BB	20180626	US20160228589	20160804
US10328025 BB	20190625	US20180989383	20180525
US10624848 BB	20200421	US20190405180	20190507
US11234929 BB	20220201	US20200811461	20200306
US11690802 BB	20230704	US20210200043	20210312
US2011136912 AA	20110609	US20100958763	20101202
US2016338952 AA	20161124	US20160228589	20160804
US2018271785 AA	20180927	US20180989383	20180525
US2019254971 AA	20190822	US20190405180	20190507
US2020197304 AA	20200625	US20200811461	20200306
US2021196628 AA	20210701	US20210200043	20210312
US2023285289 AA	20230914	US20230319794	20230518
WO11068955 A1	20110609	WO2010US58703	20101202

Patent Number	Publication Date	Application Number	Application Date
ZA201203291 A	20130731	ZA20120003291	20120507

Priority Numbers: US20090266207P [20091203]; WO2010US58703 [20101202]; CN201080055032 [20101202]; EP20100785299 [20101202]; JP20120542182T [20101202]; US20100958763 [20101202]; US20160228589 [20160804]; US20180989383 [20180525]; US20190405180 [20190507]; US20200811461 [20200306]; US20210200043 [20210312]; US20230319794 [20230518]

Probable Patent Assignee: ALCON INC

Assignees: ALCON RES LTD; ALCON INC; ALCON RES LLC; NOVARTIS AG; MEADOWS DAVID L; KETELSON HOWARD ALLEN; ALCON LABORATORIES

Non Std Assignees: ALCON RESEARCH LTD; ALCON RESEARCH LLC; ALCON RESEARCH LTD 76134 2099 FORT WORTH

Inventors: KETELSON HOWARD ALLEN; MEADOWS DAVID L; HOWARD ALLEN KETELSON; DAVID L MEADOWS; ALLEN KETELSON HOWARD

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; TEIPEL STEPHAN; CARVAJAL Y ISABEL; SIT FUNG KWONG AND SHUM; MARKS AND CLERK; JOSE F HINOJOSA CUELLAR; MEHMET NAZIM AYDIN DERIS; SHENG HSIN; HU SHENG HSIN; SCOTT A CHAPPLE ET AL; ALCON RESEARCH LTD


Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

32. Family 65133460 (US2018265694 AA)

[View in PatBase](#)

Title
[EN] MICELLES FOR MUCOADHESIVE DRUG DELIVERY

Abstract
[EN] Biocompatible block copolymer micelles for use in mucoadhesive drug delivery are provided. The micelles comprise a degradable hydrophobic polymer, a degradable synthetic hydrophilic polymer and a mucoadhesive polymer. The micelles are particularly useful for ophthalmic uses.



International Class: A61K38/13; A61K47/24; A61K49/18; A61K9/107; A61P27/02; C07K7/64; C08L53/00; C12P17/08; A61K47/34; A61K45/00; A61K47/10; A61K47/20; A61K47/32; A61K47/36; A61K47/38; A61K47/42; A61P1/00; A61P1/02; A61P1/08; A61P11/02; A61P11/06; A61P15/00; A61P25/04; A61P27/06; A61P27/16; A61P29/00; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P35/00; A61P37/08; A61K38/00; A61K49/00; A61K9/00; A61K9/06; A61K9/48; C08F293/00; C08L33/04

Cooperative Patent Class: A61K38/00; A61K47/34; A61K49/0043; A61K49/0082; A61K9/0048; A61K9/006; A61K9/1075; A61P1/00; A61P1/02; A61P1/08; A61P11/02; A61P11/06; A61P15/00; A61P25/04; A61P27/02; A61P27/06; A61P27/16; A61P29/00; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P35/00; A61P37/08; C08F2438/03; C08F293/005; C08L33/04; C08L53/00

US Class: 1/1; 524/505

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2996910 AA	20180228	CA20162996910	20160901
CA2996910 C	20230822	CA20162996910	20160901
DE602016068723 D1	20220217	DE201660068723T	20160901
EP3344232 A1	20180711	EP20160840475	20160901
EP3344232 A4	20190522	EP20160840475	20160901
EP3344232 B1	20220126	EP20160840475	20160901
ES2911715 T3	20220520	ES20160840475T	20160901
JP2018526438 T2	20180913	JP20180529696T	20160901
JP7038054 B2	20220317	JP20180529696T	20160901
US10611908 BB	20200407	US20160756758	20160901
US2018265694 AA	20180920	US20160756758	20160901
WO17035656 A1	20170309	WO2016CA51038	20160901

Priority Numbers: US20150212784P [20150901]; WO2016CA51038 [20160901]; EP20160840475 [20160901]; US20160756758 [20160901]

Probable Patent Assignee: UNIV MCMASTER

Assignees: MCMASTER UNIV; UNIV MCMASTER

Non Std Assignees: SHEARDOWN HEATHER; PROSPERI PORTA GRAEME; KEDZIOR STEPHANIE; MUIRHEAD BENJAMIN; N A

Inventors: SHEARDOWN HEATHER; PROSPERI PORTA GRAEME; KEDZIOR STEPHANIE; MUIRHEAD BENJAMIN; PROSPERI PORTA GRAEME

Agent(s): GOWLING WLG CANADA LLP; DILG HAEUSLER SCHINDELMANN PATENTANWALTSGESELLSCHAFT MBH; FELIPE FERNANDEZ POU; IWATANI RYO; TANDAN SUSAN

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

33. Family 88795108 (US2023233373 AA)

[View in PatBase](#)

Title
[EN] METHODS AND COMPOSITIONS FOR DELIVERING BIOACTIVE COMPOSITIONS TO OCULAR TISSUE USING MICRONEEDLE DEVICES

Abstract
[EN] The present invention provides a method for treating an ocular disease or condition in a subject, comprising administering to the subject's ocular tissue a composition comprising an effective amount of one or more bioactive agents, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.

International Class: A61F9/00; A61M5/178; A61K35/19; A61K35/28; A61K35/35

Cooperative Patent Class: A61F9/0017; A61K31/728; A61K35/28; A61K38/185; A61K9/0048; A61M2005/2013; A61M2005/3142; A61M2037/0023; A61M2037/0061; A61M5/178; A61M5/19; A61M5/2033; A61M5/2066; A61M5/3129; A61M5/31531; A61M5/3298; A61P27/02



Family Information

Patent Number	Publication Date	Application Number	Application Date
US2023233373 AA	20230727	US20220008049	20210611
WO21252962 A1	20211216	WO2021US37101	20210611

Priority Numbers: US20200038105P [20200611]; WO2021US37101 [20210611]; US20210008049 [20210611]

Probable Patent Assignee: AQUAVIT PHARMACEUTICALS INC

Assignees: AQUAVIT PHARMACEUTICALS INC

Inventors: CHANG SOBIN

Agent(s): NEVRIVY DANIEL J; NEVRIVY PATENT LAW GROUP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

34. Family 68260612 (US2021137964 AA)


[View in PatBase](#)

Title
[EN] GLYCAN COMPOSITIONS AND METHODS OF USE

Abstract
[EN] Compositions, e.g., pharmaceutical compositions, nutritional compositions, medical foods, and food ingredients, as well as their methods of use, are provided, for modulating exogenous substances, enzyme activities, and drug activities.

International Class: A61K31/715; A61K9/00; A61P43/00; A23L33/10; A61K31/137; A61K31/167; A61K31/21; A61K31/341; A61K31/353; A61K31/426; A61K31/429; A61K31/43; A61K31/431; A61K31/4436; A61K31/451; A61K31/485; A61K31/505; A61K31/513; A61K31/519; A61K31/606; A61K31/63; A61K31/635; A61K31/704; A61K31/706; A61K31/7072; A61K31/7076; A61K31/708; A61K38/23; A61K38/28; A61K45/00; A61K47/36; A61P1/04; A61P1/10; A61P25/04; A61P25/18; A61P25/20; A61P25/26; A61P29/00; A61P3/06; A61P31/04; A61P31/10; A61P33/00; A61P35/00; A61P37/02; A61P5/00; A61P9/12; C08B37/00; A23L33/125; A61K31/64; A23L33/21; A61K31/4745; A61K31/7064; A61K35/741; A61K45/06; A61P15/10; A61P19/02; A61P25/02; A61P25/06; A61P27/06; A61P3/10; A61P31/12; A61P31/14; A61P31/18; A61P9/00; A61P9/04; A61P9/06; C12N9/99; A23L33/00; A23L33/135; A61P1/00; A61P39/00

Cooperative Patent Class: A23L33/125; A23L33/135; A23L33/40; A23V2002/00; A61K31/715; A61K35/741; A61K9/0053; A61P1/00; A61P1/04; A61P1/10; A61P25/04; A61P25/18; A61P25/20; A61P25/26; A61P29/00; A61P3/06; A61P3/10; A61P31/04; A61P31/10; A61P33/00; A61P35/00; A61P37/02; A61P39/00; A61P43/00; A61P5/00; A61P9/12; A61K45/06



Family Information

Patent Number	Publication Date	Application Number	Application Date
CN109689067 A	20190426	CN201780056075	20170713
DE602017066625 D1	20230323	DE201760066625T	20170713
EP3484483 A1	20190522	EP20170746236	20170713
EP3484483 B1	20230308	EP20170746236	20170713
EP3651776 A1	20200520	EP20180747089	20180713
HK40030313 A1	20210226	HK20206019524	20201104
JP2019527213 T2	20190926	JP20190501469T	20170713
JP2020526541 T2	20200831	JP20200501156T	20180713
JP2023085462 A2	20230620	JP20230061508	20180713
TR2023005536 T4	20230621	TR20230005536T	20170713
US2021137964 AA	20210513	US20190316755	20170713
US2021161942 AA	20210603	US20200630116	20180713
US2023123695 AA	20230420	US20220970537	20221020
WO18013871 A1	20180118	WO2017US42022	20170713
WO19014645 A1	20190117	WO2018US42174	20180713

Priority Numbers: US20160361998P [20160713]; WO2017US42022 [20170713]; EP20170746236 [20170713]; US20180619084P [20180118]; WO2018US42174 [20180713]; JP20200501156T [20180713]; JP20200501156 [20180713]; JP20230061508 [20230405]; US20170316755 [20170713]; US20180630116 [20180713]; US20200630116 [20200110]; US20220970537 [20221020]

Probable Patent Assignee: DSM NUTRITIONAL PRODUCTS LLC

Assignees: KALEIDO BIOSCIENCES INC; KALEIDO BIOSCIECES INC; DSM NUTRITIONAL PRODUCTS LLC

Non Std Assignees: FLAGSHIP PIONEERING INC; HERCULES CAPITAL INC

Inventors: VON MALTZAHN GEOFFREY A; RUBENS JACOB ROSENBLUM; VON MALTZAHN GEOFFREY; RUBENS JACOB; GEOFFREY A VON MALTZAHN; JACOB ROSENBLUM RUBENS

Non Std Inventors: A GEOFFREY VON MALTZAHN; ROSENBLUM JACOB RUBENS

Agent(s): MAIWALD GMBH; MAIWALD PATENT U RECHTSANWALTSGESELLSCHAFT MBH; MARKS AND CLERK; ASLI BAYGUEZ; COLLAZO DIANA M ET AL; LANDO AND ANASTASI LLP; SCHAFHEIMER STEVEN NATHANIEL ET AL; LANDO AND ANASTASI LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; MA; MD; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR;


JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ;
OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ;
VC; VN; ZA; ZM; ZW

35. Family 40467503 (US2007243230 AA)

[View in PatBase](#)

Title
[EN] NASOLACRIMAL DRAINAGE SYSTEM IMPLANTS FOR DRUG THERAPY

Abstract
[EN] Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug core. The exposed surface(s) of the drug core may contact a tear or tear film fluid and release the therapeutic agent at therapeutic levels over a sustained period when the implant is implanted for use. The implant may include a retention element to retain the drug core and sheath body near the punctum, optionally comprising a shape memory alloy that can resiliently expand. An occlusive element may be attached to the retention element to at least partially occlude tear flow through the canalicular lumen.



International Class: A61F2/02; A61K31/215; A61K38/13; A61P27/02; A61P27/06; A61F2/12; A61F2/14; A61F9/00; A61M37/00; A61K31/21; A61F9/007; A61K9/00; A61L31/16; A61F; A61K; A61P; A61M; A61K31/5377; A61K31/5575; A61K38/00; A61K47/32; A61K47/34; A61K38/43; A61L27/00; A61P9/00; A61K31/573; A61K45/00; A61L27/04; A61L27/06; A61L27/16; A61L27/18; A61L27/24; A61L27/40; A61L27/52; A61L27/54; A61P29/00; A61P31/04; A61P43/00; A61F2/04; A61M35/00; A61M5/00; A61K31/216; A61K31/55; A61K31/557; A61K9/06; A61K31/165; A61L27/58; A61F13/00; A61F2/00; A61F9/02; A61K9/08

Cooperative Patent Class: A61F2/14; A61F2220/0008; A61F2250/0067; A61F2250/0087; A61F9/0017; A61F9/0026; A61F9/00772; A61F9/00781; A61K31/215; A61K31/216; A61K31/55; A61K31/557; A61K31/5575; A61K31/573; A61K38/13; A61K47/34; A61K9/00; A61K9/0017; A61K9/0051; A61K9/06; A61L31/16; A61P27/02; A61P27/06; A61P29/00; A61P31/04; A61P43/00; A61P9/00

US Class: 1/1; 424/400; 424/422; 424/423; 424/423S; 424/425; 424/426; 424/426P; 424/427; 424/427P; 424/437; 424/484; 424/484S; 424/486; 424/486S; 514/11; 514/17.2; 514/17.200S; 514/2.4; 514/2.400S; 514/20.5; 514/20.500S; 514/20.8; 514/20.800S; 514/236.2; 514/236.200S; 514/362; 514/362S; 514/530; 514/530S; 514/570; 514/622; 514/622S; 604/175; 604/285; 604/294; 623/4.1; 623/4.100P

Family Information

Patent Number	Publication Date	Application Number	Application Date	
AU2007234445 AA	20071011	AU20070234445	20070402	
AU2007234445 BB	20110721	AU20070234445	20070402	
AU2007234447 AA	20071011	AU20070234447	20070402	
AU2007234447 BB	20110714	AU20070234447	20070402	
AU2011235978 AA	20111103	AU20110235978	20111012	
AU2011235979 AA	20111103	AU20110235979	20111012	
BRPI0709663 A2	20110726	BR2007PI09663	20070402	
BRPI0709672 A2	20110719	BR2007PI09672	20070402	
BRPI0709672 B1	20190702	BR2007PI09672	20070402	
BRPI0709672 B8	20210622	BR2007PI09672	20070402	
CA2648066 AA	20080930	CA20072648066	20070402	
CA2648066 C	20120703	CA20072648066	20070402	
CA2648421 AA	20080930	CA20072648421	20070402	
CA2648421 C	20160112	CA20072648421	20070402	
CN101505681 A	20090812	CN200780017176	20070402	
CN101505681 B	20130904	CN200780017176	20070402	
CN101505683 A	20090812	CN200780017166	20070402	
CN101505683 B	20130828	CN200780017166	20070402	
CN103393483 A	20131120	CN201310329155	20070402	
CN103393483 B	20160824	CN201310329155	20070402	
CN103393496 A	20131120	CN201310338528	20070402	
CN103393496 B	20160817	CN201310338528	20070402	
DE602007051693 D1	20170831	DE200760051693T	20070402	
DE602007057832 D1	20190328	DE200760057832T	20070402	
DK2004172 T3	20190423	DK20070759964T	20070402	

Patent Number	Publication Date	Application Number	Application Date	
DK2010096 T3	201711002	DK20070759961T	20070402	
EP2004172 A2	20081224	EP20070759964	20070402	
EP2004172 A4	20130102	EP20070759964	20070402	
EP2004172 B1	20190313	EP20070759964	20070402	
EP2010096 A2	20090107	EP20070759961	20070402	
EP2010096 A4	20121121	EP20070759961	20070402	
EP2010096 B1	20170719	EP20070759961	20070402	
EP3449873 A1	20190306	EP20180199593	20070402	
ES2640458 T3	20171103	ES20070759961T	20070402	
ES2717607 T3	20190624	ES20070759964T	20070402	
HK1123968 A1	20090703	HK20090101688	20090223	
HK1125834 A1	20090821	HK20090103914	20090428	
HK1125834 A3	20090821	HK20090103914	20090428	
HK1190908 A1	20140718	HK20140104156	20140430	
HK1190908 B	20170804	HK20140104156	20140430	
HK1190909 A1	20140718	HK20140104157	20140430	
HK1190909 B	20170804	HK20140104157	20140430	
IL194514 A0	20110801	IL20070194514	20070402	
IL194515 A0	20110801	IL20080194515	20081002	
IL194515 A1	20130930	IL20070194515	20070402	
IL212113 A0	20110630	IL20070212113	20070402	
IL212113 A1	20170430	IL20070212113	20070402	
IL212114 A0	20110630	IL20070212114	20070402	
IL212114 A1	20170228	IL20070212114	20070402	
IL225842 A0	20130627	IL20070225842	20070402	
IL225842 A1	20180131	IL20070225842	20070402	
IN08380DN2008 A	20090501	IN2008DN08380	20081006	
IN08974DN2008 A	20090320	IN2008DN08974	20081024	
JP2009532132 T2	20090910	JP20090503334T	20070402	
JP2009532133 T2	20090910	JP20090503335T	20070402	
JP2012228571 A2	20121122	JP20120171816	20120802	
JP2014087650 A2	20140515	JP20130228144	20131101	
JP2015037542 A2	20150226	JP20140150364	20140724	
JP2017060789 A2	20170330	JP20160213964	20070402	
JP2017148605 A2	20170831	JP20170094500	20070402	
JP2018187396 A2	20181129	JP20180091793	20070402	
JP2019213885 A2	20191219	JP20190142914	20070402	
JP2021176523 A2	20211111	JP20210082984	20070402	
JP5208916 B2	20130612	JP20090503335T	20070402	
JP6279421 B2	20180214	JP20140150364	20140724	
JP7273891 B2	20230515	JP20210082984	20070402	
KR101062796 B1	20110906	KR20087026758	20070402	
KR101270113 B1	20130607	KR20127008750	20070402	
KR20090006153 A	20090114	KR20087026781	20081031	
KR20090014268 A	20090209	KR20087026758	20070402	
KR20110038144 A	20110413	KR20117003795	20070402	
KR20120041272 A	20120430	KR20127008750	20070402	
MX2008012601 A1	20090210	MX20080012601	20070402	

Patent Number	Publication Date	Application Number	Application Date	
MX2008012603 A1	20090210	MX20080012603	20070402	
MX299868 B	20120605	MX20080012603	20070402	
NO20084275 A	20081230	NO20080004275	20081013	
NO20084275 L	20081230	NO20080004275	20081013	
NO20084471 A	20081229	NO20080004471	20081023	
NO20084471 L	20081229	NO20080004471	20081023	
NZ571758 A	20120629	NZ20070571758	20070402	
NZ572193 A	20111028	NZ20070572193	20070402	
NZ595349 A	20130125	NZ20070595349	20070402	
NZ595623 A	20130125	NZ20070595623	20070402	
RU2008143223 A	20100510	RU20080143223	20070402	
RU2008143224 A	20100510	RU20080143224	20070402	
RU2010149066 A	20120610	RU20100149066	20101130	
RU2010149861 A	20120610	RU20100149861	20101203	
RU2413480 C2	20110310	RU20080143223	20070402	
RU2414199 C2	20110320	RU20080143224	20070402	
SG170806 A1	20110530	SG20110022605	20070402	
SG170816 A1	20110530	SG20110023116	20070402	
US10300014 BB	20190528	US20180168554	20181023	
US10383817 BB	20190820	US20170852619	20171222	
US10874606 BB	20201229	US20190544884	20190819	
US11406592 BB	20220809	US20180168335	20181023	
US2007243230 AA	20071018	US20070695545	20070402	
US2007269487 AA	20071122	US20070695537	20070402	
US2009092654 AA	20090409	US20080332219	20081210	
US2011276131 AA	20111110	US20110184690	20110718	
US2013101658 AA	20130425	US20120645261	20121004	
US2014161863 AA	20140612	US20140180592	20140214	
US2014236293 AA	20140821	US20140265071	20140429	
US2014328894 AA	20141106	US20140333349	20140716	
US2015224200 AA	20150813	US20150598262	20150116	
US2016008171 AA	20160114	US20150858555	20150918	
US2017128361 AA	20170511	US20170405991	20170113	
US2018133150 AA	20180517	US20170852619	20171222	
US2019054017 AA	20190221	US20180168335	20181023	
US2019054018 AA	20190221	US20180168554	20181023	
US2020000715 AA	20200102	US20190544884	20190819	
US2021212941 AA	20210715	US20200133980	20201224	
US2023165791 AA	20230601	US20220882552	20220806	
US7998497 BB	20110816	US20070695545	20070402	
US8691265 BB	20140408	US20120645261	20121004	
US8747884 BB	20140610	US20110184690	20110718	
US8795711 BB	20140805	US20070695537	20070402	
US9168222 BB	20151027	US20140265071	20140429	
US9549852 BB	20170124	US20150858555	20150918	
US9610194 BB	20170404	US20140180592	20140214	
US9849082 BB	20171226	US20170405991	20170113	
US9849082 K1	20220810	US20170405991	20170113	

Patent Number	Publication Date	Application Number	Application Date	
WO07115259 A2	20071011	WO2007US65789	20070402	
WO07115259 A3	20081016	WO2007US65789	20070402	
WO07115261 A2	20071011	WO2007US65792	20070402	
WO07115261 A3	20090122	WO2007US65792	20070402	
ZA200808401 A	20090624	ZA20080008401	20081002	
ZA200809003 A	20091028	ZA20080009003	20081021	

Priority Numbers: US20060787775P [20060331]; US20060871864P [20061226]; WO2007US65789 [20070402]; WO2007US65792 [20070402]; AU20110235978 [20111012]; AU20070234445 [20070402]; AU20110235979 [20111012]; AU20070234447 [20070402]; CN200780017166 [20070402]; CN200780017176 [20070402]; EP20070759961 [20070402]; EP20070759964 [20070402]; US20060787775 [20060331]; JP20090503335 [20070402]; JP20090503335T [20070402]; JP20090503334 [20070402]; JP20090503334T [20070402]; JP20090503334TT [20070402]; JP20120171816 [20070402]; JP20140150364 [20070402]; JP20160213964 [20161101]; JP20130228144 [20070402]; JP20170094500 [20170511]; JP20160213964 [20070402]; JP20180091793 [20180511]; JP20170094500 [20070402]; JP20190142914 [20190802]; JP20190142914 [20070402]; JP20210082984 [20210517]; RU20080143223 [20081030]; RU20080143224 [20081030]; US20150858555 [20150918]; US20140265071 [20140429]; US20110184690 [20110718]; US20070695545 [20070402]; US20180168554 [20181023]; US20170852619 [20171222]; US20170405991 [20170113]; US20190544884 [20190819]; US20140180592 [20140214]; US20120645261 [20121004]; US20080332219 [20081210]; US20070695537 [20070402]; US20140333349 [20140716]; US20180168335 [20181023]; US20150598262 [20150116]; US20200133980 [20201224]; US20220882552 [20220806]

Probable Patent Assignee: MATI THERAPEUTICS INC

Assignees: QLT PLUG DELIVERY INC; MATI THERAPEUTICS INC; QUADRA LOGIC TECH INC; 3088922 INC; FORSIGHT LABS LLC; REICH CARY; BOYD STEPHEN; DEEM MARK; DE JUAN EUGENE JR; GIFFORD HANSON S; RAPACKI ALAN; ALAN RAPACKI; HANSON S GIFFORD; EUGENE DE JUAN JR; CARY REICH; MARK DEEM; STEPHEN BOYD; NOVELION THERAPEUTICS INC; KLT PLUG DILIVERI INK; FORSIGHT LABS LLC A CALIFORNIA; MATI THERAPEUTICS; DE JUAN JR EUGENE; GIFFORD III HANSON G

Non Std Assignees: QLT INC; FORSIGHT NEWCO II INC; FORSIGHT LABS LLC A CALIFORNIA CORP

Inventors: RAPACKI ALAN; BOYD STEPHEN; JUAN EUGENE DE JR; GIFFORD HANSON S; REICH CARY; DEEM MARK; HANSON S GIFFORD; EUGENE DE JUAN JR; ALAN RAPACKI; MARK DEEM; CARY REICH; STEPHEN BOYD; DE JUAN JR EUGENE; DE JUAN EUGENE JR; GIFFORD III HANSON S; REICH CARY J; DE JUAN JR; GIFFORD HANSON; GIFFORD HANSON S S; GIFFORD HANON S; JUAN JR EUGENE DE; DE JUAN EUGENE; DE DZHUAN ML JUDZHIN; GIFFORD KHENSON S; BOJD STIVEN; REJXH KERI; DIM MARK; RAPAKI ALAN; GIFFORD HANSON S III; GIFFORD HANSON G III; GIFFORD III HANSON G; RAPACKI ALAN R; EUGENE DE JUAN

Non Std Inventors: DEJUAN JR; HANON S GIFFORD; DE DZHUAN ML. JUDZHIN; GIFFORD KHENSON S.; GIFFORD HANSON SIII; GIFFORD HANSON G; GIFFORD HANSON GIII

Agent(s): PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; PIZZEYS; C BRIAN BARLOW AND ASSOCIATES; NORTON ROSE CANADA SENCRL SRL LLP; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; HERNANDEZ YORCK DIPL ING; HGF LTD; SAEZ ANA; CHAN TANG AND KWOK; WILKINSON AND GRIST; GE EHRlich 1995 LTD; REINHOLD COHN AND PARTNERS; OSUGA AND ASSOCIATES; OSUGA YOSHIYUKI; CESAR RAMOS DE MIGUEL; RODYK AND DAVIDSON LLP; ANDERSON KOREN; TOWNSEND AND TOWNSEND AND CREW LLP; SCHWEGMAN LUNDBERG AND WOESSNER PA; PILLSBURY WINTHROP SHAW PITTMAN LLP; KOREN; MATI THERAPEUTICS INC; SHIMMICK JOHN K ET AL

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; AL; BA; HR; MK; RS; AE; AG; AM; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

36. Family 81668715 (US2020353056 AA)


[View in PatBase](#)

Title

[EN] COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF

Abstract

[EN] The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.



International Class: A61K38/39; C07K14/47; A61K38/48; A61K47/64; A61K9/00; A61P27/02; A61K45/00; A61K47/60; A61K47/69; A61K9/06; A61K9/08; A61K9/10; A61P17/02; A61P25/02; A61P25/14; A61P25/28; A61P29/00; A61P43/00; C07K14/78; A61K45/06; A61P25/00

Cooperative Patent Class: A61K38/39; A61K38/4886; A61K45/06; A61K47/6435; A61K9/0019; A61K9/0048; A61P27/02

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2020262096 AA	20211104	AU20200262096	20200422
BR112021021242 A2	20211221	BR20211121242	20200422
CA3132550 AA	20211005	CA20203132550	20200422
CN113795273 A	20211214	CN202080030731	20200422
EP3958889 A2	20220302	EP20200793550	20200422
EP3958889 A4	20221228	EP20200793550	20200422
HK40057250 A1	20220408	HK20226046103	20220112
JP2022530402 T2	20220629	JP20210562953T	20200422
KR20220031946 A	20220314	KR20217037786	20200422
MX2021012579 A1	20211112	MX20210012579	20200422
RU2021133797 A	20230522	RU20210133797	20200422
RU2021133797 A3	20230522	RU20210133797	20200422
SG11202112487Q A1	20211230	SG20211112487	20200422
US11389513 BB	20220719	US20200855097	20200422
US2020353056 AA	20201112	US20200855097	20200422
US2023048200 AA	20230216	US20220854986	20220630
WO20219486 A2	20201029	WO2020US29212	20200422
WO20219486 A3	20201203	WO2020US29212	20200422
WO20219486 A9	20210708	WO2020US29212	20200422

Priority Numbers: US20190836934P [20190422]; US20190933685P [20191111]; US20200959282P [20200110]; WO2020US29212 [20200422]; RU20210133797 [20200422]; US20200855097 [20200422]; US20220854986 [20220630]

Probable Patent Assignee: SUSTAIN HOLDINGS LLC

Assignees: SUSTAIN HOLDINGS LLC

Non Std Assignees: SCHLUMPF RICHARD E; BARATTA ROBERT; DELOREY SHAWN; CALKINS DAVID J; 411 SE OSCEOLA ST SUITE 203 STUART

Inventors: CALKINS DAVID J; DELOREY SHAWN; BARATTA ROBERT; SCHLUMPF RICHARD E; RICHARD E SCHLUMPF; DAVID J CALKINS

Non Std Inventors: ROBERT BARATTA; SHAWN DELOREY; SCHLUMPF RICHARD E R E; BARATTA ROBERT R; DELOREY SHAWN S; CALKINS DAVID J D J

Agent(s): WRAYS PTY LTD; ROBIC; ROBIC AGENCE PI SEC ROBIC IP AGENCY LP; LATSCHA SCHOELLHORN PARTNER AG; FRANCISCO JAVIER UHTHOFF ORIVE; MEDLER FERRO WOODHOUSE AND MILLS PLLC; MEDLER FERRO

WOODHOUSE AND MILLS PLLC; MILLS JEFFREY

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

37. Family 71412133 (US2020038323 AA)

[View in PatBase](#)

Title
[EN] OPTICALLY CLEAR, IN-SITU FORMING BIODEGRADABLE NANO-CARRIERS FOR OCULAR THERAPY, AND METHODS USING SAME

Abstract
[EN] In one aspect, the present invention relates to thermo-reversible hydrogel drug delivery compositions comprising at least one biodegradable copolymer drug carrier. In certain embodiments, the hydrogel compositions of the invention are optically clear and suitable for use in local delivery of ocular therapeutics. In other embodiments, the hydrogel compositions of the invention provide a means for controlled or sustained drug delivery.

International Class: A61K47/30; A61K47/34; A61K31/573; A61K31/728; A61K47/36; A61K47/61; A61K47/64; A61K47/69; A61K9/00; A61K9/107

Cooperative Patent Class: A61K31/573; A61K31/728; A61K47/34; A61K47/36; A61K47/61; A61K47/6455; A61K47/6903; A61K47/6907; A61K9/0024; A61K9/0048; A61K9/0051; A61K9/1075

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3600437 A1	20200205	EP20180776339	20180331
EP3600437 A4	20210106	EP20180776339	20180331
US2020038323 AA	20200206	US20180498689	20180331
US2023140691 AA	20230504	US20220091615	20221230
WO18183984 A1	20181004	WO2018US25604	20180331

Priority Numbers: US20170479716P [20170331]; WO2018US25604 [20180331]; US20180498689 [20180331]; US20190498689 [20190927]; US20220091615 [20221230]


Probable Patent Assignee: ROWAN UNIV

Assignees: ROWAN UNIV; UNIV ROWAN

Inventors: BYRNE MARK E; OSORNO LAURA L; GEORGE WEINSTEIN MINDY; BYRNE MARK; OSORNO LAURA

Agent(s): GRUENECKER PATENT U RECHTSANWAELTE PARTG MBB; SILVA DOMINGOS J ET AL; SAUL EWING ARNSTEIN AND LEHR LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



38. Family 52330124 (US2014073615 AA)

[View in PatBase](#)

Title
[EN] TREATMENT OF PSORIASIS

Abstract
[EN] A lipid layer forming composition for topical treatment of psoriasis comprises volatile silicone oil, polar lipid, C2-C4 aliphatic alcohol, and a pharmacologically effective amount of an agent for the treatment of psoriasis, wherein the silicone oil has a boiling point above 180 degrees centigrade, in particular above 200 degrees centigrade The composition does not comprise polymer silicone. Also disclosed are corresponding methods of treatment and of manufacture of the composition.


International Class: A61K31/573; A61K31/593; A61K47/24; A61K8/58; A61P17/06; A61K38/095; A61K47/10; A61K47/14; A61K8/34; A61K8/37; A61K8/55; A61K8/891; A61K9/08; A61K31/167; A61K31/192; A61K31/196; A61K31/203; A61K31/4174; A61K31/436; A61K31/439; A61K31/56; A61K47/22; A61K47/34; A61K8/04; A61K8/365; A61K8/42; A61K9/12; A61P17/00; A61P31/04; A61Q19/00; A61Q7/00; A61K31/165; A61K31/506; A61K31/60; A61K38/10; A61K38/17; A61K31/351; A61K31/4164; A61K31/575; A61K31/592; A61K31/65; A61K31/7036; A61K31/7048; A61K45/00; A61K31/045; A61K31/05; A61K31/137; A61K31/138; A61K31/14; A61K31/155; A61K31/194; A61K31/198; A61K31/327; A61K31/4196; A61K31/4412; A61K31/4418; A61K31/445; A61K31/455; A61K31/496; A61K31/522; A61K31/5375; A61K31/5578; A61K31/565; A61K31/568; A61K31/616; A61K31/662; A61K31/7056; A61K33/04; A61K33/40; A61K38/13; A61K8/23; A61K8/26; A61K8/35; A61K8/40; A61K8/41; A61K8/44; A61K8/49; A61K47/44; A61K31/245; A61K31/59; A61K9/00

Cooperative Patent Class: A61K31/56; A61K31/573; A61K31/575; A61K31/593; A61K47/24; A61K9/0014; A61K9/12; A61K9/7015; A61P17/06; A61K2800/592; A61K31/137; A61K31/165; A61K31/192; A61K31/196; A61K31/245; A61K31/351; A61K31/4174; A61K31/506; A61K31/59; A61K31/60; A61K38/095; A61K38/10; A61K38/1729; A61K47/10; A61K47/14; A61K47/44; A61K8/34; A61K8/365; A61K8/37; A61K8/375; A61K8/42; A61K8/4953; A61K8/553; A61K8/585; A61K9/08; A61P17/00; A61P31/04; A61Q19/00; A61Q7/00

US Class: 1/1; 424/60; 514/167; 514/182

Family Information

Patent Number	Publication Date	Application Number	Application Date	
AU2012251135 AA	20131107	AU20120251135	20120430	
AU2014349256 AA	20160616	AU20140349256	20141106	
AU2014349256 BB	20200430	AU20140349256	20141106	
CA2834301 AA	20131025	CA20122834301	20120430	
CA2929865 AA	20160505	CA20142929865	20141106	
CA2929865 C	20220104	CA20142929865	20141106	
CN105848684 A	20160810	CN201480062368	20141106	
CN105848684 B	20201016	CN201480062368	20141106	
CN112006989 A	20201201	CN202010951713	20141106	
DE602014048839 D1	20190711	DE201460048839T	20141106	
DK3068437 T3	20190916	DK20140861615T	20141106	
DK3068437 T4	20220926	DK20140861615T	20141106	
EP2709665 A1	20140326	EP20120779278	20120430	
EP2709665 A4	20141112	EP20120779278	20120430	
EP3068437 A1	20160921	EP20140861615	20141106	
EP3068437 A4	20170405	EP20140861615	20141106	
EP3068437 B1	20190619	EP20140861615	20141106	
EP3068437 B2	20220706	EP20140861615	20141106	
EP3610891 A1	20200219	EP20190180857	20141106	
ES2745093 T3	20200227	ES20140861615T	20141106	
ES2745093 T5	20221110	ES20140861615T	20141106	
HU045492 T2	20191230	HU20140861615T	20141106	
IN01984MN2013 A	20140926	IN2013MN01984	20131023	
IN201627017523 A	20160819	IN201627017523	20160520	



Patent Number	Publication Date	Application Number	Application Date	
IN343223 B	20200807	IN201627017523	20160520	
JP2016537339 T2	20161201	JP20160528893T	20141106	
JP6563922 B2	20190821	JP20160528893T	20141106	
KR102297951 B1	20210902	KR20167014035	20141106	
KR20160084409 A	20160713	KR20167014035	20141106	
PL3068437 T3	20200331	PL20140861615T	20141106	
PL3068437 T5	20230220	PL20140861615T	20141106	
PT3068437 T	20190926	PT20140861615T	20141106	
RS59357 B1	20191129	RS20190001174	20141106	
RS59357 B2	20221130	RS20190001174	20141106	
RU2016121389 A	20171218	RU20160121389	20141106	
RU2699651 C1	20190909	RU20160121389	20141106	
TR201913636 T4	20191021	TR20190013636T	20141106	
US10034943 BB	20180731	US20140036183	20141106	
US10363314 BB	20190730	US20180028691	20180706	
US2014073615 AA	20140313	US20120114778	20120430	
US2016303239 AA	20161020	US20140036183	20141106	
US2017360937 A9	20171221	US20140036183	20141106	
US2018311360 AA	20181101	US20180028691	20180706	
WO12150892 A1	20121108	WO2012SE00061	20120430	
WO15072909 A1	20150521	WO2014SE51313	20141106	

Priority Numbers: SE20110000340 [20110502]; WO2012SE00061 [20120430]; SE20130000710 [20131114]; WO2014SE51313 [20141106]; CN201480062368 [20141106]; EP20140861615 [20141106]; US20140036183 [20141106]; US20130114778 [20131030]; US20180028691 [20180706]; US20160036183 [20160512]

Probable Patent Assignee: LIPIDOR AB

Assignees: LIPIDOR AB; CARLSSON ANDERS; HERSLOEF BENGT; HOLMBAECK JAN

Non Std Assignees: HERSLOF BENGT; HOLMBACK JAN

Inventors: CARLSSON ANDERS; HERSLOF BENGT; HOLMBACK JAN; HERSLOEF BENGT; HOLMBAECK JAN; BENGT HERSLOEF; JAN HOLMBAECK

Non Std Inventors: HOLMB CK JAN; HERSL F BENGT; HERSLF BENGT; HOLMBCK JAN

Agent(s): E F WELLINGTON AND CO; EF WELLINGTON AND CO; AJ PARK; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; MALMQVIST MARIA; CONIMAR AB; AWAPATENT AB; AWA SWEDEN AB; SERGIO GARCIA GARCIA; JUAN PEDRO VALLEJO LOPEZ; AOKI ATSUSHI; FUKUMOTO TSUMORU; ISHIDA TAKASHI; KOGA TETSUJI; NEVINPAT; AYLIN SENER; CERMAK NAKAJIMA AND MCGOWAN LLP; CERMAK NAKAJIMA AND MCGOWAN LLP; MCGOWAN MALCOLM K; CONIMAR AB

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

39. Family 49704089 (US2011244010 AA)


[View in PatBase](#)

Title

[EN] MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME

Abstract

[EN] The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.



International Class: A61K9/00; A61F9/00; A61K47/30; A61L31/08; A61L31/16; B33Y80/00; C09D4/00; C9D4/00; A61L12/00; A61L27/54; C08F2/48; C08F220/28; G02B1/04; A61M37/00; G02C7/04; A61F9/007; B05D1/26; B05D1/36; B05D7/00; B32B27/00; A61K31/5377; A61K9/51; C08L33/08; C08L33/10; A61L12/08; A61L12/14; A61L31/06; A61L31/10; A61L31/14; C08F2/20; C08L33/06; C08L39/06; A61K9/70; A61P27/02; B05D1/00; B05D1/02; B05D1/18; B05D1/30; B05D5/00; C08F2/46

Cooperative Patent Class: A61K31/535; A61K31/5377; A61K9/0051; A61L12/00; A61L12/14; A61L2300/00; A61L27/54; A61L31/16; A61P27/02; C08F2/48; C08F220/282; C08L33/08; C08L33/10; G02B1/04; G02B1/043; A61L12/084; A61L12/143; A61L2300/436; A61L2420/08; A61L31/06; A61L31/10; A61L31/145; B33Y80/00; C08F2/20; C08F220/28; C08L33/066; C08L39/06; C08F220/1808; C08F220/20; C08F220/40; C08F222/103; C08F222/1063; C08F226/10; C08L2203/02; C08L5/08; C08L83/04

US Class: 1/1; 424/400; 424/400S; 424/402; 424/402P; 424/429; 424/429S; 424/484; 424/484S; 424/486; 424/486S; 427/2.1; 427/2.100S; 522/183; 522/183S; 526/318.41; 526/318.410S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2011233663 AA	20121018	AU20110233663	20110402
AU2011233663 BB	20160414	AU20110233663	20110402
CA2794956 AA	20120928	CA20112794956	20110402
CA2794956 C	20170502	CA20112794956	20110402
DE602011038366 D1	20170713	DE201160038366T	20110402
DE602011061203 D1	20190822	DE201160061203T	20110402
EP2555751 A1	20130213	EP20110763185	20110402
EP2555751 A4	20140514	EP20110763185	20110402
EP2555751 B1	20170531	EP20110763185	20110402
EP2555751 B8	20180214	EP20110763185	20110402
EP3195858 A1	20170726	EP20170159664	20110402
EP3195858 B1	20190807	EP20170159664	20110402
ES2634551 T3	20170928	ES20110763185T	20110402
IN09244CN2012 A	20140221	IN2012CN09244	20121030
IN386200 B	20220114	IN2012CN09244	20121030
JP2013524275 T2	20130617	JP20130502569T	20110402
JP2015232707 A2	20151224	JP20150101314	20150518
JP2017107216 A2	20170615	JP20160254508	20161227
JP2019034153 A2	20190307	JP20180155030	20180821
NZ602673 A	20140926	NZ20110602673	20110402
SG184244 A1	20121129	SG20120070918	20110402
US10045938 BB	20180814	US20180891456	20180208
US10076493 BB	20180918	US20180898329	20180216
US10188604 BB	20190129	US20180023156	20180629
US10369099 BB	20190806	US20180158587	20181012
US10413506 BB	20190917	US20180188833	20181113

Patent Number	Publication Date	Application Number	Application Date
US10632068 BB	20200428	US20190524015	20190727
US10842740 BB	20201124	US20200826485	20200323
US11077054 BB	20210803	US20200073312	20201017
US11234927 BB	20220201	US20210362203	20210629
US11510869 BB	20221129	US20220588659	20220131
US2011244010 AA	20111006	US20110065904	20110402
US2018193257 AA	20180712	US20180891456	20180208
US2018193258 AA	20180712	US20180898329	20180216
US2018338912 AA	20181129	US20180023156	20180629
US2019046435 AA	20190214	US20180158587	20181012
US2019125662 AA	20190502	US20180188833	20181113
US2020030231 AA	20200130	US20190524015	20190727
US2020268649 AA	20200827	US20200826485	20200323
US2021038509 AA	20210211	US20200073312	20201017
US2021346285 AA	20211111	US20210362203	20210629
US2022218600 AA	20220714	US20220588659	20220131
US9931296 BB	20180403	US20110065904	20110402
WO11123180 A1	20111006	WO2011US00593	20110402
WO11123180 A4	20120216	WO2011US00593	20110402

Priority Numbers: US20100341824P [20100403]; WO2011US00593 [20110402]; EP20110763185 [20110402]; EP20170159664 [20110402]; US2010041824P [20100403]; JP20130502569T [20110402]; JP20150101314 [20150518]; JP20150101314 [20110402]; JP20160254508 [20161227]; JP20160254508 [20110402]; JP20180155030 [20180821]; US20110065904 [20110402]; US20180891456 [20180208]; US20180898329 [20180216]; US20180023156 [20180629]; US20180158587 [20181012]; US20180677021P [20180527]; US20170597272P [20171211]; US20180188833 [20181113]; US20190524015 [20190727]; US20200826485 [20200323]; US20200073312 [20201017]; US20210362203 [20210629]; US20220588659 [20220131]

Probable Patent Assignee: MEDIPRINT OPHTHALMICS INC

Assignees: DOSHI PRAFUL; PRAFUL DOSHI

Non Std Assignees: MEDIPRINT OPHTHALMICS INC; DOSHI PRAFUL POWAY; MEDIPRINT OPHTHALMICS INC; DOSHI, PRAFUL

Inventors: DOSHI PRAFUL; PRAFUL DOSHI

Non Std Inventors: DOSHI PRAFUL SAN DIEGO; DOSHI PRAFUL POWAY

Agent(s): K AND L GATES; MIDDLETONS; PIPERS; PIPERS INTELLECTUAL PROPERTY; RIDOUT AND MAYBEE LLP; SMART AND BIGGAR LP; NOVAGRAAF BREVETS; PATARIN STEPHANIE; NOVAGRAAF TECHNOLOGIES; ISERN JORGE; PRESTON DAVID R; PRESTOR DAVID R; DAVID R; DAVID R PRESTON AND ASSOCIATES

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW


40. Family 71972004 (US2018333357 AA)

[View in PatBase](#)

Title
[EN] NANOEMULSIONS WITH ANTI-INFLAMMATORY ACTIVITY

Abstract

[EN] A sterile-filtered nanoemulsion having oil globules with a median size (Dv50) of about 100 nm or less and containing an oil, emulsion stabilizing polymer, a water-soluble polymer a surfactant, a tonicity modifier or stabilizer, or a combination thereof is provided. The nanoemulsion, even in the absence of an active ingredient, has ameliorative effects including anti-inflammatory activity. The present invention also provides a method of using such a nanoemulsion as an artificial tear composition for treating an ocular surface disorder, including those resulting from contact lens use, by administering an effective amount of the oil-in-water nanoemulsion of the present invention topically to an eye of a subject.



International Class: A61K31/407; A61K31/417; A61K9/00; A61K9/08; A61K31/00; A61K9/06; A61K9/107; A61K31/155; A61K31/4725; A61K31/517; A61K31/537; A61K45/06; A61K47/00; A61K9/10; A61P27/04; A61K31/137; A61K31/436; A61K31/498; A61K31/56; A61K31/573; A61K38/13; A61K47/10; A61K47/12; A61K47/18; A61K47/26; A61K47/32; A61K47/44; A61P27/02; A61K31/496; A61K31/4965; A61K31/58; A61P17/02; A61P17/10; A61P25/04; A61P29/00; A61P31/22; A61P37/02; A61P37/06; A61P37/08; A61P43/00; A61P31/00; A61P5/44; A61K47/14; A61K47/34; A61K47/36; A61K47/38

Cooperative Patent Class: A61K31/137; A61K31/436; A61K31/4725; A61K31/498; A61K31/56; A61K38/13; A61K47/10; A61K47/12; A61K47/186; A61K47/26; A61K47/32; A61K47/44; A61K9/0048; A61K9/1075; A61P27/02; A61K2300/00; A61K31/155; A61K31/517; A61K31/573; A61K45/06; A61K9/06; A61K9/10; A61P27/04; A61P29/00; A61P31/00; A61P5/44

US Class: 1/1; 424/400; 424/78.04; 514/171

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA3115664 AA	20210329	CA20193115664	20190829
CN110996904 A	20200410	CN201880043925	20180405
CN111212642 A	20200529	CN201980001967	20190829
EP3624773 A1	20200325	EP20180801539	20180405
EP3624773 A4	20210407	EP20180801539	20180405
EP3843721 A1	20210707	EP20190856338	20190829
EP3843721 A4	20221012	EP20190856338	20190829
JP2020523406 T2	20200806	JP20200514657T	20180405
US10555947 BB	20200211	US20180946709	20180405
US2018333357 AA	20181122	US20180963955	20180426
US2018333414 AA	20181122	US20180946709	20180405
US2019008920 AA	20190110	US20180116872	20180829
WO18212846 A1	20181122	WO2018US26342	20180405
WO18212955 A1	20181122	WO2018US29646	20180426
WO20047197 A1	20200305	WO2019US48721	20190829

Priority Numbers: US20180116872 [20180829]; WO2019US48721 [20190829]; US20170509015P [20170519]; US20170591548P [20171128]; WO2018US26342 [20180405]; US20180946709 [20180405]; US20180963955 [20180426]

Probable Patent Assignee: OCUGEN INC

Assignees: OCUGEN INC

Non Std Assignees: ARUMUGHAM RASAPPA; UPADHYAY ARUN; HB FUND LLC COLLATERAL AGENT AS

Inventors: ARUMUGHAM RASAPPA; UPADHYAY ARUN; MUSUNURI SHANKAR; JAIN SANDEEP; NUDELL MATTHEW; SOMASEKHAR GOPALAM; UPADHYAY ARUN K

Agent(s): BLAKE CASSELS AND GRAYDON LLP; ZBM PATENTS ZEA BARLOCCI AND MARKVARDSEN; HERRERO AND ASOCIADOS SL; CHA DON D; HDC IP LAW LLP; HDC IP LAW LLP


Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

41. Family 34367009 (US2009220611 AA)

[View in PatBase](#)

Title
[EN] MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL PHARMACEUTICAL FORM COMPRISING SAME

Abstract
[EN] The invention concerns microparticulate systems with modified release of oral active principle(s). The invention aims at providing a novel pharmaceutical with time-dependent and pH-dependent release mechanism, enabling: a) the latent period preceding the release of the active principle in the stomach; b) the pH triggering the release of the active principle in the intestine; c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. A comprises: film-forming (co)polymer (A1) insoluble in fluids of the gastrointestinal tract; ethylcellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract; plasticizing polyvinylpyrrolidone (A3); castor oil/optionally a surfactant and/or magnesium stearate lubricant (A4). B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (EUDRAGIT(R) L100-55) and a hydrophobic compound (B2) (LUBRITAB(R)). The invention also concerns medicines based on said microparticles.



International Class: A23L33/00; A61K31/155; A61K31/519; A61K31/522; A61K9/20; A61K9/48; A61K9/50; A23L1/29; A61K31/4427; A61K31/4436; A61K47/10; A61K47/12; A61K47/14; A61K47/32; A61K47/34; A61K47/38; A61K47/44; A61K9/10; A61K9/14; A61K9/26; A61K9/52; A61K9/66; A61K9/16

Cooperative Patent Class: A61K9/2077; A61K9/5073

US Class: 424/494; 424/494S; 424/495; 424/495P; 424/497; 424/497S

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2624372 AA	20080328	CA20062624372	20060927
CA2624372 C	20140401	CA20062624372	20060927
CN101277684 A	20081001	CN200680036080	20060927
CN101277684 B	20130227	CN200680036080	20060927
DE602006060356 D1	20220707	DE200660060356T	20060927
EP1931320 A2	20080618	EP20060831231	20060927
EP1931320 B1	20220615	EP20060831231	20060927
ES2922387 T3	20220914	ES20060831231T	20060927
FR2891459 A1	20070406	FR20050052985	20050930
FR2891459 B1	20071228	FR20050052985	20050930
JP2009510036 T2	20090312	JP20080532838T	20060927
JP5495565 B2	20140521	JP20080532838T	20060927
US2009220611 AA	20090903	US20060992769	20060927
WO07036671 A2	20070405	WO2006FR50944	20060927
WO07036671 A3	20070524	WO2006FR50944	20060927

Priority Numbers: FR20050052985 [20050930]; WO2006FR50944 [20060927]; EP20060831231 [20060927]

Probable Patent Assignee: FLAMEL TECHNOLOGIES SA

Assignees: FLAMEL TECH SA; MEYRUEIX REMI; DARGELAS FREDERIC; SOULA GERARD; CASTAN CATHERINE; GUIMBERTEAU FLORENCE; FLAMEL IRELAND LTD; FLAMEL TECHNOLOGIES SA

Non Std Assignees: FLAMEL TECHNOLOGIES; FLAMEL TECHNOLOGIES SOCIETE ANONYME; FLAMEL TECHNOLOGIES SOC ANONYME

Inventors: CASTAN CATHERINE; DARGELAS FREDERIC; MEYRUEIX REMI; SOULA GERARD; GUIMBERTEAU FLORENCE; FLORENCE GUIMBERTEAU; REMI MEYRUEIX; GERARD SOULA; CATHERINE CASTAN; FREDERIC DARGELAS

Agent(s): NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; OGILVY RENAULT LLP SENCRL SRL; PLASSERAUD EXPANSION MUNICH SARL; CABINET PLASSERAUD; PLASSERAUD IP; MIKEL VEIGA SERRANO; PATTON BOGGS LLP

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HN; HR; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; MK; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RS; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

42. Family 92561839 (WO22159504 A1)

[View in PatBase](#)

Title

[EN] DEUTERATED CANNABINOID COMPOUNDS

Abstract

[EN] This invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds, methods for preparation thereof, compositions comprising the same, and uses thereof for the treatment or prevention of numerous diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.

International Class: A61K31/35; A61K31/352; C07D311/78; C07D311/80

Cooperative Patent Class: A61K31/05; A61K31/352; C07B2200/05; C07C39/19; C07D311/58; C07D311/80

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO22159504 A1	20220728	WO2022US12997	20220119

Priority Numbers: US20210139220P [20210119]; US20210139239P [20210119]; US20210151127P [20210219]; US20210151138P [20210219]; US20210151145P [20210219]; US20210151159P [20210219]

Probable Patent Assignee: MERIT THERAPEUTICS INC

Assignees: MERIT THERAPEUTICS INC

Inventors: LAUFER RALPH; SUMMA VINCENZO

Agent(s): PEARL COHEN ZEDEK LATZER BARATZ LLP ET AL

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

43. Family 92561830 (WO22159507 A1)


[View in PatBase](#)

Title

[EN] COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS

Abstract

[EN] This invention relates to methods comprising administration of cannabinoid compounds and at least one additional therapeutic agent for the treatment or prevention of diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (e.g., Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.



International Class: A61K31/352; A61K45/06; A61P25/24

Cooperative Patent Class: A61K31/05; A61K31/138; A61K31/352; A61K31/403; A61K45/06; A61P25/24

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO22159507 A1	20220728	WO2022US13000	20220119

Priority Numbers: US20210139256P [20210119]

Probable Patent Assignee: MERIT THERAPEUTICS INC

Assignees: MERIT THERAPEUTICS INC

Inventors: LAUFER RALPH; SUMMA VINCENZO; HELLER CAROLINE J

Agent(s): COHEN MARK S ET AL; PEARL COHEN ZEDEK LATZER BARATZ LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

44. Family 92561837 (WO22159506 A1)

[View in PatBase](#)

Title
[EN] DEUTERATED CANNABIDIOL COMPOUNDS

Abstract
[EN] This invention relates to deuterated cannabidiol compounds, methods for preparation thereof, compositions comprising the same, uses thereof, and methods comprising administration of deuterated cannabidiol compounds and at least one additional therapeutic agent, for the treatment or prevention of diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.

International Class: A61K31/045; A61K31/05; C07C39/08; C07C39/18; C07C39/19

Cooperative Patent Class: A61K31/05; A61K31/138; A61K31/403; A61K45/06; C07B2200/05; C07C2601/16; C07C39/23

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO22159506 A1	20220728	WO2022US12999	20220119

Priority Numbers: US20210139232P [20210119]; US20210139246P [20210119]; US20210171314P [20210406]; US20210171335P [20210406]; US20210254689P [20211012]


Probable Patent Assignee: MERIT THERAPEUTICS INC

Assignees: MERIT THERAPEUTICS INC

Inventors: LAUFER RALPH; SUMMA VINCENZO

Agent(s): PEARL COHEN ZEDEK LATZER BARATZ LLP ET AL

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



45. Family 49514223 (US2012321719 AA)

[View in PatBase](#)

Title

[EN] SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT

Abstract

[EN] Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

International Class: A61K31/519; A61K31/52; A61K47/30; A61K9/28; A61P27/00; A61P27/02; A61K45/06; A61K47/58; A61K47/60; A61K47/69; A61K9/00; A61K9/16; A61K9/50; A61K9/51; A61K31/56; A61K39/395; A61K9/14; A61K47/48

Cooperative Patent Class: A61K31/519; A61K31/52; A61K45/06; A61K47/58; A61K47/60; A61K47/6921; A61K47/6931; A61K9/0048; A61K9/0051; A61K9/1641; A61K9/1647; A61K9/1676; A61K9/5026; A61K9/5031; A61K9/5146; A61K9/5153; A61P27/00; A61P27/02

US Class: 1/1; 424/130.1; 424/428; 424/490; 424/497; 514/169

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2791278 AA	20110901	CA20112791278	20110225
CA2791278 C	20151124	CA20112791278	20110225
EP2538929 A2	20130102	EP20110748181	20110225
EP2538929 A4	20140709	EP20110748181	20110225
US10369107 BB	20190806	US20180884158	20180130
US2012321719 AA	20121220	US20110581454	20110225
US2015044270 AA	20150212	US20140521904	20141023
US2016235674 AA	20160818	US20160138132	20160425
US2018161277 AA	20180614	US20180884158	20180130
US2019321297 AA	20191024	US20190502359	20190703
US2022142924 AA	20220512	US20210475528	20210915
US8889193 BB	20141118	US20110581454	20110225
US9566242 BB	20170214	US20140521904	20141023
US9937130 BB	20180410	US20160138132	20160425
WO11106702 A2	20110901	WO2011US26321	20110225
WO11106702 A3	20120126	WO2011US26321	20110225

Priority Numbers: US20100308053P [20100225]; US20100308042P [20100225]; US20100308035P [20100225]; WO2011US26321 [20110225]; US20140521904 [20141023]; US20120581454 [20120827]; US20160138132 [20160425]; US20180884158 [20180130]; US20110581454 [20110225]; US20190502359 [20190703]; US20210475528 [20210915]

Probable Patent Assignee: JOHNS HOPKINS UNIV


Assignees: UNIV JOHNS HOPKINS; KHAN YASIN A; JOHNS HOPKINS UNIV; HANES JUSTIN S; BEHRENS ASHLEY; KASHIWABUCHI RENATA T; MCDONNELL PETER J; LAI SAMUEL K

Non Std Assignees: THE JOHNS HOPKINS UNIVERSITY

Inventors: KASHIWABUCHI RENATA T; KHAN YASIN A; MCDONNELL PETER J; BEHRENS ASHLEY; HANES JUSTIN S; LAI SAMUEL K

Agent(s): BERESKIN AND PARR LLP SENCRL SRL; WRIGHT ANDREW JOHN; POTTER CLARKSON LLP; PABST PATENT GROUP LLP; PABST PATENT GROUP LLP; BARRY THOMAS F ET AL; VENABLE LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



46. Family 42802438 (US2009017097 AA)

[View in PatBase](#)

Title
[EN] HYDROGEL POLYMERIC COMPOSITIONS AND METHODS

Abstract
[EN] Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreous site for controlled release of a therapeutic agent.

International Class: A61K9/00; A61L27/00; A61K31/196; A61K31/405; A61K31/4422; A61K31/445; A61K31/496; A61K31/573; A61K47/34; A61K47/42; A61K9/06; A61P27/02; C08L101/14; A61K31/4458; A61K31/58; A61K47/10; A61P27/14; A61K31/7088; A61K38/00; A61K9/10; A61K9/127; A61P27/00; A61F2/00

Cooperative Patent Class: A61K31/196; A61K31/405; A61K31/4422; A61K31/445; A61K31/4458; A61K31/496; A61K31/573; A61K31/58; A61K47/10; A61K9/0019; A61K9/0048; A61K9/0051; A61K9/06; A61P27/00; A61P27/02; A61P27/14

US Class: 1/1; 424/427; 424/450; 424/484; 424/486; 424/486S; 514/1.1; 514/1.100P; 514/12; 514/174; 514/180; 514/2; 514/253.08; 514/330; 514/356; 514/420; 514/44; 514/44.00RS; 514/44R; 514/567

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2008275786 AA	20090115	AU20080275786	20080514
AU2008275786 BB	20131017	AU20080275786	20080514
CA2692545 AA	20090115	CA20082692545	20080514
DE602008059764 D1	20190509	DE200860059764T	20080514
DK2187980 T3	20190715	DK20080754416T	20080514
EP2187980 A1	20100526	EP20080754416	20080514
EP2187980 A4	20120808	EP20080754416	20080514
EP2187980 B1	20190417	EP20080754416	20080514
ES2733673 T3	20191202	ES20080754416T	20080514
JP2010533225 T2	20101021	JP20100516020T	20080514
JP5693954 B2	20150401	JP20100516020T	20080514
US10251954 BB	20190409	US20160186994	20160620
US11324828 BB	20220510	US20190280434	20190220
US2009017097 AA	20090115	US20070825848	20070709
US2009252781 AA	20091008	US20090485192	20090616
US2014363498 AA	20141211	US20140470081	20140827
US2016296623 AA	20161013	US20160186994	20160620
US2019247504 AA	20190815	US20190280434	20190220
US9125807 BB	20150908	US20070825848	20070709
US9370485 BB	20160621	US20140470081	20140827
US9775906 BB	20171003	US20090485192	20090616
WO09008946 A1	20090115	WO2008US06114	20080514

Priority Numbers: US20070825848 [20070709]; WO2008US06114 [20080514]; EP20080754416 [20080514]; US20090485192 [20090616]; US20140470081 [20140827]; US20160186994 [20160620]; US20190280434 [20190220]

Probable Patent Assignee: INCEPT LLC


Assignees: INCEPT LLC; SAWHNEY AMARPREET S; RANSONE II WILLIAM H; RANSONE WILLIAM H II

Non Std Assignees: MIDCAP FINANCIAL TRUST AGENT AS; BARINGS FINANCE LLC AGENT AS; OCULAR THERAPEUTIX INC

Inventors: SAWHNEY AMARPREET S; RANSONE WILLIAM H II; RANSONE II WILLIAM H; RANSONE WILLIAM H JR

Non Std Inventors: AMARPREET S SAWHNEY; WILLIAM H RANSONE II; SAWHNEY AMARPREET; RANSONE WILLIAM

Agent(s): GRIFFITH HACK; VON KREISLER SELTING WERNER; DOMPATENT VON KREISLER SELTING WERNER PARTNERSCHAFT VON PATENT U RECHTSANWAELTEN MBB; LEHMANN NOVO MARIA ISABEL; CHRISTENSEN FONDER DARDI AND HERBERT PLLC; CHRISTENSEN FONDER DARDI AND HERBERT PLLC; HERBERT CURTIS B; BENNETT DIANE



E; DARDI PETER S; DARDI AND ASSOCIATES PLLC; DARDI AND ASSOCIATES PLLC US BANK PLAZA SUITE 2000; CURTIS B; DARDI AND HERBERT PLLC; CURTIS; HERBERT CURTIS B ET AL; DARDI AND ASSOCIATES PLLC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AL; BA; MK; RS; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

47. Family 51892857 (US2014147413 AA)

[View in PatBase](#)

Title
[EN] THERAPIES THAT TARGET AUTOIMMUNITY FOR TREATING GLAUCOMA AND OPTIC NEUROPATHY

Abstract
[EN] The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

International Class: A61K31/436; A61K39/395; A61K45/06; G01N33/569; G01N33/68; A61K9/00; A61K31/382; A61K31/4168; A61K31/4178; A61K31/433; A61K31/4704; A61K31/5377; A61K31/5575; A61K31/683; A61K38/13; A61K38/17; A61K38/21; C07K16/28; A61K38/00; A61P27/02; A61P27/06; A61P37/06; G01N33/53

Cooperative Patent Class: A61K2039/505; A61K31/382; A61K31/4168; A61K31/4178; A61K31/433; A61K31/436; A61K31/4704; A61K31/5377; A61K31/5575; A61K31/683; A61K38/13; A61K38/1793; A61K38/21; A61K39/3955; A61K45/06; A61K9/0048; A61K9/0051; A61P27/02; A61P27/06; A61P37/06; C07K16/2809; G01N2800/164; G01N33/56972; G01N33/6854; G01N33/6893

US Class: 1/1; 424/154.1; 424/173.1; 424/85.4; 435/7.24; 435/7.92; 514/291

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2014147413 AA	20140529	US20120002036	20120228
US2019004064 AA	20190103	US20180032812	20180711
US2022034903 AA	20220203	US20210451194	20211018
WO12118863 A1	20120907	WO2012US27036	20120228
WO12118863 A9	20130103	WO2012US27036	20120228

Priority Numbers: US20110447379P [20110228]; US20110481400P [20110502]; WO2012US27036 [20120228]; US20120002036 [20120228]; US20140002036 [20140213]; US20180032812 [20180711]; US20210451194 [20211018]

Probable Patent Assignee: SCHEPENS EYE RESEARCH INST INC


Assignees: CHEN HUIHUI; CHEN JIANZHU; CHEN DONG FENG; SCHEPENS EYE RES INST INC; MASSACHUSETTS INST OF TECH; MASSACHUSETTS INST TECHNOLOGY; SCHEPENS EYE RES INST

Non Std Assignees: MASSACHUSETTS INST OF TECHNOLOGY; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALTH AND HUMAN SERVICES DHHS US GOVERNMENT; SCHEPENS EYE RESEARCH INST INC; NATIONAL INSTITUTES OF HEALTH; NATIONAL INSTITUTES OF HEALTH DIRECTOR DEITR; THE SCHEPENS EYE RESEARCH INSTITUTE INC; MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventors: CHEN HUIHUI; CHEN JIANZHU; CHEN DONG FENG

Agent(s): BEATTIE INGRID A ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



48. Family 75911178 (US2021255170 AA)

[View in PatBase](#)

Title
[EN] INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPIHELIAL STEM CELLS

Abstract
[EN] Compositions and methods to modulate Lef-1/TCF/Wnt signaling ex vivo or in vivo, and assays to detect those modulators, are described.

International Class: C07K14/47; C07K14/475; G01N33/50; C12N5/07; C12N5/0789

Cooperative Patent Class: A61K31/506; A61K33/00; A61K35/12; A61K48/0066; C07K14/435; C07K14/4705; C07K14/4753; C12N15/625; C12N5/0692; G01N33/5041; G01N33/5061; G01N33/5073

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2021255170 AA	20210819	US20200980268	20190313
WO19178267 A2	20190919	WO2019US22106	20190313
WO19178267 A3	20191010	WO2019US22106	20190313

Priority Numbers: US20180642320P [20180313]; WO2019US22106 [20190313]; US20190980268 [20190313]

Probable Patent Assignee: UNIV IOWA RES FOUND


Assignees: UNIV IOWA RES FOUND; ENGELHARDT JOHN F; LYNCH THOMAS J; ANDERSON PRESTON J; SHAHIN WEAM

Non Std Assignees: OF IOWA RESEARCH FOUNDATION UNIV; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALTH AND HUMAN SERVICES DHHS US GOVERNMENT

Inventors: ENGELHARDT JOHN F; LYNCH THOMAS J; ANDERSON PRESTON J; SHAHIN WEAM; ENGELHARDT JOHN; LYNCH THOMAS; ANDERSON PRESTON

Agent(s): PERDOK MONIQUE M ET AL

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW




49. Family 31522033 (US2005031697 AA)

[View in PatBase](#)

Title
[EN] COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME

Abstract
[EN] The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.



FDA Data

Application Number	Active Ingredient	Proprietary Name	Applicant	Date Of Approval
022427	KETOROLAC TROMETHAMINE	ACUVAIL	ABBVIE	20090722
022427	KETOROLAC TROMETHAMINE	ACUVAIL	ALLERGAN	20090722

International Class: A61K31/00; A61K9/00; A61K47/00; A61K31/498; A61K31/5575; A61K47/32; A61K47/38; A61K9/08; A61P27/02; A61P27/06; A61P43/00; C07D403/12; A61K31/407; A61K31/40; A61K9/14

Cooperative Patent Class: A61K31/00; A61K31/407; A61K47/38; A61K9/0048; A61P27/02; A61P27/06; A61P43/00

US Class: 424/400; 424/488; 424/488P; 514/413; 514/57; 514/57S

Family Information

Patent Number	Publication Date	Application Number	Application Date	
AT444732 E	20091015	AT20040780382T	20040805	
AU2004263149 AA	20050217	AU20040263149	20040805	
AU2004263149 BB	20100819	AU20040263149	20040805	
BRPI0413381 A	20061017	BR2004PI13381	20040805	
CA2534484 AA	20060202	CA20042534484	20040805	
DE602004023516 D1	20091119	DE200460023516T	20040805	
DE602004049488 D1	20160804	DE200460049488T	20040805	
DK1654002 T3	20100201	DK20040780382T	20040805	
DK1654002 T4	20140217	DK20040780382T	20040805	
EP1654002 A2	20060510	EP20040780382	20040805	
EP1654002 B1	20091007	EP20040780382	20040805	
EP1654002 B2	20140129	EP20040780382	20040805	
EP2113246 A1	20091104	EP20090010226	20040805	
EP2113246 B1	20160622	EP20090010226	20040805	
ES2332049 T3	20100125	ES20040780382T	20040805	
ES2332049 T5	20140327	ES20040780382T	20040805	
ES2593113 T3	20161205	ES20090010226T	20040805	
JP2007501799 T2	20070201	JP20060522767T	20040805	
PL1654002 T3	20100331	PL20040780382T	20040805	
PL1654002 T5	20140630	PL20040780382T	20040805	
US2005031697 AA	20050210	US20040911966	20040805	
US2013296396 AA	20131107	US20130933807	20130702	
US2015164863 AA	20150618	US20150629652	20150224	
US2021251961 AA	20210819	US20200132246	20201223	

Patent Number	Publication Date	Application Number	Application Date	
US8512717 BB	20130820	US20040911966	20040805	
US8992952 BB	20150331	US20130933807	20130702	
WO05014046 A2	20050217	WO2004US25540	20040805	
WO05014046 A3	20060601	WO2004US25540	20040805	

Priority Numbers: US20030493188P [20030807]; US20030493178P [20030807]; WO2004US25540 [20040805]; EP20090010226 [20040805]; EP20040780382 [20040805]; US20040911966 [20040805]; US20130933807 [20130702]; US20150629652 [20150224]; US20200132246 [20201223]

Probable Patent Assignee: ALLERGAN INC

Assignees: ALLERGAN INC; ALLERGAN SALES INC; VEHIGE JOSEPH G; GRAHAM RICHARD; LYONS ROBERT T; CHANG CHIN MING; CHANG JAMES N; KUAN TERESA H

Non Std Assignees: ALLERGAN INC IRVINE; ALLERGAN INCORPORATED

Inventors: LYONS ROBERT; CHANG JAMES; GRAHAM RICHARD; KUAN TERESA; VEHIGE JOSEPH; CHANG CHIN MING; VEHIGE JOSEPH G; LYONS ROBERT T; CHANG JAMES N; KUAN TERESA H; KUAN THERESA H

Non Std Inventors: TERESA H KUAN; ROBERT T LYONS; CHIN MING CHANG; RICHARD GRAHAM; JOSEPH G VEHIGE; JAMES N CHANG

Agent(s): DAVIES COLLISON CAVE PTY LTD; DAVIES COLLISON CAVE; GOWLING LAFLEUR HENDERSON LLP; HOFFMANN EITLE PATENT U RECHTSANWAELTE PARTMBB; HOFFMANN EITLE; CARPINTERO MARIO; FUSTER GUSTAVO NICOLAS; AOYAMA TAMOTSU; SHIBATA YASUO; SHINAGAWA HISATOSHI; TAMURA YASUO; FRANK J UXA SUITE 300; STOUT UXA BUYAN AND MULLINS LLP; ALLERGAN INC; MARK D

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

50. Family 44993761 (US2013017262 AA)

[View in PatBase](#)

Title
[EN] IMMEDIATE/DELAYED DRUG DELIVERY

Abstract
[EN] In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug.

International Class: A61K9/24; A61K31/00; A61K31/196; A61K38/12; A61K9/20; A61K45/00; A61K47/14; A61K47/38; A61K47/44; A61P19/02; A61P29/00; A61K9/42; A61K9/00; A61K38/00; A61P1/04; A61P1/06; A61P1/10; A61P25/00; A61P25/20; A61P3/06; A61P31/00; A61P37/02; A61P7/00; A61P7/02; A61P7/10; A61P9/00; A61P9/06; A61P9/08; A61P9/10; A61P9/12

Cooperative Patent Class: A61K31/00; A61K31/196; A61K38/00; A61K38/12; A61K9/2018; A61K9/2054; A61K9/2068; A61K9/209; A61P1/04; A61P1/06; A61P1/10; A61P19/02; A61P25/00; A61P25/20; A61P29/00; A61P3/06; A61P31/00; A61P37/02; A61P7/00; A61P7/02; A61P7/10; A61P9/00; A61P9/06; A61P9/08; A61P9/10; A61P9/12; Y02A50/30

US Class: 1/1; 424/465; 514/567

Family Information


Patent Number	Publication Date	Application Number	Application Date
DE602011043543 D1	20180104	DE201160043543T	20110304
DK2542227 T3	20180226	DK20110709765T	20110304
EP2542227 A2	20130109	EP20110709765	20110304
EP2542227 B1	20171122	EP20110709765	20110304
ES2659815 T3	20180319	ES20110709765T	20110304
GB201003731 A0	20100421	GB20100003731	20100305
GB201217611 A0	20121114	GB20120017611	20110304
GB2491328 A1	20121128	GB20120017611	20110304
HU036629 T2	20180730	HU20110709765T	20110304
JP2013521334 T2	20130610	JP20120556577T	20110304
JP2016026227 A2	20160212	JP20150219314	20151109
JP6162197 B2	20170712	JP20150219314	20151109
NO2542227 T3	20180421	NO11700009765	20110304
PL2542227 T3	20180430	PL20110709765T	20110304
PT2542227 T	20180221	PT20110709765T	20110304
SI2542227 T1	20180430	SI20110031396T	20110304
TR201802201 T4	20180321	TR20180002201T	20110304
US10137091 BB	20181127	US20110582940	20110304
US11065205 BB	20210720	US20180195456	20181119
US2013017262 AA	20130117	US20110582940	20110304
US2019125679 AA	20190502	US20180195456	20181119
WO1107755 A2	20110909	WO2011GB00314	20110304
WO1107755 A3	20120503	WO2011GB00314	20110304

Priority Numbers: GB20100003731 [20100305]; EP20110709765 [20110304]; WO2011GB00314 [20110304]; JP20120556577T [20110304]; JP20150219314 [20151109]; US20180195456 [20181119]; US20120582940 [20121002]

Probable Patent Assignee: DRUG DELIVERY INT LTD

Assignees: UNIV OF STRATHCLYDE; UNIV STRATHCLYDE; MULLEN ALEXANDER; STEVENS HOWARD; ECCLESTON SARAH; DRUG DELIVERY INT LTD

Non Std Assignees: OF STRATHCLYDE UNIV; UNIVERSITY OF STRATHCLYDE



Inventors: STEVENS HOWARD; ECCLESTON SARAH; MULLEN ALEXANDER; HOWARD STEVENS; SARAH ECCLESTON; ALEXANDER MULLEN

Agent(s): CHAPMAN PAUL GILMOUR; MARKS AND CLERK LLP; VALLEJO JUAN PEDRO; ASAI KENJI; HAKODA ATSUSHI; ICHIKAWA SATSUKI; KUMAKURA YOSHIO; YAMASAKI KAZUO; DESHIMARU TAKESHI; NISHIJIMA TAKAKI; TOLGA CAYLAK; HOXIE AND ASSOCIATES LLC; HOXIE AND ASSOCIATES LLC; NAISMITH ROBERT STEWART ET AL; MARKS AND CLERK LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

51. Family 49080251 (US2014088199 AA)

[View in PatBase](#)

Title
[EN] OPHTHALMIC TREATMENTS

Abstract
[EN] Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-HT receptors, such as tramadol. Typical tramadol levels would be in the range of 0.5 percent to 1.0 percent w/v. The aqueous compositions may for example be used as artificial tears, and as general ophthalmic lubricants for treating conditions such as dry eye or blepharitis. Further compositions combine ophthalmologically-active agents, such as pharmaceuticals, with opioids, such as tramadol in particular. These compositions may be used to treat the eye while reducing pain or discomfort that would normally be produced by administering these particular pharmaceuticals to the eye, and increasing the efficacy of the pharmaceuticals. Compositions are also disclosed, containing opioids with 5-HT receptor activity, which are of general use in alleviating pain in and around the eye.

International Class: A61L9/00; A61K31/135; A61K45/06; A61K9/00; A61K9/08; A61K31/137; A61K47/32; A61K47/36; A61K47/38; A61P25/04; A61P27/02; A61P29/00; A61P27/04; A61K31/4178; A61K; A61P; A61K45/00; A61P43/00; A61K9/06; A61K9/107; A61K31/717; A61K31/728; A61K31/78; A61P27/00

Cooperative Patent Class: A61K31/135; A61K31/137; A61K31/4178; A61K45/06; A61K47/32; A61K47/36; A61K9/0048; A61K9/06; A61K9/08; A61P25/04; A61P27/00; A61P27/02; A61P27/04; A61P29/00; A61P43/00; A61K2300/00

US Class: 1/1; 514/397; 514/646

Family Information

Patent Number	Publication Date	Application Number	Application Date
BR112013025493 A2	20170301	BR20131125493	20120405
CA2869280 AA	20141001	CA20122869280	20120405
CA2869280 C	20200310	CA20122869280	20120405
CN103687594 A	20140326	CN201280025096	20120405
CN107982211 A	20180504	CN201711200533	20120405
DE602012072663 D1	20201029	DE201260072663T	20120405
EP2694048 A2	20140212	EP20120721571	20120405
EP2694048 B1	20201007	EP20120721571	20120405
EP3799866 A1	20210407	EP20200200285	20120405
ES2836808 T3	20210628	ES20120721571T	20120405
GB201105731 A0	20110518	GB20110005731	20110405
GB201105732 A0	20110518	GB20110005732	20110405
HK1254720 A1	20190726	HK20180113731	20181026
JP2014513073 A2	20140529	JP20140503208	20120405
JP2014513073 T2	20140529	JP20140503208T	20120405
JP2017141243 A2	20170817	JP20170043172	20170307
JP6148664 B2	20170614	JP20140503208T	20120405
JP6419876 B2	20181107	JP20170043172	20170307
KR102165246 B1	20201013	KR20187038197	20120405
KR20140145948 A	20141224	KR20137029016	20120405
KR20190004815 A	20190114	KR20187038197	20120405
MA35070 B1	20140403	MA20130036378	20131031
MX2013011314 A1	20140327	MX20130011314	20120405
MX346312 B	20170315	MX20130011314	20120405
TN2013000405 A1	20150330	TN20130000405	20131004
US2014088199 AA	20140327	US20120009397	20120405
US2016199320 AA	20160714	US20160076098	20160321
US9913813 BB	20180313	US20160076098	20160321
WO12136969 A2	20121011	WO2012GB00330	20120405
WO12136969 A3	20130103	WO2012GB00330	20120405

Priority Numbers: GB20110005731 [20110405]; GB20110005732 [20110405]; WO2012GB00330 [20120405]; CN201280025096 [20120405]; EP20120721571 [20120405]; JP20140503208T [20120405]; JP20170043172 [20170307]; US20130009397 [20131126]; US20160076098 [20160321]

Probable Patent Assignee: OPTOSOLVE RESEARCH AND DEVELOPMENT LTD

Assignees: OPTSOLVE LLP; SHARMA ANANT; OPTOSOLVE LLP; OPTOSOLVE RES AND DEVELOPMENT LTD; OPTOSOLVE RES AND DEV LTD

Non Std Assignees: OPTOSOLVE LLP261 ALCESTER ROAD SOUTHTRAFALGAR HOUSEKINGS HEATHWEST MIDLANDSB14 6DT BIRMINGHAMGB; OPTOSOLVE RESEARCH AND DEVELOPMENT LTD

Inventors: ANANT SHARMA; SHARMA ANANT

Non Std Inventors: SHARMA ANANTGB

Agent(s): RIDOUT AND MAYBEE LLP; SMART AND BIGGAR LP; HERNANDEZ YORCK DIPL ING; STRATAGEM IPM LTD; ANA SAEZ MAESO; CLT PATENT AND TRADEMARK HK LTD; KITA AOYAMA INT PATENT BUREAU; EUGENIO PEREZ PEREZ; FORGE IP PLLC; BANFORD JONATHAN; FRANKS AND CO SOUTH LTD

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZM; ZW; ZA

52. Family 30301448 (US2004096499 AA)

[View in PatBase](#)


Title
[EN] NOVEL DOSAGE FORM

Abstract
[EN] A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

International Class: A61K31/155; A61K31/185; A61K31/19; A61K31/21; A61K31/22; A61K31/4025; A61K31/455; A61K31/53; A61K9/20; A61K9/22; A61K9/24; A61K31/4439; A61K9/26; A61K9/00

Cooperative Patent Class: A61K31/155; A61K31/19; A61K31/22; A61K31/4025; A61K31/455; A61K31/53; A61K9/2077; A61K9/2081; A61K9/209

US Class: 424/464; 424/465; 424/468; 424/468P; 424/469; 424/470



Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2003274681 AA	20040223	AU20030274681	20030801
AU2003274681 AH	20040223	AU20030274681	20030801
BRPI0313424 A	20050614	BR2003PI13424	20030801
BRPI0313424 B1	20171031	BR2003PI13424	20030801
BRPI0313424 B8	20210525	BR2003PI13424	20030801
DE60344324 D1	20130814	DE20036044324	20030801
EP1528917 A2	20050511	EP20030758649	20030801
EP1528917 B1	20130619	EP20030758649	20030801
IN00699MU2002 A	20040529	IN2002MU00699	20020805
US2004096499 AA	20040520	US20030630446	20030729
US2006024365 AA	20060202	US20050134633	20050519
US2006153916 AA	20060713	US20030522989	20030801
US7985422 BB	20110726	US20030630446	20030729
US8263125 BB	20120911	US20050134633	20050519
WO04012700 A2	20040212	WO2003IN00262	20030801
WO04012700 A3	20040401	WO2003IN00262	20030801

Priority Numbers: IN2002MU00697 [20020805]; IN2002MU00699 [20020805]; WO2003IN00262 [20030801]; IN2003MU00080 [20030122]; IN2003MU00082 [20030122]; EP20030758649 [20030801]; US20050134633 [20050519]; US20030630446 [20030729]

Probable Patent Assignee: TORRENT PHARMACEUTICALS LTD

Assignees: TORRENT PHARMACEUTICALS LTD; NADKARNI SUNIL SADANAND; GUPTA VINOD KUMAR; VAYA NAVIN; SADANAND SUNIL; KARAN RAJESH S; GUPTA VINOD K; NADKARNI SUNIL S; QUPTA VINOD K; KARAN RAJESH SINGH

Non Std Assignees: TORRENT PHARMACEUTICALS LIMITED; TORRENT PHARMACEUTICALS LTD AHMEDABAD; KAREN RAJESH SINGH

Inventors: NADKARNI SUNIL SADANAND; KARAN RAJESH SINGH; VAYA NAVIN; NAVIN VAYA; SUNIL SADANAND NADKARNI; RAJESH SINGH KARAN; VINOD KUMAR GUPTA; GUPTA VINOD KUMAR; KAREN RAJESH SINGH; SADANAND SUNIL; KARAN RAJESH S; GUPTA VINOD K; NADKARNI SUNIL S; QUPTA VINOD K

Non Std Inventors: NADKARNI SUNIL SADANAND; RAJESH SINGH KAREN; KARAN RAJESH; GUPTA VINOD; NADKARNI SUNIL; QUPTA VINOD

Agent(s): FLEISCHER ENGELS AND PARTNER MBB PATENTANWALTE; BOFF JAMES CHARLES; HEDMAN AND COSTIGAN PC; NIXON AND VANDERHYE PC; JAMES V

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NI; NO; NZ; OM; PG; PH; PL; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

53. Family 60282995 (WO15136186 A1)


[View in PatBase](#)

Title
[EN] NON-VOLATILE OPHTHALMIC COMPOSITION, IN PARTICULAR FOR TREATING DRY EYE SYNDROME

Abstract
[EN] The present invention concerns an ophthalmic composition comprising a lubricating polymer and an oligosaccharide, and the topical use of same, in particular for treating dry eye syndrome.

International Class: A61K31/7008; A61K31/7016; A61K9/00; A61P27/04; A61K31/728; A61K31/00; A61P27/00

Cooperative Patent Class: A61K31/7008; A61K31/7016; A61K47/26; A61K47/36; A61K9/0048; A61P27/00; A61P27/04



Family Information

Patent Number	Publication Date	Application Number	Application Date
CY1122457 T1	20210127	CY20201100004T	20200107
DE602015041582 D1	20191205	DE201560041582T	20150302
DK3110425 T3	20191209	DK20150713215T	20150302
EP3110425 A1	20170104	EP20150713215	20150302
EP3110425 B1	20191113	EP20150713215	20150302
ES2760523 T3	20200514	ES20150713215T	20150302
FR3018045 A1	20150904	FR20140051662	20140228
FR3018045 B1	20170616	FR20140051662	20140228
HR20192142 T1	20200221	HR20190002142	20191128
HU047396 T2	20200428	HU20150713215T	20150302
LT3110425 T	20191210	LT20150713215T	20150302
MK10007 T1	20200229	MK20190001003T	20191125
PL3110425 T3	20200331	PL20150713215T	20150302
PT3110425 T	20191211	PT20150713215T	20150302
RS59721 B1	20200131	RS20190001561	20150302
SI3110425 T1	20200131	SI20150031017T	20150302
TR201918935 T4	20191223	TR20190018935T	20150302
WO15136186 A1	20150917	WO2015FR50499	20150302

Priority Numbers: FR20140051662 [20140228]; WO2015FR50499 [20150302]; EP20150713215 [20150302]

Probable Patent Assignee: MEDICAL UNIV OF VIENNA

Assignees: LABORATOIRES THEA; THEA LAB; MEDICAL UNIV OF VIENNA

Non Std Assignees: LABORATOIRES THĀ©A

Inventors: MERCIER FABRICE; SCHMETTERER LEOPOLD; LEOPOLD SCHMETTERER; FABRICE MERCIER

Non Std Inventors: SCHMETTERER, LĀ©OPOLD

Agent(s): LAURENT CHARRAS; CABINET LAURENT AND CHARRAS; JORGE ISERN JARA; CABINET LAURENT ET CHARRAS; MUESERREF AKYOL; BUCHET ANNE ET AL

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

54. Family 48843598 (US2011104083 AA)

[View in PatBase](#)


Title
[EN] METHODS AND COSMETIC PREPARATIONS FOR THE SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO THE EYE

Abstract
[EN] Cosmetic compositions comprising therapeutic agents for the treatment of various eye conditions and methods of use are described. In particular, the invention provides cosmetic compositions comprising ophthalmic therapeutic agents in combination with a muscle fasciculating agent for application to the outer surface of the upper eyelid, perimeter of the eyelid and/or eyelashes thereby causing transfer of the therapeutic agents into the vascular network within the eyelid for delivery into all parts of the eye, including the posterior segments of the eye, the eyelid glands, conjunctiva and periocular tissue.

International Class: A61K31/519; A61K31/52; A61K31/522; A61K9/06; A61K9/70; A61P25/34; A61P9/00; A61P9/12; A61K47/38; A61K8/02; A61K9/00; A61Q1/10; A61K8/49; A61K; A61P; A61K31/00; A61P25/00; A61K31/407; A61K31/4178; A61K36/68; A61K38/13; A61K8/00; A61P21/00; A61P27/02; A61P29/00; A61P31/00; A61P31/10; A61Q17/04; A61K31/215; A61K36/185; A61K38/28; A61K39/08; A61P13/12; A61P3/10; A61P35/04; A61P5/00; A61P27/00

Cooperative Patent Class: A61K31/519; A61K31/52; A61K31/522; A61K38/28; A61K47/38; A61K8/4953; A61K9/0014; A61K9/0019; A61K9/0048; A61K9/06; A61P13/12; A61P21/00; A61P25/00; A61P25/34; A61P27/00; A61P27/02; A61P29/00; A61P3/10; A61P31/00; A61P31/10; A61P35/04; A61P5/00; A61P9/00; A61P9/12; A61Q1/10

US Class: 424/239.1; 424/239.100P; 424/400; 424/59; 424/59P; 424/725; 424/725S; 424/774; 424/774S; 514/20.5; 514/20.500S; 514/20.8; 514/263.31; 514/263.310S; 514/263.34; 514/263.340S; 514/263.36; 514/263.360S; 514/397; 514/397S; 514/411; 514/411S; 514/5.9; 514/530; 514/530S; 514/6.5; 514/6.500S



Family Information

Patent Number	Publication Date	Application Number	Application Date
CY1122417 T1	20210127	CY20191101182T	20191111
DE602010060931 D1	20190926	DE201060060931T	20101029
DK2493474 T3	20191014	DK20100827530T	20101029
EP2493474 A2	20120905	EP20100827530	20101029
EP2493474 A4	20140423	EP20100827530	20101029
EP2493474 B1	20190904	EP20100827530	20101029
EP2493475 A2	20120905	EP20100827537	20101029
EP2493475 A4	20141029	EP20100827537	20101029
EP3569223 A1	20191120	EP20190182493	20101029
ES2752008 T3	20200402	ES20100827530T	20101029
HK1175119 A1	20130628	HK20130102578	20130301
HK1175119 B	20200429	HK20130102578	20130301
HK1175120 A1	20130628	HK20130102579	20130301
HR20191828 T1	20191227	HR20190001828	20191010
HU046071 T2	20200128	HU20100827530T	20101029
LT2493474 T	20191010	LT20100827530T	20101029
PL2493474 T3	20200331	PL20100827530T	20101029
PT2493474 T	20191126	PT20100827530T	20101029
RS59483 B1	20191231	RS20190001286	20101029
SI2493474 T1	20191129	SI20100031935T	20101029
TR201913944 T4	20191021	TR20190013944T	20101029
US2011104083 AA	20110505	US20100916136	20101029
US2011104206 AA	20110505	US20100915823	20101029
US2015174211 AA	20150625	US20150642717	20150309
US9034830 BB	20150519	US20100915823	20101029
WO11053792 A2	20110505	WO2010US54736	20101029
WO11053792 A3	20110922	WO2010US54736	20101029

Patent Number	Publication Date	Application Number	Application Date
WO11053792 A4	20111124	WO2010US54736	20101029
WO11053801 A2	20110505	WO2010US54752	20101029
WO11053801 A3	20110929	WO2010US54752	20101029
WO11053801 A4	20111110	WO2010US54752	20101029

Priority Numbers: US20090256614P [20091030]; US20090289471P [20091223]; WO2010US54736 [20101029]; EP20100827530 [20101029]; WO2010US54752 [20101029]; US20100916136 [20101029]; US20100915823 [20101029]; US20150642717 [20150309]

Probable Patent Assignee: INTRATUS INC

Assignees: INTRATUS INC; DYER T AARON; NANDURI PADMA

Non Std Assignees: DYER T

Inventors: NANDURI PADMA; DYER T AARON; PADMA NANDURI; T AARON DYER

Non Std Inventors: DYER T

Agent(s): MUELLER BORE AND PARTNER PATENTANWAELTE PARTG MBB; MUELLER BORE AND PARTNER PATENTANWAELTE; ELZABURU SLP; EMILY YIP AND CO; EMILY YIP AND CO LTD; MERAL BOZKAYA; MCDERMOTT WILL AND EMERY LLP; TOFFENETTI JUDITH L

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

55. Family 70562055 (US2018207293 AA)


[View in PatBase](#)

Title

[EN] NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE

Abstract

[EN] Disclosed is a method of treating an ocular disorder, comprising contacting the eye of a subject in need thereof with an effective amount of a therapeutic nanoparticle composition, the therapeutic nanoparticle composition comprising (i) at least one population of nanostructures, (ii) a peptide attached to the at least at least one population of nanostructures, (iii) a therapeutic agent useful for the treatment of the ocular disorder attached to the at least one population of nanostructures or to the peptide; and (iv) optionally, a linkage between the at least one population of nanostructures or the peptide and the therapeutic agent.



International Class: A61K31/7088; A61K9/50; C12N15/115; A61K47/64; A61K47/65; A61K47/69; A61K45/00; A61K47/02; A61K47/52; A61K9/08; A61K9/51; A61P25/02; A61P27/02; A61P27/06; A61P27/10; A61P27/12; A61P27/14; A61P29/00; A61P3/14; A61P31/00; A61P31/04; A61P31/12; A61P37/08; A61P43/00; A61P9/10; C12N15/09; A61K31/122; A61K31/277; A61K31/382; A61K31/4704; A61K31/4709; A61K31/496; A61K31/522; A61K31/542; A61K31/55; A61K31/5575; A61K31/573; A61K31/575; A61K31/7048; A61K38/17; A61K38/18; A61K38/39; A61K38/44; A61K38/46; A61K38/48; A61K9/00; C07K5/062; C07K5/083

Cooperative Patent Class: A61K31/122; A61K31/277; A61K31/382; A61K31/4704; A61K31/4709; A61K31/496; A61K31/522; A61K31/542; A61K31/55; A61K31/5575; A61K31/573; A61K31/575; A61K31/7048; A61K38/1709; A61K38/177; A61K38/18; A61K38/185; A61K38/1866; A61K38/1891; A61K38/39; A61K38/44; A61K38/465; A61K38/484; A61K47/64; A61K47/65; A61K47/6923; A61K47/6929; A61K9/0048; A61K9/5115; B82Y5/00; C12Y106/99003; C12Y301/01064; C12Y304/21007

US Class: 1/1; 424/491

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3573603 A1	20191204	EP20180745249	20180125
EP3573603 A4	20201118	EP20180745249	20180125
JP2020514410 T2	20200521	JP20190560075T	20180125
US2018207293 AA	20180726	US20170604361	20170524
US2021000972 AA	20210107	US20180602046	20180125
WO18140580 A1	20180802	WO2018US15196	20180125

Priority Numbers: US20170450265P [20170125]; US20170459439P [20170215]; US20170604361 [20170524]; WO2018US15196 [20180125]; US20180602046 [20180125]

Probable Patent Assignee: 2C TECH CORP

Assignees: 2C TECH CORP

Non Std Assignees: NEWPORT SCIENTIFIC INC

Inventors: SHIMIZU ROBERT W; WOLDEMUSSIE ELIZABETH; CURRIE JAMES P; KANNER RICHARD

Agent(s): BOYNTON JULIETTE ALICE; ESMOND ROBERT W ET AL; STERNE KESSLER GOLDSTEIN AND FOX PLLC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

56. Family 41954919 (US2008181867 AA)

[View in PatBase](#)

Title

[EN] PROCESS FOR MANUFACTURING OPHTHALMIC OIL-IN-WATER EMULSIONS

Abstract

[EN] The present invention relates to new processes for the preparation of oil-in-water emulsions useful in ophthalmic applications. In particular, processes are provided that include preparing a pre-concentrate of the oil-in-water emulsion, and diluting the pre-concentrate obtained to form the desired oil-in-water emulsion. The present invention also provides pharmaceutical compositions comprising an oil-in-water emulsion prepared by an inventive process, and methods of using these compositions for the treatment of an eye disease or condition.

International Class: A61K31/415; A61K38/12; A61K38/13; A61K47/10; A61K47/44; A61K9/00; A61K9/107; A61K; A61K31/192; A61K31/5575; A61K31/573; A61K38/00; A61K47/14; A61K47/18; A61K9/10; A61P27/02; A61K47/08; A61K31/21; A61K31/216; A61K31/57; A61K38/02; A61K39/395; A61K48/00; A61P27/00

Cooperative Patent Class: A61K31/415; A61K9/0048; A61K9/1075; A61P27/02

US Class: 1/1; 424/130.1; 424/130.100S; 424/400; 424/400S; 424/85.4; 424/85.400P; 514/12.1; 514/12.100S; 514/13.3; 514/13.300S; 514/18.3; 514/18.300S; 514/180; 514/180S; 514/2; 514/20.8; 514/20.800S; 514/3.7; 514/3.700S; 514/44; 514/44.00AS; 514/44A; 514/530; 514/530S; 514/7.6; 514/7.600S; 514/9; 514/9.4; 514/9.400S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2007336206 AA	20080626	AU20070336206	20071221
AU2007336206 BB	20140220	AU20070336206	20071221
CA2672973 AA	20090617	CA20072672973	20071221
CA2672973 C	20160308	CA20072672973	20071221
DE602007060111 D1	20200507	DE200760060111T	20071221
EP2129364 A2	20091209	EP20070858100	20071221
EP2129364 B1	20200415	EP20070858100	20071221
ES2796116 T3	20201125	ES20070858100T	20071221
IL199458 A0	20100328	IL20070199458	20071221
IL199458 A1	20150430	IL20070199458	20071221
IN04028DN2009 A	20100101	IN2009DN04028	20090618
IN272807 B	20160429	IN2009DN04028	20090618
JP2011506266 T2	20110303	JP20090542104T	20071221
JP2014028865 A2	20140213	JP20130232889	20131111
JP5850602 B2	20160203	JP20090542104T	20071221
US2008181867 AA	20080731	US20070962324	20071221
US9364461 BB	20160614	US20070962324	20071221
WO08074885 A2	20080626	WO2007EP64489	20071221
WO08074885 A3	20081009	WO2007EP64489	20071221

Priority Numbers: US20060876200P [20061221]; WO2007EP64489 [20071221]; EP20070858100 [20071221]; JP20090542104 [20071221]; JP20090542104T [20071221]; JP20130232889 [20131111]; JP20090542104TT [20071221]; US20070962324 [20071221]

Probable Patent Assignee: SANTEN SAS

Assignees: NOVAGALI PHARMA SA; SANTEN SAS; CANDILLON PASCAL; LAFOSSE JULIEN; LALLEMAND FREDERIC; LAMBERT GREGORY; RABINOVICH GUILATT LAURA; NOVAGALI PHARMA S A; NOVAGALI PHARMASA

Non Std Assignees: SANTEN ES ER ES; SANTEN ES SA

Inventors: CANDILLON PASCAL; RABINOVICH GUILATT LAURA; LAMBERT GREGORY; LAFOSSE JULIEN; LALLEMAND FREDERIC; JULIEN LAFOSSE; PASCAL CANDILLON; LAURA RABINOVICH GUILATT; GREGORY LAMBERT; FREDERIC LALLEMAND

Agent(s): GRIFFITH HACK; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; OGILVY RENAULT LLP SENCRL SRL; STOLMAR AND PARTNER PATENTANWAELTE PARTG MBB; DE MAREUEIL VILLETTE CAROLINE; CABINET ICOSA 8 RUE



DU TEXEL; ICOSA; ANGEL PONS ARINO; REINHOLD COHN AND PARTNERS; YOUNG AND THOMPSON; CABINET
PLASSERAUD ET AL

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; PL; PT;
RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM;
DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; HR; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR;
LS; LY; MA; MD; ME; MG; MK; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RS; RU; SC; SD; SG; SL;
SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

57. Family 72876137 (US10821075 BA)

[View in PatBase](#)

Title
[EN] COMPOSITIONS FOR TOPICAL APPLICATION OF A MEDICAMENTS ONTO A MAMMALIAN BODY SURFACE

Abstract
[EN] Drug-delivery systems are described which can serve as platforms for topical delivery of a variety of active pharmaceutical ingredients (API) to the surface of a mammalian body. Methods for the preparation and use of the compositions are also described. In some embodiments, the disclosed topical formulations include an API, a penetration enhancer/cosolvent, a gelling agent, and a neutralizing agent (to adjust pH). As compared to prior compositions, the disclosed topical formulations use a relatively small number of safe components and are easy to prepare with a high yield of finished product.

International Class: A61K47/06; A61K47/10; A61K47/22; A61K31/192; A61K47/08; A61K47/18; A61K47/32; A61K9/00; A61K9/06
Cooperative Patent Class: A61K31/192; A61K45/06; A61K47/08; A61K47/10; A61K47/18; A61K47/183; A61K47/32; A61K9/0014; A61K9/06

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN111065415 A	20200424	CN201880057195	20180711
US10821075 BA	20201103	US20170648316	20170712
US2020352856 AA	20201112	US20170648316	20170712
WO19014380 A1	20190117	WO2018US41692	20180711

Priority Numbers: US20170648316 [20170712]; US20170663517 [20170728]; WO2018US41692 [20180711]

Probable Patent Assignee: BLANCHARD JAMES

Assignees: BLANCHARD JAMES

Inventors: BLANCHARD JAMES

Agent(s): HAYES SOLOWAY PC; HAYES SOLOWAY PC; SOLOWAY NORMAN P ET AL; HAYES SOLOWAY PC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

58. Family 60899864 (US2015335704 AA)

[View in PatBase](#)

Title
[EN] PHARMACEUTICAL COMPOSITIONS COMPRISING GELS AND METHODS FOR FABRICATING THEREOF

Abstract
[EN] Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described.

International Class: A61K31/5377; A61K31/5575; A61K31/7036; A61K38/14; A61K45/06; A61K47/10; A61K47/34; A61K9/00; A61K9/06; A61K38/13

Cooperative Patent Class: A61K31/5377; A61K31/5575; A61K31/7036; A61K38/14; A61K45/06; A61K47/10; A61K47/34; A61K9/0048; A61K9/06; A61K31/7042; A61K38/13; A61K31/167; A61K38/38; A61K9/0014

US Class: 1/1; 424/133.1; 424/94.64; 514/15.2; 514/171; 514/174; 514/179; 514/180; 514/20.5; 514/20.8; 514/224.5; 514/236.2; 514/249; 514/251; 514/252.16; 514/253.04; 514/253.08; 514/254.07; 514/264.11; 514/266.24; 514/275; 514/282; 514/291; 514/300; 514/312; 514/317; 514/324; 514/338; 514/350; 514/357; 514/40; 514/401; 514/411; 514/414; 514/44R; 514/450; 514/46; 514/50; 514/530; 514/535; 514/548; 514/562; 514/566; 514/570; 514/622; 514/626; 514/652; 514/653

Family Information

Patent Number	Publication Date	Application Number	Application Date
US10561607 BB	20200218	US20160395830	20161230
US2015335704 AA	20151126	US20150719157	20150521
US2017105931 AA	20170420	US20160395830	20161230
US2017112936 AA	20170427	US20170399258	20170105
US2020155450 AA	20200521	US20200773749	20200127

Priority Numbers: US20140002711P [20140523]; US20150719157 [20150521]; US20160395830 [20161230]; US20170399258 [20170105]; US20200773749 [20200127]

Probable Patent Assignee: HARROW HEALTH INC

Assignees: IMPRIMIS PHARMACEUTICALS INC; HARROW IP LLC

Non Std Assignees: B RILEY COMMERCIAL CAPITAL LLC ADMINISTRATIVE AGENT AS; HARROW HEALTH INC; SWK FUNDING LLC COLLATERAL AGENT AS; HARROW EYE LLC; IMPRIMIS NJOF LLC; IMPRIMISRX LLC; IMPRIMISRX NJ LLC; OAKTREE FUND ADMINISTRATION LLC ADMINISTRATIVE AGENT AS; VISIONOLOGY EQUITY LLC; VISIONOLOGY INC; VISIONOLOGY MSO INC

Inventors: KAROLCHYK JOHN SCOTT; SAADEH DENNIS ELIAS

Agent(s): WAGENKNECHT IP LAW GROUP PC; WAGENKNECHT IP LAW GROUP PC

59. Family 32323240 (US2005232972 AA)

[View in PatBase](#)


Title
[EN] DRUG DELIVERY VIA PUNCTAL PLUG

Abstract
[EN] A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

International Class: A61K31/4709; A61K31/496; A61K31/549; A61K31/557; A61F2/00; A61F9/00; A61M35/00; A61F9/007; A61K9/00; A61K38/13; A61K31/5575

Cooperative Patent Class: A61F9/0017; A61F9/007; A61F9/00772; A61K31/5575; A61K38/13; A61K9/0051

US Class: 1/1; 424/427; 424/427P; 514/223.2; 514/223.200; 514/253.08; 514/253.080; 514/300; 514/312; 514/355; 514/356; 514/530; 514/573; 514/620; 514/622; 604/294; 604/521



Family Information

Patent Number	Publication Date	Application Number	Application Date	
US2005232972 AA	20051020	US20040825047	20040415	
US2010040670 AA	20100218	US20090604202	20091022	
US2012277694 AA	20121101	US20120533676	20120626	
US2015132358 AA	20150514	US20140472844	20140829	
US2017056322 AA	20170302	US20160247574	20160825	
US2017172916 AA	20170622	US20170427578	20170208	
US2019216727 AA	20190718	US20190360561	20190321	
US2020138701 A9	20200507	US20190360561	20190321	
US9463114 BB	20161011	US20140472844	20140829	

Priority Numbers: US20040825047 [20040415]; US20090604202 [20091022]; US20120533676 [20120626]; US20140472844 [20140829]; US20160247574 [20160825]; US20170427578 [20170208]; US20190360561 [20190321]

Probable Patent Assignee: MATI THERAPEUTICS INC

Assignees: ODRICH STEVEN; MATI THERAPEUTICS INC; QLT PLUG DELIVERY INC; QUADRA LOGIC TECH INC; GLAZER LIANE C; ODRICH STEVEN A

Non Std Assignees: 3088922 INC; FORSIGHT LABS LLC; FORSIGHT NEWCO II INC; QLT INC

Inventors: ODRICH STEVEN; ODRICH STEVEN A; GLAZER LIANE C

Agent(s): NOTARO AND MICHALOS; SCHWEGMAN LUNDBERG AND WOESSNER PA; KOREN; MATI THERAPEUTICS INC

60. Family 76691110 (KR20190132108 A)

[View in PatBase](#)

Title
[EN] CARRIER COMPLEX AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Abstract
[EN] The present invention relates to a carrier composite and, more specifically, to a carrier composite including: a carrier which includes a porous metal organic framework having a plurality of pores; and a delivery target substance which is supported on the carrier. By the above, the present invention: enables the delivery target substance to be penetrated in a local part of an eye ball at high concentration in-invasively; controls a speed at which the delivery target substance is released within eye tissues; and is able to increase patient convenience by increasing a time period, in which the delivery target substance remains at a site of action, and thus, increasing a dosing cycle. According to embodiments of the present invention, a self-decomposition is easy in tissues and thus, accumulation in the human body can be prevented, and the decomposed material can be harmless to a living body and does not affect the chemical structure and pharmacological action of the supported delivery target material.

International Class: A61K31/221; A61K45/06; A61K47/24; A61K9/00; A61P27/02

Cooperative Patent Class: A61K31/221; A61K45/06; A61K47/24; A61K9/0048; A61K9/0087; A61P27/02; Y02A50/30

Family Information

Patent Number	Publication Date	Application Number	Application Date
KR102090736 B1	20200423	KR20180057377	20180518
KR20190132108 A	20191127	KR20180057377	20180518


Priority Numbers: KR20180057377 [20180518]

Probable Patent Assignee: SEOUL NAT UNIV R AND DB FOUNDATION

Assignees: SEOUL NAT UNIV R AND DB FOUNDATION; INDUSTRIAL ACADEMIC COOPERATION GROUP SEOUL NATIONAL UNIV

Non Std Assignees: SEOUL NATIONAL UNIV R AND DB FOUNDATION; SEOUL NATIONAL UNIVERSITY R AND DB FOUNDATION

Inventors: CHOI YOUNG BIN; KIM SE NA



61. Family 54124186 (US2013157963 AA)

[View in PatBase](#)

Title
[EN] OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS

Abstract
[EN] Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.

International Class: A61K31/498; A61K31/5575; A61K47/32; A61K9/08; A61P27/06; A61K47/30; A61K; A61P; A61K31/4025; A61K31/407; A61K31/4164; A61K31/417; A61K31/4178; A61K31/4184; A61K31/4709; A61K31/496; A61K31/5377; A61K31/568; A61K31/573; A61K38/00; A61K47/02; A61K47/10; A61K47/34; A61K47/40; A61P27/02; A61K47/26; A61K31/4985; A61K38/13; A61K47/18; A61K9/00

Cooperative Patent Class: A61K31/407; A61K31/417; A61K31/4178; A61K31/496; A61K31/498; A61K31/4985; A61K31/5377; A61K31/5575; A61K31/568; A61K31/573; A61K38/13; A61K47/02; A61K47/32; A61K47/34; A61K9/0048; A61K9/08; A61P27/02; A61P27/06; A61K2300/00

US Class: 1/1; 514/169; 514/179; 514/180; 514/20.5; 514/20.8; 514/236.2; 514/249; 514/253.08; 514/397; 514/401; 514/413; 514/622; 514/769; 514/772.1; 525/419

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2012351948 AA	20140710	AU20120351948	20121214
BR112014014678 A2	20170613	BR20141114678	20121214
BR112014014678 A8	20170613	BR20141114678	20121214
CA2859583 AA	20140616	CA20122859583	20121214
CA2859583 C	20200218	CA20122859583	20121214
CN104114154 A	20141022	CN201280069915	20121214
DE602012034243 D1	20170817	DE201260034243T	20121214
EP2790673 A2	20141022	EP20120808637	20121214
EP2790673 B1	20170705	EP20120808637	20121214
ES2641621 T3	20171110	ES20120808637T	20121214
HK1203148 A1	20151023	HK20150103704	20150416
HK1203148 B	20180427	HK20150103704	20150416
IN05198CN2014 A	20160219	IN2014CN05198	20140707
JP2015500347 T2	20150105	JP20140547530T	20121214
JP6150079 B2	20170621	JP20140547530T	20121214
KR20140103168 A	20140825	KR20147019700	20121214
RU2014129268 A	20160210	RU20140129268	20121214
TR201713817 T4	20171121	TR20170013817T	20121214
US2013157963 AA	20130620	US20120715972	20121214
US2014128329 AA	20140508	US20140152380	20140110
US9579385 BB	20170228	US20140152380	20140110
WO13090842 A2	20130620	WO2012US69939	20121214
WO13090842 A3	20131010	WO2012US69939	20121214

Priority Numbers: US20110576453P [20111216]; WO2012US69939 [20121214]; EP20120808637 [20121214]; US20120715972 [20121214]; US20140152380 [20140110]

Probable Patent Assignee: ALLERGAN INC

Assignees: ALLERGAN INC; GRAHAM RICHARD S; SRIKUMAR RAMAKRISHNAN; GORE ANURADHA V; PUJARA CHETAN P; GULMEZIAN MELISSA; PRINN KRISTIN

Non Std Assignees: ALLERGAN INC2525 DUPONT DRIVE, T2-7HIRVINECA92612US; ALLERGAN INC2525 DUPONT DRIVEIRVINECA92612US; ALLERGAN INC IRVINE

Inventors: GRAHAM RICHARD S; SRIKUMAR RAMAKRISHNAN; GORE ANURADHA V; PUJARA CHETAN P; GULMEZIAN MELISSA; PRINN KRISTIN; RICHARD S GRAHAM; RAMAKRISHNAN SRIKUMAR; ANURADHA V GORE; KRISTIN PRINN; MELISSA GULMEZIAN; CHETAN P PUJARA

Non Std Inventors: GORE ANURADHA VUS; GULMEZIAN MELISSAUS; PUJARA CHETAN PUS; GRAHAM RICHARD SUS; SRIKUMAR RAMAKRISHNANUS; PRINN KRISTINUS; GORE ANURADHA V ALISO VIEJO; PUJARA CHETAN P IRVINE; GRAHAM RICHARD S IRVINE; GULMEZIAN MELISSA IRVINE; PRINN KRISTIN COSTA MESA; SRIKUMAR RAMAKRISHNAN ALISO VIEJO

Agent(s): DAVIES COLLISON CAVE; DAVIES COLLISON CAVE PTY LTD; GOWLING LAFLEUR HENDERSON LLP; GOWLING WLG CANADA LLP; HOFFMANN EITLE PATENT U RECHTSANWAELTE PARTMBB; HOFFMANN EITLE; FUSTER GUSTAVO NICOLAS; CHINA PATENT AGENT HK LTD; ASAI KENJI; HAKODA ATSUSHI; ICHIKAWA SATSUKI; KUMAKURA YOSHIO; YAMASAKI KAZUO; UGUR GUERSAD YALCINER; LORENZ; WURST JOHN ET AL; ALLERGAN INC

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; ZM; ZW; VN; ZA

62. Family 61323287 (US2017135955 AA)

[View in PatBase](#)

Title

[EN] SURFACTANT-STRIPPED MICELLE COMPOSITIONS WITH HIGH CARGO TO SURFACTANT RATIO

Abstract

[EN] Provided are compositions and methods relating to hydrophobic agent loaded-micelle. The micelles comprise surfactant (such as poloxamer) and have hydrophobic agents incorporated therein. The compositions substantially lack surfactant that is not associated with the micelles. The compositions are able to achieve high hydrophobic agent:surfactant molar ratio. The compositions can be used for drug delivery and imaging applications.

International Class: A61K47/10; A61K9/107; A61K31/07; A61K31/122; A61K31/337; A61K31/343; A61K31/436; A61K31/565; A61K31/567; A61K31/568; A61K31/593; A61K31/7048; A61K38/13; A61K45/00; A61K49/00; A61K51/12; A61K31/01; A61K31/23; A61K31/355; A61K31/592; A61K47/34

Cooperative Patent Class: A61K31/01; A61K31/07; A61K31/122; A61K31/23; A61K31/232; A61K31/337; A61K31/343; A61K31/355; A61K31/436; A61K31/565; A61K31/567; A61K31/568; A61K31/592; A61K31/593; A61K31/7048; A61K38/13; A61K47/34; A61K49/0021; A61K49/0032; A61K49/0041; A61K49/227; A61K51/1227; A61K9/1075

US Class: 1/1; 424/9.6

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2954064 AA	20161230	CA20152954064	20150702
CA2954064 C	20181030	CA20152954064	20150702
CN107148265 A	20170908	CN201580046842	20150702
CN107148265 B	20190405	CN201580046842	20150702
DE602015027739 D1	20190425	DE201560027739T	20150702
EP3164111 A1	20170510	EP20150815151	20150702
EP3164111 A4	20170705	EP20150815151	20150702
EP3164111 B1	20190403	EP20150815151	20150702
JP2017524686 T2	20170831	JP20170500063T	20150702
JP6235755 B2	20171122	JP20170500063T	20150702
US2017135955 AA	20170518	US20150322593	20150702
US9757334 BB	20170912	US20150322593	20150702
WO16004369 A1	20160107	WO2015US39082	20150702

Priority Numbers: US20140020233P [20140702]; US20140020249P [20140702]; WO2015US39082 [20150702]; EP20150815151 [20150702]; US20150322593 [20150702]

Probable Patent Assignee: RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK

Assignees: RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK; RES FOUND FOR STATE UNIV OF NEW YORK; UNIV NEW YORK STATE RES FOUND


Non Std Assignees: ZHANG YUMIAO; JEON MANSIK; KIM CHULHONG; LOVELL JONATHAN; SONG WENTAO; GENG JUMIN; RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK AMHERST; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALTH AND HUMAN SERVICES DHHS US GOVERNMENT

Inventors: ZHANG YUMIAO; JEON MANSIK; KIM CHULHONG; LOVELL JONATHAN; SONG WENTAO; GENG JUMIN

Non Std Inventors: LOVELL JONATHAN NIAGARA FALLS; ZHANG YUMIAO BUFFALO; SONG WENTAO BROOKLYN; GENG JUMIN WILLIAMSVILLE; KIM CHULHONG NAMGU POHANG

Agent(s): MACRAE AND CO; SIMPSON TOBIAS RUTGER; MATHYS AND SQUIRE LLP; MINORI PATENT PROFESSION CORP; HODGSON RUSS LLP; ROMAN PAUL J JR ET AL; HODGSON RUSS LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



63. Family 54600646 (US2015025020 AA)

[View in PatBase](#)

Title
[EN] SELF-PRESERVED OIL DISPERSIONS COMPRISING BORIC ACID

Abstract
[EN] The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005 percent to 0.075 percent in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.


International Class: A61K33/22; A61K47/10; A61K47/18; A61K47/26; A61K47/34; A61K9/107; A61K; A61K31/335; A61K31/4402; A61K31/445; A61K31/4535; A61K31/454; A61K31/4545; A61K31/495; A61K31/55; A61K31/551; A61K31/5575; A61K38/00; A61K38/22; A61K38/28; A61K39/00; A61K39/395; A61K45/00; A61K47/02; A61K47/04; A61K47/06; A61K47/14; A61K47/20; A61K47/22; A61K47/24; A61K47/44; A61P27/02; A61K38/02; A61K38/13; A61K38/18; A61K38/29; A61K31/436; A61K31/573; A61K9/00

Cooperative Patent Class: A61K31/436; A61K31/5575; A61K31/573; A61K33/22; A61K38/13; A61K47/02; A61K47/10; A61K47/186; A61K47/26; A61K47/34; A61K47/44; A61K9/0048; A61K9/107; A61K9/1075; A61P27/02

US Class: 1/1; 514/180; 514/20.5; 514/291; 514/530; 514/772

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2013224043 AA	20140821	AU20130224043	20130222
AU2013224043 BB	20170727	AU20130224043	20130222
BR112014020698 A2	20170620	BR20141120698	20130222
BR112014020698 A8	20170718	BR20141120698	20130222
CA2862932 AA	20140728	CA20132862932	20130222
CN104220048 A	20141217	CN201380009668	20130222
EA201400869 A1	20141230	EA20140000869	20130222
EP2630952 A1	20130828	EP20120156652	20120223
EP2816998 A1	20141231	EP20130707332	20130222
HK1203153 A1	20151023	HK20150103726	20150416
HK1203154 A1	20151023	HK20150103727	20150416
ID201601559 A	20160318	ID2014P0005100	20130222
ID50381 B	20180327	ID2014P0005100	20130222
IN06853DN2014 A	20150522	IN2014DN06853	20140814
JP2015509494 T2	20150330	JP20140558119T	20130222
JP2018039828 A2	20180315	JP20170202485	20171019
JP6231499 B2	20171115	JP20140558119T	20130222
KR20140124405 A	20141024	KR20147026658	20130222
MX2014010005 A1	20150309	MX20140010005	20130222
MY169504 A	20190415	MY20140002437	20130222
NZ627861 A	20160226	NZ20130627861	20130222
PH2014501906 A	20141124	PH20140501906	20140822
SG11201405098P A1	20140926	SG20141105098	20130222
TH155614 A	20160906	TH20141004871	20130222
TW201347786 A	20131201	TW20130106150	20130222
TWI564032 B	20170101	TW20130106150	20130222
UA112669 C2	20161010	UA20140008067	20130222
US2015025020 AA	20150122	US20130380655	20130222
US9682147 BB	20170620	US20130380655	20130222
WO13124415 A1	20130829	WO2013EP53556	20130222



Priority Numbers: EP20120156652 [20120223]; US20120602369P [20120223]; WO2013EP53556 [20130222]; EP20130707332 [20130222]; JP20140558119T [20130222]; US20130380655 [20130222]

Probable Patent Assignee: SANTEN SAS

Assignees: SANTEN SAS; NOVAGALI PHARMA SA; NOVAGALI PHARMA S A

Non Std Assignees: SANTEN SAS1 RUE PIERRE FONTAINEBATIMENT GENAVENIR IVF-91000EVRYFR; GARRIGUE JEAN SEBASTIEN; PHILIPS BETTY; LALLEMAND FREDERIC

Inventors: GARRIGUE JEAN SEBASTIEN; PHILIPS BETTY; LALLEMAND FREDERIC; JEAN SEBASTIEN GARRIGUE; BETTY PHILIPS; LALLEMAND FRDRIC; GARRIGUE JEAN SBASTIEN; XFFFD RIC LALLEMAND FRAND XFFFD D AND; XFFFD BASTIEN GARRIGUE JEAN S AND; LALLEMAND FR D RIC

Non Std Inventors: FREDERIC LALLEMAND; PHILIPS BETTYFR; GARRIGUE JEAN SEBASTIENFR; LALLEMAND FREDERICFR; GARRIGUE JEAN S BASTIEN

Agent(s): AJ PARK; BALDWINS INTELLECTUAL PROPERTY; BORDEN LADNER GERVAIS LLP; ICOSA; ELLA CHEONG HONG KONG LTD; ACHMAD FATCHY; FUJITA KAZUKO; BEATRIZ ALVAREZ DE LUCIO; YOUNG AND THOMPSON

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; ZM; ZW; VN; ZA

64. Family 57485657 (US2016074321 AA)

[View in PatBase](#)

Title

[EN] OPHTHALMIC COMPOSITION, METHOD FOR PREPARING THE SAME, AND USE OF THE SAME

Abstract

[EN] The present invention is directed to an ophthalmic composition, method for preparing the same, and use of the same. The ophthalmic composition includes a mixture of lipid nano-dispersion and gel substrate, wherein the lipid nano-dispersion includes a first lipid, a second lipid, and emulsifier; in which the first lipid exists in form of solid lipid as staring material, and the second lipid exists in form of liquid lipid as staring material. The ophthalmic composition can better reduce the symptoms of dry eye, and is safe, convenient and economical to use, and can be used during daytime without blocking of vision.

International Class: A61K9/127; A61P27/02; A61K; A61P; A61K47/30; A61K47/44; A61K47/10; A61K47/14; A61K47/24; A61K47/32; A61K47/38; A61K9/00; A61K9/06; A61K9/107

Cooperative Patent Class: A61K47/10; A61K47/14; A61K47/24; A61K47/32; A61K47/38; A61K47/44; A61K9/0048; A61K9/06; A61K9/1075; A61P27/02

US Class: 424/400; 514/174; 514/180; 514/20.8; 514/291; 514/40; 514/530; 514/570; 514/772.5; 514/781; 514/786

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2013384818 AA	20151112	AU20130384818	20130327
CN105431138 A	20160323	CN201380076332	20130327
CN105431138 B	20190111	CN201380076332	20130327
DE602013032234 D1	20180215	DE201360032234T	20130327
EP2978409 A1	20160203	EP20130880074	20130327
EP2978409 A4	20170111	EP20130880074	20130327
EP2978409 B1	20180110	EP20130880074	20130327
HK1216146 A1	20161021	HK20160104022	20160408
TW201440790 A	20141101	TW20140110968	20140325
US2016074321 AA	20160317	US20130787248	20130327
WO14153733 A1	20141002	WO2013CN073259	20130327

Priority Numbers: WO2013CN073259 [20130327]; EP20130880074 [20130327]

Probable Patent Assignee: COMPREHENSIVE DRUG ENTERPRISES LTD

Assignees: COMPREHENSIVE DRUG ENTERPRISES LTD; UNIV FUDAN; COMPREHENSIVE DRUG ENTPR LTD; FUNDAN UNIV


Non Std Assignees: FUDAN UNIV; COMPREHENSIVE DRUG ENTERPRISES LTD SHATIN

Inventors: LU WEIYUE; WEI GANG; LEE BENJAMIN TAK KWONG; LAM SHUN CHIU DENNIS; ZHANG WENJIAN; LAU JOHNSON YIU NAM; LI DEHUANG; LIU YAONAN; LIN SHUNCHAO; ZHANG WEN JIAN; LU WEI YUE

Non Std Inventors: LAU JOHNSON YIU NAM NEWPORT BEACH

Agent(s): PHILLIPS ORMONDE FITZPATRICK; DF MP DOERRIES FRANK MOLNIA AND POHLMAN PATENTANWAELTE RECHTSANWAELTE PARTG MBB; NORDMEYER PHILIPP WERNER; MELVIN LI INTELLECTUAL PROPERTY LTD; TEE AND HOWE INTELLECTUAL PROPERTY ATTORNEYS

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



65. Family 34118083 (US2007020336 AA)


[View in PatBase](#)

Title

[EN] CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY

Abstract

[EN] The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1 percent (w/v) to about 90 percent (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10 percent (w/v) to about 99.9 percent (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.



International Class: A61K31/404; A61K31/42; A61K31/5377; A61K31/5513; A61K31/565; A61K31/573; A61K31/58; A61K38/13; A61K47/69; A61K9/10; A61P27/02; B82Y5/00; A61K47/48; A61K9/00; A61K31/185; A61K31/19; A61K31/551; A61K31/557; A61K31/57; A61K31/716; A61K31/717; A61K31/724; A61K38/12; A61K38/39; A61K9/14; A61K31/403; A61K31/506; A61P29/00; A61P31/04; A61P31/12; A61K31/715; A61P27/00

Cooperative Patent Class: A61K31/404; A61K31/42; A61K31/5377; A61K31/5513; A61K31/565; A61K31/573; A61K31/58; A61K38/13; A61K47/6905; A61K47/6951; A61K9/0043; A61K9/0048; A61K9/10; A61P27/02; A61P29/00; A61P31/04; A61P31/12; B82Y5/00

US Class: 424/133.1; 424/486; 424/486P; 424/489; 514/11; 514/17.2; 514/17.200S; 514/171; 514/171S; 514/174; 514/179; 514/179S; 514/180; 514/180S; 514/182; 514/182S; 514/2; 514/2.4; 514/2.400S; 514/20.5; 514/20.500S; 514/20.8; 514/20.800S; 514/221; 514/221S; 514/275; 514/275S; 514/3.7; 514/3.700S; 514/380; 514/380S; 514/411; 514/411S; 514/44R; 514/54; 514/54S; 514/557; 514/557S; 514/573; 514/573S; 514/58; 514/58S; 514/914; 536/103

Family Information

Patent Number	Publication Date	Application Number	Application Date
DE602006055261 D1	20180524	DE200660055261T	20060721
EP1909755 A2	20080416	EP20060808951	20060721
EP1909755 B1	20180425	EP20060808951	20060721
ES2675043 T3	20180706	ES20060808951T	20060721
PL1909755 T3	20181031	PL20060808951T	20060721
TR201810394 T4	20180921	TR20180010394T	20060721
US2007020336 AA	20070125	US20060489466	20060720
US2012028944 AA	20120202	US20110014964	20110127
US2013142791 AA	20130606	US20130758955	20130204
US2014186443 AA	20140703	US20130106265	20131213
US7893040 BB	20110222	US20060489466	20060720
US8633172 BB	20140121	US20130758955	20130204
US8999953 BB	20150407	US20130106265	20131213
WO07012974 A2	20070201	WO2006IB02769	20060721
WO07012974 A3	20070712	WO2006IB02769	20060721

Priority Numbers: US20050701621P [20050722]; US20060795563P [20060428]; EP20060808951 [20060721]; WO2006IB02769 [20060721]; US20060489466 [20060720]; US20110014964 [20110127]; US20130758955 [20130204]; US20130106265 [20131213]

Probable Patent Assignee: OCULIS EHF

Assignees: OCULIS EHF; LOFTSSON THORSTEINN; STEFANSSON EINAR

Inventors: LOFTSSON THORSTEINN; STEFANSSON EINAR

Non Std Inventors: THORSTEINN LOFTSSON; EINAR STEFANSSON

Agent(s): HEDLEY NICHOLAS JAMES MATTHEW ET AL; COLES ANDREA BIRGIT; KILBURN AND STRODE LLP; ISERN JORGE; TOLGA CAYLAK; BUCHANAN INGERSOLL AND ROONEY PC; DENTONS US LLP

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HN; HR; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RS; RU; SC; SD; SG; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

66. Family 42970725 (US2010203103 AA)

[View in PatBase](#)

Title

[EN] THERAPEUTIC COMPOSITIONS FOR TREATMENT OF INFLAMMATION OF OCULAR AND ADNEXAL TISSUES

Abstract

[EN] The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.

International Class: A61K38/00; A61K38/17; A61P27/00; A61P27/02; A61P29/00; G02C7/04; A61K38/13; A61P27/06; A61K31/7088; A61K31/7105; A61K31/713; A61K39/395; A61K45/00; A61L27/00; C07K14/47; C07K14/715; C12N15/09; C12N15/113; A61K31/7125; A61K47/32; A61K47/36; A61K47/38; A61K47/40; A61K47/46; A61K48/00; A61K9/06; A61K9/08; A61K9/10; A61K9/12; A61K9/20; A61P43/00; A61K36/16; A61K36/258; A61K36/45; A61K36/537; A61K36/82; A61K36/87; A61K38/06; A61K38/18; A61K38/19; A61K38/20; A61K38/21; A61K45/06; A61K49/00; A61K9/00; A61K31/5375; A61K31/5377; A61K31/542; A61K31/56; A61K31/661; A61K31/7135; A61K31/714; A61K33/06; A61K35/56; A61K35/60; A61K36/185; A61K38/12

Cooperative Patent Class: A61K31/00; A61K31/7088; A61K31/7105; A61K35/00; A61K36/00; A61K36/16; A61K36/258; A61K36/45; A61K36/537; A61K36/82; A61K36/87; A61K38/063; A61K38/13; A61K38/1709; A61K38/1816; A61K38/2006; A61K38/21; A61K39/395; A61K39/3955; A61K45/06; A61K9/0051; A61M1/00; A61P27/02; A61P27/06; A61P29/00; A61P43/00; G01N33/00; A61K2300/00

US Class: 424/130.1; 424/130.100S; 424/133.1; 424/133.100S; 424/134.1; 424/134.100S; 424/142.1; 424/142.100S; 424/144.1; 424/144.100S; 424/158.1; 424/173.1; 424/173.100S; 424/429; 424/429P; 424/523; 424/523S; 424/682; 424/682S; 424/728; 424/728S; 424/729; 424/729S; 424/732; 424/732S; 424/746; 424/746S; 424/752; 424/752S; 424/766; 424/766S; 424/85.5; 424/85.500S; 424/85.6; 424/85.600S; 514/10; 514/11; 514/110; 514/110S; 514/12; 514/12.2; 514/12.200S; 514/16.6; 514/16.600S; 514/171; 514/171S; 514/19.1; 514/19.100S; 514/19.3; 514/19.300S; 514/2.3; 514/2.300S; 514/20.8; 514/226.5; 514/226.500S; 514/231.2; 514/231.200S; 514/44.00AS; 514/44.00RS; 514/44A; 514/44R; 514/52; 514/52S


Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2008289552 AA	20090226	AU20080289552	20080815
AU2008289552 BB	20141009	AU20080289552	20080815
AU2014227534 AA	20141009	AU20140227534	20140919
AU2014227534 BB	20170119	AU20140227534	20140919
CA2640986 AA	20081024	CA20082640986	20080815
CA2640986 C	20141021	CA20082640986	20080815
DE602008047291 D1	20161222	DE200860047291T	20080815
EP2187900 A2	20100526	EP20080795360	20080815
EP2187900 A4	20110817	EP20080795360	20080815
EP2187900 B1	20161109	EP20080795360	20080815
JP2011516400 I2	20110526	JP20100521046T	20080815
JP2016065089 A2	20160428	JP20150227544	20151120
JP5894364 B2	20160330	JP20100521046T	20080815
US10105441 BB	20181023	US20080298380	20080815
US2010203103 AA	20100812	US20080298380	20080815
US2013273065 AA	20131017	US20130795327	20130312
WO09025763 A2	20090226	WO2008US09776	20080815
WO09025763 A3	20090423	WO2008US09776	20080815

Priority Numbers: US20070965135P [20070816]; US20080130687P [20080602]; WO2008US09776 [20080815]; AU20080289552 [20080815]; AU20140227534 [20140919]; EP20080795360 [20080815]; JP20100521046T [20080815]; US20080298380 [20080815]; US20130795327 [20130312]; US20100298380 [20100428]

Probable Patent Assignee: SCHEPENS EYE RESEARCH INST INC

Assignees: SCHEPENS EYE RES INST; SCHEPENS EYE RESEARCH INST INC; DASTJERDI MOHAMMAD; DANA REZA; SCHEPENS EYE RES INST INC



Non Std Assignees: SCHEPENS EYE RESEARCH INSTITUTE; SCHEPENS EYE RESEARCH INST; SCHEPENS EYE RESEARCH INST INC20 STANIFORD STREETBOSTONMA02114-2500US; THE SCHEPENS EYE RESEARCH INSTITUTE INC

Inventors: DASTJERDI MOHAMMAD; DANA REZA; REZA DANA; MOHAMMAD DASTJERDI

Non Std Inventors: DASTJERDI MOHAMMADUS; DANA REZAUS

Agent(s): FPA PATENT ATTORNEYS PTY LTD; FREEHILLS PATENT AND TRADE MARK ATTORNEYS; FREEHILLS PATENT ATTORNEYS; HERBERT SMITH FREEHILLS; MBM INTELLECTUAL PROPERTY LAW LLP; MBM INTELLECTUAL PROPERTY AGENCY; PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER PARTG MBB; HAILE ALISON VICTORIA; LAHRTZ FRITZ; ISENBRUCK BOESL HOERSCHLER LLP; KAWAMOTO KAZUYA; OSAKABE SUGURU; SHIMIZU HATSUSHI; BEATTIE INGRID A; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; BEATTIE INGRID A ET AL; MINTZ LEVIN COHN FERRISGLOVSKY AND POPEO PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AL; BA; MK; RS; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

67. Family 44994640 (US2013022676 AA)

[View in PatBase](#)

Title
[EN] PULSATILE DRUG RELEASE

Abstract
[EN] In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a pulse at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a pulsed release of drug.

International Class: A61K9/22; A61K9/24; A61K9/28; A61K31/437; A61K47/14; A61K47/38; A61K47/44; A61K9/30; A61P25/20; A61K31/4985; A61K31/519; A61K45/00; A61K47/06; A61K9/42; A61K9/00; A61K9/20

Cooperative Patent Class: A61K31/437; A61K9/209; A61K9/282; A61K9/2866; A61K9/288; A61P25/20; Y02A50/30

US Class: 1/1; 424/465; 514/249; 514/259.3; 514/300

Family Information

Patent Number	Publication Date	Application Number	Application Date
DE602011043757 D1	20180104	DE201160043757T	20110304
DK2542228 T3	20180305	DK20110709763T	20110304
EP2542228 A2	20130109	EP20110709763	20110304
EP2542228 B1	20171129	EP20110709763	20110304
ES2660544 T3	20180322	ES20110709763T	20110304
GB201003766 A0	20100421	GB20100003766	20100305
GB201217619 A0	20121114	GB20120017619	20110304
GB2491775 A1	20121212	GB20120017619	20110304
HU037287 T2	20180828	HU20110709763T	20110304
JP2013521332 T2	20130610	JP20120556575T	20110304
JP2016040309 A2	20160324	JP20150219312	20151109
JP6165824 B2	20170719	JP20150219312	20151109
NO2542228 T3	20180428	NO11700009763	20110304
PL2542228 T3	20180731	PL20110709763T	20110304
PT2542228 T	20180226	PT20110709763T	20110304
SI2542228 T1	20180531	SI20110031426T	20110304
TR201802596 T4	20180321	TR20180002596T	20110304
US2013022676 AA	20130124	US20110582913	20110304
US9474719 BB	20161025	US20110582913	20110304
WO11107749 A2	20110909	WO2011GB00306	20110304
WO11107749 A3	20120503	WO2011GB00306	20110304

Priority Numbers: GB20100003766 [20100305]; EP20110709763 [20110304]; WO2011GB00306 [20110304]; JP20120556575T [20110304]; JP20150219312 [20151109]


Probable Patent Assignee: OF STRATHCLYDE UNIV

Assignees: UNIV STRATHCLYDE; UNIV OF STRATHCLYDE; MULLEN ALEXANDER; STEVENS HOWARD; ECCLESTON SARAH

Non Std Assignees: OF STRATHCLYDE UNIV; UNIVERSITY OF STRATHCLYDE; DRUG DELIVERY INT LTD

Inventors: STEVENS HOWARD; ECCLESTON SARAH; MULLEN ALEXANDER; HOWARD STEVENS; SARAH ECCLESTON; ALEXANDER MULLEN

Agent(s): CHAPMAN PAUL GILMOUR; MARKS AND CLERK LLP; VALLEJO JUAN PEDRO; ASAI KENJI; HAKODA ATSUSHI; ICHIKAWA SATSUKI; KUMAKURA YOSHIO; YAMASAKI KAZUO; DESHIMARU TAKESHI; NISHIJIMA TAKAKI; TOLGA CAYLAK; HOXIE AND ASSOCIATES LLC; CHAPMAN PAUL ET AL; MARKS AND CLERK LLP



Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

68. Family 64637443 (US2018200263 AA)

[View in PatBase](#)

Title
[EN] TOPICAL TREATMENT REGIMENS CONTAINING A PROSTAGLANDIN F2a ANALOG AND A TOPICAL STEROID

Abstract
[EN] Disclosed herein is a topical treatment regimen including a prostaglandin F2a analog and a topical steroid for treating skin conditions, including skin pigmentation disorders associated with hypopigmentation such as vitiligo and nonfacial vitiligo. Examples of prostaglandin F2a analogs include bimatoprost, carboprost, dinoprost, fluprostenol, latanoprost, prostamide F2a, tafluprost, travoprost, and unoprostone, with bimatoprost being preferred. Examples of topical steroids include aclometasone, betamethasone, clobetasol, clobetasone, difluocortolone, fluocinolone, fluprednidene, flurandrenolide, fluticasone, halometasone, hydrocortisone, methylprednisolone, mometasone, prednicarbate, and triamcinolone, with mometasone being preferred. The topical treatment regimen includes one or more topical compositions, with the prostaglandin F2a analog and the topical steroid being contained either in separate topical compositions or in the same topical composition.

International Class: A61K31/353; A61K31/436; A61K31/557; A61K31/58; A61K36/82; A61K38/13; A61K9/00; A61P17/00
Cooperative Patent Class: A61K2300/00; A61K31/353; A61K31/436; A61K31/557; A61K31/5575; A61K31/573; A61K31/58; A61K36/82; A61K38/13; A61K9/0014; A61P17/00

US Class: 1/1; 514/171

Patent Number	Publication Date	Application Number	Application Date
US2018200263 AA	20180719	US20160742727	20160706
WO17007799 A1	20170112	WO2016US41065	20160706

Priority Numbers: US20150189441P [20150707]; WO2016US41065 [20160706]; US20160742727 [20160706]

Probable Patent Assignee: GRIMES PEARL E

Assignees: GRIMES PEARL E

Inventors: GRIMES PEARL E

Agent(s): CHRISMAN J GREGORY ET AL; PEARNE AND GORDON LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

69. Family 54084979 (IN01423CH2011 A)

[View in PatBase](#)

Title
[EN] METHOD AND COMPOSITION FOR SOLUBILISATION OF HYDROPHOBIC COMPOUND

Abstract
[EN] The invention pertains to a method and composition that produces solutions and nano-suspensions to enhance the dissolution rate/solubility of hydrophobic compounds as well as to the solubilized compounds produced by carrying out such process, and are subsequently processed into suitable dosage forms.

International Class: A61K



Family Information

Patent Number	Publication Date	Application Number	Application Date
IN01423CH2011 A	20130614	IN2011CH01423	20110425
IN298063 B	20180629	IN2011CH01423	20110425

Priority Numbers: IN2011CH01423 [20110425]
Probable Patent Assignee: DR N SUBRAMANIAN
Non Std Assignees: DR N SUBRAMANIAN; S ABIMANYU; P CHANDRA SEKAR
Non Std Inventors: DR N SUBRAMANIAN; S ABIMANYU; P CHANDRA SEKAR; N SUBRAMANIAN

70. Family 56829935 (US2015265535 AA)

[View in PatBase](#)

Title

[EN] SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF CATIONIC PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Abstract

[EN] Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one neutral phospholipid; c) at least one liquid crystal hardener; and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.

International Class: A61K38/08; A61K47/30; A61K9/06; A61K9/08; A61K9/20; A61K31/522; A61K38/00; A61K38/04; A61K45/00; A61K47/08; A61K47/12; A61K47/14; A61K47/20; A61K47/22; A61K47/24; A61K47/28; A61K9/10; A61K9/12; A61K9/48; A61K9/70; A61K9/72; A61K31/18; A61K31/58; A61K38/26; A61K47/26; A61K31/00; A61K47/44; A61K9/00; A61K31/4196; A61K31/519; A61K38/21; A61K9/127

Cooperative Patent Class: A61K31/00; A61K31/4196; A61K31/519; A61K31/522; A61K38/08; A61K38/09; A61K38/095; A61K38/13; A61K38/21; A61K38/26; A61K38/27; A61K38/28; A61K47/12; A61K47/14; A61K47/20; A61K47/24; A61K47/26; A61K47/28; A61K47/30; A61K47/44; A61K9/00; A61K9/06; A61K9/08; A61K9/1075; A61K9/1274; A61K9/20

US Class: 424/85.4; 514/11.7; 514/259.41; 514/263.37; 514/383; 514/785; 514/9.7

Family Information


Patent Number	Publication Date	Application Number	Application Date
AU2013371094 AA	20150813	AU20130371094	20131227
AU2013371094 BB	20161117	AU20130371094	20131227
BR112015015707 A2	20170711	BR20151115707	20131227
CA2888711 AA	20150417	CA20132888711	20131227
CA2888711 C	20180102	CA20132888711	20131227
CN105050587 A	20151111	CN201380068015	20131227
EP2938331 A1	20151104	EP20130866593	20131227
EP2938331 A4	20160810	EP20130866593	20131227
IN01082KN2015 A	20160108	IN2015KN01082	20150420
JP2016508140 T2	20160317	JP20150550321T	20131227
JP6246834 B2	20171213	JP20150550321T	20131227
KR101586789 B1	20160119	KR20120157562	20121228
KR20140086722 A	20140708	KR20120157562	20121228
MX2015008400 A1	20160216	MX20150008400	20131227
NZ710472 A	20160429	NZ20130710472	20131227
PH2015501183 A	20150817	PH20150501183	20150527
RU2015131112 A	20170201	RU20150131112	20131227
RU2649810 C2	20180404	RU20150131112	20131227
US2015265535 AA	20150924	US20130440058	20131227
WO14104784 A1	20140703	WO2013KR12259	20131227
WO14104784 A4	20140731	WO2013KR12259	20131227

Priority Numbers: KR20120157562 [20121228]; WO2013KR12259 [20131227]

Probable Patent Assignee: CHONG KUN DANG PHARMACEUTICAL CORP

Assignees: CHONG KUN DANG PHARMACEUTICAL CORP; CHONG KUN DANG PHARM CORP; CHONG KUN DANG FARMASYUTIKAL KORP; CHONG KUN DANG CORP

Non Std Assignees: YU HA NA; KI MIN HYO; YANG WON KYU; AN SUNG WON; JUNG SUNG BUM; BAIK HYE JUNG; KO JIN YOUNG; N A



Inventors: YU HA NA; KI MIN HYO; YANG WON KYU; AN SUNG WON; JUNG SUNG BUM; BAIK HYE JUNG; KO JIN YOUNG; HA NA YU; HYE JUNG BAIK; WON KYU YANG; JIN YOUNG KO; SUNG BUM JUNG; SUNG WON AN; MIN HYO KI; YOUNG KO JIN; WON AN SUNG; NA YU HA; HYO KI MIN; BUM JUNG SUNG; KYU YANG WON; JUNG BAIK HYE; YU KHA NA; BAIK KHIE DZUNG; YANG VON KIU; KO DZIN JOUNG; DZUNG SUNG BUM; AN SUNG VON; KI MIN KHIO

Agent(s): CULLENS PATENT AND TRADE MARK ATTORNEYS; CULLENS PTY LTD; SPRUSON AND FERGUSON; CASSAN MACLEAN; CASSAN MACLEAN IP AGENCY INC; D YOUNG AND CO LLP; TAKASHIMA HAJIME; FABIAN GONZALEZ DE LA MORA; OOO YURIDICHESKAYA GORODISSKIY I PARTNERY FA; AHN SO YOUNG; DR AHN INT PATENT LAW OFFICE

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

71. Family 59292002 (US2016287704 AA)

[View in PatBase](#)

Title
[EN] TOPICAL PHARMACEUTICAL COSMETIC AND DISINFECTANT COMPOSITIONS COMPRISING PHOSPHATIDYLCHOLINE

Abstract
[EN] A topical carrier consists of 99 percent by weight or more of phosphatidylcholine and volatile solvent selected from the group consisting of: ethanol and its combinations with C3-and/or C4-alcohol and/or volatile silicone oil. The carrier may additionally comprise up to 1 percent by weight of antioxidant, colorant, odorant, and/or preservative, and up to 2 percent by weight of denaturant. Also disclosed are pharmaceutical, cosmetic and disinfectant compositions consisting of the carrier and pharmaceutically active agent, cosmetically active agent and/or disinfectant agent.

International Class: A61K38/095; A61K47/24; A61K8/55; A61K9/08; A61K47/10; A61K8/34; A61K8/891; A61K31/047; A61K31/14; A61K31/155; A61K31/167; A61K31/196; A61K31/235; A61K31/351; A61K31/4164; A61K31/436; A61K31/506; A61K31/565; A61K31/573; A61K31/7036; A61K47/02; A61K8/58; A61Q17/00; A61Q17/04; A61Q19/00

Cooperative Patent Class: A61K31/047; A61K31/14; A61K31/155; A61K31/167; A61K31/196; A61K31/235; A61K31/351; A61K31/4164; A61K31/436; A61K31/506; A61K31/565; A61K31/573; A61K31/7036; A61K38/095; A61K47/02; A61K47/10; A61K47/24; A61K8/34; A61K8/553; A61K8/585; A61K8/891; A61K9/0014; A61K9/08; A61Q17/005; A61Q17/04; A61Q19/00

US Class: 1/1; 424/59

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2014349257 AA	20160609	AU20140349257	20141106
CA2929867 AA	20160505	CA20142929867	20141106
EP3068436 A1	20160921	EP20140861613	20141106
EP3068436 A4	20170412	EP20140861613	20141106
IN201627017521 A	20160819	IN201627017521	20160520
RU2016121390 A	20171218	RU20160121390	20141106
SE201300709 A1	20150515	SE20130000709	20131114
US2016287704 AA	20161006	US20140036567	20141106
US2018071391 A9	20180315	US20140036567	20141106
WO15072910 A1	20150521	WO2014SE51314	20141106

Priority Numbers: SE20130000709 [20131114]; WO2014SE51314 [20141106]; SE20110000340 [20110502]; WO2012SE00061 [20120430]; US20140036567 [20141106]; US20130114778 [20131030]

Probable Patent Assignee: LIPIDOR AB

Assignees: LIPIDOR AB

Non Std Assignees: HERSLOF BENGT; HOLMBACK JAN

Inventors: HOLMBACK JAN; HERSLOF BENGT; HERSLOEF BENGT; HOLMBAECK JAN

Non Std Inventors: HOLMB CK JAN; HERSL F BENGT; JAN HOLMBAECK; BENGT HERSLOEF

Agent(s): AJ PARK; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; AWAPATENT AB

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

72. Family 32712749 (US2006122113 AA)

[View in PatBase](#)

Title

[EN] MIXTURES OF POLYPEPTIDES, COMPOSITIONS CONTAINING AND PROCESSES FOR PREPARING SAME, AND USES THEREOF

Abstract

[EN] The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13 percent to 38 percent of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68 percent of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.

International Class: A61K38/02; A61P1/00; A61P25/28; A61P37/00; C07K14/00; A61K38/00; C07K1/00; C07K; A61K; A61K38/17; A61P; A61P31/04; C07K2/00; C08G; C08G69/10; A61P25/00; A61K31/4738; A61K31/4745; A61K31/5415; C07K14/435; C07K14/705; A61K38/16; A61K31/74

Cooperative Patent Class: A61K38/02; A61P1/00; A61P25/00; A61P25/28; A61P37/00; C07K14/001

US Class: 424/78.17; 424/78.170P; 424/78.37; 424/85.4; 424/85.400P; 514/10.8; 514/10.800S; 514/12; 514/12.1; 514/12.100S; 514/12.2; 514/12.200S; 514/18.2; 514/18.200S; 514/18.3; 514/18.300S; 514/20.8; 514/20.800S; 514/224.8; 514/224.800S; 514/283; 514/283S; 514/317; 514/317S; 514/8.3; 514/8.300S; 530/350; 530/350S

Family Information

Patent Number	Publication Date	Application Number	Application Date
CY1117704 T1	20170517	CY20161100457T	20160524
DE602005048515 D1	20160407	DE200560048515T	20050909
DK1797109 T3	20160411	DK20050795337T	20050909
EP1797109 A2	20070620	EP20050795337	20050909
EP1797109 A4	20090617	EP20050795337	20050909
EP1797109 B1	20160224	EP20050795337	20050909
ES2572811 T3	20160602	ES20050795337T	20050909
HR20160455 T1	20160715	HR20160000455	20160428
HU028833 T2	20170130	HU20050795337T	20050909
IL181802 A0	20070704	IL20050181802	20050909
IL181802 A1	20161031	IL20050181802	20050909
PL1797109 T3	20161130	PL20050795337T	20050909
SI1797109 T1	20160729	SI20050032068	20050909
TR201605552 T4	20160523	TR20160005552T	20050909
US2006122113 AA	20060608	US20050223408	20050909
US2007054857 AA	20070308	US20060541263	20060929
US7560100 BB	20090714	US20050223408	20050909
WO06029411 A2	20060316	WO2005US32553	20050909
WO06029411 A3	20060803	WO2005US32553	20050909


Priority Numbers: US20040608844P [20040909]; WO2005US32553 [20050909]; EP20050795337 [20050909]; US20050223408 [20050909]; US20060541263 [20060929]

Probable Patent Assignee: YEDA RESEARCH AND DEVELOPMENT CO LTD

Assignees: YEDA RES AND DEV; SCHWARTZ MICHAL; FRENKEL ANTON; AHARONI RINA; PINCHASI IRIT; DOLITZKY BEN ZION; ARNON RUTH; ANTON FRENKEL; BEN ZION DOLITZKY; MICHAL SCHWARTZ; RINA AHARONI; IRIT PINCHASI; RUTH ARNON; TEVA PHARMA

Non Std Assignees: YEDA RESEARCH AND DEVELOPMENT CO; YEDA RESEARCH AND DEVELOPMENT CO LTD; TEVA PHARMACEUTICAL IND LTD; TEVA PHARMACEUTICALS USA INC; TEVA PHARMACEUTICAL INDUSTRIES LTD; TEVA PHARMACEUTICAL IND

Inventors: ARNON RUTH; SCHWARTZ MICHAL; DOLITZKY BEN ZION; PINCHASI IRIT; FRENKEL ANTON; AHARONI RINA; ANTON FRENKEL; BEN ZION DOLITZKY; MICHAL SCHWARTZ; RINA AHARONI; IRIT PINCHASI; RUTH ARNON



Agent(s): D YOUNG AND CO LLP; ARIAS JUAN; TEVA PHARMACEUTICAL IND LTD; NAZLI TUGBA KORKUT OEZSOY; COOPER AND DUNHAM LLP; JOHN P

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; AL; BA; HR; MK; YU; AE; AG; AM; AU; AZ; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; ID; IL; IN; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR; LS; MA; MD; MG; ML; MN; MR; MW; MX; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

73. Family 44051722 (US2009298956 AA)

[View in PatBase](#)

Title
[EN] SELF-PRESERVED EMULSIONS

Abstract
[EN] The use of multifunctional synthetic compounds to both stabilize and preserve therapeutic emulsions is described. The multifunctional synthetic compounds have unique molecular arrangement wherein a phosphate group is linked to one, two or three quaternary ammonium functionalities via a substituted propenyl group, and each quaternary ammonium functionality is further linked to at least one hydrocarbon chain. The pharmaceutical emulsions which include these multifunctional compounds may be prepared without heating or homogenization, and may not require the use of any additional stabilizing or preserving agents.

International Class: A61K47/00; A61K9/00; A61K9/107; A61K47/14; A61K47/18; A61K47/24; A61K38/00; A61K47/36; A61K47/38; A61P27/00

Cooperative Patent Class: A61K47/14; A61K47/18; A61K47/24; A61K9/0043; A61K9/0046; A61K9/0048; A61K9/107; A61K9/1075; A61P27/00

US Class: 514/785

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2009260572 AA	20091223	AU20090260572	20090527
AU2009260572 BB	20150723	AU20090260572	20090527
BRPI0912302 A2	20151020	BR2009PI12302	20090527
CA2725523 AA	20091223	CA20092725523	20090527
CA2725523 C	20170110	CA20092725523	20090527
DE602009038416 D1	20160616	DE200960038416T	20090527
EP2278953 A2	20110202	EP20090767290	20090527
EP2278953 B1	20160504	EP20090767290	20090527
ES2586283 T3	20161013	ES20090767290T	20090527
JP2011521957 T2	20110728	JP20110511775T	20090527
KR20110010788 A	20110207	KR20107028352	20090527
KR20160123400 A	20161025	KR20167029032	20090527
US2009298956 AA	20091203	US20090472880	20090527
WO09154978 A2	20091223	WO2009US45282	20090527
WO09154978 A3	20100422	WO2009US45282	20090527

Priority Numbers: US20080056675P [20080528]; WO2009US45282 [20090527]; EP20090767290 [20090527]; US20080056675 [20080528]; US20090472880 [20090527]

Probable Patent Assignee: NOVARTIS AG

Assignees: ALCON RES LTD; ALCON RESEARCH LTD; CHOWHAN MASOOD A; GHOSH MALAY; NOVARTIS AG


Non Std Assignees: ALCON RESEARCH LTD FORT WORTH

Inventors: GHOSH MALAY; CHOWHAN MASOOD A; CHOWAN MASOOD A; CHOWHAN MASOOD

Non Std Inventors: MASOOD A CHOWHAN; MALAY GHOSH; MASOOD A CHOWAN

Agent(s): PHILLIPS ORMONDE FITZPATRICK; SMART AND BIGGAR; LEDERER AND KELLER PATENTANWAELTE PARTNERSCHAFT MBB; BEST MICHAEL; CARVAJAL Y ISABEL; ALCON; MICHAEL REIN ET AL; ALCON RESEARCH LTD

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AL; BA; RS; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



74. Family 46545797 (US2012027723 AA)

[View in PatBase](#)

Title

[EN] TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION

Abstract

[EN] The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.

International Class: A61K31/00; A61K31/195; A61K31/4415; A61K31/455; A61K31/51; A61K31/525; A61K45/06; A61P27/06; A61P31/00; A61P35/00; A61P37/02; A61K31/145; A61K31/155; A61K31/197; A61K31/198; A61K31/205; A61K31/445; A61K31/47; A61K31/496; A61K31/519; A61K31/5377; A61K31/541; A61K31/5415; A61K31/66; A61K31/7048; A61K31/7076; A61K31/714; A61K33/24; A61K38/06; A61K38/21; A61P25/00; A61P27/02; A61K31/185

Cooperative Patent Class: A61K31/00; A61K31/155; A61K31/185; A61K31/195; A61K31/197; A61K31/198; A61K31/205; A61K31/4415; A61K31/4462; A61K31/455; A61K31/4985; A61K31/51; A61K31/519; A61K31/525; A61K31/585; A61K31/662; A61K31/7076; A61K31/714; A61K38/063; A61K38/13; A61K45/06; A61P25/00; A61P27/02; A61P27/06; A61P31/00; A61P35/00; A61P37/02; Y02A50/30

US Class: 1/1; 424/649; 424/649S; 424/85.7; 424/85.700P; 424/94.1; 424/94.100S; 514/114; 514/114S; 514/17.7; 514/17.700S; 514/222.5; 514/222.500S; 514/223.5; 514/223.500S; 514/236.2; 514/236.200S; 514/251; 514/251S; 514/252.12; 514/252.120S; 514/252.16; 514/252.160S; 514/276; 514/276S; 514/311; 514/311S; 514/315; 514/315S; 514/348; 514/348S; 514/356; 514/356S; 514/37; 514/37S; 514/46; 514/46S; 514/52; 514/52S; 514/556; 514/556S; 514/561; 514/561S; 514/562; 514/562S; 514/563; 514/563S; 514/634; 514/634S; 514/665; 514/665S

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP2393490 A1	20111214	EP20100702324	20100204
US2012027723 AA	20120202	US20110190812	20110726
US2016206579 AA	20160721	US20160064151	20160308
WO10089355 A1	20100812	WO2010EP51384	20100204

Priority Numbers: EP20090305105 [20090204]; WO2010EP51384 [20100204]; EP20100702324 [20100204]; US20110190812 [20110726]; US20160064151 [20160308]

Probable Patent Assignee: INST NAT SANTE RECH MED


Assignees: INST NAT SANTE RECH MED; PICAUD SERGE; INSERM INST NAT DE LA SANTE ET DE LA RECH MEDICALE

Non Std Assignees: INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; INSERM INST NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) INST; NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM INST; NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE I

Inventors: PICAUD SERGE

Agent(s): HIRSCH DENISE MARIE; HIRSCH DENISE

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; SE; SI; SK; SM; TR; AE; AG; AL; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RS; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



75. Family 47993968 (US2013156853 AA)

[View in PatBase](#)

Title

[EN] LIQUID COMPOSITIONS OF INSOLUBLE DRUGS AND PREPARATION METHODS THEREOF

Abstract

[EN] A liquid composition of an insoluble medicament and a preparation method thereof are disclosed. The composition includes insoluble medicament, oil for injection, phospholipid, and solvent; the percentage by weight of each component is as follows: insoluble medicament 0.01-10 percent, oil for injection 0 percent -20 percent, phospholipid 10-80 percent, solvent 20-89 percent. The preparation method for the composition includes the following steps: dissolving an insoluble medicament into solvent or oil for injection or a mixture thereof firstly, and then adding other components, and mixing uniformly; or dissolving an insoluble medicament into a mixture of other components, and mixing uniformly; or dissolving an insoluble medicament into part of solvent firstly, and then adding into a mixed solvent of other components and the remaining solvent, and mixing uniformly.



International Class: A61K47/24; A61K47/44; A61K9/00; A61K9/107; A61K9/08; A61K47/10; A61K47/14; A61K47/16; A61K47/34; A61K47/46; A61K9/48; A61P35/00

Cooperative Patent Class: A61K47/24; A61K47/44; A61K9/0019; A61K9/08; A61K9/107; A61P35/00

US Class: 1/1; 424/451; 514/234.5; 514/27; 514/283; 514/34; 514/393; 514/449; 514/450; 514/49; 514/777; 514/786

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN101926757 A	20101229	CN201010268940	20100901
CN101926757 B	20130102	CN201010268940	20100901
EP2612655 A1	20130710	EP20110821127	20110831
EP2612655 A4	20150805	EP20110821127	20110831
JP2013536805 T2	20130926	JP20130526308T	20110831
US2013156853 AA	20130620	US20110819407	20110831
US9339553 BB	20160517	US20110819407	20110831
WO12028101 A1	20120308	WO2011CN079194	20110831

Priority Numbers: CN201010268940 [20100901]; WO2011CN079194 [20110831]; WO2011CN79194 [20110831]

Probable Patent Assignee: PEKING UNIV

Assignees: UNIV BEIJING; PEKING UNIV; DAI WENBING; ZHANG XUAN; WANG JIANCHENG; ZHANG QIANG

Non Std Assignees: PEKING UNIVERSITY

Inventors: WENBING DAI; JIANCHENG WANG; QIANG ZHANG; XUAN ZHANG; DAI WENBING; ZHANG XUAN; WANG JIANCHENG; ZHANG QIANG

Agent(s): CHUNG HSU MIN; HARRISON GODDARD FOOTE LLP; ARAI EIICHI; FUJITA TAKASHI; HIRAKI YUSUKE; TANAKA NATSUO; SUTHERLAND ASBILL AND BRENNAN LLP; AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

76. Family 31934476 (US2006241017 AA)

[View in PatBase](#)

Title
[EN] NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX

Abstract

[EN] The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.


International Class: A01N37/18; A01N43/42; A61K; A61K31/00; A61K38/00; C07K5/00; C07K5/06; C07K7/00; C07K7/64; A61K31/4422; A61K31/472; A61K31/546; A61K31/57; A61K31/573; C07D207/00; C07D207/34; C07D211/00; C07D211/80; C07D217/00; C07D217/26; C07D239/00; C07D239/10; C07D257/00; C07D257/04; C07D333/00; C07D333/70; C07D403/00; C07D403/10; C07D471/00; C07D471/04; C07D498/00; C07D498/14; C07D501/00; C07D501/22; C07J5/00; A01N43/34; A61K47/48; A61P43/00; C07K5/062; C07K7/50; A61K31/167; A61K31/505; A61K47/18; A61P25/00; A61P29/00; A61P9/00; A61K38/02; A61P3/00; A61K31/197; A61K31/198; A61K38/16; A61K31/337; A61K31/401; A61K31/473; A61K31/4738; A61K31/4745; A61K31/496; A61K31/519; A61K31/522; A61K31/7028; A61K31/704; A61K31/7042; A61K31/7048; A61K31/7056; A61K38/04; A61K38/05; A61K38/08; A61K38/10; C07C229/00; C07C69/00; C07C69/88; A61K31/21; A61K31/22; A61K31/343; A61K31/4164; A61K31/44; C07C229/02; C07D213/00; C07D213/80; C07D233/00; C07D233/54; C07D307/00; C07D307/93; A61K31/216; A61K31/215; A61K31/223; A61K31/24; A61K31/43; A61K31/436; A61K31/4365; A61K31/58; A61K31/616; A61K31/702; A61K38/13; A61P37/06; C07C229/36; C07C69/612; C07C69/757; C07D207/16; C07D491/16; C07D495/04; C07D499/68; C07H15/203; C07H17/08; C07J71/00; C07K229/00; C07C229/04; A61K31/196; A61K6/00

Cooperative Patent Class: A61K38/02; A61K38/13; A61K47/542; A61P25/00; A61P29/00; A61P3/00; A61P43/00; A61P9/00; C07K5/06191; C07K7/645; Y02A50/30; A61K38/12; A61P37/06; C07C229/08; C07C229/22; C07C229/26; C07C229/36; C07C233/47; C07C2602/22; C07D207/33; C07D209/10; C07D209/14; C07D211/34; C07D211/90; C07D215/38; C07D217/26; C07D223/16; C07D239/10; C07D261/20; C07D265/18; C07D275/04; C07D295/185; C07D311/24; C07D311/32; C07D333/58; C07D401/06; C07D401/12; C07D403/10; C07D405/14; C07D409/06; C07D413/06; C07D473/18; C07D473/34; C07D493/04; C07D493/10; C07D495/04; C07D498/06; C07D498/14; C07D499/14; C07D501/22; C07D501/34; C07D501/46; C07D501/56; C07F9/572; C07F9/65616; A61K38/10; A61K45/06

US Class: 514/1; 514/1.2; 514/1.200S; 514/1.3; 514/1.300S; 514/15; 514/156; 514/156S; 514/159; 514/159S; 514/16.3; 514/16.300S; 514/166; 514/169; 514/169S; 514/176; 514/19; 514/192; 514/192S; 514/197; 514/2; 514/2.3; 514/2.300P; 514/20.5; 514/20.500S; 514/200; 514/200S; 514/251; 514/251S; 514/255.01; 514/255.010S; 514/26; 514/263.3; 514/263.300S; 514/26S; 514/28; 514/283; 514/283S; 514/28S; 514/290; 514/290S; 514/291; 514/291S; 514/301; 514/304; 514/304S; 514/305; 514/305S; 514/31; 514/312; 514/312S; 514/317; 514/317S; 514/355; 514/355S; 514/356; 514/399; 514/399S; 514/423; 514/423S; 514/43; 514/43S; 514/449; 514/449S; 514/457; 514/457S; 514/468; 514/468S; 514/506; 514/510; 514/533; 514/538; 514/538S; 514/547; 514/547S; 514/551; 514/61; 514/8; 530/300; 530/300S; 530/321; 536/123.1; 536/6.5; 540/335; 540/57; 546/114; 546/318; 546/318S; 546/90; 548/341.5; 548/341.500S; 548/535; 549/458; 549/458S; 560/170; 560/170S; 560/173; 560/71; 560/71P; 560/80; 560/88; 562/441; 562/441S; 562/444; 562/567; 562/570; 562/570P

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2004289174 AA	20050526	AU20040289174	20040729
AU2004289174 AB	20050526	AU20040289174	20040729
AU2004289174 BB	20110519	AU20040289174	20040729
CA2534342 AA	20060130	CA20042534342	20040729
CA2534342 C	20160510	CA20042534342	20040729
CN101123878 A	20080213	CN200480028222	20040729
EP1660017 A2	20060531	EP20040816791	20040729
EP1660017 A4	20110309	EP20040816791	20040729
IL173382 A0	20060611	IL20040173382	20040729
IN00708DN2009 A	20100806	IN2009DN00708	20090129
IN00942DN2006 A	20070817	IN2006DN00942	20060222
IN04586DN2009 A	20110506	IN2009DN04586	20090714
IN05497DN2009 A	20100430	IN2009DN05497	20090827
IN234270 B	20090619	IN2006DN00942	20060222
JP2007510621 T2	20070426	JP20060522125T	20040729



Patent Number	Publication Date	Application Number	Application Date
JP2013035863 A2	20130221	JP20120219487	20121001
KR20060073584 A	20060628	KR20067002214	20040729
KR20120116991 A	20121023	KR20127022817	20040729
KR20130081319 A	20130716	KR20137015399	20040729
NZ545570 A	20120727	NZ20040545570	20040729
NZ601772 A	20121026	NZ20040601772	20040729
NZ601780 A	20121026	NZ20040601780	20040729
SG145693 A1	20080929	SG20080056244	20040729
SG178721 A1	20120329	SG20120005310	20040729
US2006241017 AA	20061026	US20060343557	20060130
US2006287244 AA	20061221	US20060442027	20060526
US2010004481 AA	20100107	US20090556968	20090910
US2010069446 AA	20100318	US20090557030	20090910
US2010069489 AA	20100318	US20090557080	20090910
US2012289471 AA	20121115	US20120449791	20120418
US7589233 BB	20090915	US20060442027	20060526
US8173840 BB	20120508	US20060343557	20060130
US8188311 BB	20120529	US20090557030	20090910
US8563776 BB	20131022	US20090556968	20090910
WO05046575 A2	20050526	WO2004US24901	20040729
WO05046575 A3	20071004	WO2004US24901	20040729
WO07089745 A2	20070809	WO2007US02475	20070129
WO07089745 A3	20080821	WO2007US02475	20070129
ZA200600660 A	20070425	ZA20060000660	20050123

Priority Numbers: US20030491331P [20030729]; WO2004US24901 [20040729]; US20090491331P [20090129]; US20030491331 [20030729]; JP20060522125 [20040729]; JP20060522125 [20121001]; JP20060522125T [20121001]; US20060343557 [20060130]; US20060442027 [20060526]; US20090556968 [20090910]; US20090557030 [20090910]; US20090557080 [20090910]; US20120449791 [20120418]

Probable Patent Assignee: SIGNATURE R AND D HOLDINGS LLC

Assignees: SIGNATURE PHARMACEUTICALS LLC; SIGNATURE R AND D HOLDINGS LCC; SIGNATURE R AND D HOLDINGS LLC; CHANDRAN V RAVI; CHANDRAN V R; SIGNATURE R AND D HOLDINGS

Non Std Assignees: SIGNATURE Rand D HOLDINGS LLC; CHANDRAN V; D HOLDINGS LLC; SIGNATURE R AMP AMP

Inventors: CHANDRAN V RAVI; CHANDRAN V; CHANDRAN V R; RAVI CHANDRAN V

Non Std Inventors: V RAVI CHANDRAN

Agent(s): PHILLIPS ORMONDE FITZPATRICK; BORDEN LADNER GERVAIS LLP; KITA AOYAMA INT PATENT BUREAU; ONE LEGAL LLC; SCULLY SCOTT MURPHY AND PRESSER PC; MARK J CHOEN SCULLY SCOTT MURPHY AND PRESSER PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; GT; HN; KM; KN; LA; LY; MY; NG; RS; SM; SV

77. Family 44043771 (US2011206773 AA)

[View in PatBase](#)

Title

[EN] SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES

Abstract

[EN] Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye.

International Class: A61K31/519; A61K31/57; A61K31/58; A61K9/00; A61K9/16; A61K31/216; A61K31/517; A61K31/573; A61K9/14; A61P27/02; B65D69/00

Cooperative Patent Class: A61K31/519; A61K31/57; A61K31/58; A61K9/0051; A61K9/1647; A61K9/1694; A61K31/216; A61K31/517; A61K31/573; A61K9/0048; A61P27/02

US Class: 206/223; 206/223S; 206/568; 424/489; 424/489S; 424/501; 424/501P; 514/179; 514/179S; 514/180; 514/180S; 514/2.9; 514/210.05; 514/210.06; 514/210.08; 514/210.1; 514/249; 514/266.4; 514/266.400S; 514/530; 514/530S

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP2296621 A1	20110323	EP20090751516	20090520
US2011206773 AA	20110825	US20100945246	20101112
US2016101054 AA	20160414	US20140263566	20140428
WO09143288 A1	20091126	WO2009US44732	20090520

Priority Numbers: US20080054511P [20080520]; US20080054519P [20080520]; WO2009US44732 [20090520]; US20080054506P [20080520]; US20100945246 [20101112]; US20090260522P [20091112]; US20140263566 [20140428]

Probable Patent Assignee: YALE UNIV


Assignees: UNIV IOWA RES FOUND; UNIV YALE; UNIVERSTIY OF IOWA RES FOUNDATION; HUANG JOHN J; KEUHN MARKUS; ROBINSON REBECCA; KWON YOUNG H; SALUJA SANDEEP; BERTRAM JAMES; LAVIK ERIN

Non Std Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION; YALE UNIVERSITY; YALE UNIV; OF IOWA RESEARCH FOUNDATION UNIV; UNIVERSTIY OF IOWA RESEARCH FOUNDATION

Inventors: HUANG JOHN J; KEUHN MARKUS; ROBINSON REBECCA; KWON YOUNG H; SALUJA SANDEEP; BERTRAM JAMES; LAVIK ERIN; KUEHN MARKUS

Agent(s): BASSETT RICHARD SIMON; POTTER CLARKSON LLP; VORNDRAN CHARLES ET AL; PABST PATENT GROUP LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



78. Family 61559304 (EP2979689 A1)

[View in PatBase](#)

Title
[EN] COMPOSITION FOR AN EYE DROP AND DELIVERY SYSTEM THEREFOR

Abstract
[EN] The present application describes an ophthalmic composition including a foaming agent, adapted for topical administration to the eye from an applicator capable of dispensing a foam.

International Class: A61K31/535; A61K9/12

Cooperative Patent Class: A61K31/00; A61K31/196; A61K31/407; A61K31/46; A61K31/496; A61K31/498; A61K31/522; A61K31/535; A61K31/55; A61K38/12; A61K38/13; A61K9/0048; A61K9/122

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP2979689 A1	20160203	EP20140178883	20140729

Priority Numbers: EP20140178883 [20140729]

Probable Patent Assignee: SYGENE TECHNOLOGIES

Assignees: SYGENE TECHNOLOGIES

Inventors: GRANT CALVIN

Agent(s): EKE PHILIPPA DIANNE; SAUNDERS AND DOLLEYMORE LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR

79. Family 59104670 (WO15060812 A1)

[View in PatBase](#)

Title

[EN] TREATING OCULAR DISEASE WITH EFFLUX TRANSPORTER INHIBITORS

Abstract

[EN] Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subject's eye. In one aspect, the ocular disease is at least one of diabetic retinopathy, macular degeneration, endophthalmitis, glaucoma, cataracts, ocular herpes. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9).

International Class: A61K38/00; A61K38/13; A61P27/02

Cooperative Patent Class: A61K31/496; A61K31/545; A61K31/546; A61K31/573; A61K38/00; A61K38/13; A61K38/14; A61K39/39558; A61K45/06; A61K9/0048; A61P27/02

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO15060812 A1	20150430	WO2013US65944	20131021

Priority Numbers: WO2013US65944 [20131021]

Probable Patent Assignee: UNIV HOWARD

Assignees: UNIV HOWARD

Non Std Assignees: HOWARD UNIV

Inventors: MANGAT HARPAL S; KARLA PRADEEP K

Agent(s): KRATZ RUDY ET AL


Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

80. Family 32174749 (US2005178286 AA)

[View in PatBase](#)

Title
[EN] DYNAMICALLY MODIFIABLE POLYMER COATINGS AND DEVICES

Abstract
[EN] A dynamic coating includes at least one polymeric layer for attachment to a surface. The polymeric layer includes at least one electrically conducting polymer including layer, wherein under influence of a dynamic signal applied to the polymeric layer, a contact angle of the polymeric layer dynamically and substantially increases or decreases upon oxidation or reduction of the polymer. The polymeric layer can also expand or contract upon oxidation or reduction. The coating can be used for a variety of applications including a non-toxic biofouling preventative system and for forming low voltage electrowetting pumps.



International Class: B63B1/34; B63B59/00; B63B59/04; C09D5/16; F04B19/00; G03C1/85; B63B1/00; C09D5/24; C09D5/25; C09D7/00; C23F15/00; B63B1/36; B81C1/00; B05D5/12; C08L21/00; H01B1/20; H01B5/14; B63B1/38; B63B1/32; A61K9/00; A61K9/70; B32B3/00; B08B17/00; B08B17/02; B08B17/06; A61F2/00; A61F2/02; A61F2/12; A61L27/00; B64D15/00; A41D31/00; A61F2/24; A61L2/02

Cooperative Patent Class: B63B1/36; B63B59/04; B81C1/00206; C09D5/1662; F04B19/006; Y02T70/10; Y10T428/25; B08B17/06; E02B9/06; E04D13/002; F05C2253/12; Y02E10/20; A61F2/0077; A61F2/12; A61F2002/0086; A61F2002/009; B08B17/065; B64D15/00; Y10T428/24355; A41D31/305; A61F2/24; A61L2/02; A61M2025/006; A61M25/00; A61M25/0017; Y10T428/24372

US Class: 106/16; 106/16P; 114/222; 114/67.00R; 114/67.00RP; 114/67R; 424/400; 424/400P; 428/141; 428/141S; 428/143; 428/143S; 428/323; 428/323S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2005280637 AA	20060309	AU20050280637	20050217
AU2005280637 BB	20080214	AU20050280637	20050217
AU2005280637 BH	20080306	AU20050280637	20050217
CA2556662 AA	20060811	CA20052556662	20050217
CA2556662 C	20110802	CA20052556662	20050217
DE602005045474 D1	20150129	DE200560045474T	20050217
EP1716451 A2	20061102	EP20050810325	20050217
EP1716451 A4	20080326	EP20050810325	20050217
EP1716451 B1	20141217	EP20050810325	20050217
JP2007529090 T2	20071018	JP20060553362T	20050217
JP4870578 B2	20120208	JP20060553362T	20050217
US2005178286 AA	20050818	US20040780424	20040217
US2006219143 AA	20061005	US20050202532	20050812
US2007227428 AA	20071004	US20060567103	20061205
US2010126404 AA	20100527	US20090624503	20091124
US2010226943 AA	20100909	US20090550870	20090831
US7117807 BB	20061010	US20040780424	20040217
US7143709 BB	20061205	US20050202532	20050812
US7650848 BB	20100126	US20060567103	20061205
US8997672 BB	20150407	US20090624503	20091124
US9016221 BB	20150428	US20090550870	20090831
WO06025857 A2	20060309	WO2005US04972	20050217
WO06025857 A3	20060810	WO2005US04972	20050217
WO08070625 A2	20080612	WO2007US86289	20071203
WO08070625 A3	20080731	WO2007US86289	20071203

Priority Numbers: US20040780424 [20040217]; WO2005US04972 [20050217]; EP20050810325 [20050217]; US20050202532 [20050812]; US20060567103 [20061205]; US20090624503 [20091124]; US20090550870 [20090831]; US20060567103 [20061005]

Probable Patent Assignee: OF FLORIDA RESEARCH FOUNDATION INC UNIV

Assignees: UNIV FLORIDA; THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC; OF FLORIDA RESEARCH FOUNDATION INC UNIV; UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC; BRENNAN ANTHONY B; BANNEY RONALD H; WILSON LESLIE H; SCHUMACHER JAMES F; ESTES THOMAS G; FEINBERG ADAM W; CARMAN MICHELLE L; BANNEY RONALD HOWARD; SCHUMACHER JAMES FREDERICK; TURNAGE MICHELLE CARMAN; SPIECKER MARK M; LONG CHRISTOPHER JAMES; BAGAN JOSEPH W; BOHN CLAYTON JR

Non Std Assignees: BOHN CLAYTON C JR; OF FLORIDA UNIV; OF FLORIDA RESEARCH FOUNDATION INC GAINESVILLE UNIV; BOHN CLAYTON CJR; NAVY US GOV SECRETARY; NAVY SECRETARY OF UNITED STATES OF AMERICA; NAVY SECRETARY OF UNITED STATES OF AMERICA OFFICE OF NAVAL RESEARCH; UNIVERSITY OF FLORIDA; FLORIDA RESEARCH FOUNDATION INC UNIV; FLORIDA UNIV; NAVY SECRETARY OF UNITED STATES OF AMERICA OFFICE

Inventors: BRENNAN ANTHONY B; BOHN CLAYTON JR; BANNEY RONALD H; BOHN CLAYTON C JR; WILSON LESLIE H; SCHUMACHER JAMES F; ESTES THOMAS G; FEINBERG ADAM W; CARMAN MICHELLE L; SCHUMACHER JAMES FREDERICK; BANNEY RONALD HOWARD; TURNAGE MICHELLE CARMAN; BAGAN JOSEPH W; LONG CHRISTOPHER JAMES; SPIECKER MARK M; BOHN JR CLAYTON C

Non Std Inventors: ANTHONY B BRENNAN; CLAYTON JR BOHN; BOHN JR CLAYTON; CLAYTON BOHN JR; RONALD H BANNEY; BOHN CLAYTON C; BOHN CLAYTON JR CLUTE; BRENNAN ANTHONY B GAINESVILLE; BANNEY RONALD H GAINESVILLE; BOHN CLAYTON CJR; BOHN CLAYTON; BANNEY RONALD; BRENNAN ANTHONY; WILSON LESLIE; CARMAN MICHELLE; ESTES THOMAS; SCHUMACHER JAMES; FEINBERG ADAM

Agent(s): COLLISON AND CO; GOUDREAU GAGE DUBUC; LAVERY DE BILLY LLP; PATENTANWAELTE BAUER VORBERG KAYSER PARTNERSCHAFT MBB; FERRECCIO RINALDO; BOTTI AND FERRARI SRL; ONDA HIRONORI; ONDA MAKOTO; AKERMAN SENTERFITT; CANTOR COLBURN LLP; NEIL R; LEFKOWITZ GREGORY M

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; AL; BA; HR; LV; MK; YU; AE; AG; AM; AU; AZ; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; ID; IL; IN; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; MA; MD; MG; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; BH; DO; GT; HN; KM; KN; LA; LY; ME; MT; MY; NG; RS; SV

81. Family 58125685 (US2014378391 AA)

[View in PatBase](#)

Title

[EN] OPHTHALMIC LIPOPHILIC DRUG DELIVERY VEHICLE FORMULATIONS

Abstract

[EN] The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.

International Class: A61K47/02; A61K47/08; A61K47/26; A61K47/38; A61K47/40; A61K47/44; A61K31/138; A61K31/4174; A61K31/4439; A61K31/444; A61K31/47; A61K31/4709; A61K31/498; A61K31/53; A61K31/542; A61K31/546; A61K31/55; A61K31/7052; A61K31/724; A61K38/13; A61K47/18; A61K47/34; A01N25/00; A01N33/02; A01N37/18; A01N43/50; A01N43/58; A01N43/60; A61K31/165; A61K31/415; A61K31/495; A61K31/50; A61K31/54; A61K31/545; A61K47/00; A61K9/08; A61P27/02

Cooperative Patent Class: A61K31/4174; A61K31/5575; A61K47/02; A61K47/08; A61K47/10; A61K47/26; A61K47/38; A61K47/40; A61K47/44; A61K9/0048; A61K31/138; A61K31/439; A61K31/4409; A61K31/4439; A61K31/444; A61K31/47; A61K31/4709; A61K31/498; A61K31/53; A61K31/542; A61K31/546; A61K31/55; A61K31/7052; A61K31/724; A61K31/765; A61K38/13; A61K47/34; A61P27/02

US Class: 514/20.5; 514/206; 514/210.05; 514/217.07; 514/226.5; 514/243; 514/249; 514/29; 514/312; 514/335; 514/338; 514/396; 514/58; 514/622; 514/652; 514/653; 514/769; 514/788.1

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2014378391 AA	20141225	US20130924189	20130621
US2014378401 AA	20141225	US20130132822	20131218
US8999938 BB	20150407	US20130924189	20130621
WO14204791 A1	20141224	WO2014US42221	20140613

Priority Numbers: US20130924189 [20130621]; US20130132822 [20131218]

Probable Patent Assignee: PS THERAPY INC

Assignees: GNT LLC

Non Std Assignees: PRESBYOPIA THERAPIES LLC; PS THERAPIES LTD; PS THERAPY INC

Inventors: HORN GERALD

Agent(s): WOOD PHILLIPS KATZ CLARK AND MORTIMER; POLYAKOV MARK V ET AL

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

82. Family 58176608 (WO14208901 A1)

[View in PatBase](#)

Title

[EN] OIL-IN-WATER TYPE EMULSION COMPOSITION FOR POORLY WATER-SOLUBLE DRUG AND METHOD FOR PREPARING SAME

Abstract

[EN] The present invention relates to an oil-in-water type emulsion composition for a drug that is poorly soluble in water, and a method for preparing the same. In particular, the present invention relates to an oil-in-water type emulsion composition for topical administration or injection, comprising, in order to improve the solubility of a poorly water-soluble drug, a surfactant in which a hydrophobic moiety has two or more chain structures in such a manner that, with respect to (A) the poorly water-soluble drug, the weight ratio of (B) the surfactant is 1:0.5-100, and a method for preparing the same.

International Class: A61K47/30; A61K47/44; A61K9/10; A61K9/107

Cooperative Patent Class: A61K9/0048; A61K9/0051; A61K9/107

Family Information

Patent Number	Publication Date	Application Number	Application Date
KR2015000405 A	20150102	KR20140067190	20140602
WO14208901 A1	20141231	WO2014KR04895	20140602

Priority Numbers: KR20130072739 [20130624]


Probable Patent Assignee: KOLMAR KOREA

Assignees: YOU WOO YOUNG; KOLMAR KOREA; KOREA KOLMAR HOLDINGS CO LTD

Inventors: KWEON DON SUN; YOU WOO YOUNG

Agent(s): LEE CHEO YOUNG ET AL

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JP; KE; KG; KM; KN; KP; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



83. Family 58066394 (US2014369997 AA)

[View in PatBase](#)

Title
[EN] PHARMACEUTICAL COMPOSITION FOR A FOAMING EYE DROP

Abstract
[EN] The present application describes a method of creating a foaming ophthalmic formulation. The described formulation includes the addition of a foaming agent. The resulting solution is designed to be distributed by a non-aerosol foaming bottle/or aerosol.

International Class: A61K31/713; A61K38/02; A61K39/395; A61K45/06; A61K47/26; A61K9/12
Cooperative Patent Class: A61K31/713; A61K38/00; A61K45/00; A61K45/06; A61K47/38; A61K9/0048; A61K9/122
US Class: 424/130.1; 514/20.8; 514/44R; 514/781; 530/350; 530/387.1; 536/23.1; 536/95

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2014369997 AA	20141218	US20120385123	20120202

Priority Numbers: US20110463378P [20110216]; US20120385123 [20120202]

Probable Patent Assignee: PASE

Assignees: GRANT CALVIN ALEXANDER; PASE

Inventors: GRANT CALVIN ALEXANDER

84. Family 53663180 (US2013116215 AA)

[View in PatBase](#)

Title

[EN] COMBINATION THERAPIES FOR TREATING NEUROLOGICAL DISORDERS

Abstract

[EN] The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the invention demonstrate additive or synergistic effect in silico and in vivo. The invention also relates to methods of treatment of neurological and neurodegenerative diseases including the pharmaceutical combinations of the invention.

International Class: A61K31/165; A61K31/196; A61K31/337; A61K31/40; A61K31/4045; A61K31/4174; A61K31/428; A61K31/4406; A61K31/4422; A61K31/48; A61K31/51; A61K31/5377; A61K31/549; A61K31/56; A61K31/655; A61K31/663; A61K45/06; A61K31/395

Cooperative Patent Class: A61K31/165; A61K31/196; A61K31/337; A61K31/395; A61K31/40; A61K31/4045; A61K31/4174; A61K31/428; A61K31/4406; A61K31/4422; A61K31/48; A61K31/51; A61K31/5377; A61K31/549; A61K31/56; A61K31/655; A61K31/663; A61K45/06

US Class: 514/108; 514/151; 514/171; 514/223.5; 514/236.5; 514/276; 514/288; 514/357; 514/367; 514/428

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2013116215 AA	20130509	US20120660205	20121025
WO13061161 A2	20130502	WO2012IB02768	20121025
WO13061161 A3	20131107	WO2012IB02768	20121025

Priority Numbers: US20110552922P [20111028]; US20120660205 [20121025]

Probable Patent Assignee: ANAXOMICS BIOTECH SL

Assignees: PUJOL ALBERT; LLEO ALBERTO; ALOY PATRICK; COMA MIREIA; GOMIS XAVIER; MAS JOSE MANUEL; OLIVA BALDOMERO; ANAXOMICS BIOTECH SL; GREEN BCN CONSULTING SERVICES SL

Inventors: PUJOL ALBERT; LLEO ALBERTO; ALOY PATRICK; COMA MIREIA; GOMIS XAVIER; MAS JOSE MANUEL; OLIVA BALDOMERO

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



85. Family 48909245 (US2013189246 AA)

[View in PatBase](#)

Title

[EN] TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES

Abstract

[EN] Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina.

International Class: A01N33/02; A61K31/13; A61K31/192; A61K31/421; A61K31/427; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/535; A61K45/06; A61K9/00; A61K9/08; A61P27/02; A61P27/06; A61K45/00; A61K47/36; A61K47/44; C07C59/215; A61K31/426; C07D213/65; C07D263/14; C07D265/06; C07D277/10

Cooperative Patent Class: A61K2300/00; A61K31/192; A61K31/421; A61K31/426; A61K31/427; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/535; A61K45/06; A61K9/0048; A61K9/08; A61P27/02; A61P27/06; C07D213/65; C07D263/14; C07D265/06; C07D277/10

US Class: 424/133.1; 424/94.64; 514/171; 514/20.5; 514/228.8; 514/29; 514/345; 514/365; 514/374; 514/44A; 514/45; 514/569

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP2501227 A1	20120926	EP20100830543	20101105
EP2501227 A4	20130410	EP20100830543	20101105
JP2013510852 T2	20130328	JP20120538861T	20101105
US2013189246 AA	20130725	US20100509712	20101105
WO11059881 A1	20110519	WO2010US55540	20101105

Priority Numbers: US20090260439P [20091112]; US20100378624P [20100831]; WO2010US55540 [20101105]; US20100509712 [20101105]

Probable Patent Assignee: TRUSTEES OF COLUMBIA UNIV IN CITY OF NEW YORK


Assignees: UNIV COLUMBIA; PETRUKHIN KONSTANTIN

Non Std Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK; TRUSTEES OF COLUMBIA UNIV IN CITY OF NEW YORK

Inventors: PETRUKHIN KONSTANTIN

Agent(s): JAPPY JOHN WILLIAM GRAHAM; GILL JENNINGS AND EVERY LLP; ASAI KENJI; HAKODA ATSUSHI; ICHIKAWA SATSUKI; KUMAKURA YOSHIO; YAMASAKI KAZUO; BOCK JOEL N; SNR DENTON US LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; RU; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



86. Family 54081176 (US2013150311 AA)

[View in PatBase](#)

Title
[EN] MIXED POLOXAMER EXCIPIENTS

Abstract
[EN] In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.

International Class: A61K31/137; A61K31/167; A61K31/195; A61K31/337; A61K31/381; A61K31/397; A61K31/4015; A61K31/407; A61K31/4439; A61K31/445; A61K31/4468; A61K31/4525; A61K31/4545; A61K31/47; A61K31/4745; A61K31/495; A61K31/496; A61K31/517; A61K31/53; A61K31/5377; A61K31/546; A61K31/551; A61K31/56; A61K31/58; A61K31/64; A61K31/704; A61K31/7048; A61K31/7068; A61K38/13; A61K47/34; A61P1/00; A61P1/08; A61P11/06; A61P25/00; A61P25/04; A61P25/18; A61P25/26; A61P25/28; A61P3/00; A61P3/06; A61P3/10; A61P31/04; A61P35/00; A61P37/06; A61P37/08; A61P9/10; C08J3/12; C08L71/02

Cooperative Patent Class: A61K31/137; A61K31/167; A61K31/195; A61K31/337; A61K31/381; A61K31/397; A61K31/4015; A61K31/407; A61K31/4439; A61K31/445; A61K31/4468; A61K31/4525; A61K31/4545; A61K31/47; A61K31/4745; A61K31/495; A61K31/496; A61K31/517; A61K31/53; A61K31/5377; A61K31/546; A61K31/551; A61K31/56; A61K31/58; A61K31/64; A61K31/704; A61K31/7048; A61K31/7068; A61K38/13; A61K47/10; A61K9/2031; A61P1/00; A61P1/08; A61P11/06; A61P25/00; A61P25/04; A61P25/18; A61P25/26; A61P25/28; A61P3/00; A61P3/06; A61P3/10; A61P31/04; A61P35/00; A61P37/06; A61P37/08; A61P9/10

US Class: 514/172; 514/180; 514/20.5; 514/207; 514/210.02; 514/210.13; 514/220; 514/236.8; 514/242; 514/252.17; 514/253.08; 514/255.04; 514/266.4; 514/283; 514/29; 514/290; 514/311; 514/317; 514/321; 514/329; 514/34; 514/342; 514/424; 514/438; 514/449; 514/49; 514/561; 514/626; 514/653; 514/772

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2013150311 AA	20130613	US20110324395	20111213
WO13088216 A1	20130620	WO2012IB02562	20121129

Priority Numbers: US20110324395 [20111213]

Probable Patent Assignee: SUPRATEK PHARMA INC

Assignees: ALAKHOV VALERY; PATEL KISHORE; PIETRZYNSKI GRZEGORZ; SUPRATEK PHARMA INC

Inventors: ALAKHOV VALERY; PATEL KISHORE; PIETRZYNSKI GRZEGORZ

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

87. Family 43550917 (US2010330146 AA)

[View in PatBase](#)

Title
[EN] CONTACT LENSES FOR EXTENDED RELEASE OF BIOACTIVE AGENTS CONTAINING DIFFUSION ATTENUATORS

Abstract
[EN] An appliance for the delivery of at least one bioactive agent to the eye has at least one diffusion attenuator within a hydrophilic or silicone-hydrogel contact lens. The bioactive agent can be a drug or a nutraceutical. The diffusion attenuator can be a plurality of solid particles or phase separated liquid aggregates within at least one continuous phase of the lens where the diffusion attenuators promote a tortuous path for the diffusion of the bioactive agent to mediate the rate by which the bioactive agent diffuses from the contact lens. The diffusion attenuator can be homogeneously dispersed throughout at least one continuous phase of the lens to modify the diffusivity of the bioactive agent through that phase. The diffusion attenuator can have little or no affinity for the bioactive agent or can be miscible with the bioactive agent. The diffusion attenuator can be incorporated while forming the contact lens by polymerization of a monomer mixture containing the diffusion attenuator. For liquid diffusion attenuators, the liquid can be co-absorbed with a solvent into the lens followed by removal of the solvent, where the bioactive agent can be co-absorbed or subsequently absorbed after the loading of the diffusion attenuator. The diffusion attenuator can be Vitamin E.

International Class: A61F2/14; A61K31/355; A61K31/4196; A61K31/5377; A61K31/573; A61P27/02; A61P27/06; A61P29/00; A61P31/00; A61K9/00; A61P27/00; C08G18/00; C08G18/83; C08G63/00; C08G63/08; G02B1/04; G02C7/04

Cooperative Patent Class: A61K47/10; A61K9/0051; A61P27/02; A61P27/06; A61P29/00; A61P31/00; G02B1/043

US Class: 424/424; 424/424P; 424/427; 424/429; 427/164; 427/164S; 514/180; 514/180S; 514/236.2; 514/236.200S; 514/383; 514/383S; 514/458; 514/458S

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2010330146 AA	20101230	US20100841504	20100722
US8404265 BB	20130326	US20100841504	20100722
WO09094466 A2	20090730	WO2009US31714	20090122
WO09094466 A3	20091029	WO2009US31714	20090122

Priority Numbers: US20080011860P [20080122]; US20080073141P [20080617]; WO2009US31714 [20090122]; US20100841504 [20100722]

Probable Patent Assignee: OF FLORIDA RESEARCH FOUNDATION INC UNIV


Assignees: UNIV FLORIDA; CHAUHAN ANUJ; KIM JINAH

Non Std Assignees: OF FLORIDA RESEARCH FOUNDATION INC UNIV; UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC

Inventors: KIM JINAH; CHAUHAN ANUJ

Agent(s): SALIWANCHIK LLOYD AND SALIWANCHIK A PROFESSIONAL ASSOCIATION; SALIWANCHIK LLOYD AND SALIWANCHIK;A PROFESSIONAL ASSOCIATION; SALIWANCHIK LLOYD AND EISENSCHENK; BUESE MARK A

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



88. Family 40814093 (US2009306224 AA)

[View in PatBase](#)

Title

[EN] USE OF ROLL COMPACTED PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS


Abstract

[EN] The use of Schuelpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described.

International Class: A61K9/16; A61K47/04; A61K47/02; A61K31/19; A61K47/00; A61K9/20

Cooperative Patent Class: A61K9/1611; A61K9/1694

US Class: 424/465; 514/571; 514/770



Family Information

Patent Number	Publication Date	Application Number	Application Date
CN101522174 A	20090902	CN200680055294	20060510
EP2023898 A1	20090218	EP20060755131	20060510
IN04523KN2008 A	20090313	IN2008KN04523	20081107
IN253087 B	20120629	IN2008KN04523	20081107
JP2009536164 T2	20091008	JP20090508144T	20060510
US2009306224 AA	20091210	US20060299997	20060510
US8377994 BB	20130219	US20060299997	20060510
WO07128349 A1	20071115	WO2006EP62215	20060510

Priority Numbers: WO2006EP62215 [20060510]

Probable Patent Assignee: EVONIK DEGUSSA GMBH

Assignees: EVONIK DEGUSSA CO LTD; EVONIK DEGUSSA GMBH; DEGUSSA; DEGUSSA GMBH; GRAY ANN; HOFMANN RALPH; EVONIK DEGUSSA GMEH; DRECHSLER MARGARETE

Non Std Assignees: EVONIK DEGUSSA CO

Inventors: HOFMANN R; DRECHSLER M; GRAY A; GRAY ANN; HOFMANN RALPH; DRECHSLER MARGARETE

Non Std Inventors: R HOFMANN; A GRAY; M DRECHSLER; MDRECHSLER; RHOFMANN; AGRAY; ANN GRAY; DR RALPH HOFMANN; MARGARETE DRECHSLER

Agent(s): SMITH GAMBRELL AND RUSSELL; SMITH GAMBRELL AND RUSSELL LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; NL; PL; PT; RO; SE; SI; SK; TR; YU; AE; AG; AM; AU; AZ; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

89. Family 30301447 (US2004096501 AA)

[View in PatBase](#)

Title
[EN] NOVEL DRUG DELIVERY SYSTEM

Abstract
[EN] A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.

International Class: A61K31/155; A61K31/185; A61K31/19; A61K31/455; A61K9/20; A61K9/22; A61K9/26; A61K9/00; A61K9/24

Cooperative Patent Class: A61K31/155; A61K31/19; A61K31/455; A61K9/2081; A61K9/5021

US Class: 424/400; 424/400P; 424/464; 424/465; 424/468; 424/469; 424/469P; 424/472; 424/472S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2003274680 AA	20040223	AU20030274680	20030801
AU2003274680 AH	20040223	AU20030274680	20030801
IN00698MU2002 A	20040529	IN2002MU00698	20020805
US2004096501 AA	20040520	US20030630348	20030729
US2006018933 AA	20060126	US20050134631	20050519
US2006018934 AA	20060126	US20050134632	20050519
US7976871 BB	20110712	US20050134631	20050519
US8216609 BB	20120710	US20030630348	20030729
US8268352 BB	20120918	US20050134632	20050519
WO04012699 A2	20040212	WO2003IN00261	20030801
WO04012699 A3	20040401	WO2003IN00261	20030801

Priority Numbers: IN2002MU00696 [20020805]; IN2002MU00698 [20020805]; WO2003IN00261 [20030801]; IN2003MU00081 [20030122]; IN2003MU00696 [20020805]; US20050134631 [20050519]; US20030630348 [20030729]; US20050134632 [20050519]

Probable Patent Assignee: TORRENT PHARMACEUTICALS LTD

Assignees: TORRENT PHARMACEUTICALS LTD; KARAN RAJESH SINGH; GUPTA VINOD KUMAR; VAYA NAVIN; NADKARNI SUNIL S; KARAN RAJESH S; GUPTA VINOD K; NADKARNI SUNIL SADANAND


Non Std Assignees: TORRENT PHARMACEUTICALS LIMITED; MADKARNI SUNIL SADANAND

Inventors: NADKARNI SUNIL SADANAND; KARAN RAJESH SINGH; VAYA NAVIN; GUPTA VINOD KUMAR; MADKARNI SUNIL SADANAND; NADKARNI SUNIL S; KARAN RAJESH S; GUPTA VINOD K

Non Std Inventors: NAVIN VAYA; SUNIL SADANAND NADKARNI; RAJESH SINGH KARAN; NANDKARNI SUNIL SADANANDN; SUNIL SADANAND MADKARNI; VINOD KUMAR GUPTA; NADKARNI SUNIL; KARAN RAJESH; GUPTA VINOD

Agent(s): HEDMAN AND COSTIGAN PC; JAMES V; HEDMAN AND COSTIGAN

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BJ; BR; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GW; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MC; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW



90. Family 28520375 (US2004022844 AA)

[View in PatBase](#)

Title
[EN] USE OF GRANULAR MATERIALS BASED ON PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS

Abstract
[EN] The use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions, the pharmaceutical compositions per se, as well as an adsorbate consisting of the granular material and at least one further substance selected from pharmaceutical active constituents and auxiliary substances, and the production of such adsorbates, are described.

International Class: A61K31/00; A61K31/167; A61K31/355; A61K31/60; A61K31/616; A61K47/04; A61K9/02; A61K9/06; A61K9/10; A61K9/14; A61K9/18; A61K9/20; A61K9/48; A61P29/00; A61P39/06; A61P43/00; A61K31/165; A61K31/352; A61K47/02; A61P39/00; A61K9/16; A61K33/00

Cooperative Patent Class: A61K31/00; A61K31/355; A61K31/60; A61K9/1611; A61K9/2009; A61K9/485; A61P29/00; A61P39/06; A61P43/00; B01J20/103; B01J20/28057

US Class: 424/452; 424/452P; 424/465; 424/465S; 424/724; 424/724S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2002321191 AA	20030512	AU20020321191	20020706
CA2465369 AA	20040429	CA20022465369	20020706
CN1582169 A	20050216	CN20028021935	20020706
DE10153078 A1	20030522	DE20011053078	20011030
DE60243263 D1	20120830	DE20026043263	20020706
EP1439858 A1	20040728	EP20020754850	20020706
EP1439858 B1	20120704	EP20020754850	20020706
JP2005508977 T2	20050407	JP20030539719T	20020706
JP4320254 B2	20090826	JP20030539719T	20020706
US2004022844 AA	20040205	US20020281223	20021028
US7815936 BB	20101019	US20020281223	20021028
WO03037379 A1	20030508	WO2002EP07588	20020706

Priority Numbers: DE20011053078 [20011030]; WO2002EP07588 [20020706]; EP20020754850 [20020706]; US20010331533P [20011119]; US20020281223 [20021028]

Probable Patent Assignee: EVONIK OPERATIONS GMBH

Assignees: DEGUSSA AG; DEGUSSA; EVONIK DEGUSSA GMBH

Non Std Assignees: HASENZAHL STEFFEN; MEYER JUERGEN; HEYM JUERGEN; HEYM JURGEN; MEYER JURGEN; DEGUSSA GMBH; EVONIK OPERATIONS GMBH

Inventors: HASENZAHL STEFFEN; HEYM JURGEN; MEYER JURGEN; MEYER JUERGEN; HEYM JUERGEN; JURGEN HEYM; JURGEN MEYER; STEFFEN HASENZAHL

Agent(s): SPRUSON AND FERGUSON; MARKS AND CLERK; SMITH GAMBRELL AND RUSSELL LLP

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; GA; GD; GE; GH; GM; GN; GQ; GW; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NO; NZ; OM; PH; PL; RO; RU; SD; SG; SI; SL; SN; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW


91. Family 51780492 (US2012215184 AA)

[View in PatBase](#)

Title
[EN] CYLINDRICAL OCULAR INSERTS

Abstract
[EN] Ocular inserts including a cylindrical body, a lumen and a hydrophilic polymer and strips thereof are suitable for contact with an eye of a subject suffering from an eye disorder. While in contact with an eye, the ocular inserts may be used for releasing various agents, including pharmaceutically active agents, and effecting a treatment of one or more eye disorders.

International Class: A61F9/00; A61M35/00; B29D11/00; A61K31/439
Cooperative Patent Class: A61F9/0017; A61K31/535; A61K9/0051
US Class: 264/2.7; 264/2.700S; 604/290; 604/290P; 604/294; 604/294S



Family Information

Patent Number	Publication Date	Application Number	Application Date
US2012215184 AA	20120823	US20120397185	20120215
WO12112636 A1	20120823	WO2012US25162	20120215

Priority Numbers: US20110444213P [20110218]; US20120397185 [20120215]
Probable Patent Assignee: VALEANT INT BARBADOS SRL
Assignees: VALEANT INTERNAT BARBADOS SRL; VALEANT INT BARBADOS SRL; LIM JOHNSON
Non Std Assignees: VALEANT INTERNATIONAL BARBADOS SRL; BARCLAYS BANK PLC SUCCESSOR AGENT AS; GOLDMAN SACHS LENDING PARTNERS LLC; VALEANT INT BERMUDA
Inventors: LIM JOHNSON
Agent(s): VILLACORTA GILBERTO M ET AL; FOLEY AND LARDNER LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

92. Family 31881077 (US2006211599 AA)

[View in PatBase](#)

Title
[EN] REVERSIBLY HEAT-GELABLE AQUEOUS COMPOSITION

Abstract
[EN] The present invention relates to a reversibly heat-gelable aqueous composition comprising a reversibly heat-gelable aqueous composition according to conventional technique, to which a thixotropic property-increasing substance is added. The thixotropic property-increasing substance is preferably at least one member selected from the group consisting of sugar alcohol, lactose, carmellose or pharmaceutically acceptable salts thereof and cyclodextrin. This composition can be stored at room temperature and accordingly, it is quite convenient for users to carry about the same.

International Class: A61K47/12; A61K47/18; A61K47/26; A61K47/34; A61K47/38; A61K47/40; A61K9/00; A61K9/06; A61K31/185; A61K31/5383; A61K31/717; A61K31/737; A61K31/77; A61K45/00; A61K47/10; A61P27/02; A61P31/04; A61K47/16; A61K31/00; A61P27/06; A61P29/00; A61P31/10; A61P31/10; A61P31/12; A61P35/00; A61P37/02; A61P37/08

Cooperative Patent Class: A61K31/5383; A61K47/26; A61K47/34; A61K47/38; A61K9/0014; A61K9/0019; A61K9/0024; A61K9/0043; A61K9/0046; A61K9/0048; A61P27/02; A61P27/06; A61P29/00; A61P31/10; A61P31/04; A61P31/10; A61P31/12; A61P35/00; A61P37/02; A61P37/08

US Class: 514/1; 514/1P; 514/230.2; 514/230.200P; 514/781; 514/781S

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1681065 A1	20060719	EP20040799523	20041101
EP1681065 A4	20111228	EP20040799523	20041101
JP2005042026 A1	20070426	JP20050515218T	20041101
JP4947977 B1	20120606	JP20050515218T	20041101
JP4947977 B2	20120606	JP20050515218T	20041101
KR101144647 B1	20120508	KR20067008092	20041101
KR20060108628 A	20061018	KR20067008092	20041101
US2006211599 AA	20060921	US20060414498	20060501
US2011263587 AA	20111027	US20110175394	20110701
WO05042026 A1	20050512	WO2004JP16500	20041101

Priority Numbers: JP20030371572 [20031031]; WO2004JP16500 [20041101]; JP20050515218 [20041101]; US20110175394 [20110701]; US20060414498 [20060501]

Probable Patent Assignee: WAKAMOTO PHARMACEUTICAL CO LTD

Assignees: WAKAMOTO PHARMA CO LTD; SUZUKI HIDEKAZU

Non Std Assignees: WAKAMOTO PHARMACEUTICAL CO LTD; WAKAMOTO PHARMACEUTICAL CO

Inventors: SUZUKI HIDEKAZU

Agent(s): ASAI KENJI; HAKODA ATSUSHI; HIRAYAMA KOJI; KUMAKURA YOSHIO; OGAWA NOBUO; C IRVIN MCCLELLAND OBLON SPIVAK MCCLELLAND MAIER AND NEUSTADT PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

93. Family 49609389 (WO11113904 A1)

[View in PatBase](#)

Title


[EN] MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION

Abstract

[EN] The present invention relates to a GABAB receptor agonist for use in the prevention and treatment of a disease associated with retinal ganglion cell degeneration. The present invention also relates to a pharmaceutical composition for the prevention and treatment of a disease associated with retinal ganglion cell degeneration which comprises a GABAB receptor agonist and optionally one or more pharmaceutically acceptable excipients.

International Class: A61K31/197; A61K45/06; A61P27/02; A61P27/06

Cooperative Patent Class: A61K31/00; A61K31/197; A61K45/06; A61P27/02; A61P27/06; Y02A50/30



Family Information

Patent Number	Publication Date	Application Number	Application Date
WO11113904 A1	20110922	WO2011EP54071	20110317

Priority Numbers: EP20100305264 [20100317]

Probable Patent Assignee: INST NAT SANTE RECH MED

Assignees: INST NAT SANTE RECH MED; PICAUD SERGE

Non Std Assignees: INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Inventors: PICAUD SERGE

Agent(s): HIRSCH DENISE

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PE; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

94. Family 47845117 (US2011082151 AA)

[View in PatBase](#)

Title

[EN] SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR

Abstract

[EN] The present invention relates to new sulfonylurea modulators of endothelin receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

International Class: A61K31/496; A61K31/4985; A61K31/506; A61K31/519; A61P1/04; A61P11/06; A61P25/06; A61P25/28; A61P29/00; A61P35/00; A61P9/00; A61P9/10; A61P9/12; C07D403/12; A61K31/497

Cooperative Patent Class: A61K31/497; A61P1/04; A61P11/06; A61P25/06; A61P25/28; A61P29/00; A61P35/00; A61P9/00; A61P9/10; A61P9/12; C07D403/12

US Class: 514/250; 514/255.05; 514/255.050S; 514/262.1; 514/262.100S; 514/274; 514/274S; 544/296; 544/296S

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2011082151 AA	20110407	US20100796527	20100608
WO10144477 A2	20101216	WO2010US37812	20100608
WO10144477 A3	20110421	WO2010US37812	20100608

Priority Numbers: US20090186605P [20090612]; US20100796527 [20100608]


Probable Patent Assignee: AUSPEX PHARMACEUTICALS INC

Assignees: AUSPEX PHARMACEUTICALS INC; RAO TADIMETI; ZHANG CHENGZHI

Inventors: RAO TADIMETI; ZHANG CHENGZHI

Agent(s): BENNETT DENNIS A; GLOBAL PATENT GROUP LLC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PE; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



95. Family 48766770 (US2011091459 AA)

[View in PatBase](#)

Title

[EN] IMIDAZOLE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M3

Abstract

[EN] The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

International Class: A61K31/4178; A61K31/42; A61K31/421; A61K31/433; A61K31/4353; A61K31/436; A61K31/439; A61K31/454; A61K31/519; A61K31/52; A61K31/54; A61K31/542; A61K31/662; A61K31/7088; A61K38/13; A61K38/17; A61K39/395; A61P1/16; A61P27/06; A61P29/00; C07D405/06

Cooperative Patent Class: A61K31/407; A61K31/4178; A61K31/42; A61K31/421; A61K31/433; A61K31/4353; A61K31/436; A61K31/439; A61K31/454; A61K31/519; A61K31/52; A61K31/54; A61K31/542; A61K31/662; A61K31/7088; A61K38/13; A61K45/06; A61P1/16; A61P27/06; A61P29/00; C07D405/06

US Class: 424/133.1; 424/133.100S; 424/134.1; 424/134.100P; 424/154.1; 424/154.100S; 424/173.1; 424/173.100S; 514/1.1; 514/1.100S; 514/129; 514/129S; 514/20.5; 514/20.500S; 514/226.5; 514/226.500S; 514/227.2; 514/227.200S; 514/262.1; 514/262.100S; 514/263.2; 514/263.200S; 514/278; 514/278S; 514/291; 514/291S; 514/319; 514/319S; 514/323; 514/323S; 514/363; 514/363S; 514/377; 514/377S; 514/378; 514/378S; 514/397; 514/397S; 514/44.00RS; 514/44R; 548/315.4; 548/315.400S

Family Information


Patent Number	Publication Date	Application Number	Application Date
US2011091459 AA	20110421	US20090635944	20091211

Priority Numbers: US20080121715P [20081211]; US20090635944 [20091211]

Probable Patent Assignee: AUSPEX PHARMACEUTICALS INC

Assignees: AUSPEX PHARMACEUTICALS INC

Inventors: GANT THOMAS G; SHAHBAZ MANOUCHEHR M



96. Family 41618747 (US2008066739 AA)

[View in PatBase](#)

Title
[EN] METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION

Abstract
[EN] Systems and methods for delivery of a drug to the respiratory system of a patient where the drug is supplied at a positive pressure relative to atmospheric pressure are provided. In particular, the drugs are delivered to the respiratory system of a patient who is capable of unassisted breathing. With the systems and methods of the present disclosure, medication available in a variety of forms is introduced in a controlled fashion into the air stream in aerosol, nebulized, or vaporized form.


International Class: A61K9/12; A61K9/72; A61M11/00; A61M11/02; A61M15/00; A61M16/00; A61M16/06; A62B7/00; A62B9/00; A61M16/10

Cooperative Patent Class: A61M11/005; A61M11/008; A61M11/041; A61M11/042; A61M11/047; A61M15/00; A61M15/001; A61M15/0085; A61M15/009; A61M15/025; A61M16/0051; A61M16/0057; A61M16/0066; A61M16/0069; A61M16/024; A61M16/06; A61M16/109; A61M16/161; A61M2016/0027; A61M2016/0039; A61M2205/3569; A61M2205/3592; A61M2205/6054; A61M2205/6072; A61M2205/8206; A61M2206/14; A61M2230/06; A61M2230/201; A61M2230/205; A61M2230/30; A61M16/0683; A61M16/08; A61M16/107; A61M16/14; A61M16/142; A61M2202/0208; A61M2202/03; A61M2205/3368; A61M11/001; A61M11/002; A61M11/044; A61M15/02; A61M16/0808; A61M16/1075; A61M16/108; A61M16/16; A61M16/209; A61M2016/0021; A61M2016/0033; A61M2205/3553; A61M2205/3561; A61M2205/3584; A61M2205/75; A61M15/0005; A61M15/0066; A61M15/0086; A61M16/1085; A61M2202/062; A61M2205/3306; A61M2205/3317; A61M2205/3653; A61M2205/368; A61M2205/3693; A61M2205/60; A61M2206/10

US Class: 128/200.14; 128/200.140P; 128/200.140S; 128/200.16; 128/200.160S; 128/200.21; 128/200.210P; 128/200.24; 128/203.12; 128/203.120S; 128/203.26; 128/203.260P; 128/203.29; 128/203.290S; 128/204.17; 128/204.170S

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2662777 AA	20090319	CA20072662777	20070920
CN101553210 A	20091007	CN200780043067	20070920
EP1902742 A1	20080326	EP20070018538	20070920
EP1911481 A2	20080416	EP20070018536	20070920
EP1911481 A3	20090506	EP20070018536	20070920
IN01083KN2009 A	20090522	IN2009KN01083	20090320
JP2010504171 T2	20100212	JP20090529388T	20070920
US2008066739 AA	20080320	US20070627692	20070126
US2008066741 AA	20080320	US20070689315	20070321
US2008078382 AA	20080403	US20060552871	20061025
US2008142010 AA	20080619	US20070950180	20071204
US2008271732 AA	20081106	US20080037513	20080226
WO08036798 A2	20080327	WO2007US78994	20070920
WO08036798 A3	20080814	WO2007US78994	20070920
WO08036801 A2	20080327	WO2007US78999	20070920
WO08036801 A3	20080731	WO2007US78999	20070920
WO08116165 A2	20080925	WO2008US57847	20080321
WO08116165 A3	20091230	WO2008US57847	20080321
WO08116165 A9	20090611	WO2008US57847	20080321



Priority Numbers: US20060826271P [20060920]; US20060552871 [20061025]; US20070627692 [20070126]; WO2007US78999 [20070920]; US20070689315 [20070321]; US20070950180 [20071204]; US20070915315P [20070501]; US20070915379P [20070501]; US20070915390P [20070501]; US20080037513 [20080226]; US20070915408P [20070501]

Probable Patent Assignee: NEXT SAFETY INC

Assignees: NEXT SAFETY INC; BALLOU BERNARD L; HARTLEY CHRIS; LEMAHIEU EDWARD; DUVALL LYNDELL; HUNTER CHARLES ERIC; CRISS RON; MCNEIL LAURIE; HUNTER JOCELYN; HEBRANK JACK; WETZEL PAUL; STERN TOM; JONES CHARLES; BALLOU BERNARD L JR

Inventors: HARTLEY CHRIS; BALLOU BERNARD L; HEBRANK JACK; WETZEL PAUL; CRISS RON; HUNTER JOCELYN; STERN TOM; HUNTER CHARLES ERIC; LEMAHIEU EDWARD; MCNEIL LAURIE; DUVALL LYNDELL; JONES CHARLES; CHARLES JONES; CHRIS HARTLEY; RON CRISS; JOCELYN HUNTER; ERIC HUNTER CHARLES; TOM STERN; LAURIE

MCNEIL; EDWARD LEMAHIEU; JACK HEBRANK; PAUL WETZEL; LYNDELL DUVALL; BALLOU JR BERNARD L; BALLOU BERNARD L JR; WEAVER PHILIP; COLVARD GEORGE; PIERCE ANDY; ROLAND TIMOTHY

Non Std Inventors: BALLOU BERNARD; HUNTER CHARLES

Agent(s): SIM AND MCBURNEY; REHBERG HUEPPE AND PARTNER; THOMAS KAYDEN HORSTEMEYER AND RISLEY LLP; LEE CYNTHIA J; THOMAS KAYDEN HORSTEMEYERAND RISLEY LLP; RISLEY DAVID R; THOMAS KAYDEN HORSTEMEYER AND RISLEY LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; PL; PT; RO; SE; SI; SK; TR; YU; RS; AE; AG; AM; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; AO

97. Family 30066142 (US2002156122 AA)

[View in PatBase](#)


Title
[EN] STATINS (HMG-COA REDUCTASE INHIBITORS) AS A NOVEL TYPE OF IMMUNOMODULATOR, IMMUNOSUPPRESSOR AND ANTI-INFLAMMATORY AGENT

Abstract
[EN] The present invention relates to methods of causing MHC-class II or CD40 mediated immunomodulation, immunosuppression and anti-inflammatory action, in a subject suffering from or susceptible of suffering from a condition involving inappropriate immune response, which comprises administering to the subject at least one statin, or a functionally or structurally equivalent molecule, in an amount effective to modulate MHC class II or CD40 expression in the subject.

International Class: H01J29/02; H01J9/02; A61K31/22; A61K31/225; A61K31/365; A61K31/366; A61K31/40; A61K31/401; A61K31/404; A61K31/44; A61K31/505; A61K31/60; A61K45/00; A61P1/04; A61P17/02; A61P17/06; A61P25/00; A61P29/00; A61P3/10; A61P37/02; A61P37/04; A61P37/06; C07D207/34; C07D209/18; C07D213/55; C07D239/42; C07D309/30; A61K45/06; A61P37/00; H01J1/18; A61K31/21; A61K31/185; A61K31/192; A61K31/198; A61K31/403; A61K31/405; A61K31/66; A61K33/242; A01N43/42; A61K31/35; A61K31/557; A61K31/59; A61K31/65; A61K38/21; H01J1/30; H01J31/00; H01J31/12

Cooperative Patent Class: H01J2201/319; H01J2329/00; H01J29/02; H01J9/025; A61K31/22; A61K31/225; A61K31/365; A61K31/366; A61K31/40; A61K31/401; A61K31/404; A61P1/04; A61P17/02; A61P17/06; A61P25/00; A61P29/00; A61P3/10; A61P37/02; A61P37/04; A61P37/06; A61K45/06; A61P37/00; A61K31/192; A61K31/198; A61K31/405; A61K31/44; A61K31/66; A61K33/242

US Class: 313/309; 313/351; 313/496; 424/649; 424/649P; 424/85.5; 424/85.500P; 424/85.6; 424/85.600P; 424/85.7; 424/85.700S; 514/109; 514/109S; 514/12; 514/153; 514/153S; 514/159; 514/159S; 514/167; 514/167S; 514/17.9; 514/17.900S; 514/20.5; 514/20.500S; 514/256; 514/256S; 514/277; 514/277S; 514/420; 514/420S; 514/423; 514/423P; 514/423S; 514/46; 514/460; 514/460S; 514/492; 514/492S; 514/547; 514/547S; 514/548; 514/548S; 514/562; 514/562S; 514/569; 514/569S; 514/570; 514/570S; 514/573; 514/573S; 707/3; 707/999.003



Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2001292810 AA	20020402	AU20010292810	20010919
AU200192810 A1	20020402	AU20010092810	20010919
AU200210521 A1	20020402	AU20020010521	20010919
AU200210521 A5	20020402	AU20020010521	20010919
AU2002210521 AA	20020402	AU20020210521	20010919
AU2003202797 AA	20030902	AU20030202797	20030122
AU2003202797 BB	20071129	AU20030202797	20030122
AU2003206016 AA	20030902	AU20030206016	20030122
AU2009201646 AA	20090521	AU20090201646	20090427
CA2422820 AA	20030318	CA20012422820	20010919
CA2474077 AA	20030731	CA20032474077	20030122
CA2474201 AA	20040722	CA20032474201	20030122
EP1322306 A2	20030702	EP20010978396	20010919
EP1467763 A1	20041020	EP20030701708	20030122
EP1467764 A1	20041020	EP20030702899	20030122
IL154977 A0	20031031	IL20010154977	20010919
JP2004512278 T2	20040422	JP20020528264T	20010919
TW512381 B	20021201	TW20010123088	20010919
US2002156122 AA	20021024	US20010960471	20010919
US2002159973 AA	20021031	US20020056288	20020123
US2002159974 AA	20021031	US20020056608	20020123
US2003060500 AA	20030327	US20020056133	20020123
US2003060501 AA	20030327	US20020056606	20020123
US2003060502 AA	20030327	US20020056645	20020123
US2003065019 AA	20030403	US20020056646	20020123

Patent Number	Publication Date	Application Number	Application Date
US2004013643 AA	20040122	US20030349549	20030122
US2004102512 AA	20040527	US20030718731	20031120
US2005187285 AA	20050825	US20050111185	20050420
US2007003636 AA	20070104	US20060432861	20060512
US6611093 BA	20030826	US20000664873	20000919
WO0224194 A2	20020328	WO2001EP11485	20010919
WO0224194 A3	20030313	WO2001EP11485	20010919
WO0224194 C2	20020919	WO2001EP11485	20010919
WO0225688 A2	20020328	WO2001US29315	20010919
WO0225688 A3	20030710	WO2001US29315	20010919
WO03061702 A1	20030731	WO2003IB00607	20030122
WO03061702 C2	20031127	WO2003IB00607	20030122
WO03061703 A1	20030731	WO2003IB00646	20030122
WO03061703 C2	20031224	WO2003IB00646	20030122

Priority Numbers: US20000664873 [20000919]; WO2001US29315 [20010919]; US20000664871 [20000919]; WO2001EP11485 [20010919]; US20020056608 [20020123]; WO2003IB00646 [20030122]; WO2003IB00607 [20030122]; AU20030206016 [20030122]; AU20090201646 [20090427]; US20010960471 [20010919]; US20020056288 [20020123]; US20020056133 [20020123]; US20020056606 [20020123]; US20020056645 [20020123]; US20020056646 [20020123]; US20030349549 [20030122]; US20030718731 [20031120]; US20050111185 [20050420]; US20050233584 [20050922]; US20060432861 [20060512]

Probable Patent Assignee: DISPLAY RESEARCH LABORATORIES INC

Assignees: DISPLAY RES LAB INC; NOVIMMUNE SA; NOVIMMUNE S A; MACH FRANCOIS; NOVIMMUNE S A

Non Std Assignees: DISPLAY RESEARCH LABORATORIES INC; NOVIMMUNE SA

Inventors: HAVEN DUANE A; KASANO KAZUHIKO; NAUGLER W EDWARD JR; NAUGLER JR W EDWARD; MACH FRANCOIS; NAUGLER EDWARD

Non Std Inventors: DUANE A HAVEN; W EDWARD NAUGLER JR; KAZUHIKO KASANO; FRANCOIS MACH; NAUGLER W

Agent(s): FISHER ADAMS KELLY; FISHER ADAMS KELLY CALLINANS; FISHER ADAMS KELLY PTY LTD; SPRUSON AND FERGUSON; SMART AND BIGGAR; ROBIC; FUKUMOTO TSUMORU; HIGUCHI SOTOJI; ISHIDA TAKASHI; NISHIYAMA MASAYA; TSURUTA JUNICHI; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; DORSEY AND WHITNEY LLP

Designated States: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR; BG; CZ; EE; HU; SI; SK; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NO; NZ; PH; PL; RO; RU; SD; SG; SL; SN; SZ; TD; TG; TJ; TM; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; EC; OM; TN; ZM; SC; VC

98. Family 43084551 (IN01270MU2007 A)

[View in PatBase](#)

Title

[EN] STABLE TOPICAL COMPOSITIONS COMPRISING HYALURONATE LYASE WITH PHARMACEUTICALLY ACCEPTABLE ACTIVE AGENT

Abstract

[EN] The present invention provides a stable topical composition comprising at least one pharmaceutically acceptable active agent along with hyaluronate lyase, wherein hyaluronate lyase is stabilized in the said composition by immobilization. The invention relates to an agent for treating, prophylaxis and/or metaphylaxis of functional and structural disorders of the skin and/or mucosa on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations in to skin.

International Class: A61K8/63

Family Information

Patent Number	Publication Date	Application Number	Application Date
IN01270MU2007 A	20090327	IN2007MU01270	20070703

Probable Patent Assignee: WOCKHARDT LTD

Non Std Assignees: WOCKHARDT LTD

Non Std Inventors: MAINDE CHANDRASHEKHAR; KARMAKAR DIPANKAR

99. Family 34064725 (US2007065472 AA)


[View in PatBase](#)

Title

[EN] BENZYL-1,3-THIAZOLIDINE-2,4-DIONE COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH AND/OR FOR REDUCING THE LOSS OF KERATIN FIBERS

Abstract

[EN] The benzyl-1,3-thiazolidine-2,4-dione compounds having the structural formula (I), or salt and/or solvate thereof; are useful active agents for inducing and/or stimulating the growth of mammalian keratin fibers and/or reducing the loss and/or increasing the density thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for caring for or making up the hair or the eyelashes.



International Class: A61K31/426; A61K8/30; A61K8/49; A61P17/00; A61P17/04; A61Q7/00; A61Q7/02; C07D277/00; C07D277/34; A61P17/14; A61P43/00; C07D277/20

Cooperative Patent Class: A61K2800/782; A61K31/426; A61K8/49; A61P17/04; A61P17/14; A61P43/00; A61Q7/00; A61Q1/10

US Class: 424/401; 514/369

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1738742 A2	20070103	EP20060115286	20060612
EP1738742 A3	20090225	EP20060115286	20060612
FR2887442 A1	20061229	FR20050051789	20050628
JP2007008938 A2	20070118	JP20060177277	20060627
US2007065472 AA	20070322	US20060476053	20060628

Priority Numbers: FR20050051789 [20050628]; US20050697966P [20050712]; US20060476053 [20060628]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL

Non Std Assignees: L OREAL; L OREAL SOCIETE ANONYME; L OREAL SOC ANONYME; L OREAL SA; L'OREAL; LOREAL; LOREAL SA

Inventors: DALKO MARIA; BOULLE CHRISTOPHE

Non Std Inventors: CHRISTOPHE BOULLE; MARIA DALKO

Agent(s): MISZPUTEN LAURENT ET AL; LOREAL; BUCHANAN INGERSOLL AND ROONEY PC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; NL; PL; PT; RO; SE; SI; SK; TR; YU; RS

100. Family 42440135 (WO08130211 A1)

[View in PatBase](#)

Title
[EN] DYNAMIC, STECHIOMETRIC SOLUTION FOR SUPPORT AND INDUCED EQUILIBRIUM

Abstract
[EN] The present invention describe a series of compositions which behave as a dynamic, stochiometric solution for support and induced equilibrium for active principals for ophthalmic and dermatological uses, which act as bactericides, antiinflammatories etc., reducing and/or avoiding the pain, heartburn, irritation and other distress caused by use thereof.

International Class: A61K47/00; A61K47/14; A61K47/32

Cooperative Patent Class: A61K47/02; A61K47/12; A61K47/14; A61K47/18; A61K47/186; A61K47/20; A61K47/26; A61K47/32; A61K9/0014; A61K9/0048

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO08130211 A1	20081030	WO2007MX00055	20070420

Priority Numbers: WO2007MX00055 [20070420]

Probable Patent Assignee: SERRAL S A DE C V

Assignees: SERRAL S A DE C V; MARTINEZ GOMEZ MAGDALENA; AVILES SOSA YOLANDA; GONZALEZ RODRIGUEZ BETHEL

Non Std Assignees: SERRAL DE CV SA

Inventors: AVILES SOSA YOLANDA; MARTINEZ GOMEZ MAGDALENA; GONZALEZ RODRIGUEZ BETHEL

Agent(s): SOLORZANO LEIRO GUILLERMO JAVIER


Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

101. Family 33174684 (US2008025940 AA)

[View in PatBase](#)

Title

[EN] ADMINISTRATION OF 3-SULFANYLPROPANAMIDE COMPOUNDS FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF



Abstract

[EN] 3-Sulfanylpropanamide compounds of formula (I) or salts and/or solvates thereof: are useful for caring for and/or making up keratin fibers, especially human keratin fibers, to induce and/or stimulate the growth, to stop the loss and/or to increase the density thereof, and/or to improve the appearance and/or to reduce the canities thereof, and/or to stimulate the pigmentation and/or to limit the depigmentation and/or bleaching thereof.

International Class: A61K31/095; A61K31/10; A61K31/16; A61K8/30; A61K8/46; A61P17/00; A61P17/14; A61Q7/00; C07C323/00; C07C323/58; A61K31/165; A61K31/341; A61K8/42; A61K8/49; A61Q1/00; A61Q5/00; C07C321/00; C07C321/16; C07D307/00; C07D307/52; A61K31/557; A61K31/5575; A61K45/00; A61P43/00; A61Q1/02; A61Q1/10; A61Q5/02; A61Q5/12; C07C323/60; C07D307/66; A61K31/4192; C07C233/00; C07C233/05; C07D249/00; C07D249/04; C07D307/54

Cooperative Patent Class: A61K31/10; A61K31/16; A61K8/46; A61K8/496; A61K8/4973; A61K8/69; A61P17/14; A61P43/00; A61Q5/10; A61Q7/00; C07C2601/04; C07C323/60; A61K2800/782; A61K31/165; A61K31/341; A61P17/00; A61Q1/10; A61Q5/00; C07D307/52

US Class: 424/70.1; 424/70.100S; 424/70.7; 424/70.700P; 514/359; 514/359S; 514/471; 514/471S; 514/625; 514/625S; 548/261; 548/261S; 549/493; 549/493S; 564/192; 564/192S

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1853352 A2	20071114	EP20060723068	20060123
FR2881427 A1	20060804	FR20050050279	20050131
JP2008528539 T2	20080731	JP20070552609T	20060123
US2008025940 AA	20080131	US20070882331	20070731
WO06079568 A2	20060803	WO2006EP01545	20060123
WO06079568 A3	20061026	WO2006EP01545	20060123

Priority Numbers: FR20050050279 [20050131]; US20050670020P [20050411]; WO2006EP01545 [20060123]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; BOULLE CHRISTOPHE; BRETON PHILIPPE

Non Std Assignees: L OREAL; LOREAL; L OREAL SOCIETE ANONYME; L OREAL SOC ANONYME; L'OREAL; LOREAL SA

Inventors: BRETON PHILIPPE; BOULLE CHRISTOPHE

Non Std Inventors: PHILIPPE BRETON; CHRISTOPHE BOULLE

Agent(s): LOREAL; BUCHANAN INGERSOLL AND ROONEY PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LY; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

102. Family 30738209 (US2006026775 AA)


[View in PatBase](#)

Title

[EN] CARE/MAKEUP COMPOSITIONS COMPRISING A 2-ALKYLIDENEAMINOXYACETAMIDE COMPOUND FOR STIMULATING THE GROWTH OF THE HAIR OR EYELASHES AND/OR SLOWING LOSS THEREOF

Abstract

[EN] A regime/regimen (and compositions therefor) for inducing and/or stimulating the growth of keratinous fibers and/or slowing the loss and/or increasing the density thereof, notably human hair and/or eyelashes, entails administering to a mammalian subject in need of such treatment, for such period of time as required to elicit the desired effect, a thus effective amount of at least one 2-alkylideneaminoxyacetamide compound having the formula (1):



International Class: A61K31/165; A61K31/341; A61K31/381; A61K45/06; A61K8/42; A61K8/49; A61P17/14; A61Q7/00; A61K45/00; A61K8/30; A61Q1/10; A61Q5/00; A61Q5/02; A61Q5/12; A61K8/00; A61C5/00; A61K7/06

Cooperative Patent Class: A61K31/165; A61K31/341; A61K31/381; A61K45/06; A61K8/42; A61K8/4973; A61K8/4986; A61P17/14; A61Q1/10; A61Q7/00; A61K2800/782

US Class: 424/401; 424/70.1; 424/70.7; 8/405; 8/405P

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1587486 A2	20051026	EP20040701417	20040112
FR2849773 A1	20040716	FR20030050001	20030115
FR2849773 B1	20060714	FR20030050001	20030115
JP2006515025 T2	20060518	JP20050518728T	20040112
JP4037887 B2	20080123	JP20050518728T	20040112
US2006026775 AA	20060209	US20050181910	20050715
US7396525 BB	20080708	US20050181910	20050715
WO04069213 A2	20040819	WO2004IB00291	20040112
WO04069213 A3	20050120	WO2004IB00291	20040112

Priority Numbers: FR20030050001 [20030115]; US20030441733P [20030123]; WO2004IB00291 [20040112]; US20050181910 [20050715]; WO2004IB00291 [20040121]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; BOULLE CHRISTOPHE; DALKO MARIA; ROZOT ROGER

Non Std Assignees: L OREAL; L'OREAL; LOREAL; L"OREAL; LOREAL SA

Inventors: BOULLE CHRISTOPHE; DALKO MARIA; ROZOT ROGER

Agent(s): BUCHANAN INGERSOLL PC INCLUDING BURNS DOANE SWECKER AND MATHIS; BUCHANAN INGERSOLL PC; (INCLUDING BURNS DOANE SWECKER AND MATHIS); BUCHANAN INGERSOLL AND ROONEY PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; PL; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

103. Family 30454612 (US2004105875 AA)



[View in PatBase](#)

Title

[EN] COMPOSITION CONTAINING A SECONDARY OR TERTIARY CARBONYL AMINE, METHOD OF USE THEREOF, COMPOUNDS

Abstract

[EN] The present invention relates to a cosmetic process for treating wrinkled skin, by topical application to the skin of a composition containing, in a physiologically acceptable medium, at least one secondary or tertiary carbonyl amine of formula (I): 1



The invention also relates to a novel family of carbonyl amines, and also to compositions containing them.

International Class: A61K31/427; A61K35/36; A61K8/49; A61P17/14; A61Q7/00; C07D417/06; A61K31/4178; A61K31/422; C07D405/06; C07D409/06; C07D413/06; A61K8/30; C07D417/00; A61K31/137; A61K8/00; A61K8/02; A61K8/41; A61P17/00; A61P17/16; A61Q19/00; A61Q19/08; C07C225/00; C07C225/16; A61K31/429; A61K31/5575; A61P43/00; A61Q1/10; A61Q5/00; A61Q5/02; A61Q5/10; C07D513/04; A61K7/06; A61K31/33; A61K31/41; A61K31/4164; A61K31/4166; A61K31/4196; A61K31/425; A61K8/18; A61K8/33; A61K8/40; A61K8/46; A61K31/17; A61K31/421; A61K31/426; C07D233/28; C07D263/16; C07D263/30; C07D277/12; C07D277/60; C07D513/02; A61K7/00; A61K7/075; A61K7/48

Cooperative Patent Class: A61K2800/782; A61K31/427; A61K35/36; A61K8/49; A61K8/4913; A61K8/4986; A61P17/14; A61P43/00; A61Q7/00; C07D417/06; A61K8/41; A61P17/16; A61Q19/08; C07C225/16

US Class: 424/401; 424/70.1; 424/70.100P; 514/365; 514/365S; 514/366; 514/369; 514/376; 514/376S; 514/389; 514/389S; 514/397; 514/398; 514/461; 514/588; 514/649; 548/148; 548/148S; 548/183; 548/183S; 548/226; 548/226S; 548/315.1; 548/315.100S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2003299068 AA	20040419	AU20030299068	20030925
AU2003299068 BB	20080605	AU20030299068	20030925
BRPI0314490 A	20050802	BR2003PI14490	20030925
CA2499689 AA	20050321	CA20032499689	20030925
CN1703259 A	20051130	CN20038025452	20030925
EP1405633 A1	20040407	EP20030292265	20030915
EP1545708 A2	20050629	EP20030798227	20030925
FR2845000 A1	20040402	FR20020012018	20020927
FR2845000 B1	20050527	FR20020012018	20020927
FR2845288 A1	20040409	FR20020012261	20021003
FR2845288 B1	20060519	FR20020012261	20021003
JP2004269499 A2	20040930	JP20030344961	20031002
JP2006518338 T2	20060810	JP20050501926T	20030925
JP3745355 B2	20060215	JP20030344961	20031002
KR20050067397 A	20050701	KR20057005150	20030925
MXPA05003126 A1	20060309	MX2005PA03126	20030925
RU2005112734 A	20060227	RU20050112734	20030925
RU2316325 C2	20080210	RU20050112734	20030925
US2004105875 AA	20040603	US20030670327	20030926
US2006008436 AA	20060112	US20030671508	20030929

Patent Number	Publication Date	Application Number	Application Date
US2008076809 AA	20080327	US20070902864	20070926
US7294641 BB	20071113	US20030671508	20030929
WO04028441 A2	20040408	WO2003FR02823	20030925
WO04028441 A3	20040506	WO2003FR02823	20030925
WO04028441 C1	20070118	WO2003FR02823	20030925

Priority Numbers: FR20020012018 [20020927]; US20020415462P [20021003]; WO2003FR02823 [20030925]; FR20020012261 [20021003]; US20020426375P [20021115]; US20030670327 [20030926]; US20030671508 [20030929]; US20070902864 [20070926]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; LOREAL; BOULLE CHRISTOPHE; DALKO MARIA; ROZOT ROGER; LOOREAL

Non Std Assignees: L OREAL; L OREAL SA; L'OREAL; SOCIETE L OREAL S A; L OREAL SOC SA; L OREAL SA SOC; L OREAL S A SOC; LOREAL SA

Inventors: BOULLE CHRISTOPHE; DALKO MARIA; ROZOT ROGER; MARIA BOULLE CHRISTOPHE ROZOT; CAVEZZA ALEXANDRE; DAL KO MARIJA; BULL KRISTOF; ROZO ROZHE

Non Std Inventors: CHRISTOPHE BOULLE; ROGER ROZOT; MARIA DALKO; BOULLE CHRISTOPHE ROZOT ROGER DALKO MARIA; DAL'KO MARIJA; BULL' KRISTOF; ALEXANDRE CAVEZZA

Agent(s): GRIFFITH HACK; ROBIC; LOREAL; BUCHANAN INGERSOLL PC INCLUDING BURNS DOANE SWECKER AND MATHIS; BUCHANAN INGERSOLL PC; (INCLUDING BURNS DOANE SWECKER AND MATHIS); BUCHANAN INGERSOLL AND ROONEY PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NI; NO; NZ; OM; PG; PH; PL; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

104. Family 40992723 (US2008118553 AA)

[View in PatBase](#)

Title

[EN] TANNATE SALT FORM OF POLYPEPTIDE MIXTURES, THEIR PREPARATION AND USE

Abstract

[EN] The subject invention provides a composition comprising a mixture of polypeptides in the form of a tannate salt wherein each polypeptide is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine and L-Lysine, methods of preparation and uses thereof.

International Class: A61K31/375; A61K31/485; A61K31/522; A61K31/5415; A61K31/55; A61K31/70; A61K38/17; A61K38/22; A61K39/08; A61K39/395; A61K48/00; A61K38/04; C07K5/00; C07K7/00

Cooperative Patent Class: A61K38/00; C07K14/001

US Class: 424/145.1; 424/239.1; 424/451; 424/470; 424/489; 424/752; 514/17.9; 514/183; 514/217; 514/224.8; 514/263.31; 514/282; 514/291; 514/304; 514/305; 514/389; 514/44; 514/44R; 514/458; 514/474; 514/53; 514/559; 514/665; 514/725; 514/8; 977/906

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2008118553 AA	20080522	US20070811684	20070612
WO07146331 A1	20071221	WO2007US13864	20070612

Priority Numbers: US20060813303P [20060612]; US20070811684 [20070612]

Probable Patent Assignee: TEVA PHARMACEUTICAL IND LTD

Assignees: KOMLOSH ARTHUR A; FRENKEL ANTON; TEVA PHARMA

Non Std Assignees: TEVA PHARMACEUTICAL IND LTD; TEVA PHARMACEUTICALS USA INC; TEVA PHARMACEUTICAL INDUSTRIES LTD; TEVA PHARMACEUTICAL IND

Inventors: KOMLOSH ARTHUR A; FRENKEL ANTON

Agent(s): COOPER AND DUNHAM LLP

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

105. Family 31493588 (US2005169863 AA)


[View in PatBase](#)

Title

[EN] 2-THIOACETAMIDE COMPOSITIONS FOR STIMULATING THE GROWTH OF KERATIN FIBERS AND/OR FOR REDUCING LOSS THEREOF

Abstract

[EN] 2-Thioacetamide compounds are suited for inducing and/or stimulating the growth of human keratin fibers, for example human hair, and/or reducing the loss and/or increasing the density thereof.



International Class: A61K31/16; A61K31/165; A61K31/21; A61K31/215; A61K31/223; A61K31/335; A61K31/341; A61K31/40; A61K31/4015; A61K31/428; A61K31/429; A61K31/44; A61K31/4402; A61K31/4468; A61K31/5375; A61K31/695; A61K8/00; A61K8/30; A61K8/46; A61K8/49; A61P17/00; A61P17/14; A61P43/00; A61Q1/00; A61Q1/02; A61Q1/10; A61Q5/00; A61Q5/02; A61Q7/00; C07D207/00; C07D207/09; C07D207/27; C07D211/00; C07D211/58; C07D213/00; C07D213/40; C07D213/84; C07D277/00; C07D277/74; C07D295/00; C07D295/12; C07D307/00; C07D307/14; C07D307/52; C07D323/00; C07D513/00; C07D513/04; A61K8/58; A61K8/69; A61K7/02; A61K7/032; A61K7/06; A61K7/075; A61K7/09

Cooperative Patent Class: A61K2800/782; A61K8/49; A61K8/4926; A61P17/14; A61P43/00; A61Q7/00; A61K8/46; A61K8/4913; A61K8/4933; A61K8/4973; A61K8/585; A61K8/69

US Class: 424/70.5

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1502576 A2	20050202	EP20040291767	20040712
EP1502576 A3	20050622	EP20040291767	20040712

Patent Number	Publication Date	Application Number	Application Date
FR2858216 A1	20050204	FR20030009476	20030731
FR2858216 B1	20080404	FR20030009476	20030731
JP2005060391 A2	20050310	JP20040224865	20040730
US2005169863 AA	20050804	US20040897115	20040723

Priority Numbers: FR20030009476 [20030731]; US20030495100P [20030815]; US20040897115 [20040723]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL

Non Std Assignees: L OREAL; L OREAL SA; L'OREAL; LOREAL; LOREAL SA

Inventors: BOULLE CHRISTOPHE; BRETON PHILLIPE; ROZOT ROGER; BRETON PHILIPPE

Non Std Inventors: CHRISTOPHE BOULLE; PHILIPPE BRETON; ROGER ROZOT

Agent(s): LOREAL; BURNS DOANE SWECKER AND MATHIS L L P

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR

106. Family 30552236 (US2004242665 AA)

[View in PatBase](#)

Title



[EN] HAIR COMPOSITION CONTAINING A STYRYLPYRAZOLE COMPOUND, AND USE THEREOF FOR STIMULATING OR INDUCING HAIR OR EYELASH GROWTH AND/OR REDUCING LOSS THEREOF

Abstract

[EN] Haircare compositions containing, formulated into physiologically acceptable media therefor, effective amounts of a styrylpyrazole compound of formula (I), or salt thereof, to stimulate or induce hair growth and/or to reduce loss thereof: 1

PatBase

(I)



International Class: A61K8/49; A61Q5/00; A61Q7/00; C07D231/38; A61K8/30; C07D231/00; A61K31/415; A61K8/00; A61P17/14; A61P43/00; A61Q1/10; A61Q5/02; C07D231/12; C07D231/14; A61K7/06; A61K7/075

Cooperative Patent Class: A61K8/494; A61P17/14; A61P43/00; A61Q7/00; C07D231/38

US Class: 514/406

Family Information

Patent Number	Publication Date	Application Number	Application Date
AT361739 E	20070615	AT20030778455T	20031024
AU2003285454 AA	20040525	AU20030285454	20031024
AU2003285454 AH	20040525	AU20030285454	20031024
DE60313791 D1	20070621	DE20036013791T	20031024
DE60313791 T2	20080124	DE20036013791T	20031024
EP1558203 A2	20050803	EP20030778455	20031024
EP1558203 B1	20070509	EP20030778455	20031024
ES2287542 T3	20071216	ES20030778455T	20031024
FR2846232 A1	20040430	FR20020013522	20021029
FR2846232 B1	20041210	FR20020013522	20021029
JP2006517909 T2	20060803	JP20040547709T	20031024
PT1558203 I	20070723	PT20030778455T	20031024
US2004242665 AA	20041202	US20030694892	20031029
WO04039306 A2	20040513	WO2003FR03160	20031024
WO04039306 A3	20040624	WO2003FR03160	20031024

Priority Numbers: FR20020013522 [20021029]; US20020425276P [20021112]; WO2003FR03160 [20031024]; US20030694892 [20031029]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; BOULLE CHRISTOPHE; ROZOT ROGER

Non Std Assignees: L OREAL; SOCIETE L OREAL S A; L OREAL SA SOC; L OREAL S A SOC; L'OREAL; L OREAL SOC SA; LOREAL; LOREAL SA

Inventors: BOULLE CHRISTOPHE; ROZOT ROGER

Non Std Inventors: CHRISTOPHE BOULLE; ROGER ROZOT

Agent(s): LOREAL

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NI; NO; NZ; OM; PG; PH; PL; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

107. Family 32396844 (US2007092467 AA)


[View in PatBase](#)

Title

[EN] OXYACETAMIDE COMPOUNDS USEFUL FOR STIMULATING OR INDUCING THE GROWTH AND/OR RETARDING THE LOSS OF KERATIN FIBERS

Abstract

[EN] Oxyacetamide compounds that are inhibitors of type-1 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and which have the formula (I), or salts and/or solvates thereof: are useful for inducing and/or stimulating the growth of human keratin fibers, e.g., human head hair and/or eyelashes, and/or for retarding the loss and/or increasing the density thereof and/or for caring for and/or making up such keratin fibers.



International Class: A61K8/30; A61K8/42; A61K8/49; A61P17/00; A61P17/14; A61Q1/02; A61Q1/10; A61Q7/00; C07C233/00; C07C233/11; C07D215/00; C07D215/26; C07D233/00; C07D233/58; C07C235/00; C07C235/20; C07C235/24; C07D207/00; C07D207/32; C07D207/325; C07D233/54; C07D277/00; C07D277/64; C07D307/00; C07D307/14; C07D307/52; C07D307/91; A61K31/165; A61K31/167; A61K31/341; A61K31/343; A61K31/365; A61K31/4164; A61K31/428; A61K31/47; A61K8/58; A61P43/00; A61P7/00; C07D235/00; C07D235/08; A61K31/496; A61K31/506; A61K31/5375; A61K31/5377; A61K31/541; A61K31/695; A61K7/032; A61K7/06

Cooperative Patent Class: A61K8/42; A61K8/49; A61K8/4926; A61K8/4946; A61P17/14; A61P43/00; A61P7/00; A61Q1/10; A61Q7/00; A61K2800/782; A61K8/4913; A61K8/4973; C07C235/20; C07C235/24; C07D207/325; C07D215/26; C07D233/64; C07D277/64; C07D307/14; C07D307/52; C07D307/91

US Class: 424/70.1; 424/70.100P; 514/210.17; 514/210.170S; 514/227.5; 514/227.500S; 514/235.2; 514/235.200S; 514/235.5; 514/235.500S; 514/252.14; 514/252.140S; 514/275; 514/275S; 514/340; 514/340S; 514/341; 514/341S; 514/406; 514/406S; 514/63; 514/63S

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1763382 A1	20070321	EP20050757128	20050418
FR2869224 A1	20051028	FR20040004298	20040422
FR2869224 B1	20060609	FR20040004298	20040422
JP2007533708 T2	20071122	JP20070508932T	20050418
US2007092467 AA	20070426	US20060583792	20061020
WO05107687 A1	20051117	WO2005FR00926	20050418

Priority Numbers: FR20040004298 [20040422]; US20040566599P [20040430]; WO2005FR00926 [20050418]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; BOULLE CHRISTOPHE; BRETON PHILIPPE; ROZOT ROGER; NEUWELS MICHEL

Non Std Assignees: L OREAL; L OREAL SOCIETE ANONYME; L OREAL SOC ANONYME; L'OREAL; L AND 39 OREAL; LOREAL; LOREAL SA

Inventors: BOULLE CHRISTOPHE; BRETON PHILIPPE; ROZOT ROGER; NEUWELS MICHEL

Non Std Inventors: CHRISTOPHE BOULLE; MICHEL NEUWELS; PHILIPPE BRETON; ROGER ROZOT

Agent(s): LOREAL; BUCHANAN INGERSOLL AND ROONEY PC

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR; LS; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

108. Family 31958937 (WO05048979 A2)

[View in PatBase](#)

Title


[EN] PHARMACEUTICAL COMPOSITION HAVING CASING WITH MULTIPLE MICRO TABLETS

Abstract

[EN] A modified release pharmaceutical composition is disclosed. The composition consists of casing comprising at least two micro tablets, which are coated with rate controlling agent(s) optionally in combination with auxiliary pharmaceutical exceipient(s), wherein each micro tablet comprises core particles comprising pharmaceutical active ingredient and rate controlling agent(s), the said core particles optionally coated with rate controlling agent(s), wherein the ratio of pharmaceutical active ingredient to total rate controlling agent(s) ranges between 1: 0.1 to 1: 100 of each micro tablet.

International Class: A61K9/00; A61K9/48

Cooperative Patent Class: A61K31/137; A61K31/20; A61K31/454; A61K31/554; A61K9/4808



Family Information

Patent Number	Publication Date	Application Number	Application Date
IN01045MU2003 A	20050909	IN2003MU01045	20031006
IN209877 B	20070921	IN2003MU01045	20031006
WO05048979 A2	20050602	WO2004IN00307	20041004
WO05048979 A3	20060427	WO2004IN00307	20041004

Priority Numbers: IN2003MU01045 [20031006]

Probable Patent Assignee: TORRENT PHARMACEUTICALS LIMITED

Assignees: TORRENT PHARMACEUTICALS LTD; GUPTA VINOD KUMAR; VAYA NAVIN

Non Std Assignees: TORRENT PHARMACEUTICALS LIMITED

Inventors: GUPTA VINOD KUMAR; VAYA NAVIN

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GW; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MC; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW


109. Family 41698966 (IN01012MU2005 A)

[View in PatBase](#)

Title
[EN] NOVEL DRUG DELIVERY SYSTEM

Abstract
[EN] A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

International Class: A61K9/00; A61K9/16



Family Information


Patent Number	Publication Date	Application Number	Application Date
IN01012MU2005 A	20070831	IN2005MU01012	20050826

Probable Patent Assignee: TORRENT PHARMACEUTICALS LTD
Non Std Assignees: TORRENT PHARMACEUTICALS LTD
Non Std Inventors: GUPTA VINOD KUMAR; NADKARNI SUNIL SADANAND; KARAN RAJESH SINGH; VAYA NAVIN

[View in PatBase](#)

[EN] ADMINISTRATION OF NOVEL PHENYLFURYL METHYLTHIAZOLIDINE-2,4-DIONE AND PHENYLTHIENYL METHYLTHIAZOLIDINE-2,4-DIONE COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF KERATINOUS FIBERS AND/OR SLOWING LOSS THEREOF

[EN] Novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds having the following formula and the salts or their solvates thereof: are useful for stimulating or inducing the growth of keratinous fibers and/or slowing down their loss and/or increasing their density and/or improving their appearance, and also for caring for or making up keratinous fibers, e.g., for caring for or making up the hair or eyelashes.



US Class: 514/369; 548/183

Patent Number	Publication Date	Application Number	Application Date
EP1775294 A1	20070418	EP20060120810	20060918
FR2891543 A1	20070406	FR20050053017	20051005
JP2007126451 A2	20070524	JP20060273313	20061004
US2007078175 AA	20070405	US20060543193	20061005

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; NL; PL; PT; RO; SE; SI; SK; TR; YU

111. Family 34064954 (US2007059265 AA)


[View in PatBase](#)

Title

[EN] BENZYLIDENE-1,3-THIAZOLIDINE-2,4-DIONE COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH AND/OR FOR REDUCING THE LOSS AND/OR FOR INCREASING THE DENSITY OF KERATIN FIBERS

Abstract

[EN] The benzylidene-1,3-thiazolidine-2,4-dione compounds having the structural formula (I), or salt and/or solvate and/or isomer thereof: are useful active agents for inducing and/or stimulating the growth of mammalian keratin fibers and/or reducing the loss and/or increasing the density thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for caring for or making up the hair or the eyelashes.



International Class: A61K31/426; A61K8/30; A61K8/49; A61Q7/00; C07D277/00; C07D277/24; A61Q1/00; A61Q5/00; A61K45/00; A61P17/00; A61P17/14; A61P43/00; C07D277/20; C07D277/34

Cooperative Patent Class: A61K2800/782; A61K31/426; A61K8/49; A61P17/14; A61P43/00; A61Q7/00; C07D277/20; A61K8/69; A61Q1/10

US Class: 424/70.1; 424/70.100; 424/70.100P; 514/369; 514/369S

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1739083 A1	20070103	EP20060115283	20060612
FR2887444 A1	20061229	FR20050051793	20050628
JP2007008936 A2	20070118	JP20060177275	20060627
US2007059265 AA	20070315	US20060476123	20060628

Priority Numbers: FR20050051793 [20050628]; US20050697972P [20050712]; US20060476123 [20060628]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL

Non Std Assignees: L OREAL; L OREAL SOCIETE ANONYME; L OREAL SOC ANONYME; L OREAL SA; L'OREAL; LOREAL; LOREAL SA

Inventors: BOULLE CHRISTOPHE

Non Std Inventors: CHRISTOPHE BOULLE

Agent(s): LOREAL; BUCHANAN INGERSOLL AND ROONEY PC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; NL; PL; PT; RO; SE; SI; SK; TR; YU

112. Family 30590160 (US2004235831 AA)

[View in PatBase](#)



Title

[EN] COMPOSITION FOR CARING FOR THE HAIR OR THE EYELASHES, CONTAINING A PYRAZOLECARBOXAMIDE COMPOUND, USE THEREOF FOR STIMULATING THE GROWTH OF THE HAIR AND THE EYELASHES AND/OR FOR REDUCING THEIR LOSS

Abstract

[EN] The invention relates to a composition for caring for or making up the hair or the eyelashes, which is intended to limit their loss and/or to increase their density, and containing a pyrazole compound of formula (I), or a salt thereof: 1

PatBase



in which: R 1 and R 2 represent H; an optionally substituted C 1 -C 20 alkyl; or at least one ring optionally containing at least one hetero atom, these rings possibly being fused, comprising a carbonyl or thiocarbonyl function, and possibly being substituted; R 3 and R 5 represent H, a halogen, OR 6, SR 6, NR 6 R' 6, CN, CF 3, COR 6, CSR 6, COOR 6, COSR 6, CSOR 6, CSSR 6, NR 6 COR' 6, NR 6 CSR' 6, OCOR 6, SCOR 6, CSNR 6 R' 6, SO 2 R 6, SO 2 NR 6 R' 6, NR 6 SO 2 R' 6, NR 6 C(-NR' 6)NR? 6 R'? 6, SiR 6 R' 6 R? 6, A or at least one ring optionally containing at least one hetero atom, these rings possibly being fused, comprising a carbonyl or thiocarbonyl function and possibly being substituted; R 4 represents H, A, COR 6, CSR 6, COOR 6, CONR 6 R' 6, CSNR 6 R' 6, SO 2 R 6, SO 2 NR 6 R' 6 or at least one ring optionally containing a hetero atom, these rings possibly being fused, comprising a carbonyl or thiocarbonyl function, and possibly being substituted; R 6, R' 6, R? 6 and R'? 6 represent H; an optionally substituted C 1 -C 20 alkyl; at least one ring optionally containing at least one hetero atom, these rings possibly being fused, comprising a carbonyl or thiocarbonyl function, and possibly being substituted with at least one substituent R; A represents an optionally substituted C 1 -C 20 alkyl.

International Class: A61K8/30; A61K8/49; A61P17/00; A61P17/14; A61Q7/00; A61K31/415; A61K31/4155; A61K31/496; A61P43/00; A61Q1/02; A61Q1/10; A61Q5/00; C07D231/00; C07D231/14; C07D405/00; C07D405/12; A61K17/14; A61K31/454; A61K31/5377; A61K31/541; A61K7/06

Cooperative Patent Class: A61K8/494; A61P17/14; A61P43/00; A61Q7/00; A61K2800/782

US Class: 514/227.5; 514/227.500P; 514/235.5; 514/235.500S; 514/254.05; 514/254.050S; 514/326; 514/326S; 514/406; 514/406S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2003295041 AA	20040618	AU20030295041	20031120
EP1565150 A1	20050824	EP20030786035	20031120
FR2847160 A1	20040521	FR20020014534	20021120
JP2006519755 T2	20060831	JP20040554612T	20031120
US2004235831 AA	20041125	US20030716410	20031120
WO04047776 A1	20040610	WO2003FR03436	20031120

Priority Numbers: FR20020014534 [20021120]; US20020428721P [20021125]; WO2003FR03436 [20031120]; US20030716410 [20031120]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; ROZOT ROGER

Non Std Assignees: L OREAL; SOCIETE L OREAL S A; L OREAL SA SOC; L OREAL S A SOC; L'OREAL; L OREAL SOC SA; LOREAL; LOREAL SA

Inventors: ROZOT ROGER; BOULLE CHRISTOPHE

Non Std Inventors: ROGER ROZOT; CHRISTOPHE BOULLE

Agent(s): LOREAL

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; HR; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NI; NO; NZ; OM; PG; PH; PL; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

113. Family 28091351 (WO03016500 A2)

[View in PatBase](#)

Title
[EN] HUMAN TOXICOLOGICALLY RELEVANT GENES AND ARRAYS

Abstract
[EN] The invention provides for a set of toxicologically relevant human genes which may be used to predict toxicological responses on a cellular, organ, or system level. Methods of identifying, selecting, isolating, and evaluating toxicologically relevant human genes are provided. Arrays comprising human genes that are useful for toxicological screening of drugs, pharmaceutical compounds, or chemicals are also provided. The human array provides a method by which toxicological responses can analyzed in a rapid and efficient manner. Methods of identifying and isolating human genes for a human array are also provided. Further, methods of making a human gene array and using a human gene array are disclosed. These methods are also useful for isolating human genes and for discovery of novel human genes. Also provided is a database of human toxicological responses which are useful for predicting toxicological response to agents on a cellular level, organ-by-organ, and system-by-system. Methods of obtaining such databases containing human toxicological data and methods of use are also provided herein. Further, algorithms which allows for evaluation and/or 1 analysis of toxicological data are also provided herein.

International Class: C12Q1/68; C12Q1/6883; C07H21/00; C07H21/04; C12M1/34; C12N; C12P19/34; G01N33/04; G01N33/50; G06F19/00

Cooperative Patent Class: C12Q1/6883; C12Q2600/158

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2002323286 AA	20030303	AU20020323286	20020816
EP1427850 A2	20040616	EP20020757259	20020816
EP1427850 A4	20060208	EP20020757259	20020816
WO03016500 A2	20030227	WO2002US26514	20020816
WO03016500 A3	20030619	WO2002US26514	20020816

Priority Numbers: US20010313080P [20010816]; WO2002US26514 [20020816]

Probable Patent Assignee: PHASE 1 MOLECULAR TOXICOLOGY I

Assignees: PHASE 1 MOLECULAR TOXICOLOGY I; ADKINS KARISSA; ALLEN PHILLIPPE; DUNN ROBERT T II; KIER LARRY D; NEFT ROBIN E; PICKETT GAVIN G; SCHMEISER KATJA

Non Std Assignees: PHASE 1 MOLECULAR TOXICOLOGY INC; DUNN ROBERT T

Inventors: ALLEN PHILLIPPE; ADKINS KARISSA; NEFT ROBIN E; PICKETT GAVIN G; KIER LARRY D; DUNN ROBERT T II; SCHMEISER KATJA

Non Std Inventors: GAVIN G PICKETT; LARRY D KIER; PHILLIPPE ALLEN; KARISSA ADKINS; ROBIN E NEFT; KATJA SCHMEISER; ROBERT T II DUNN; DUNN ROBERT T


Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; GA; GD; GE; GH; GM; GN; GQ; GW; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MA; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NO; NZ; OM; PH; PL; RO; RU; SD; SG; SI; SL; SN; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW

114. Family 31815923 (FR2860431 A1)

[View in PatBase](#)

Title

[EN] USE OF PHENYLAZO BENZENE, PYRIDINE OR PYRIDAZINE DERIVATIVES AS AGENTS FOR INDUCING AND/OR STIMULATING GROWTH OF HUMAN KERATINIC FIBERS AND/OR INHIBITING THEIR LOSS AND/OR INCREASING THEIR DENSITY



Abstract

[EN] Use of phenylazo benzene, pyridine or pyridazine derivatives (I) as agents for inducing and/or stimulating growth of human keratinic fibers and/or inhibiting their loss and/or increasing their density: Use of phenylazo benzene, pyridine or pyridazine derivatives of formula (I) as agents for inducing and/or stimulating growth of human keratinic fibers and/or inhibiting their loss and/or increasing their density [Image] Ra, Rb: H, halo, CF₃, CN, OR, SR, NRR, NRC(NR)NRR, COR, CSR, COOR, CONRR, CH₂COOR, CSNRR, NRCSR, NRCSNRR, NRCOR, NRCONRR, SO₂NRR, NRSO₂R, NRSO₂NRR, SO₂R or NO₂; 1-10C (un)saturated alkyl optionally substituted with A1 or with (un)saturated 3- to 7-membered rings optionally containing heteroatoms, optionally substituted with A2 and optionally fused with at least one ring optionally containing heteroatoms; or aryl or heteroaryl optionally substituted with A2 and optionally fused with at least one ring optionally containing heteroatoms; X, Y: CR_c or N, optionally in N-oxide or quaternized form, but not both N in N-oxide or quaternized form; R_c: Ra or Rb; n, m: 0-5; R: H, (un)saturated 1-10C alkyl, or aryl or heteroaryl optionally substituted with A2; A1H, halo, CF₃, CN, OR, SR, NRR, NRC(NR)NRR, COR, CSR, COOR, CONRR, CH₂COOR, CSNRR, NRCSR, NRCSNRR, NRCOR, NRCONRR, SO₂NRR, NRSO₂R, NRSO₂NRR, SO₂R or NO₂; A21-10C alkyl, OR1, SR1, NR1R1, COOR1, COR1 or CH₂COOR1; R1H or (un)saturated 1-10C alkyl; and heteroatoms: N, O, S or Se. Independent claims are also included for: (1) Topical composition for care or make-up of human keratinic fibers, comprising at least one compound (I); (2) Cosmetic treatment of human keratinic fibers and/or the skin from which they emerge by applying the above composition to the fibers and/or skin. ACTIVITY: Endocrine-Gen. No biological data available. MECHANISM OF ACTION: None given.

International Class: A61K8/30; A61K8/40; A61K8/46; A61K8/49; A61K8/70; A61Q1/02; A61Q1/10; A61Q7/00; A61K7/06

Cooperative Patent Class: A61K8/40; A61K8/466; A61K8/49; A61K8/4926; A61K8/494; A61K8/70; A61Q1/10; A61Q7/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
FR2860431 A1	20050408	FR20030050639	20031002

Priority Numbers: FR20030050639 [20031002]

Probable Patent Assignee: LOREAL SA

Assignees: OREAL; LOREAL SA

Non Std Assignees: L OREAL

Inventors: BOULLE CHRISTOPHE

Non Std Inventors: CHRISTOPHE BOULLE

Agent(s): LOREAL

115. Family 20158853 (US2002035070 AA)

[View in PatBase](#)

Title

[EN] METHOD OF REGULATING HAIR GROWTH USING METAL COMPLEXES OF OXIDIZED CARBOHYDRATES

Abstract

[EN] A method for regulating the growth of hair comprising administering to a mammal, an effective amount of a composition comprising: (a) from about 0.001 percent to about 99.9 percent, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate; and (b) from about 0.1 percent to about 99.999 percent, by weight, of a vehicle.

International Class: A61K31/70; A61K8/19; A61K8/27; A61K8/365; A61K8/58; A61K8/60; A61K8/73; A61P17/14; A61Q5/00; A61Q5/02; A61Q7/00; A61K31/315; A61K7/06

Cooperative Patent Class: A61K2800/58; A61K31/70; A61K8/19; A61K8/27; A61K8/365; A61K8/58; A61K8/60; A61K8/73; A61K8/731; A61K8/733; A61K8/736; A61K8/737; A61P17/14; A61Q3/00; A61Q5/00; A61Q5/006; A61Q5/02; A61Q5/06; A61Q5/12; A61Q7/00

US Class: 514/23; 514/23P; 514/492; 514/492S; 514/494; 514/494S; 514/495; 514/495S; 514/499; 514/499S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2001280779 AA	20020205	AU20010280779	20010725
AU200180779 A1	20020205	AU20010080779	20010725
AU200180779 A5	20020205	AU20010080779	20010725
US2002035070 AA	20020321	US20010909441	20010719
WO0207685 A2	20020131	WO2001US23424	20010725
WO0207685 A3	20020829	WO2001US23424	20010725
WO0207685 C1	20031030	WO2001US23424	20010725

Priority Numbers: US20000220755P [20000726]; WO2001US23424 [20010725]; US20010909441 [20010719]

Probable Patent Assignee: PROCTER AND GAMLE CO

Assignees: PROCTER AND GAMBLE

Non Std Assignees: PROCTER AND GAMBLE CO; THE PROCTER AND GAMBLE COMPANY; PROCTER AND GAMLE CO

Inventors: GARDLIK JOHN MICHAEL; COMSTOCK BRYAN GABRIEL; SEVERYNSE STEVENS DIANA

Non Std Inventors: JOHN MICHAEL GARDLIK; DIANA SEVERYNSE STEVENS; BRYAN GABRIEL COMSTOCK

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BJ; BR; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GW; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MC; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NL; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; SN; SZ; TD; TG; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW

116. Family 28215877 (US2002119174 AA)

[View in PatBase](#)

Title

[EN] COMPOSITIONS USEFUL FOR REGULATING HAIR GROWTH CONTAINING METAL COMPLEXES OF OXIDIZED CARBOHYDRATES

Abstract

[EN] A stable cosmetic, dermatological, or pharmaceutical composition comprising: (a) from about 0.001 percent to about 99.9 percent, by weight, of at least one metal complex of an oxidized carbohydrate; wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate nor lithium gluconate; and (b) from about 0.1 percent to about 99.999 percent, by weight, of a vehicle, wherein the vehicle comprises at least about 5 percent, by weight of the composition, of propylene glycol.

International Class: A61K31/7032; A61K31/715; A61K33/00; A61K33/30; A61K33/34; A61K8/19; A61K8/27; A61K8/365; A61K8/49; A61K8/60; A61K8/73; A61P17/00; A61Q19/00; A61Q3/00; A61Q5/00; A61Q5/02; A61Q5/06; A61Q7/00; A61K31/00; A61K31/70; A61K7/00; A61K7/06; A61K7/48; A61P17/14

Cooperative Patent Class: A61K2800/58; A61K31/7032; A61K31/715; A61K33/00; A61K33/30; A61K33/34; A61K8/19; A61K8/27; A61K8/365; A61K8/49; A61K8/4953; A61K8/60; A61K8/73; A61K8/731; A61K8/733; A61K8/736; A61K8/737; A61P17/00; A61P17/14; A61Q19/00; A61Q3/00; A61Q5/006; A61Q5/02; A61Q5/06; A61Q7/00

US Class: 424/401; 424/401P; 514/54; 514/54S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2001280780 AA	20020205	AU20010280780	20010725
AU200180780 A1	20020205	AU20010080780	20010725
AU200180780 A5	20020205	AU20010080780	20010725
US2002119174 AA	20020829	US20010909440	20010719
WO0207700 A2	20020131	WO2001US23425	20010725
WO0207700 A3	20020829	WO2001US23425	20010725
WO0207700 C1	20031030	WO2001US23425	20010725

Priority Numbers: US20000220756P [20000726]; WO2001US23425 [20010725]; US20010909440 [20010719]

Probable Patent Assignee: PROCTER AND GAMBLE CO

Assignees: PROCTER AND GAMBLE; COMSTOCK BRYAN GABRIEL; GARDLIK JOHN MICHAEL; SEVERYNSE STEVENS DIANA

Non Std Assignees: PROCTER AND GAMBLE CO; THE PROCTER AND GAMBLE COMPANY

Inventors: GARDLIK JOHN MICHAEL; COMSTOCK BRYAN GABRIEL; SEVERYNSE STEVENS DIANA

Non Std Inventors: JOHN MICHAEL GARDLIK; DIANA SEVERYNSE STEVENS; BRYAN GABRIEL COMSTOCK

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BJ; BR; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GW; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MC; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NL; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; SN; SZ; TD; TG; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW